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Abstract
A community-based cross-sectional household seroepdemiological survey was conducted
in the Republic of Yemen to estimate the prevalence of HBV infection as well as
hepatitis B vaccine coverage and effectiveness amongst children vaccinated in the
country's Expanded Programme on Immunisation (EPI). Study subjects were randomly
selected from five provinces in the country based on probability proportional to size.
The prevalence of HBV chronic infection amongst women of childbearing age
participating in the survey was 5.08% and places Yemen amongst the group of countries
with a high endemicity of HBV infection (> 5%). This is much lower than earlier
estimates by hospital-based studies in Yemen estimating the prevalence of HBV chronic
infection to be 12.5-16.6% amongst women of childbearing age. This prevalence estimate
is more consistent with research findings from other neighbouring Middle East countries.
There was evidence that perinatal transmission is not a major mode of HBV infection in
Yemen. This is mainly the result of the low prevalence of HBV chronic infection
amongst women of childbearing age (5.08%), the low prevalence of hepatitis B e
antigenaemia (HBeAg) (12.84%) amongst HBV chronic carrier women, and the low
infectivity (21.14%) ofHBeAg positive chronic carrier mothers.
The prevalence of children completely vaccinated with hepatitis B vaccination was
8.63%. This estimate is lower than hepatitis B vaccination coverage estimates presented
by the EPI in Yemen. The prevalence of incompletely vaccinated children was 12.47%. If
these children completed their vaccination schedule, this would have increased the
proportion of completely vaccinated children to more double than its current level. There
were differences in hepatitis B vaccine coverage by area/province of residence indicating
inequitable distribution, availability or accessibility to health services, with a bias
towards better provision, or at least uptake of immunisation services in urban areas.
Hepatitis B vaccine was found to be highly immunogenic and effective in preventing
HBV infection amongst children aged 1-3 participating in the survey.
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In conclusion, this research demonstrates that HBV infection is not as major a public
health problem in Yemen as originally expected, and this misconception needs to be
corrected. Hepatitis B vaccine coverage, on the other hand, is low and must be increased.
There is no need to amend the current hepatitis B vaccine schedule. Nevertheless, vaccine
coverage should be increased with an emphasis on a more equitable distribution, access,
and availability of hepatitis B vaccines.
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Chapter 1
Hepatitis B Virus Infection
A Global Health Problem
1.1 Introduction:
Worldwide approximately 2 billion individuals, a third of the world's population, have
been infected with the hepatitis B virus (HBV) (Viral Hepatitis, 2000; Vaccine and
Immunisation News, 1996). It is estimated that there are over 350 million chronic carriers
infected with the virus across the globe (WHO, 2000; Zuckerman, 1996). The World
Health Organisation estimates that 1 - 2 million deaths occur annually as a result ofHBV
infection (WHO, 2000; Zuckerman, 1996).
Approximately 25% of HBV chronic carriers develop chronic hepatitis, liver cirrhosis
and hepatocellular carcinoma (HCC), the three main complications of HBV chronic
infection. HCC is the fourth most common cause of mortality from cancer and the eighth
most common incident cancer worldwide (Parkin et al., 1999). It is estimated that 54% -
80% of liver cancers can be attributed to HBV chronic infection (Parkin et al., 1999;
Zuckerman, 1996). The HBV is described as the world's most common carcinogen,
second only to tobacco (Maynard et al., 1989; Vaccine and Immunisation News, 1996).
The course of infection depends on the age at exposure to HBV, with age at infection
being the major determinant of whether a person becomes a chronic carrier. The risk of
becoming a chronic carrier and consequently developing complications of HBV chronic
infection is inversely proportional to age (Edmunds et al., 1993).
The distribution of HBV chronic carriers is not uniform across the globe and the majority
of HBV chronic carriers are found in developing countries. Liver cancer is also mainly a
problem of developing countries, which contribute 81% of all deaths resulting from liver
cancer (Parkin et al., 1999). The global distribution of HCC follows a pattern similar to
that of HBV chronic carriers and occurs predominantly in regions where HBV infection
is highly endemic, particularly China and Sub-Saharan Africa.
In 1982, a vaccine was licensed for active immunoprophylaxis against HBV infection.
The first vaccines available were plasma derived but later recombinant vaccines were
developed. Both types of vaccine have proven to be safe, highly effective, and, recently
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cost-effective, available at a cost most countries can afford. As the success of treatment
for HBV infection remains low and antiviral therapy expensive, prevention of infection
by vaccinating with hepatitis B vaccine remains the best option for health ministries and
policy makers.
In 1991 the World Health Assembly (WHA), recommended the integration of hepatitis B
vaccines to immunisation campaigns of countries with an intermediate to high endemicity
by 1995, and to all countries by 1997. Although many countries have adopted this
recommendation whilst struggling to keep their health systems afloat the main challenge
facing developing countries is reaching highly deprived populations through a primary
health care infrastructure that is in many cases exhausted and short of funds.
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Hepatitis B Viral Epidemiology
In The Middle East
1.2 Background:
The Middle East is comprised of a group of countries that show considerable variation in
their economy, population characteristics and growth rate, literacy and educational levels,
geography, climate, development, political system and level of health care. The Arabian
Peninsula covers well over 3 million square kilometres of which Saudi Arabia alone
comprises 2.3 million square kilometres. Countries of the Arabian Peninsula (Gulf States)
include Saudi Arabia, Kuwait, Qatar, Bahrain, United Arab Emirates (UAE), Sultanate of
Oman and the Republic of Yemen (Map 1). Middle East countries directly neighbouring
the Arabian Peninsula include Egypt, Jordan, Iran, Iraq, Lebanon, Sudan and Syria.
The Gulf States of the Arabian Peninsula excluding Yemen form an economic,
geographic and political alliance called the Gulf Council for Cooperation (GCC). These
countries have been experiencing unprecedented growth since the discovery of oil. Health
care has been a high priority in these countries, especially in Saudi Arabia and UAE,
which provide free hospital care for all their citizens at a standard competing with the
best in the world.
HBV infection is a major public health problem in the Middle East. The majority of the
countries in the region fall into the group of countries with an intermediate and high
endemicity of HBV infection.
In this chapter, the epidemiology of HBV infection in the Arabian Peninsula and its
neighbouring Middle Eastern countries will be reviewed. Firstly, the incidence and
prevalence of HBV infection in the region and the different modes and ages of
transmission of infection in these countries will be discussed. This will be followed by a
description of the risk factors associated with HBV infection in these countries. Then the
preventive measures against HBV infection in the countries of the region will be
presented. Finally, the epidemiology ofHBV infection in The Republic of Yemen will be
reviewed. Throughout the text the terms HBV chronic infection, HBV chronic carrier,
HBsAg chronic carrier will be used interchangeably.
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Arabian Peninsula and Neighbouring Middle East Countries
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1.3 Literature review search strategy:
Information and data in this review was obtained from four sources. The main source of
information was literature published in international journals on the epidemiology of
HBV infection and chronic carriage, hepatitis B vaccines, hepatitis B vaccine
effectiveness, and control of HBV infection. This provided general information on the
global situation of infection with HBV and regional (Middle East) information (with an
emphasis on Yemen) on HBV infection, carrier status, mode of transmission, risk factors,
and vaccination. Keywords used in the Thesaurus search of Medline and Popline, and the
search of Pubmed were [hepatitis, hepatitis B virus, Middle East, hepatitis B vaccines,
vaccine effectiveness, Bahrain, Egypt, Iran, Iraq, Jordan, Kuwait, Lebanon, Libya,
Middle East, Morocco, Oman, Palestine, Qatar, Saudi Arabia, Sudan, Syria, Tunisia,
United Arab Emirates and Yemen]. These terms were combined in the search limiting
results to articles relevant to the review. A further search was conducted for articles cited
in the primary articles, which expanded information obtained from primary reading
material. On some occasions cited articles from journals not available at libraries in the
UK or the internet were requested from overseas. The second source of information was
Middle East country reports and workshops on viral hepatitis. The World Health
Organisation (WHO) library at the Ministry of Public Health and Population (MOPHP) in
Sanaa, Republic of Yemen was searched for all reports and publications on viral hepatitis
in the region and the country. Reports on hepatitis B viral epidemiology in Yemen were
obtained from the MOPHP. Information on vaccine types and coverage were kindly
provided by Mr. Mohammed Kulaise, the Director of the Expanded Programme on
Immunisation (EPI) at the MOPHP in Sanaa, Yemen. The third source of information
was books and editorials on viral infections and HBV that were purchased, borrowed
from the library of the London School of Hygiene and Tropical Medicine, or obtained
from Professor Andrew Hall and Dr. lain Murray-Lyon. Finally, the MOPHP kindly
provided copies of its Expanded Programme on Immunisation (EPI) five-year plan, its
plan to introduce hepatitis B vaccine to the EPI, its request for funding submitted to the
Global Alliance for Vaccine and Immunisation (GAVI), as well as other useful and
related reports and documents.
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1.4 Epidemiology:
Based on the prevalence of HBV chronic carriers (individuals positive for hepatitis B
surface antigen (HBsAg) for longer than six months) amongst adults in the general
population, countries are divided into three main groups. Countries with a prevalence of
HBV chronic carriers less than 2% are classified as countries with a low endemicity of
infection; those with a prevalence of HBV chronic carriers between 2 - 5 % are classified
as having an intermediate endemicity of infection; and countries with a prevalence of
HBV chronic carriers exceeding 5% are classified as having a high endemicity of
infection (Hall, 1994).
Middle East countries provide a good reflection of the global epidemiology of HBV
infection, with the prevalence of HBV chronic carriers varying considerably between and
within these countries. Countries of the region fall into all three groups of low,
intermediate and high endemicity of HBV infection. However, the majority of countries
in the region have an intermediate and high endemicity of HBV chronic carriers (Andre,
2000; Hall, 1994; WHO, 1995).
1.4.1 HBV chronic infection:
National HBV chronic carrier rates in the Middle East range from as low as 1.5% in
Kuwait to as high as 18.5% in Yemen (Ashraf et al., 1986; El-Guneid et al., 1993).
Studies conducted in the Middle East show that the prevalence of chronic carriers in these
countries ranges from 3 - 11% in Egypt, 1.1 - 2.5% in Iran, 3.4 - 5 % in Iraq, 2.6 - 10%
in Jordan, 1.5 - 2.9% in Kuwait, 2.9% in Lebanon, 2 - 6% in Libya, 2.3 - 10% in Oman,
1.8 - 6% in Palestine, 2.8 - 16.7% in Saudi Arabia, 16 - 26% in Sudan, 3.3 - 6.5% in
Tunisia, 2 - 6 % in the United Arab Emirates and 7.4 - 18.5% in Yemen (Al-Faleh et al.,
1992; Al-Nakib et al., 1986; Al-Owais et al., 2000; Arya et al., 1985; Ashrafet al., 1986;
Awidi et al., 1984; Basalamah et al., 1984; Coursaget et al., 1994; El-Gouli, 1984; EI-
Guneid et al., 1993; El-Hamzi, 1989; El-Shafie, 1992; Ghavanini et al., 2000; McCarthy
et al., 1994; Nabulski et al., 1997; Nashef et al., 1992; Parande et al., 1986; Ragaa et al.,
2001; Ramia et al., 1986; Scott et al., 1992; Scrimgeour et al., 1999; Soliman et al., 1995;
Talkuder et al., 1982; Toukan et al., 1988; Toukan et al., 1990; WHO, 1995; Yassin et al.,
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2002). These studies have been conducted on various populations with the intention of
giving an accurate estimate of the prevalence of HBV chronic carriers in a representative
sample of the general population (table 104.1 A). These groups included apparently
healthy adults with no evidence of previous or present HBV infection, school children,
infants, pregnant women, healthy blood donors and health care staff. The HBV carrier
rates differed from one study to another, even when conducted amongst the same
population and within the same country. This may be due to different study designs or
sample populations, where, for example, higher rates of infection have been observed in
community-based studies than in studies conducted amongst blood donors (Toukan,
1990). Blood donors do not necessarily represent the general population. In some
settings, blood donors tend to be healthier than individuals in the general population and
as a result are more willing and capable of donating blood. In one study in Saudi Arabia,
blood donors appeared to have a lower prevalence of HBsAg (13.9%) when compared to
the general population (16.7%) (p=OA) (El-Hamzi, 1989). On the other hand, in countries
where donors are paid for their blood donation, these blood donors may have higher rates
of infection than the general population. Moreover, the blood donor relatives of patients
suffering chronic liver disease (CLD) requiring blood transfusions may themselves have
higher rates of viral hepatitis and liver disease than the general population. In Yemen,
Scott et al found blood donors had a significantly higher prevalence of HBsAg chronic
infection (20.6%) than apparently healthy non-donor individuals (12.1%) (p=0.02) (Scott
et al., 1990). It is unclear whether these blood donors were paid or volunteer blood
donors. As a result, one must not generalise findings based on studies conducted on blood
donors. Another possible explanation for the differences in the HBV carrier rates may be
due to the use of different measurement techniques used from one study to another. There
are many kits and reagents available that differ in generation, specificity and sensitivity.
Most of the serological assays performed were done using commercial Enzyme Linked
Immunosorbent Assay (ELISA) or Microparticle Enzyme Immunoassay (MEIA), Radio-
Immunoassay (RIA) and Reverse Passive Haemagglutination (RPHA). Tests done using
RPHA were usually confirmed by ELISA or RIA. The majority of these studies did not
clarify if samples positive by ELISA or MEIA were re-tested or tested by neutralisation
to confirm the serological findings, which may be one explanation why the results were
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so different. In Yemen El-Guneid et al, found a much higher hepatitis B e antigenaemia
(HBeAg) (59.3%) amongst healthy individuals than Scott et al (9.7%). They attributed
this to the more sensitive micropartic1e enzyme immunoassay technique (Imx HBe,
Abbott) used for the detection of HBeAg in their study (El-Guneid et al., 1993). Still, a
common finding for all these studies, irrespective of the study population or measurement
technique, is that they all confirm high HBV carrier rates in the majority of the countries
in the Middle East (see table 1.4.1 A).
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In addition to the marked geographic variation of HBV carrier rates between Middle East
countries, there is marked geographic variation of rates within these countries. In Saudi
Arabia, for example, the prevalence of chronic carrier females was 25% in the Jaizan
region (the Southwest province bordering Yemen) and this was significantly higher
(p<0.00003) than the prevalence of chronic carrier females which was 7.3% in the Najran
region (El-Hamzi, 1989). Jordan also shows significant differences (p < 0.02) in carrier
rates between villages ranging from 5.7% in one village to 12.8% in another (Toukan et
al., 1990).
While some studies conducted in the region found a significantly higher rate of anti-HBc
positivity and HBV chronic carriers amongst males (Awidi et al., 1984; Ramia et al.,
1986), another group did not find significant evidence of higher anti-HBc positivity or
HBV chronic carrier rates amongst males (Al-Faleh., 1992; El-Hamzi, 1989; Parande et
al., 1986). A WHO collaborative study on HBV in which 20 countries participated did
not find a statistically significant difference in the prevalence of HBsAg between males
and females (Sobeslavsky, 1980).
Table 1.4.1 B presents HBV chronic carrier rates and hepatitis B vaccination status and
coverage in Middle East countries devised by Toukan (Toukan, 1997). Since its
publication in 1997, there have been some changes and the table has been modified
accordingly. In Yemen, for example, hepatitis B vaccination was introduced to the
Expanded programme on Immunisation (EPI) in 1998. In Tunisia, hepatitis B vaccination
has also been introduced to the EP!. In Iraq, coverage of the EPI has been markedly
affected by the economic sanctions imposed on the country following the second Gulf
War. In addition, Qatar is currently conducting selective vaccination of certain high-risk
groups such as contacts of HBsAg positive pregnant women, in an attempt to improve the
effectiveness of its hepatitis B control programme.
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Table 1.4.1 B
HBV chronic carrier and hepatitis B vaccination status in Middle East countries
Adapted from Toukan A.V. 1997 - Control of Hepatitis B in the Middle East
Endemicity and HBsAg HBV Vaccine in Selective HBV Vaccination
country Carrier EPI Vaccination Coverage
State
Low endemicity
Bahrain 0.9-1.25% Yes Yes 89%
Iran 1% Yes 81%
Israe1* 1-1.8% Yes Yes 92%
Kuwait 1.5% Yes Yes 94%
Intermediate Endemicity
Cyprus 2-2.5% Yes Yes 68%
Iraq 4-5% Yes 59%
Libya 2-6% Yes
UAE 2-5% Yes Yes 90%
High Endemicity
Egypt 3-11% Yes Unclear 82%
Jordan 3-10% Yes No 90%
Oman 2-10% Yes Yes 99%
Palestine* 2-6% Yes Yes
Saudi Arabia 7-17% Yes Yes 95%
Tunisia* 6.5% Yes
Yemen* 12-18.5% Yes No 12%
Unclear
Lebanon 2.9% No No
Syria Yes Yes 76%
Qatar* Yes Yes 90%
* countnes with modified data.
1.4.2 Age-specific prevalence:
A few studies conducted in Saudi Arabia provide information on age-specific prevalence
of HBV chronic infection. A community-based seroepidemiological survey in all
provinces of Saudi Arabia conducted by Al-Faleh et al amongst 1575 Saudi Arabian
children aged 1 - 10 years found the highest prevalence of HBsAg positivity (9.7%)
among 1-year-old children (Al-Faleh et al., 1992). In a hospital-based serosurvey in the
Riyadh province, Ramia et al found the prevalence ofHBsAg positivity amongst children
less than 3 years to be 4.8% and 4.4%, respectively, in males and females. Ramia et al
found that the prevalence of HBV chronic infection peaked in 10-14 year-old children
reaching 7.8% and 5.3%, respectively, in males and females (Ramia et al., 1986).
Prevalence of HBV chronic infection decreased with advancing age in a similar pattern in
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both sexes. A study among Saudi Arabian children living in the Jaizan province revealed
HBsAg, anti-HBs and anti-HBc to be 11.1%, 9.5% and 7.4%, respectively (Arya et al.,
1986). A study among 3588 healthy ambulatory men in the Eastern Province of Saudi
Arabia found the highest prevalence of HBsAg to be 13.6% and 9.8%, respectively,
among 35-45 year-old and 46-55 year-old men (Talkuder et al., 1982). These men were
tested using RPHA and were not confirmed by ELISA or RIA.
In Jordan the prevalence of HBV chronic carriers was approximately 10% (95% c.l. 8.2
to 11.7) throughout all age groups, with evidence of HBV infection (any marker of HBV
infection) increasing directly with age, reaching 92% in those over 60 years (Toukan et
al., 1990). Amongst individuals positive for HBsAg, 32% were HBeAg positive (95%
C.l. 23 to 40.7%). Most HBeAg positive individuals were children under 10 years of age,
while anti-HBe was found mainly in adults (Toukan et al., 1990). A study in Palestine
found the age-specific prevalence appeared to increase with age and HBsAg was highest
amongst individuals aged 20-29 years (4.3%) and 30-39 years (5.3%), after-which the
prevalence ofHBsAg declined and remained approximately 2.8% (Yassin et al., 2002).
In Yemen, Scott et al found age to be a highly significant risk factor for HBV
seropositivity and chronic infection. The estimated odds ratio associated with increasing
10-year age intervals was 1.37 and 1.51, respectively, for HBV chronic infection and
total markers (Scott et al., 1990).
1.4.3 Incidence of HBV infection:
Information on the incidence of viral hepatitis in Middle East countries is limited.
Available information shows that in 1994 the incidence of acute viral hepatitis (AVH) in
the Middle East ranged from 22/100000 in Syria to 126/100000 in the United Arab
Emirates (WHO, 1995). These incidence rates are for the general population and were
presented at the WHO regional workshop on the prevention and control of viral hepatitis
in 1995. The figures were obtained from regular reporting but it is unknown how reliable
and accurate these figures are because few methodological details were described in the
report. Consequently, estimating the role of HBV infection in the incidence of AVH in
these countries poses a problem as does the comparison of incidence rates between them.
Nevertheless, available data estimates that HBV is responsible for 61% of cases of AVH
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in Egypt, 38% in Iraq, 40% in Algeria, 39 - 49% in Jordan, 12 - 36% in Kuwait, 10 -
20% in Libya, 5% in Qatar, 66% in Tunisia and 27% in Yemen (Al-Kandari et al., 1987;
El-Gouli et al., 1984; El-Guneid et al., 1997; Toukan, 1990; Toukan et al., 1990; WHO,
1995).
There are a number of difficulties and limitations when estimating incidence rates of viral
hepatitis attributable to HBV infection in the Middle East. First of all, the majority of
HBV infections occur asymptomatically in childhood, resulting in a high carrier rate that
passes undetected during the early years of life. Amongst adults and older children only
30 - 40% of cases of AVH become symptomatic and are diagnosed. These rates are only
the tip of the iceberg, with the remaining majority of cases with sub-clinical infection and
elevated biochemical markers undetected. As a result, whatever incidence rate is
calculated will be an underestimate of the true incidence ofHBV infection. Secondly, this
estimate will have to be corrected for underreporting. In Middle Eastern countries this
will largely be due to a lack of efficient surveillance programmes within these countries
and deficiencies in diagnostic measures and techniques especially in rural areas. Thirdly,
in many of these countries AVH is reported as one entity without the classification of
cases of AVH according to etiologic agent. Fourthly, these incidence rates and reported
cases are significantly affected by the health seeking behaviour of individuals in these
countries. It is unknown what proportion of cases of AVH seek traditional therapists, pass
unnoticed or seek professional medical treatment (and are thus consequently reported). It
is also suspected that there is under-reporting of incident cases in some countries such as
Jordan and Lebanon due to the large number of patients treated in the private sector.
Table 1.4.3 shows the incidence rates of acute viral hepatitis in some countries in the
Middle East.
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Table 1.4.3
Incidence of acute viral hepatitis in some Middle East countries - 1994
Country Incidence AVH % duetoHBV % due to other viruses Reference
Egypt 61% WHO,1995
Iran 26/100000 Not available WHO,1995
Iraq 86/100000 38% WHO,1995
Jordan 37/100000 39-49% 48%HAV WHO,1995;
Toukan et al., 1990
Kuwait 95/100000 11.5 - 36.5% 25-77% HAV WHO, 1995; Al-
18.7% HeV Kandari et al., 1987
3%HEV
Libya 30/100000 Not available WHO,1995
Morocco 15.71 100000 Not available WHO,1995
Oman 80/100000 Not available WHO,1995
Qatar 5% WHO,1995
Syria 22/100000 Not available WHO,1995
UAE 126/100000 Not available WHO,1995
Yemen 27% 5.1%HAV El-Guneid et al.,
6.4% HeV 1997
14%HEV
2.6%HeV
51.3% Unknown
1.5 Mode of transmission:
HBV infection can be transmitted at 3 stages in life; around the time of birth, during
childhood, and in adult life (Hall, 1994). The main modes of transmission are mother-to-
child (perinatal), child-to-child (horizontal), sexual and parenteral. The role of each of
these modes varies across the globe. In developed countries (also countries with low
endemicity of HBV infection) sexual transmission and intravenous drug abuse in
adolescence and adult life account for the majority of cases of HBV transmission. In
developing countries (countries with intermediate and high endemicity of HBV
infection), mother-to-child and child-to-child transmission during the early years of life
are the major modes of transmission of HBV infection. Placental breakdown and leakage
of maternal blood during delivery, in utero infection, infection postnatally through
breastmilk, babies ingestion of blood, and small scratches to the baby during birth are
postulated mechanisms of perinatal transmission (Zuckerman et al., 1996). There is no
significant evidence supporting the role of the latter three mechanisms of perinatal
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transmission. In about 10 - 50 % of cases of HBY infection the mode of transmission is
unknown (Al-sowmely, 1998; Stevens et al., 1992).
The main factors determining perinatal transmission are the mothers HBsAg and HBeAg
status (Hwang et al., 1985). The presence of HBeAg in the mother's serum correlates
with HBY DNA load and is considered a marker of infectivity. If a HBY chronic carrier
mother is HBeAg positive this indicates there is a high risk of the baby acquiring HBY
infection and consequently becoming a HBY chronic carrier. Studies have found that
70 - 90% of infants born to mothers who were HBeAg positive became HBY chronic
carriers compared to 10 - 31% of infants born to mothers who were HBeAg negative or
anti-HBe positive (CDC, 1991; Gilbert, 1981; Hall, 1994; Hwang et al., 1985;
Papaevangelou et al., 1979). Chotard et al found that children with a HBeAg positive
mother had a higher risk of becoming HBsAg positive compared to children of HBeAg
negative mothers (Relative Risk [RR] 124:1 95% C.I. 12 to 1277) (Chotard et al., 1991).
In Southeast Asia, for example, the high rate of mother-to-child transmission of HBY
infection has been attributed to the high rates of HBeAg amongst chronic carrier women
of childbearing age in these countries. Nevertheless, one must be cautious when
predicting the potential risk of perinatal transmission of HBY infection based on the
prevalence of HBeAg amongst women of childbearing age. Hall clarifies that although
HBeAg positivity in carrier women of childbearing age is a good reflector of the potential
risk of perinatal transmission, HBeAg positive African women had a lower risk of
transmitting HBY to their offspring because they had lower HBY DNA concentrations
compared to their Southeast Asian counterparts (Hall, 1994; Wong et al., 1984). In a
study in Senegal, out of 12 children born to HBeAg positive mothers, only two of the
children became HBY chronic carriers (Chotard et al., 1992).
In the Middle East, the majority of HBY infections occur through childhood and perinatal
transmission. Sexual and parenteral transmission are not common modes of infection in
the Middle East. Sexual transmission is uncommon on a large scale probably due to the
conservative culture of Middle Eastern societies. Nevertheless, wife-to-husband
transmission was suggested to be important in one study in Tunisia (Coursaget et al.,
1994). HBY chronic infection was found in 18% (6/33) of husbands of HBsAg carrier
mothers compared to only 4-6% in the general population, and 75% (3/4) of husbands of
36
HBeAg positive mothers were HBsAg positive (Coursaget et al., 1994). Other studies
supported evidence for sexual transmission of HBV infection in the Middle East based on
finding a higher prevalence of HBV chronic infection amongst married individuals
compared to single individuals but did not adjust for other factors such as age (Ragaa et
al., 2001; Yassin et al., 2002). The role of parenteral transmission of HBV infection in
health institutions should also be currently limited due to the routine screening of blood
and blood products. However, it has been reported that in some countries of the Middle
East hospital or health centre waste products are not treated in the proper manner and that
a lot of these waste products lie on streets and are accessible to children which poses a
serious health risk and hazard (Yassin et al., 2002). The number of intravenous drug
abusers in the Middle East appears to remain low when compared to other regions.
Studies investigating the role of perinatal compared to childhood transmission in the
Middle East have produced variable results. While one group of studies proposes that
childhood transmission is a major mode of transmission of HBV infection with perinatal
transmission being relatively unimportant, another group proposes that perinatal
transmission plays an important and significant role in contributing to the pool of HBV
chronic carriers. Considering the heterogeneity of Middle Eastern populations and the
differences in the prevalence of chronic carriers and HBeAg positivity amongst women
of childbearing age within them, inter-country differences in the mode of transmission
probably exist.
Supporting the role of childhood transmission in the Middle East, Toukan et al suggested
that person-to-person, non-sexual, non-parenteral and intrafamilial contact is the major
mode of transmission between asymptomatic HBV carriers and susceptible individuals
(Toukan et al., 1990). A combined study in four Middle-Eastern countries (Egypt, Jordan,
Kuwait, Saudi Arabia) (see table 1.5.1) found that only 21% (n=25/120) of children born
to HBsAg positive mothers became chronic carriers (Toukan , 1996). This was attributed
to the low prevalence (13%) of HBeAg amongst HBsAg positive mothers, although 94%
(n=15116) ofHBeAg positive mothers transmitted HBV to their infants.
A study in Kuwait found the prevalence of HBsAg among pregnant women to be 2.9%
(n=45/1554) of whom 7.3% were positive for HBeAg, 65.8% were anti-HBe positive,
and 26.8% had neither the HBeAg nor anti-HBe. Based on the low prevalence ofHBeAg
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amongst pregnant mothers they predicted a low transmission rate of virus to offspring.
30% of the infants of HBeAg positive mothers developed HBV infection (based on just
one case) (Al-Nakib et al., 1986). In Lebanon, there is a similar prevalence of HBsAg
(2.9%) (n=16/558) and HBeAg (6.3%) amongst pregnant women (Nabulski et al., 1997)
and therefore one would expect a low mother-to-child transmission of HBV infection as
in Kuwait.
In a study in Jaizan province in Saudi Arabia, it was in light of the low prevalence of
HBsAg amongst women of childbearing age (4.9%) as well as the low HBeAg positivity
of 9% (n=6/67) in males and females alike that it was suggested that perinatal
transmission is unlikely to playa numerically important role in HBV hyperendemicity
(Arya et al., 1985).
A study investigating materno-foetal transmission of HBV in Saudi Arabia found 2.8%
(n=140/5000) of pregnant women positive for HBsAg. A two year follow up of fifty
HBsAg positive women of whom 12% (n=6/50) were positive for HBeAg and their
newborn children showed that none became HBsAg positive (Basalamah et al., 1984). A
similar study conducted on 3020 women showed an overall prevalence of 3.9% for
HBsAg amongst pregnant women in Saudi Arabia of which 11% (n=13/119) were
positive for HBeAg (Ramia et al., 1984). A study by the same authors looking into
transplacental transmission of HBV infection by HBsAg carrier mothers suggested a lack
of evidence for perinatal transmission (Ramia et al., 1988). In another study in Saudi
Arabia, based on finding high interfamilial clustering of HBV infection in families with
HBsAg positive fathers but HBsAg negative mothers, Ramia suggested that person-to-
person (horizontal) transmission rather than perinatal transmission was responsible for
the spread of HBV infection within these families (Ramia, 1990).
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Table 1.5.1
Maternal-neonatal transmission of HBV infection by mothers HBsAglHBeAg status
Adapted from Toukan et al. 1990
HBsAg HBsAg HBeAg HBsAg HBeAg HBsAg HBsAg HBsAg
Positive Positive Positive Positive Negative Positive Negative Positive
Mother Baby Mother Baby Mother Baby Mother Baby
Country Total No No. 0/0 No. % No. % No. % No. % No. No. %
Saudi 49 8 16 7 14 6 86 42 86 2 5 - - -
Arabia
Egypt 35 13 37 6 16 6 100 29 83 7 24 30 0 0
Jordan 23 3 13 2 9 2 100 21 91 1 5 28 0 0
Kuwait 13 1 8 1 8 1 100 12 92 0 0 - - -
Total 120 25 21 16 13 15 94 104 87 10 10 58 0 0
On the other hand, there are studies supporting the role of perinatal transmission of HBV
infection in the Middle East. Al-Faleh et al, in Saudi Arabia found a high rate of HBsAg
positivity (9.7%) among children aged one year and accordingly suggested the possibility
of significant HBV transmission during the perinatal period or soon after it (Al-Faleh et
al., 1992). It is unlikely that these cases resulted from childhood transmission considering
that this is uncommon in the first year of life.
In a study in Yemen, approximately 17% (n=40/243) of pregnant women were positive
for HBsAg. Thirty-two percent (95% C.L 3.8 to 67.8) of these HBV chronic carrier
women were positive for HBeAg (n=9/28) (El-Guneid et al., 1993). The high prevalence
of HBeAg amongst pregnant Yemeni women points to the potential importance of
perinatal transmission of HBV infection from mother to child. Another study in Yemen
suggested the rate of mother-to-child transmission of HBV infection from HBsAg
positive mothers to their newborns to be 50% (n= 10/20) based on cord blood specimens
positive for HBsAg (Abdul Raheem et al., 1991). The prevalence of HBeAg was not
measured in the 20 HBsAg positive mothers.
Studies in Egypt also indicate that perinatal transmission is relatively high. El-Nawawy et
al detected HBsAg in 8% (n=12/150) of pregnant mothers and 17% (n=2/12) of their
infants (El-Nawawy et al., 1996). None of the HBsAg positive mothers or their infants
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was HBeAg positive. However, because the number of HBV chronic carriers is small,
one cannot draw a definitive conclusion. Similarly, in another study conducted in Egypt,
17% (n=6/35) of infants born to HBsAg positive mothers were HBeAg positive (Ghaffar
et al., 1989). HBsAg was positive in 25%, 22% and 37% of cord, 3 month and 6 month
blood specimens, respectively. Out of six babies who became infected from HBeAg
positive mothers, five (83%) showed infection at three months and only one showed
infection at six months. Table 1.5.2 shows hepatitis B e antigen and antibody prevalence
among HBsAg positive women found in some of the studies conducted in the region.
Table 1.5.2
HBeAgianti-HBe status amongst HBV chronic carrier women
in the Middle East
Country HBsAg HBeAg Anti-HBe Transmission Reference
Positive Positive Positive Rate
Pregnant Carrier Carrier
Women Women Women
Lebanon 2.9% 6.3% Nabulski et al., 1997
Kuwait 2.9% 7.3 % 65.8 % AI-Nakibet al., 1986
Yemen 15% 50% Abdul Raheem et al., 1991
Yemen 16.6% 31.1 % EIGuneidet al., 1993
Egypt 8% 0 17% EI-Nawawyet al., 1996
Saudi Arabia 2.8% 12% 88% Basalamah et al., 1984
Saudi Arabia 3.9% 11 % 75 % 16% Ramia et al., 1984
1.6 Factors associated with HBV infection:
The most common factors found to be associated with HBV infection and carrier status in
the Middle East are family size, socioeconomic status, age, educational status and a
history of previous blood transfusion, surgery or contact with a jaundiced person.
Evidence supporting the role of large family size in increasing the risk of HBV infection
was observed in Jordan and Saudi Arabia (Ramia, 1990; Toukan, 1990). There was
pronounced familial clustering of HBV infection and a significant correlation was found
between family size and the proportion of HBsAg positive family members. In families
where the mother was a HBsAg carrier there was higher intrafamilial clustering of HBV
infection than in families where the father was a HBsAg carrier (Ramia, 1990). In Jordan,
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34% of the siblings of HBsAg positive individuals were also found to be carriers of the
virus (Toukan, 1990; Toukan, 1996). Toukan further emphasised that evidence for
childhood transmission early in life existed because of a similar pattern of infection
among adult HBV carriers. 39% of adult siblings of adult carriers were also found to
carry the virus compared to 10% of their spouses.
The effect of socioeconomic status on HBV transmission in Jordan was examined using a
specially developed socioeconomic index. This showed significantly greater HBsAg
prevalence in lower (14.4%) than in upper (2.4%) socioeconomic groups (Toukan et al.,
1990). Another study supporting this evidence showed the prevalence of HBsAg to be
11% and 4%, respectively, among low and high socioeconomic strata (Toukan, 1996).
Earlier studies have also shown the prevalence of HBsAg to be 6.9% and 0.7%,
respectively, in low and upper socioeconomic groups (Awidi et al., 1984). Similar
findings have been reported from other Middle Eastern countries such as Syria, where the
risk of infection was found to be higher in children of low socioeconomic status when
compared to children of high socioeconomic status (WHO, 1995). Ghaffar et al, also
found higher rates of HBV infection among children of low socioeconomic status in
Egypt (Ghaffar et al., 1989). Members of poor families share bedding, eating and
household utensils, which may be sources of infected saliva or serum. Poor families tend
to live in small dwellings and crowding brings these individuals into close contact, which
may facilitate childhood transmission (Toukan, 1990).
The association of a history of jaundice, previous blood transfusions, and surgery with
HBV infection and carrier status has been reported in Jordan, Egypt, Libya and Yemen.
In Yemen, a multi variable analysis found age, a history of jaundice, and a combined
history of blood transfusion and surgery, to be associated with HBV infection (Scott et
al., 1990). The odds ratio associated with increasing 10-year age intervals was 1.37 and
1.51 for the carrier status and total markers, respectively. The adjusted odds ratio for a
combined history of surgery and blood transfusion was 3.76 (95% C.l. 1.11 to 6.82) and
the adjusted odds ratio for a history of jaundice was 1.42 (95% C.l. 1.01 to 2.01). Toukan
et al reported similar findings in Jordan but additionally found past or present HBV
infection associated with rural background, injections, tattooing, sexual exposure and
surgical procedures (Toukan et al., 1990). It would be useful to know the nature of these
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injections and by whom they were administered. Involvement of non-health personnel
may be an important explanatory factor for infections resulting from these injections. In
Egypt, for example, involvement of non-health personnel in parenteral and surgical
procedures was found to be associated with a higher risk ofHBV infection (WHO, 1995).
A large number of surgical procedures such as tattooing and circumcision are also carried
out by unqualified individuals in Egypt, which is the case in many other Middle Eastern
countries and it is important to investigate the role ear piercing and circumcision may
have in the transmission of HBV infection in these countries.
In Egypt, Ghaffar et al examined risk factors for perinatal transmission. Apart from the
proven importance of HBeAg/ anti HBe status in perinatal transmission, they found that
maternal history of schistosomal infection was significantly associated with perinatal
transmission (Ghaffar et al., 1989). A possible explanation for this association was that
schistosomal infection resulted in impaired cell-mediated immunity, which might
contribute to the presence of a higher titre of HBsAg, and hence increased viraemia and
infectivity. It was also suggested that due to a cross-reaction between schistosomal and
HBV antigens, schistosomal antigens transmitted to the newborn from the mother can
depress the newborns immune reaction against HBV by immunological tolerance or by
an antigen specific suppressor mechanism. They also found higher rates of perinatal HBV
transmission in rural areas, families of low socioeconomic status, as well as from mothers
with low educational status. A negative correlation between prevalence of HBV infection
and educational levels has also been reported from Iran (Amini et al., 1993; WHO, 1995).
Families of low educational and socioeconomic status are more likely to be associated
with poor personal hygiene and low standards of living which probably increase their risk
of exposure to HBV infection.
1.7 Control:
The most common methods employed for the control of HBV infection in the Middle
East are active immunisation (universal and targeted), routine blood screening for
HBsAg, and ensuring safe injection practices. Due to belief that childhood transmission
accounts for the majority of cases of HBV infection, its high cost and the large proportion
of household deliveries in many Middle East countries, passive immunisation using
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Hepatitis B Immunoglobulin (HBIG) is uncommon in the Middle East. Due to cultural
sensitivity and expectations that sexual transmission is uncommon, safe sex is not
officially promoted in most countries of the region.
1.7.1 Active vaccination:
In 1987, the WHO Hepatitis Technical Advisory Group recommended integration of
hepatitis B vaccine into the Expanded Programme on Immunisation (EPI). In 1991, the
Yaounde Conference witnessed the recommendation of global infant hepatitis B
immunisation as part of the EPI by the EPI Global Advisory Group (EPI-GAG)
Committee. In 1992, the World Health Assembly (WHA) endorsed a recommendation
that hepatitis B vaccine should be integrated into national immunisation programmes in
countries with high endemicity by 1995 and in all countries by 1997. Considering that the
majority of HBV infections in the Middle East result from childhood and perinatal
transmission, universal infant immunisation appears to be an attractive option for most
countries of the region.
Hepatitis B vaccine is the first vaccine effective in preventing cancer or a sexually
transmitted disease (STD). Two types of vaccine are currently available, plasma derived
and recombinant hepatitis B vaccine, although the latter is superseding the former in
national vaccination programmes. The efficacy of both vaccines is very similar. The
effectiveness of hepatitis B vaccines has been demonstrated in numerous studies (Chotard
et aI., 1992; Coursaget et aI., 1986; Hall et aI., 1993; Lee et aI., 1997; Maupas et aI.,
1981; Whittle et aI., 1991). In the Gambia, for example, the vaccine given in infancy has
been shown to be 84% effective in preventing HBV infection and 94% effective in
preventing HBV chronic infection (Hall et aI., 1993). Currently recommended and
implemented schedules of hepatitis B vaccination vary, but generally follow a pattern of
2 -3 injections at monthly intervals followed by a booster dose 6 - 12 months after the
initial dose (Stevens et al., 1992). Immunisation is considered to have occurred if the
concentration of antibody (anti-HBs) is greater than 10mIU/L (Hall, 1993). Most
individuals should remain protected for 5 - 10 years following vaccination even if anti-
HBs is no longer detectable by immunoassay (Banatvala et al., 2000; CDC, 1991;
Chotard et al., 1992; Hall, 1993; Stevens et aI., 1992). This has been attributed to the
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development of a rapid anamnestic response upon exposure to infection or booster doses,
indicating persistence of immunologic memory (Stevens et al., 1992).
In order to prevent perinatal transmission, infants born to HBV chronic carrier mothers
should receive HBIG immediately following delivery or vaccine as early as possible
within the first 48 hours following delivery. Due to high cost, unavailability and logistical
considerations of delivery, HBIG is not administered in most developing countries. On
the other hand, vaccination at delivery appears to be an economically attractive option,
particularly in developing countries. The most difficult challenge facing this option is
how to identify children at risk and how to vaccinate children within 48 hours following
delivery in developing countries with a high rate of perinatal transmission where the
majority of deliveries occur at home.
Studies assessing the effectiveness of hepatitis B vaccine alone compared to hepatitis B
vaccine with HBIG found that hepatitis B vaccine given alone within 48 hours of birth is
nearly as effective as the combined regimen in preventing perinatal transmission of HBV
(Mahoney et al., 1993; Poomerawan et al., 1990; Wong et al., 1984; Xu et al., 1985).
Poomerawan et al found that only 3.4% (n=2/58) of newborns of HBeAg positive carrier
mothers receiving vaccine alone within 12 hours became chronic carriers as opposed to
an expected 70 - 90% (Poomerawan et al., 1990). Mahoney et al found that 3-4 year-old
children whom were vaccinated at birth were protected from both perinatal and childhood
transmission (Mahoney et al., 1993).
The earliest Middle Eastern countries to introduce hepatitis B vaccine into their EPI were
Saudi Arabia and Qatar in 1989. These were followed by Oman in 1990, Bahrain, Iraq,
Syria, UAE in 1991, Egypt in 1992, Palestine in 1993, and Jordan in 1995. In 1998,
Yemen introduced Hepatitis B vaccine into its EPI providing free vaccine to all children
under one-year of age. The vaccine was initially introduced to one district per
governorate and later on expanded to all districts in the country starting with the main
urban health facilities of each district. The Yemeni Ministry of Public Health and
Population (MOPHP) also introduced a cost recovery programme, in which children aged
more than one-year and adults could obtain hepatitis B vaccine after paying a nominal fee
for the vaccine. The MOPHP claims that the cost recovery programme was highly
successful in the first year and that the MOPHP collected considerable revenue but the
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cost recovery programme was ended by the government mid 2001 because of financial
constraints and legal implications (MOPHP(A), 2001). It is reported that hepatitis B
vaccine was well accepted by the population and health workers in Yemen, however, at
the beginning of 2000 some rumours about adverse effects were spread but the impact of
these rumours was low on existing vaccine uptake (MOPHP(A), 2001).
Vaccination coverage in Middle East EPI vaccination programmes has been good overall.
Gulf States in particular, are reported to have excellent coverage reaching 99%, 95%,
94% 90%, 90%, 90% and 89% respectively, in Oman, Saudi Arabia, Kuwait, UAE,
Qatar, Jordan and Bahrain, for all recommended doses by one year of age (Toukan, 1997;
WHO, 1995). It was estimated that by 1996, 90% of children under 12-years in Saudi
Arabia were fully immunised (table 1.4.1 B).
A few studies have examined the effectiveness of EPI hepatitis B vaccination in
preventing HBV infection and chronic infection in Middle Eastern countries. A study in
Saudi Arabia demonstrated that the hepatitis B vaccination programme was highly
effective and had a tremendous impact on the prevalence of HBV infection amongst
children in Saudi Arabia. In 1999, ten years after introducing hepatitis B vaccination to
the EPI, the prevalence of HBV chronic infection had declined to 0.31% compared to
6.7% which was the prevalence of HBV chronic infection just prior to introduction of
hepatitis B vaccine to the EPI in October 1989 (Al-Faleh et al., 1999). In Palestine, there
has also been a notable decline in the incidence rate of HBV infection since 1994, which
was attributed to the universal hepatitis B vaccination programme started one year earlier.
The incidence of acute HBV infection in 1999/2000 was one sixth the incidence of acute
HBV infection in 1993, which was presumed to be largely due to the introduction of
universal hepatitis B vaccination in 1993 (Yassin et al., 2002).
Many Middle Eastern countries such as Bahrain, Kuwait, Oman, Palestine, Qatar, Saudi
Arabia, and UAE are reported to have also introduced vaccination targeted at high-risk
groups (WHO, 1995). In Bahrain and Oman, for example, two high-risk groups are
vaccinated; health care workers and susceptible contacts (e.g. household members) of
HBsAg carriers. Most Middle East countries do not have mandatory vaccination for their
health care employees. A study in Libya explained that health care workers are exposed
to an occupational risk and argued the importance of introducing mandatory hepatitis B
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vaccination of health care workers who come into direct contact with blood or blood
products, and the need to provide advice and counselling to those who become infected
(Daw et al., 2000). The study also emphasised the importance that hospitals and health
service providers minimise such risks among their employees by implementing strict
guidelines on sharp instruments, blood or body fluids, and decontamination. In general, it
has been argued that targeted approaches are less effective due to the difficulty in
reaching at-risk populations, at-risk people becoming infected before being reached, and
the fact that up to 50% of reported hepatitis B cases have no identifiable risk or exposure
(Stevens et al., 1992; Zuckerman., 1996).
Qatar is reported to have introduced good hepatitis B vaccine monitoring and surveillance
activities (WHO, 1995). All contacts of carriers are traced and vaccinated. As part of
their routine antenatal care, pregnant women are screened for HBsAg, and those positive
are screened for HBeAg. All newborns in the country receive their first dose of hepatitis
B vaccine in the delivery room. Babies born to HBeAg positive mothers also receive
HBIG (WHO, 1995). In the UAE, in 1995, there were ongoing efforts to develop a
national strategy for the prevention and control of viral hepatitis. There is no information
on the effectiveness of such targeted programmes in these countries.
The major obstacles facing the introduction of hepatitis B vaccine to the EPI are
economic and political. Sudan up until 1995, had not introduced hepatitis B vaccine to
any groups due to a lack of financial resources (WHO, 1995). Iraq, during and shortly
after the second Gulf War could not sustain its vaccination programme, but resumed its
vaccination programme in 1994, which has most probably been disrupted during the third
Gulf War. In 1995, Lebanon had not introduced hepatitis B vaccine to its EPI. It is
believed that there are large numbers of children being vaccinated in the private sector in
Lebanon but their number is unknown.
Although Yemen, the poorest country in the Arabian Peninsula is reported to have one of
the highest HBV carrier rates in the Middle East, it was the last of these countries to
introduce hepatitis B vaccine to its EPI. According to routine data the EPI vaccination
coverage in 1991 for BCG, DPT (3 doses), Polio (3 doses) and Measles, respectively, was
99%, 89%, 89% and 74% by one year of age (Al-sowmely, 1998). More recently and
realisticly, according to a proposal submitted by the Yemeni MOPHP to the Global
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Alliance for Vaccines and Immunisation (GAVI), vaccine coverage in 2000 for BCG,
DPT (3 doses), Polio (3 doses), and Measles, respectively, was 78.2%, 72.8%, 72.8%,
and 71.4% by one year of age (MOPHP(B), 2001). In November 1998, the MOPHP
introduced plasma-derived hepatitis B vaccine then changed to recombinant hepatitis B
vaccine in December 1999, both purchased from Cheil-Jedang Corporation in South
Korea. Both vaccines are low dose vaccines (1.5 micrograms) and their purchase in large
quantities through UNICEF makes it an economically competitive and attractive option.
There have been some studies showing that very low dose vaccines, as an economic
option, produce acceptable immunogenic responses amongst infants of non-carrier
mothers, similar to that of standard doses (Moyes et al., 1987). These studies have not
investigated vaccine efficacy amongst infants of carrier mothers. The vaccine
manufacturer Cheil-Jedang recommends giving double the dose to infants of carrier
mothers (Cheil-Jedang, 1996). However, considering the reported high HBV chronic
carrier rates amongst women of childbearing age in Yemen and the lack of routine
screening for HBsAg amongst pregnant women allowing the identification of children at
risk, it is highly unlikely that the vaccine manufacturer's recommendations are or will be
implemented. This leaves infants born to HBV chronic carrier mothers at potential risk of
acquiring HBV infection through perinatal transmission.
The first, second and third doses of hepatitis B vaccine, in Yemen, are administered at 2,
3 and 9 months respectively. The first and second doses of hepatitis B vaccine coincide
with the first and second doses of DPT/Oral Polio vaccines and the third dose with
Measles vaccine. As the MOPHP introduces the new pentavalent vaccine, consequently,
the hepatitis B vaccine schedule will be modified and the first, second and third doses of
hepatitis B vaccine will be given at 6 weeks, 10 weeks and 14 weeks, coinciding with the
existing DPT/Oral Polio vaccine schedule (MOPHP(A), 2001). The BCG birth dose and
Measles dose at 9 months will remain unchanged.
Data available from Yemen suggests that hepatitis B vaccine coverage was 9% in 1999
and increased to 14.8% in 2000 for all three doses of hepatitis B vaccine by one-year of
age (MOPHP(B), 2001; MOPHP(C), 2001). In its five-year plan the EPI acknowledged
that there was no independent assessment of hepatitis B vaccine coverage in Yemen
performed in the last three years and expressed the importance that surveys must be
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performed to assess hepatitis B vaccine coverage. According to the figures available it is
clear that the MOPHP did not achieve its target of completely vaccinating 40% of
children under one-year of age with hepatitis B vaccine. What the MOPHP claimed to
achieve was 42% hepatitis B vaccine coverage with at least one dose of hepatitis B
vaccine. This may be due to the later administration of the third dose of hepatitis B
vaccine given with Measles at nine months of age. Nevertheless, according to MOPHP
reports, uptake for Measles vaccine (71%) remained much higher than uptake for the
third dose of HBV vaccine (9%), which was administered at the same time (MOPHP(C),
2001). A similar picture has been observed in South Africa where hepatitis B vaccine
coverage dropped sharply from 99% to 53% to 34% for the first, second and third doses,
respectively. In contrast polio vaccine coverage was maintained at 97 - 99% (Schoub et
al., 1991). On the other hand, Gust et al found that integrating hepatitis B vaccine to the
EPI increased children's contact with the EPI from 50% to 95%, and increased children
fully immunised from 20% to 88% (Gust et al., 1991). Accordingly, it is probably
incorrect to assume that uptake for a newly introduced vaccine will be good just because
uptake for an existing vaccination programme is. However, one would expect good
primary health care (PHC) services, a sufficient and sustainable supply of vaccine,
adequate training of health care staff, and appropriate health education programmes to
improve vaccine uptake and coverage. It remains to be seen if introduction of the
pentavalent vaccine and the consequential reduction in the number of injections given to
each child per visit, less time spent in health centre per visit, and better record keeping all
contribute towards increasing hepatitis B vaccine coverage and the proportion of
completely vaccinated children in Yemen.
1.7.2 Blood screening and safe injection:
All Middle Eastern countries routinely screen blood for HBsAg. Jordan and Egypt started
screening as early as 1967 and 1970, respectively. In Yemen, it has been reported that
occasional shortages of screening supplies occur (WHO, 1995). Some countries, such as
Oman in 1993, have also started screening for hepatitis C virus (HCV).
The majority of Middle Eastern countries use disposable needles and syringes. It is also
reported that they adequately sterilise surgical equipment and utensils (WHO, 1995).
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1.8 Hepatitis B virus infection in Yemen
Yemen lies in the South-West comer of the Arabian Peninsula covering an area of
555,000 square kilometres. The Republic of Yemen was formed following the unification
of former North and South Yemen in 1990. In 1999, the population of Yemen was
approximately 18.5 million and had one of the highest population growth rates in the
world (3.7%) with an estimated population doubling time of 20 years. The country is
divided into 20 administrative regions called governorates (provinces) with each
governorate consisting of a number of districts. The population of Yemen is widely
dispersed throughout an irregular terrain of mountainous regions, coastal plain, desert,
plateau, and to a much lesser extent islands. Yemen has a Gross National Product (GNP)
per capita of 350 US$ and is categorised among the poorest countries in the world with
approximately 50% of the population living below the poverty line and 30% of the
population living in absolute poverty.
The overall public expenditure on the health sector is low in Yemen which accounts for
only 1.4% of the Gross Domestic Product (GDP) and approximately 5% of total
government expenditure. The MOPHP is responsible for all public health services in
Yemen and is organised into three sectors: medical services and primary health care;
health development and planning; and pharmaceutical and medical supplies; with an
undersecretary chairing each sector. The EPI is part of the medical services and primary
health care sector. Yemen adopted the primary health care approach to health services in
1978 and has utilised a traditional facility-based, three-tier health delivery system of
health units, health centres and hospitals, which provide health care at three levels:
primary health care supported by secondary and tertiary referral care. In Yemen, there are
711 temporary health units in small villages, 1149 fixed health units in medium size
villages, 469 health centres in large villages, 79 district hospitals with 2968 beds, 25
governorate hospitals with 3517 beds and 14 specialised hospitals with 3814 beds
(MOPHP(C), 2001). In 1999, there were 2.16 physicians and 5.9 hospital beds per 10,000
individuals in the general population. The widely dispersed population throughout
Yemen, especially in rural areas where the population is spread over 65,000 rural villages
and hamlets presents a significant challenge to the provision of health services. In 1995,
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less than 50% of the total population and 30% of the rural population had access to health
care (MOPHP(C), 2001).
Only a few studies have investigated the epidemiology of HBV infection in Yemen.
These studies focused on the prevalence of HBV infection, risk factors associated with
HBV infection, HBV genotyping, and on the etiologic agents of acute viral hepatitis in
Yemen. These studies were mainly hospital-based seroepidemiological surveys carried
out in the cities of Sanaa, Taiz, Hodeidah and Hajja. Study subjects were predominantly
blood donors, pregnant women or outpatients. There were attempts to include rural
populations into some of the studies in order to have a more representative sample of the
general population. All the cities named above are located in the Northern Governorates
(provinces) of Yemen (formerly North Yemen). No information has been found in the
literature on the epidemiology of HBV infection in the Southern and Eastern regions of
the country. Whether geographical differences between these regions and the Northern
Governorates exist remains unknown. In a study by Scott et al, no statistically significant
difference in the prevalence of hepatitis B carriers or seropositives was detected between
the four different collection sites in North Yemen after controlling for age (Scott et al.,
1990).
1.S.1 Acute viral hepatitis:
In a study investigating the etiologic agents of acute viral hepatitis (AVH) serum samples
were collected from 78 patients in the acute phase of viral hepatitis. HBV was the most
frequent causative agent being responsible for 26.9% (n=21178) of cases of AVH. This
was followed by hepatitis E virus (HEV) responsible for 14% (n=11178) of cases.
Hepatitis A virus (HAV), hepatitis C virus (HCV) and hepatitis D virus (HDV) were each
responsible for 5.1% (n=4178), 6.4% (n=5178) and 2.6% (n=2178), respectively, of cases
of AVH (El-Guneid et al., 1997). In 51.3% (n=40178) of cases of AVH no virological
marker could be identified. These cases were not tested for Cytomegalovirus (CMV) and
Epstein-Barr virus (EBV), however, the investigators suggested that these were unlikely
to be the etiologic agents of AVH. As HBV mutants are becoming increasingly
recognised and may not be detected with standard assays (Chen, 2000), a possibility
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exists that HBV mutants may be responsible for these unclassified cases of AVH in
Yemen.
These cases of AVH due to HBV infection are likely to be only the tip of the iceberg of
HBV infection. In Yemen, the majority of infections occur during childhood and only
10% of infected children develop symptoms of acute viral hepatitis. Approximately 90%
of infected children will have sub-clinical infections and pass undetected. Additionally,
only 30 - 40% of infected adults develop symptoms with the remainder also passing
unnoticed.
1.8.2 HBV chronic infection:
Studies in Yemen have shown the prevalence of HBV chronic infection to range from
7.4% to 18.5% amongst adults in the general population (Abdul Raheem et al., 1991; EI-
Guneid et al., 1993; Haidar NA, 2002; Ragaa et al., 2001; Sallam et al., 2002; Scott et al.,
1990). The two studies carried out in the early nineties by El-Guneid et al and Scott et al
found the prevalence of HBV chronic infection to be 12.7% and 18.5%, respectively (EI-
Guneid et al., 1993; Scott et al., 1990). El-Guneid et al suggested that the higher
prevalence (18.5%) found in their study was probably due to differences in the
prevalence of HBV markers in different geographic regions, age structure of the
populations studied, and the use of more sensitive confirmatory tests for doubtful results.
Such results would be confirmed by an enhanced enzyme immunoassay or using a third
generation micro-particle enzyme immunoassay (El-Gunied et al., 1993). The total
number of subjects with evidence of prior HBV infection was 399 (45.4%) and 321
(59.8%), respectively, in the studies conducted by Scott et al and El-Guneid et al. Scott et
al and El-Guneid et al found the prevalence of HBeAg amongst HBV chronic carriers to
be 9.7% (n=9/93) and 69.8% (n=50/86), respectively.
Scott et al and El-Guneid et al, respectively, showed the prevalence of HBsAg amongst
pregnant women to be 12.5% (n=9/72) and 16.6% (n=40/241) (p>0.46). El-Guneid et al
further found that out of 28 pregnant women positive for HBsAg, 31.1% were positive
for HBeAg (95% C.l. 13.6% to 48.6%). Abdul Raheem et al found 15% of pregnant
women positive for HBsAg and suggested that perinatal transmission occurred in 50% of
cases (n=10/20) although they did not examine HBeAg amongst these pregnant women
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(Abdul Raheem et al. 1991). Nevertheless, the high transmission rate presented in their
study strongly suggests that a large proportion of these HBY chronic carrier women were
HBeAg positive. This suggests a potentially high rate of perinatal transmission from
HBsAg positive mothers contributing to the pool of HBY carriers in Yemen. Ideally this
needed to be confirmed on a larger sample of women of childbearing age ascertaining the
HBeAg and HBY DNA status of these women. It has been shown that the risk of
perinatal transmission of HBY infection in countries with high HBY chronic carrier rates
may reach 40 - 50% (Sobeslavsky, 1980).
A more recent study conducted on individuals attending at the central health laboratory in
Sanaa in response to a campaign to control HBY infection found the prevalence of HBY
chronic infection to be 7.4% (22112321), and based on this the study investigators
surprisingly proposed that Sanaa could be classified as an area of intermediate rather than
high endemicity of HBY (Ragaa et al., 2001). There is no information on the nature of
this campaign or how representative the respondents to the campaign were of the general
population in Sanaa. The study by Ragaa et al provided the only existing information on
the prevalence of HBY chronic infection amongst children less than five years which was
2.2%. The study investigators suggested that this was probably the result of perinatal
transmission or early parenteral exposure through circumcision or ear piercing. Another
study conducted from April 1997 to September 1999 investigating the prevalence of
HBY infection amongst blood donors in a hospital in Hajjah, situated North of the capital
Sanaa, found the prevalence of HBY chronic infection to be 9.8% amongst 7868 blood
donors, and concluded that the endemicity of HBY infection was high in Hajjah
governorate (Haidar NA, 2002).
Another recent study analysing the HBY core promoter sequences from blood donors at
two blood banks in Yemen (Sanaa and Aden) found the prevalence of HBY chronic
infection to be 10.7% (107/999) of whom 39% (42/107) had detectable DNA levels
(Sallam et al., 2002). Surprisingly, only 3 (7.3%) out of 41 HBY DNA positive donors
had detectable HBeAg when tested by commercial enzyme immunoassay. This raises
doubts about the extent to which HBeAg positivity can be correlated with HBY DNA
levels. As for genotyping, analysis performed on 18 surface gene sequences showed them
to be of subtype ayw and with genotype D sequences.
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Hepatitis Delta virus (HDV) super-infection was found among 2% of HBsAg positive
sera in two studies (El-Guneid et al, 1993; Scott et al., 1990). This is lower than other
Middle Eastern countries such as Kuwait and Saudi Arabia where super-infection with
HOV occurred in 40% and 20%, respectively, of healthy HBV carriers (Toukan et al.,
1990).
1.8.3 Chronic Liver Disease:
There is no national cancer registry in Yemen and it is important that one is developed in
the near future, as in Saudi Arabia where a national cancer register was established in
1992 and all cancer cases in the country must be reported by law since 1994 (Al-Radi et
al., 2000). Anecdotal reports by clinicians and hospital staff indicate that CLO is
increasingly being recognised as a common health problem in Yemen. A study
investigating the pattern and distribution of malignant neoplasms amongst Yemeni
patients found gastrointestinal malignancies to be the most common cancers (22%) in
Yemen (Al-thobhani et al., 2001). Within the gastrointestinal tract, the most commonly
affected site was the liver (33%) and second most common type was hepatocellular
carcinoma (Al-thobhani et al., 2001). This was consistent with earlier studies in the
Southern-Eastern provinces in Yemen and studies in Saudi Arabia which also found
gastrointestinal tract malignancies to be the most common cancers amongst patients in
these populations (Bawazir et al., 1998; Al-Radi et al., 2000). In Saudi Arabia, HBV and
HCV were suggested to be the main causative factor of hepatocellular carcinoma (AI-
Radi et al., 2000). A model developed by the Vaccine Assessment and Monitoring
(VAM) team at WHO headquarters estimates that over 2000 Yemeni adults die each year
from hepatocellular carcinoma and cirrhosis resulting from HBV chronic infection
(MOPHP(A), 2001). The evidence of an association between HBV and CLD is extensive
across the globe (Arthur et al., 1984; Omer et al., 2001; Parkin et al., 1999; Toukan,
1996). In Yemen, HBV chronic carrier rates were significantly lower amongst healthy
individuals (18.5%) than amongst patients with CLO (24.1%) (p=0.03) (El-Guneid et al.,
1993). The presence of any HBV marker was 59.8% and 75.9% (p=0.0016) in healthy
individuals and patients with CLD, respectively. Similarly, a study in Hajjah showed the
prevalence of HBV chronic infection amongst patients suspected of having liver disease
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(14.9%) was higher than healthy blood donors (9.8%) (Haidar NA, 2002). All this
evidence strongly suggests that HBV infection plays a significant role in the etiology of
CLD in Yemen and deserves further investigation.
1.8.4 Factors associated with HBV infection:
A number of different factors were associated with HBV chronic infection in Yemen by
univariable analysis but only age, a history of jaundice, and a combined history of
transfusion and surgery remained statistically significantly associated with HBV infection
by multivariable analysis after adjusting for the remaining variables in the analysis (Scott
et aI., 1990). Multivariable analysis revealed age to be a highly significant risk factor for
both HBV infection and HBV chronic infection. The adjusted odds ratio associated with
increasing lO-year age intervals was 1.37 and 1.51 for HBV chronic infection and HBV
infection, respectively (Scott et aI., 1990). A history of surgery and blood transfusion
were associated with HBV infection. However, these associations remained significant
only when a combined history of blood transfusion and surgery was given [adjusted OR
2.76 (95% C.I. 1.11 to 6.82)] (Scott et aI. 1990). A history of jaundice was also a
significant risk factor for HBV infection [adjusted OR 1.42 (95% C.I. 1.01 to 2.01)].
When adjusted for age, neither sex nor qat chewing (a stimulant plant commonly chewed
in Yemen) were significant risk factors associated with HBV infection (Scott et aI.,
1990). Similarly, a study in Hajjah found age to be significantly associated with HBV
chronic infection by multivariable analysis but also found sex to be significantly
associated with HBV chronic infection (Haidar NA, 2002).
No significant association was found between the presence of hepatitis B markers and
parenteral treatment, visits to dentists and doctors, tattoos, and socioeconomic factors
such as sewage disposal, water supply, electricity supply and household crowding (Scott
et aI., 1990).
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1.9 Conclusion:
Upon reviewing the literature on the epidemiology of HBV infection and carrier status in
the Middle East, HBV infection is clearly a major public health problem in many
countries in the region. Toukan estimates that HBV infection might account for up to 2%
of all eventual deaths in a Middle Eastern birth cohort (Toukan, 1996). In Jaizan province
of Saudi Arabia the high HBsAg carrier rate of 19.9% amongst males was consistent with
the provinces high male dominant prevalence of hepatocellular carcinoma (Arya et al.,
1985). In Jordan there was a significantly higher prevalence of HBsAg in patients with
CLD (54%) than in asymptomatic carriers (10%) (p=0.001) (Toukan et al., 1988).
Similarly in Yemen, the prevalence of HBsAg amongst patients with CLD (24.1%) was
significantly higher than asymptomatic carriers (18.5%) (p=0.03) (El-Guneid et al.,
1993). The high prevalence of HBsAg amongst patients with CLD indicates that HBV
infection most probably plays a significant role in the pathogenesis of CLD.
The majority of the countries in the region have an intermediate and high endemicity of
HBV infection. In countries reporting low endemicity of HBV infection, it may well be
that these figures are only the tip of the iceberg with many cases undetected due to the
large number of sub-clinical infections, inadequate surveillance, diagnosis and
underreporting.
There is marked variation in carrier rates between and within Middle Eastern countries.
HBV chronic carrier rates range from as low as 1.5% in countries such as Kuwait to as
high as 18.5% in countries such as Yemen. In Saudi Arabia, carrier rates witness a
fourfold increase from one region to another. Why such differences exist within the same
country remains unexplained. In Jordan, intra-country differences have been attributed to
socioeconomic status. In the Saudi Arabian population, which is considered a relatively
homogeneous population, socioeconomic status was not found to be an explanatory factor
for these differences in prevalence of chronic carriers. Even when conducted on the same
population, studies have produced different results. Many studies in the region have not
examined age-specific prevalence of HBsAg carrier status, which makes examination of
the pattern of infection in the region a difficult process. However, most of the studies in
the region indicate that most transmission of HBV infection in the region occurs during
the early years of life, with adult transmission being relatively uncommon.
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Transmission of HBV infection occurring during the early years of life in the region,
appears to be a combination of perinatal and childhood transmission. On one hand, a
group of studies suggests that transmission predominantly occurs during childhood. On
the other hand observing a high prevalence of infection amongst infants and a high rate of
HBeAg amongst chronic carrier mothers in some settings suggests that perinatal
transmission cannot be disregarded as an important mode of transmission contributing to
the pool of HBV chronic carriers. Most probably the role played by either of these modes
of transmission differs from one country to another. Obviously, determining the role
either mode of transmission has will have important policy implications. If perinatal
transmission is found to be a common mode of transmitting HBV infection, this will
indicate that vaccinating children against HBV at 6-8 weeks of age will be too late to
prevent mother-to-child HBV infection. Under such circumstances, one must aim to
vaccinate newborns at birth or within 48 hours of delivery at the latest. In some settings,
such as Yemen, where the majority of deliveries occur at home, introducing such a
procedure will encounter numerous obstacles. One of the major concerns will be the
difficulty of delivering vaccines to home deliveries occurring in remote areas considering
that 75% of the Yemeni population lives in rural areas and is dispersed over
approximately 65,000 rural hamlets.
Hepatitis B vaccination strategies may vary depending on the prevalence of chronic
carriers, mode and age of infection, and health sector resources. Control measures vary
from one Middle Eastern country to another. Some countries, such as Qatar have
excellent control programmes. Not only do they vaccinate all newborns in the delivery
room but they also screen and vaccinate eligible contacts of carriers. The effectiveness of
these measures in reducing infection and carrier rates has not been examined. Another
group of countries, such as Sudan, due to economic constraints, has not yet introduced
hepatitis B vaccination, despite having one of the highest rates of chronic carriers in the
region.
Yemen, the poorest country in the Arabian Peninsula has the highest prevalence of
chronic carriers. There is limited information available on the pattern of transmission and
age-specific prevalence of HBV in the population. The high prevalence of HBeAg
amongst pregnant women found in one study and the high rate of materno-foetal
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transmission suggested in another indicate that a high rate of perinatal transmission of
HBV infection may exist. However, these findings require further confirmation by a
larger and, most importantly, a more representative sample from the Yemeni population.
The studies conducted in the Middle Eastern region have collectively found that HBV
infection is a serious public health problem in the region. Still many related questions
specific to the region remain unanswered. Effectiveness of hepatitis B vaccine in
preventing HBV infection and chronic carrier status, risk factors for infection and carrier
status, the proportion of CLD attributable to HBV infection, the extent of perinatal
transmission of HBV infection, and the pattern of HBV infection amongst different age-
groups are only examples of the many questions that deserve further investigation.
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Chapter 2: Study Methods:
2.1 Study objectives:
This study was conducted with the intention of satisfying the following objectives:
2.1.1 Primary objectives:
1- Measure the prevalence of HBV infection (hepatitis B core antibody positive) and
HBV chronic infection (hepatitis B surface antigen positive) amongst children aged
1-3 years in Yemen and estimate the proportion of these cases resulting from
perinatal transmission (i.e. the extent of perinatal transmission of HBV infection and
chronic infection in Yemen).
2- Measure the prevalence of HBV infection, HBV chronic infection and hepatitis B e
antigenaemia (HBeAg) amongst women of childbearing age in Yemen and estimate
the potential risk of perinatal transmission of HBV from these women.
3- Investigate whether the prevalence of HBV infection and chronic infection amongst
children and mothers varies between geographic regions and provinces in Yemen.
2.1.2 Secondary objectives:
1- Evaluate the effectiveness of the hepatitis B vaccination programme in preventing
HBV infection and HBV chronic infection amongst children vaccinated in the
country's Expanded Programme on Immunisation (EPI).
2- Measure hepatitis B vaccination coverage amongst children aged 1-3 years old
participating in the study.
3- Examine the pattern of HBV infection and HBV chronic infection amongst children
aged 4-9 years in Yemen prior to the introduction of HBV vaccination to these
age-groups and its influence on the prevalence of HBV infection amongst these
cohorts of children. This would serve as a baseline measure of the prevalence of HBV
infection amongst children aged 4-9 years against which the effectiveness of hepatitis
B vaccination in reducing the prevalence of HBV infection can be compared in the
future.
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To achieve these objectives a survey was conducted consisting of two main parts. Firstly,
a population-based cross-sectional household sero-epidemiological survey of a
representative sample of children aged 1-3 and their mothers (women of childbearing
age). This was followed by a nested case-control analysis of children aged 1-3 and
mothers participating in the survey. Secondly, a population-based cross-sectional sero-
epidemiological survey of children aged 4-9 years, sampled from within the same
households of children aged 1-3.
2.2 Cross-sectional survey amongst children aged 1-3 and their mothers:
2.2.1 Type of study:
A community-based cross-sectional household sero-epidemiological survey was
conducted amongst Yemeni children aged 1-3 years and their mothers. This measured the
prevalence of anti-HBc positivity and HBV chronic infection amongst children aged
1 - 3 and women of childbearing age, perinatal transmission of HBV, hepatitis B vaccine
coverage, and geographic variation in the prevalence of anti-HBc positivity and HBV
chronic infection.
2.2.2 Population:
This study was conducted on a representative sample of Yemeni children aged 1-3 and
the mothers of these children participating in the survey.
2.2.3 Sample size:
Sample size was calculated separately for each of the study objectives. This was mainly
due to the different population groups under investigation (mothers and children) and the
different prevalence rates for the investigated variables expected amongst them. Expected
prevalence rates were estimated based on the prevalence of the variable under
investigation reported by previous studies amongst the relevant age-groups in Yemen or
neighbouring Middle-Eastern countries, as well as the expected or known mode of
transmission of HBV infection in the country or region.
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All sample sizes were calculated using the WHO Practical Manual for Sample Size
Determination (Lwanga SK, 1991) and EPI-INFO Version 6 using the STATCALC
utility.
2.2.3.1 Prevalence of HBV chronic infection amongst children aged 1-3 years:
The sample size was calculated based on an expected HBV chronic infection prevalence
of 10% amongst Yemeni children aged 1-3 and a desired precision of 3% (7-13%) with
95% confidence. The expected prevalence of 10% was based on a prevalence of
approximately 18% for HBV chronic infection amongst adults in the general population
in Yemen and evidence suggesting mother-to-child and horizontal transmission as being
the major modes of transmission of HBV infection in the region. This sample size was
adequate if the prevalence of HBV chronic infection was found to be 5%. In order to
adjust for the clustering of the sampling process, it was estimated that it was sufficient to
multiply the calculated sample size by a factor of 2 to adjust for the design effect of the
survey and obtain the same desired precision. This was also done to ensure a sufficient
number of study participants required for the case-control analysis. This was further
extended to the remaining sample size calculations of children aged 1-3 and mothers
participating in the survey.
Expected prevalence
Level of Confidence
Precision (7% - 13%)
10%
95%
3%
Table (2.2.3.1) shows sample size needed to measure the prevalence of HBV chronic
infection amongst children aged 1-3 with a 2% and 3% precision at the 90 and 95% levels
of confidence, adjusted for design effect.
Table 2.2.3.1
Sample size for measuring the prevalence of HBV chronic infection
amongst children aged 1-3 years - adjusted for design effect (x2)
Expected Prevalence Absolute Precision Level of Confidence Sample Size
10% 2% 95% 1728
10% 3% 95% 768
10% 2% 90% 1218
10% 3% 90% 542
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2.2.3.2 Prevalence of HBV chronic infection amongst mothers:
The prevalence of HBV chronic infection amongst Yemeni women of childbearing age
was expected to be approximately 16% with a desired precision of 3% (13-19%) at the
95% confidence level. The expected prevalence of 16% was based on a reported
prevalence of 15% to 18% for HBV chronic infection amongst pregnant women in
Yemen.
Expected prevalence
Level of Confidence
Precision (13% - 19%)
16%
95%
3%
Table (2.2.3.2) shows the sample size adjusted for design effect (x2) needed to measure
the prevalence of HBV chronic infection amongst women of childbearing age with a 2%
and 3% precision at the 90 and 95% levels of confidence.
Table 2.2.3.2
Sample size for measuring the prevalence of HBV chronic infection
amongst mothers - adjusted for design effect (x2)
Expected prevalence Absolute Precision Level of Confidence Sample Size
16% 2% 95% 2450
16% 3% 95% 1088
16% 2% 90% 1726
16% 3% 90% 766
The sample size required to achieve a 3% precision at the 95% level of confidence was
1088 women. This was large enough to cover the sample size required for measuring the
prevalence ofHBV chronic carriers amongst Yemeni children aged 1-3 (768 children).
The final sample size of children aged 1-3 and their mothers was rounded up to 1100
children aged 1-3 and their mothers to be included in the cross-sectional study, which
was expected to be sufficient to fulfil the primary objectives of the survey with the
desired power.
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2.2.3.3 Hepatitis B vaccine coverage:
Measuring hepatitis B vaccine coverage was one of the secondary objectives of the study.
The sample size of 1100 children was expected to be sufficiently large enough to estimate
vaccine coverage to within 3 percentage points of the true value at the 95% level of
confidence based on a vaccine coverage of 42% for all three doses by one year of age, as
has been proposed in anecdotal evidence.
2.2.4 Sampling methods:
This survey followed a complex sampling scheme. This scheme was adopted to
accommodate a number of factors. Firstly, there was no epidemiological data on HBV
infection from the Southern and Eastern regions of the country (formerly South Yemen)
and it was suspected that differences existed in the pattern and prevalence of HBV
infection between these regions and the more mountainous regions in the North.
Therefore, the study was designed in a way to ensure the inclusion of these regions in the
study population. Secondly, the recently introduced hepatitis B vaccination programme
was gradually introduced starting with one health centre in each governorate and is being
further introduced to all health centres in provinces. Thirdly, it was intended to draw a
sample representative of the prevalence of HBV infection in the country overall, which
would provide generalisable information essential for public health policy-making.
The sample population of the survey was drawn from five main survey domains with
each governorate (province) included in the study forming one survey domain. It was
planned to draw an equal number of study participants from each survey domain. The
governorates included in the survey were Sanaa City municipality, Aden, Taiz, Shabwa,
and Hodeidah (excluding Taiz and Hodeidah cities). The population of these five
governorates constitutes approximately 24 % of the country's overall population.
These governorates were selected because they are considered representative of Yemen's
geographic regions, tribes and socioeconomic classes; include governorates from the
Southern and Eastern regions of the country (former South Yemen); and because of the
feasibility of doing a household survey in these governorates. The total population of
these five governorates combined together is 68% rural and 32% urban. The sample
selected from Sanaa City municipality (political capital) and Aden (economic capital)
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was considered representative of urban populations, and the sample selected from Taiz,
Hodeidah and Shabwa (which are mainly rural areas except for Taiz and Hodeidah cities,
which were excluded from Taiz and Hodeidah governorates sample population)
predominantly represented rural populations. This was adopted because of the difficulty
in clearly dividing the population living in these governorates into urban and rural
populations based on characteristics other than population size. The Central Statistical
Organisation (CSO) in Yemen classifies any population exceeding 5000 individuals as
urban. However, there are many populations in Yemen exceeding 5000 individuals that
cannot be correctly considered urban populations due to the lack of essential services and
infrastructure that an urban population would normally have. Additionally, population
size projected for 2001 by the CSO was only done at the district level with no projections
done at the village and town level. To have this done at the village level for each and
every population in the five governorates of the survey would be time consuming and
expensive. Moreover, the changes that took place in geographic and administrative
divisions in 1999 significantly changed governorate population size and require new
projections to be done at the village level.
Households were selected from within these five provinces and any child aged 1-3 years,
regardless of sex, fulfilling the inclusion criteria whose parents witnessed verbal consent
was obtained participated in the survey. The sampling methodology performed was
similar to that developed by the EPI of the WHO, which is a type of cluster sampling
survey, used to estimate vaccination status among young children (Bennett et al., 1991).
Within each province, five districts/enumeration areas were selected as primary sampling
units based on probability proportional to size (PPS). This was carried out by creating a
cumulative population list for all the districts/enumeration areas in each of the five
provinces and selecting a systematic sample starting from a random point. The sampling
interval was calculated by dividing the total population size of the province by the
number of districts/enumeration areas to be selected (in this survey five). A number lying
within the range of this sampling interval was randomly chosen, using Epi-info, and was
fitted into position in the cumulative population list and whatever district this number
was part of was taken as the first district/enumeration area to be sampled in the province.
The sampling interval was then added to the random number to select the second
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district/enumeration area and this process was repeated until five districts/ enumeration
areas were selected from each province. Data on population size was based on population
size and distribution projections for 2001 prepared by the Yemeni CSO.
The minimum number of individuals selected from each district/enumeration area was 44
children aged 1-3 and their mothers equally sampled from two different starting points in
the district/enumeration area (minimum 22 children aged 1-3 and mothers from each of
the two starting points in the district/enumeration area). This gave every individual living
in the province an equal probability of being selected (self-weighting sampling
procedure). The daily minimum target number of children aged 1-3 and mothers sampled
was 22 with no more than two days spent in each district/enumeration area.
2.2.4.1 Selection of households:
Three teams of study investigators participated in the fieldwork throughout the survey
and these would either split up in the streets of towns and cities or in the compounds and
aggregations of households of villages. The teams would visit one household after
another until the daily target number of children aged 1-3 and mothers was achieved.
Different procedures were used for the selection of individuals from rural governorates
(Taiz, Shabwa, and Hodeidah) than urban governorates (Sanaa City municipality and
Aden).
Once the five districts from Taiz, Hodeidah and Shabwa were selected based on PPS
sampling using the CSO projected district population size and distribution data for 2001,
villages and towns were selected from within these districts based on PPS (as described
in the selection of districts within provinces) using these district's village and town
cumulative population list projected for 2001 specifically prepared for the study. Within
villages and towns households were randomly selected. The first household to be
sampled in a town/village was selected based on selecting a central point or street in the
town/village, numbering the households on that street or vicinity and randomly selecting
one of the households using numbered cards. If the household was not inhabited by a
child aged 1-3, a coin was tossed (to determine whether to go right or left) and when
appropriate every third household was visited until an eligible household was identified.
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However, if this was an aggregation of households in a village and there were not many
households then all the households were visited. Once identifying and gaining access to
an eligible household and after obtaining consent an interviewer administered
questionnaire was completed and children aged 1 - 3 years and their mothers were bled
to test for serological markers of HBV infection. Only one child aged 1 - 3 per mother
was included in the study sample. If more than one child aged 1 -3 per mother was
present in the household, one of these children was randomly selected, by tossing a coin,
for inclusion to the study sample. If the study investigators failed to obtain a blood
sample from the randomly selected child aged 1-3 then the study investigator would
obtain a sample from the remaining child aged 1-3. If there was more than one mother
with a child aged 1 -3 in the household, all consenting mothers with a child aged 1 -3
present in the household were included in the study sample. Within a household each
mother and child pair that were eligible were considered to be a family unit. Once the
first consenting household had been surveyed all the neighbouring households (starting
with the nearest) in the village or town were approached until the target number of 22
children and their mothers from this starting point of the primary sampling unit had been
attained. It was initially planned to use village/town maps when available to mark
surveyed households and streets in villages/towns, however, most commonly none of
these were available nor were these needed.
In villages usually all the households in the village had to be visited to obtain the target
number of children aged 1-3. If a village was completely surveyed and the target sample
size from this starting point of the primary sampling unit had not been achieved, the team
would move on to the nearest village and the same process for selecting the first and
subsequent households for sampling was repeated in the next village until the target
number of children aged 1-3 and mothers was attained. The same process was repeated in
all five districts of the three rural provinces (Taiz, Shabwa and Hodeidah). The process
implemented at the second starting point was identical to what was done at the first
starting point.
In Sanaa City municipality and Aden, which are urban areas and for which maps were
available, five enumeration areas were selected as primary sampling units based on PPS.
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Population size for enumeration areas was projected for 2001 with a fixed number of 44
individuals selected from each enumeration area. Within these enumeration areas,
sampling was initiated from a street blindly pointed out from a map of this enumeration
area. The first household to be sampled on the street was selected based on numbering the
households on the street and randomly selecting a household from the street using
numbered cards. If the household was not inhabited by a child aged 1-3, a coin was
tossed (to determine whether to go right of left) and every third household was visited
until an eligible household was identified. Once identifying and gaining access to an
eligible household and after obtaining consent an interviewer administered questionnaire
was completed and both child aged 1 - 3 years and the mother were bled and tested for
serological markers of HBV infection. Only one child aged 1 - 3 per mother was
included in the study sample. If more than one child aged 1 -3 per mother was present in
the household, one of these children was randomly selected, by tossing a coin, for
inclusion to the study sample. If the study investigators failed to obtain a blood sample
from the randomly selected child aged 1-3 then the study investigator would obtain a
sample from the other child aged 1-3. If there was more than one mother with a child
aged 1 -3 in the household, all consenting mothers with a child aged 1 -3 present in the
household were included in the study sample. Within a household each mother and child
pair that were eligible were considered to be a family unit.Upon the completion of
surveying the first household all the households that roughly lied within a 50 metre radius
of the first household were surveyed including to the study population all eligible
consenting households inhabited by a 1 -3 year old child until the target number of 22
children aged 1-3 and their mothers from this starting point of the primary sampling unit
had been attained. If no more eligible households could be identified within the 50-metre
radius the team would move on to the nearest street and the same process for selecting the
first and subsequent households for sampling was repeated until the target number of
children aged 1-3 and mothers was attained. The process implemented at the second
starting point was the same as what was done at the first starting point. The same process
was repeated in all five enumeration areas of both urban provinces (Sanaa City
municipality and Aden).
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2.2.4.2 Community participation:
In order to maximise community co-operation mainly in rural areas attempts were made
to promote community acceptance. Prior to surveying a village or town, community
leaders, tribal leaders, village elders, and relevant local authorities were informed about
the nature of the visit of the study investigators. Appropriate meetings and discussions
were held focusing on the objectives and benefits of the survey. These community leaders
in tum were requested to encourage the village population to participate in the survey and
co-operate with study investigators. This proved to be an effective mechanism of leading
study participants to feel part of the survey and perceive it to be for their benefit, thereby
improving their cooperation. Moreover, following the selection of a village or town at
least one local facilitator was identified in advance, or contacted on the day of the
fieldwork, prior to visiting households, and recruited to maximise the co-operation of the
village inhabitants and to assist in the days activities in the area.
Inclusion criteria:
All children aged 1-3 years and their mothers willing to participate in the survey from
whom witnessed verbal consent was obtained.
Exclusion criteria:
1- Children and mothers refusing to participate in the study (children's exclusion was
based on their guardian's refusal to allow them to participate in the study).
2- Seriously ill children or children and mothers with a history of bleeding disorders
would have been excluded although such children were not encountered.
2.2.4.3 Obtaining consent:
Upon identifying and gaining access to a household occupied by a child aged 1-3 years
the team of study investigators (consisting of two individuals) would introduce
themselves or be introduced by a facilitator to the head of the household and/or the
mother of the child. In order to ensure that the same correct and complete information
was given to each study participant, study investigators used an information sheet to give
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the head of the household and/or the mother of the child a brief explanation of the
research objectives. They were also informed that the visit to their household would
involve two main procedures. The first was the completion of an interviewer
administered questionnaire. The second was obtaining a blood sample from both mother
and child to test for markers of HBV infection. Potential participants in the study were
provided with sufficient information on potential risks and benefits to enable them to
make an informed decision on whether or not to participate in the study. Study subjects
were reassured on confidentiality and safety issues involving the questionnaire and blood
sampling and were then asked if they had any questions. These were answered by the
study investigators. Literate parents were offered an Arabic language information sheet
prepared specifically for the household survey describing the research objectives,
procedures to be carried-out in the household, and the benefits from the study (refer to
information sheet, Annex III).
Following the above, study participants were asked for their witnessed verbal consent for
the mothers and child's inclusion in the study sample of the cross-sectional survey. The
reason verbal consent was requested rather than written consent is because approximately
75% of the Yemeni population is illiterate and this is more pronounced in rural areas.
Requesting study participants to provide written consent would have been difficult and
impractical. It was attempted to obtain the consent of both mother and father of the child.
If the father was not present the mother was asked if the father might object to their
inclusion in the study sample (which only happened on a few occasions). In these cases
an attempt was made to obtain the fathers consent. When either parent refused the
inclusion of the child and mother in the study population, efforts were made to address
their concerns and alleviate their fears and they were encouraged to participate in the
survey. If however, following this either parent refused to participate in the survey, the
household members were not included in the study sample, with subjects refusing to
participate being free to do so at their own wish. Out of the 1577 surveyed eligible
households that were inhabited by a child aged 1-3 years old, 16% (260) refused to allow
their child to participate in the survey for various reasons such as fear of injections, side
effects, complications, or suspicions about the intentions of the study investigators.
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2.2.4.4 Questionnaire:
Individuals participating in the survey were subjected to an interviewer administered
questionnaire. The questionnaire focusing on the child aged 1-3 and the mother asked
about the child's personal and vaccination history, mother, father, the household's
characteristics and socioeconomic status (refer to questionnaire I, Annex I). The
questionnaire did not include any sensitive or embarrassing questions.
The mother or father of the child was the target person to be interviewed. If this was not
possible the aunt, uncle, grandfather or grandmother of the child was interviewed.
Interviews were conducted in study participant's households and the questionnaire was
administered and filled by one of the study investigators participating in the survey
specifically trained for this purpose. The study investigator would systematically go over
the questions reading them out as written and fill the form according to the response of
the person interviewed. This was expected to minimise inter-observer and responder bias,
especially because both respondent and investigator did not know the child's serological
status at the time the interview was conducted. Chapter 3 presents a full description and
discussion of the serological tests performed on study participants.
2.2.4.5 Quality control:
Everyday after completing the household survey the primary study investigator would
review every questionnaire completed by the other study investigators as well as
questionnaires completed by himself. During this process the primary study investigator
would check questionnaires for errors, missing information and inconsistencies, and filled
the coding column on the questionnaire preparing data from the questionnaire to be
entered into the database. If errors, inconsistencies, or missing information was detected
the study investigator completing the questionnaire was asked to clarify these issues. It
was expected that having conducted the interview on the same day the interviewer would
have a better recollection and memory of the issues s/he might be asked about compared
to if s/he had been asked about this at a later date. If however, there was missing
information the study investigator could not confidently clarify it was left blank and was
coded as missing data. On a few occasions, when it was practical and reasonable,
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information on hepatitis B vaccination status recorded on vaccination cards was verified
by checking children's vaccination records retained at vaccinating health centres. Quality
control checks and procedures were also implemented throughout the process of data
entry and analysis of data (refer to Chapter 4 Data Description and Methods of Analysis).
2.3 Case-control analysis:
Following the cross-sectional survey and analysis a case-control analysis was performed
on children aged 1-3 years and their mothers, and children aged 4-9 participating in the
cross-sectional survey, drawing cases and controls according to the variables or the
outcome being investigated.
The case-control study analysed:
1- The effectiveness of the EPI hepatitis B vaccination programme in preventing HBV
infection (anti-HBc positivity) amongst children by comparing HBV infection
amongst vaccinated and unvaccinated children.
2- The effectiveness of the hepatitis B vaccination programme in preventing HBV
chronic infection amongst children by comparing HBV chronic infection amongst
vaccinated and unvaccinated children.
3- Variables associated with hepatitis B vaccine coverage amongst children aged 1-3
years.
4- Variables associated with anti-HBc positivity and HBV chronic infection amongst
children aged 1-3 and mothers, as well as children aged 4-9 years.
2.3.1 The effectiveness of hepatitis B vaccination in preventing HBV chronic
infection:
Cases:
HBV chronic carrier children aged 1-3 years (children repeatedly positive for HBsAg and
negative for IgM anti-HBc).
Controls:
Children negative for hepatitis B surface antigen.
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Exposure:
Hepatitis B vaccination. Children receiving all three doses of vaccine in whatever
schedule were considered completely vaccinated. Children receiving one or two doses
were considered incompletely vaccinated children.
This allowed calculation of the odds of exposure which estimated the relative odds of
HBV chronic infection amongst completely vaccinated compared to unvaccinated
children. Sample size was calculated based on an expected 42% vaccination coverage
(based on anecdotal evidence) amongst children negative for HBsAg (controls) and an
expected relative risk of 0.3 with an 80% power at the 0.05 level of significance. Table
2.3.1 shows that 38 cases were needed to carryout the analysis with an 80% power. All
sample sizes for the case-control analysis were calculated using Power Epicentre
Software version 1.3 by Dr. Inskip and MRC Laboratories.
Table 2.3.1
Number of cases required in analysis for estimating the effectiveness of hepatitis B
vaccination in preventing HBV chronic infection amongst vaccinated children.
Control case ratio 9:1, power = 80%, level of significance = 0.05
Proportion vaccinated amongst controls
Relative Risk 0.1 0.2 0.3 0.4 0.5 0.6 0.7
0.2 105 51 34 25 20 17 16
0.3 146 73 49 38 32 28 27
0.4 210 107 74 58 50 46 47
0.5 317 165 116 94 83 79 82
It was predicted that if the prevalence of HBV chronic carriers generated from the
sero-epidemiological survey of children aged 1-3 years was 5 - 10%, a sufficient number
of cases would be available to allow the case-control analysis with an 80% power at the
0.05 level of significance.
2.3.2 The effectiveness of hepatitis B vaccination in preventing anti-HBc positivity:
Cases:
HBV infected children aged 1-3 years (children repeatedly positive for anti-HBc).
Controls:
Children negative for hepatitis B core antibody.
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Exposure:
Hepatitis B vaccination. Children receiving all three doses of vaccine in whatever
schedule were considered completely vaccinated. Children receiving one or two doses
were considered incompletely vaccinated children. This allowed calculation of the odds
of exposure which estimated the relative odds of HBV infection amongst completely
vaccinated compared to unvaccinated children.
Sample size was calculated based on an expected 42% vaccination coverage amongst
children negative for anti-HBc and an expected relative risk of 0.3 with an 80% power at
the 0.05 level of significance. Table 2.3.2 shows that 42 cases were needed to carryout
the analysis with an 80% power. The cross-sectional survey was expected to generate a
sufficient number of cases for estimating the effectiveness of HBV vaccination in
preventing HBV infection with an 80% power.
Table 2.3.2
Number of cases required in analysis for estimating the effectiveness of hepatitis B
vaccination in preventing anti-HBc positivity amongst vaccinated children.
Control case ratio 4:1, power = 80%, level of significance = 0.05
Proportion vaccinated amongst controls
Relative Risk 0.1 0.2 0.3 0.4 0.5 0.6 0.7
0.2 116 57 38 28 23 20 19
0.3 161 81 55 42 36 32 32
0.4 232 119 82 65 56 53 53
0.5 352 184 130 105 93 89 93
Inclusion and exclusion criteria in case-control analysis for estimating the
effectiveness of hepatitis B vaccination in preventing anti-HBc positivity and HBV
chronic infection:
Inclusion criteria:
Children aged 1-3 years who had a full and accurate vaccination history whether by
vaccination cards or vaccination records from a vaccinating health centre.
Exclusion criteria:
Children aged 1-3 years from who an accurate vaccination history could not be obtained.
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2.4 Cross-sectional survey amongst children aged 4-9 years:
2.4.1 Type of study:
A population-based cross-sectional household sero-epidemiological survey was
conducted amongst Yemeni children aged 4-9 years in order to examine the pattern and
age-specific prevalence of HBV infection and chronic infection amongst unvaccinated
Yemeni children. This would provide a baseline measure of HBV infection and chronic
infection amongst a cohort of unvaccinated children upon which the effectiveness of the
hepatitis B vaccination programme in reducing HBV infection and chronic infection
could be evaluated in the future. It would also give a picture of the pattern of childhood
transmission of HBV infection in Yemen.
2.4.2 Population:
This study was conducted on a representative sample of Yemeni children aged 4-9 years.
2.4.3 Sample size:
Sample size was calculated based on an expected prevalence for HBV chronic infection
of approximately 10%, based on a prevalence of approximately 18% for HBV chronic
infection amongst adults in the general population in Yemen and evidence suggesting
mother-to-child and horizontal transmission as being the major modes of transmission of
HBV infection in the region with a desired precision of 3% (7%-13%) at the 90% level of
confidence. The sample size was multiplied by 1.5 to adjust for the design effect in the
study. Sample size was calculated using the WHO Practical Manual for Sample Size
Determination (Lwanga SK, 1991) and EPI-INFO Version 6 using the STATCALC
utility. Table 2.4.3 shows that this can be achieved with a sample size of 407 children.
This was rounded up to a target number of 420 children aged 4-9.
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Table 2.4.3
Sample size for measuring the prevalence of HBV chronic infection amongst
Yemeni children aged 4-9 years - adjusted for design effect (x loS)
Expected Prevalence Absolute Precision Level of Confidence Sample Size
10% 3% 95% 576
10% 3% 90% 407
It was planned to equally divide the sample size over the six years of age (age-groups)
extending from 4-9 years, with 70 children sampled from each year of age. It was also
initially intended to sample an equal number of children from each year of age (age-
group) from each province. In other words approximately fourteen children would have
been randomly selected for each of the six age-groups extending from 4-9 years from
each survey domain giving a total of eighty-four children aged 4-9 from each of the five
survey domains.
2.4.4 Sampling methods:
At the same time as the household survey amongst children aged 1-3 years was being
carried out, any child present in the household aged 4-9 years was considered eligible to
participate in the cross-sectional survey of children aged 4-9 years.
From approximately 50% of the households of children aged 1-3, children aged 4-9 years
were randomly selected for inclusion to the survey of children aged 4-9. Prior to filling in
the interviewer administered questionnaire and blood sampling of these 4-9 year old
children, parents or guardians were also requested for their witnessed verbal consent for
the inclusion of these children to the study sample of children aged 4-9 (as was done for
children aged 1-3). Parents or guardians refusing were free to do so at their own wish.
Upon obtaining witnessed verbal consent from the child's parent/guardian, children
participating in the survey of children aged 4-9 were subjected to the completion of an
interviewer administered questionnaire and the withdrawal of a blood sample for
serological testing, similar to what occurred with children aged 1-3.
The questionnaire focusing on the child aged 4-9 was similar to the questionnaire of
children aged 1-3 and asked about the child's personal and vaccination history, mother,
father, the household's characteristics and socio-economic status (refer to questionnaire
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II, Annex II). The sample quality control procedures described in 2.2.4.5 were applied to
the questionnaires of these children as well.
2.S Staff recruitment and training:
The group of study investigators conducting the fieldwork consisted of a minimum of six
members divided into three teams with two study investigators in each team. Each team
consisted of a qualified medical doctor or psychologist and a qualified nurse or laboratory
technician. One of the qualified medical doctors was the primary study investigator. The
qualified medical doctors/psychologists were recruited based on having a minimum of
three years experience in their profession or a reasonable relation and background with
the governorates or villages surveyed. Nurses/laboratory technicians were recruited based
on having a minimum of three years experience in a paediatric ward and active
involvement in drawing blood samples from children and infants. Depending on the
circumstances different study investigators had to be recruited in some of the
governorates surveyed.
Study investigators were trained on all aspects of the survey such as filling questionnaires
and blood sampling during a two-week workshop prior to initiating the
seroepidemiological survey. During this workshop study investigators learnt about the
types of hepatitis virus infections, the objectives of this survey, survey methodology, and
the types of bias and how to avoid them. They were trained on selecting and approaching
households, procedures within households, inclusion and exclusion criteria of study
participants, obtaining consent, blood sampling and handling procedures, how to conduct
the interviewer administered questionnaire, specific responsibilities during the survey,
and finally health and safety guidelines. Every study investigator was given a survey
manual specifically prepared for this survey which contained all the necessary
information and guidelines of any procedures which were implemented throughout the
survey (refer to fieldworker manual, Annex N). Study investigators were advised to keep
the fieldworkers manual with them throughout the survey as a reference. Additionally,
throughout the fieldwork, each team of study investigators had continuous 2-way radio
contact with the primary study investigator in case they needed his advice, instructions,
or feedback.
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2.6 Ethical issues:
The seroepidemiological survey was designed taking into account the confidentiality,
freedom, anonymity, benefits, and safety of study participants.
Ethical approval for this study was obtained from the Ministry of Public Health and
Population in Yemen and from the Ethics Committee of the London School of Hygiene
and Tropical Medicine.
2.6.1 Confidentiality:
During the interview and prior to filling the questionnaire respondents were asked about
their preferences on the presence or absence of subjects in the room. Every effort was
made to meet the interviewee's preferences. No more than two study investigators were
present in the room at the same time when the questionnaire was being filled. Whilst the
interview was being carried out, individuals present from the study subjects side were
kept to a minimum, unless this was contrary to the respondents wishes. After filling the
questionnaire strict confidentiality was ensured for the respondents personal and
household characteristics and details. Completed questionnaires were labelled with a
unique identification number for both mother and child separately, and kept in a safe and
inaccessible place where they were kept under lock and key. No one other than the
primary study investigator had access to individuals completed questionnaires. No
information on study participants was discussed or disclosed to anybody else.
2.6.2 Anonymity:
Blood samples sent for laboratory analysis were labelled with the unique identification
number of the study participant. Consequently, the primary study investigator as well as
laboratory staff handling and testing samples were unable to identify study participants.
Laboratory results were recorded for identification numbers and not named individuals
(i.e. maintaining anonymity of study participants).
At the stage of data analysis the only individuals gaining access to the study subject's
details were the primary investigator, his supervisor, and his statistical advisor.
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2.6.3 Freedom:
Only individuals from whom witnessed verbal consent was obtained were included in the
study population. Subjects refusing to participate in the survey were free to do so at their
own wish and were not included in the study sample.
2.6.4 Safety:
A basic principle of health interventions and epidemiological survey's is first to do no
harm to study participants, whether this harm may be mental or physical.
It was anticipated before the study was carried out that discomfort or distress amongst
study participants may result from the interviewer administered questionnaire or
venesection of mother and more importantly the child. Therefore, this was taken into
consideration when the questionnaire was designed. First of all the questionnaire did not
investigate sensitive or culturally unacceptable issues. Secondly, there were no
embarrassing questions. Thirdly, the focus of the questionnaire was on the child and to a
lesser extent the mother, which was less likely to embarrass the mother. Finally, the
questionnaire was kept as short as possible.
Venesection was the main procedure that may have caused discomfort to subjects
participating in the study. This was more common amongst children than adults mainly
because children perceive venesection as a more frightening experience than adults and
because children were more likely to perceive the study investigators in their household
as strangers and dislike contact with them. This would reach its peak when the child was
held to obtain the blood sample. Therefore, attempts were made to minimise this
occurring especially whilst the questionnaire was being completed. During the interview
the study team attempted to be as friendly, nice and playful with the child as possible.
Before the blood sample was withdrawn the mother was requested to hold the child
giving him/her a sense of security. Following this one study investigator calmly and
firmly held the child in place and distracted his/her attention from the other study
investigator performing venepuncture.
As far as household safety was concerned, the medical doctor/psychologist in the team of
study investigators visiting households was responsible for supervising the
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implementation of health and safety guidelines and would have dealt with health related
events if they occurred.
It was anticipated that the main potential health and safety hazards in this study would
result from the sampling, transportation and storage of blood and the disposal of used
needles. In order to ensure the safety of study subjects, study investigators and the
environment the following measures and guidelines were strictly implemented:
1- All blood samples were collected aseptically usmg alcohol swabs and sterilised
disposable needles.
2- The study investigator withdrawing blood ensured that there was no bleeding from
the site of venepuncture and no contamination of the household with drops of blood.
The study investigator applied a bandage to the site of venepuncture when needed.
3- Children sampled for blood were held in their mother's lap in order to reassure the
child. When withdrawing blood samples from children both study investigators with
the co-operation and permission of the mother held the child in a secure and fixed
position. This was to prevent injury that may result from sudden movements or
attempts by the child to remove the needle that may occur at the time of blood
sampling or due to the sting of the needle.
4- All products involved in blood sampling such as used needles, cotton wool and
bandages were disposed of in a safe needle disposable box, which was taken with the
team back to base and disposed of in the local health centre at the end of each
working day. Under no circumstances were used or unused items involved in blood
sampling procedures left in households of study participants.
5- For transportation, blood samples were collected in sealed vaccutainers. This
prevented any spillage or leaking of blood. Sealed vaccutainers were held in racks
and stored in mobile refrigerated blood transportation systems.
6- Upon arrival to base, blood samples were centrifuged and serum was separated from
the residual blood clot. The serum from each study participant was divided into two
serum samples, one original and one backup, which were stored in sealed cryovials in
a freezer. Residual products were disposed of safely.
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7- Throughout the process of handling blood or its derivatives study investigators were
wearing disposable gloves.
8- Study investigators participating in the study were screened for hepatitis B surface
antigen to exclude any of them being a HBV chronic carrier.
9- Study investigators, particularly those handling blood, were asked if they were
vaccinated against HBV. Those who were not already vaccinated were advised to get
vaccinated as early as possible before the fieldwork was initiated and were offered
free hepatitis B vaccination.
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Chapter 3: Laboratory Methods:
In this chapter the methods of handling and storage of samples will be described,
serological tests and assays performed will be presented, and the interpretation of these
serological tests according to the manufacturer's recommendations will be explained.
Finally, internal and external quality control measures and procedures to ensure reliable
and valid results will be discussed.
3.1 Serum sample handling and storage:
The primary study investigator ensured that serum samples were adequately stored and
handled throughout the survey. The primary study investigator also supervised the
laboratory processing and handling of samples and attended as an observer approximately
25% of the laboratory assay shifts and discussed relevant issues with laboratory
technicians performing the runs or the laboratory manager. The serum samples were
processed at Sanaa Medical Laboratory, Hadda Street, Sanaa, Republic of Yemen. This
laboratory was selected after assessing all the laboratories in Yemen capable of
performing the assays and was visited by Professor Andrew Hall and the primary study
investigator on 10th July 2001 to discuss with the manager assay procedures, quality
control and related issues. Serum samples were stored, handled and processed as follows:
1- Serum was separated from blood after it was allowed to clot at a temperature between
10 to 37 degrees centigrade, as this prevents the aggregation of immunoglobulin in
the clot.
2- Laboratory technicians and study investigators handling or processmg serum
specimens were all vaccinated with hepatitis B vaccine.
3- The serum sampled from every subject participating in the survey was placed in two
separate cryovials. One was referred to as the original sample and the second was
referred to as the backup sample. This was done to avoid repeated freezing/thawing
cycles (which were kept to a minimum) or an insufficient quantity of serum. The
second sample was used as a backup sample in case anything went wrong with the
original one or its quantity was insufficient.
4- All samples, original and backup, were placed in cryovials with a plastic screw cap.
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5- Cryovials were labelled using pre-printed labels capable of withstanding wetting and
freezing with the corresponding study subjects identification number (IDNO)
(children aged 1-3 IDNO 1001 to 2286, children aged 4-9 IDNO 7001 to 7469, and
mother IDNO 4001 - 5286).
6- Serum samples were stored at -10 to -20 degrees centigrade in chest freezers with lid
locks and temperature warning lights.
7- Original and backup samples were stored in different freezers placed in two different
locations that both had a backup electricity supply in case there were any power
failures and were checked everyday, once in the morning and once at night.
8- Once a serum sample was frozen it remained frozen until the time of serological
testing in order to avoid bacterial contamination. This is also why sterile vaccutainers
were used for the collection of blood and the skin puncture site was cleansed with an
antiseptic prior to blood collection.
9- Twenty-four hours prior to performing the first serological assay, samples were taken
out of the freezer and placed in a refrigerator overnight.
10-After samples were allowed to thaw in a refrigerator overnight these were removed
from the refrigerator early in the morning of performing the serological assay.
11- Serum samples and all human sourced materials (e.g. positive controls) were handled
on a potentially infectious basis and using disposable gloves.
12-Before pipetting serum samples the cryovials were mixed by gently inverting the
cryovials a few times ensuring the mixture of any precipitate settled on the base of the
cryovials during their storage, in order to ensure the consistency of the results.
13-Haemolysed samples or samples showing particulate matter were centrifuged prior to
testing in order to avoid inconsistent results.
14-When it was recommended by the manufacturer's assay procedures, serum samples
were centrifuged prior to pipetting and performing the analysis (IMx HBsAgV2, IMx
AUSAB) or prior to repeat testing (IMx HBe2, IMx HBsAgV2).
15-The plastic screw caps of cryovials were removed and 200 micrograms of serum was
pipetted from each cryovial and placed in the reaction cell (sample well) of the micro-
particle enzyme immunoassay (MEIA).
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16-The plastic screw caps were replaced onto the cryovials, which were put back in the
refrigerator until the next serological assay was performed according to the order of
serological tests described below.
17-A new sterile disposable pipette tip was used for each serum sample in the survey and
caution was exercised in handling patient specimens to prevent cross contamination
of specimens or the contamination of the laboratory with drops of serum. No serum
samples were pipetted by mouth.
18-The sample IDNO on the cryovial was cross-checked with the sample IDNO entered
into the IMx system in order to ensure that there were no numbering errors of
samples.
19-According to manufacturer's recommendations all specimens requiring repeat testing
or that were Gray Zone Reactive (GZR) were centrifuged at 8000 Relative
Centrifugal Force (RCF) for 10 minutes prior to any repeat or confirmatory testing.
GZR specimens are specimens with SIN (Sample rate/Calibrator rate) between 1.6
and 2.0. The German Federal Public Authority (Paul Ehrlich Institute, Langen,
Germany) recommends that GZR specimens be retested (Abbott, 2000).
3.2 Serological tests:
3.2.1 Children:
Serological tests on the serum of children aged 1-3 and 4-9 were carried out according to
the following order:
1- All children were tested for HBsAg.
2- Children initially positive for HBsAg or GZR were retested for HBsAg.
3- All children initially positive for HBsAg were tested for Immunoglobulin-M
hepatitis B core antibody (IgM anti-HBc) with the intention of retesting IgM anti-
HBc positive samples. However, none of the samples was initially IgM anti-HBc
positive so no retesting had to be done for this serological marker.
4- All children were tested for total hepatitis B core antibody (anti-HBc).
5- Children initially positive for anti-HBc were retested for anti-HBc.
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6- Children aged 1-3 with evidence of hepatitis B vaccination were tested for
hepatitis B surface antibody (anti-HBs), which was measured in milli-
international units per millilitre (mIU/mL).
3.2.2 Mothers:
Serological tests on mother's sera were carried out according to the following order:
1- All mothers were tested for HBsAg.
2- Mothers initially positive for HBsAg or GZR were retested for HBsAg.
3- All mothers initially positive for HBsAg were tested for hepatitis B e antigen
(HBeAg).
4- Mothers initially positive for HBeAg were retested for HBeAg.
5- All mothers were tested for total anti-HBc.
6- Mothers initially positive for anti-HBc were retested for anti-HBc.
Serum samples were tested for all of these serological markers (HBsAg, IgM anti-HBc,
total anti-HBc, HBeAg, and anti-HBs) using Microparticle Enzyme Immunoassay
(MEIA) referred to as MEIA from here onwards.
3.3 Serological assays:
Serological assays were performed on the IMx System (Abbott Laboratories, USA) using
the IMx System Software Module version 6.0 minimum and the IMx Hepatitis B Assay
Module version 11.0 minimum. All the laboratory tests were performed in Sanaa starting
on the 17thOctober 2001 and were completed by the end of January 2002. The laboratory
equipment was accurately calibrated and maintained in accordance with the
manufacturer's recommendations. Reagent kits, calibrators, controls, and diluent buffers
were stored and used according to manufacturer's instructions and recommendations.
Prior to performing serological assays all reagent kits, calibrators, controls, and diluent
buffers were checked to ensure that none of these was beyond or reaching the expiry date.
What follows is a presentation of the serological assays performed on the serum samples
of study participants.
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3.3.1 Abbott/IMx HBsAg(V2) kit (No. 2228-22):
The IMx HBsAg(V2) assay is a qualitative third generation MEIA for the detection of
HBsAg in human serum or plasma. This assay was designed for use with human serum or
plasma from individual patient and donor specimens (Abbott, 2000).
The HBsAg(V2) assay kit consists of IMx HBsAg(V2) Reagent Pack, 100 reaction cells,
and IMx HBsAg(V2) MODE 1 Calibrator developed by Abbott Laboratories Diagnostics
Division, USA, for use on the IMx System (Abbott, 2000).
In addition to the HBsAg(V2) Kit, performing the HBsAg assay requires the IMx HBsAg
Controls, IMx Probe Cleaning Solution, and IMx MEIA Diluent Buffer.
The principles of the procedure are as follows (Abbott, 2000):
1- Initially, a probe removes the serum sample from the sample well in the carousel
of the IMx System and delivers the sample and anti-HBs coated microparticles to
the incubation well of the reaction cell.
2- If HBsAg is present in the serum sample it will bind to the anti-HBs coated
microparticles forming an antibody-antigen complex.
3- A biotinylated anti-HBs solution is then added to the reaction mixture forming an
antibody-antigen-antibody complex.
4- A portion of the mixture containing the antibody-antigen-antibody complex
bound to the microparticles is transferred to a glass fibre matrix, onto which the
microparticles irreversibly bind.
5- An anti-biotin: alkaline phosphatase conjugate is dispensed onto the matrix and
binds to the antibody-antigen-antibody complex.
6- The matrix is then washed to remove unbound material.
7- A substrate, 4-methylumbelliferyl phosphate is added to the matrix and the
fluorescent product is measured by the MEIA optical assembly.
8- The presence or absence of HBsAg is determined by comparing the rate of
formation of fluorescent product to the Cutoff, which is calculated from the IMx
HBsAg MODE 1 Calibrator rate (the noise signal of a completely negative
sample). The IMx HBsAg MODE 1 Calibrator is recalcified human plasma
nonreactive for HBsAg, HIV-l Ag, anti-HBs, anti-HCV, and anti-HIV-1IHIV-2.
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Interpretation of HBsAg results:
The IMx HBsAg(V2) assay calculates a ratio of the sample rate to the MODE 1
Calibrator rate where, SIN = Sample Rate/MODE 1 Calibrator Rate. This was interpreted
according to the manufacturer's recommendations as follows:
1- Specimens and controls with SIN < 2.000 were classified as nonreactive by the
IMx HBsAg(V2) assay and did not need further testing (HBsAg negative).
2- Specimens and controls with SIN > 2.000 were classified as initially reactive, and
all specimens that were initially reactive were retested after centrifugation.
Specimens were centrifuged according to the manufacturer's recommendations at
8000 RCF for 10 minutes.
3- If repeat testing showed the specimen to be less than the cutoff, the original assay
was classified as non-repeatedly reactive (HBsAg negative). The main causes of
non-repeatedly reactive samples are contamination or the presence of particulate
matter in the serum sample such as fibrin clots or cellular material (Abbott, 2000).
4- If repeat testing showed the specimen to be greater than or equal to the cutoff, the
specimen was classified as repeatedly reactive and was presumed positive for
HBsAg (HBsAg positive).
5- Grey Zone Reactive (GZR) samples were samples with 1.600 < SIN < 1.999.
These samples were retested and their results were interpreted as described in 3
and 4 above.
3.3.2 Abbott/IMx anti-HBc Core kit (No. 2259-20):
The IMx Core assay is a MEIA for the qualitative detection of total antibody to hepatitis
B core antigen in human serum or plasma and is indicated as an aid in the diagnosis of
ongoing or previous hepatitis B virus infection (Abbott, 1992).
The hepatitis Core kit consists of IMx Core Reagent Pack and IMx Core MODE 1
Calibrator developed by Abbott Laboratories Diagnostics Division, USA, for use on the
IMx System. In addition to the IMx Core Kit, performing the assay requires the IMx Core
Controls, IMx Probe Cleaning Solution, and IMx MEIA Diluent Buffer.
The principles of the procedure are as follows (Abbott, 1992):
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1- Initially, a probe removes the serum sample from the sample well in the carousel
of the IMx System and delivers the sample, specimen diluent, and recombinant
DNA derived hepatitis B core antigen (HBcAg) coated microparticles to the
incubation well of the reaction cell.
2- If anti-HBc is present in the serum sample it binds to the HBcAg coated
microparticles forming an antibody-antigen complex.
3- A portion of the mixture containing the antibody-antigen complex bound to the
microparticles is transferred to a glass fibre matrix, onto which the microparticles
irreversibly bind.
4- Antibody to hepatitis B core antigen: alkaline phosphatase conjugate is dispensed
onto the matrix and binds with the antigenic sites of HBcAg which are not bound
with sample anti-HBc.
5- The matrix is then washed to remove unbound material.
6- A substrate, 4-methylumbelliferyl phosphate is added to the matrix and the
fluorescent product is measured by the MEIA optical assembly.
7- The presence or absence of anti-HBc in the serum sample is determined by
comparing the rate of formation of fluorescent product to the Cutoff, which is
calculated from the IMx Core MODE 1 Calibrator rate. The IMx Core MODE 1
Calibrator consists of recalcified human plasma nonreactive for HBsAg,
HIV-l Ag, anti-HCV, anti-HIV-IIHIV-2, anti-HBc, and anti-HBs.
Interpretation of anti-HBc results:
The IMx Core assay calculates a ratio of the sample rate to the cutoff rate where, SICO =
Sample RatelCutoff Rate. The Cutoff rate is determined by dividing the MODE 1
Calibrator Rate by 2. The SICO rate was interpreted according to the manufacturer's
recommendations as follows:
1- Specimens and controls with SICO rate in the range of 1 to 3 were classified as
nonreactive by the criteria of the IMx Core assay and did not require further
testing (anti-HBc negative).
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2- Specimens and controls with sica in the range of 0.002 to 1 were classified as
initially reactive by the criteria of the IMx Core assay. All specimens that were
initially reactive were retested.
3- Specimens which were found to be repeatedly reactive were considered anti-HBc
positive by the criteria of the IMx Core assay (anti-HBc positive).
3.3.3 AbbottlIMx IgM anti-HBc Core -M kit (No. 2260-20):
The IMx Core-M assay is a MEIA for the qualitative determination of IgM antibody to
hepatitis B core antigen (HBcAg) in human serum or plasma and is indicated for use as
an aid in the diagnosis of acute or recent (usually six months or less) hepatitis B virus
infection (Abbott (A), 1997).
The hepatitis Core-M kit consists of IMx Core-M Reagent Pack, IMx Core-M MODE 1
Calibrator, and MEIA reaction cells developed by Abbott Laboratories Diagnostics
Division, USA, for use on the IMx system. In addition to the IMx Core-M Kit,
performing the assay requires the IMx Core-M Controls, IMx Probe Cleaning Solution,
and IMx MEIA Diluent Buffer.
The principles of the procedure are as follows (Abbott (A), 1997):
1- Initially, a probe removes the serum sample from the sample well in the carousel
of the IMx System and dilutes it.
2- Microparticles coated with goat anti-human antibody, specific for human IgM, are
used to immunologically bind the IgM in the sample.
3- A recombinant DNA HBcAg solution is added. If IgM anti-HBc is present in the
sample, the HBcAg binds to the microparticle-antibody complex.
4- Antibody to hepatitis B core antigen: alkaline phosphatase conjugate is dispensed
and binds to the microparticle-antibody-antigen complex.
5- After washing to remove unbound material, a substrate, 4-methylumbelliferyl
phosphate is added to the matrix and the fluorescent product is measured by
MEIA optical assembly.
6- IMx Core-M sample rate values are proportional to the quantity of IgM anti-HBc
in the sample. Sample rate values are compared to the IMx Core-M MODE 1
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Calibrator rate to give an index value, which is used to deterrnine whether a
sample is positive or negative.
Interpretation of IgM anti-HBc results:
The presence or absence of IgM anti-HBc is determined by the index value comparing
the rate of formation of fluorescent product in the sample to the MODE 1 Calibrator rate.
Index values were interpreted according to the manufacturer's recommendations as
follows:
1- Specimens with indexes less than 0.8 were considered nonreactive for
IgM anti-HBc by the criteria of the IMx Core-M assay (lgM anti-HBc negative).
2- Specimens with indexes greater than 1.2 were considered reactive for
IgM anti-HBc by the criteria of the IMx Core-M assay (IgM anti-HBc positive).
3- There were no specimens with indexes between 0.8 and 1.2, which would have
been considered grey zone reactive (GZR). It is recommended that individuals
with GZR results be monitored (one week intervals) to distinguish rising from
falling IgM anti-HBc levels.
3.3.4 AbbottllMx HBe2 kit (No. 4B14-20):
The IMx HBe2 assay is a MEIA for the qualitative determination of HBeAg in human
serum or plasma screened positive for HBsAg and is indicated as an aid in the diagnosis
of hepatitis B viral infection (Abbott (B), 1997).
The hepatitis HBe2 kit consists of IMx HBe2 Reagent Pack, IMx HBe2 MODE 1
Calibrator, and reaction cells developed by Abbott Laboratories Diagnostics Division,
USA, for use on the IMx system. In addition to the IMx HBe2 Kit, performing the assay
requires IMx HBe2 Controls, IMx MEIA Diluent Buffer, and IMx Probe Cleaning
Solution.
The principles of the procedure are as follows (Abbott (B), 1997):
1- Initially, a probe delivers the serum sample and microparticles coated with anti-
HBe to the incubation well of the reaction cell.
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2- If present, the HBeAg in the sample binds to the anti-HBe coated microparticles
forming an antibody-antigen complex.
3- A portion of the antigen-antibody complex bound to the microparticles is
transferred to a glass fibre matrix.
4- The microparticles bind irreversibly to the glass fibre matrix.
5- The matrix is washed to remove unbound materials.
6- An anti-HBe: alkaline phosphatase conjugate is dispensed onto the matrix and
binds to the antibody-antigen complex.
7- After washing to remove unbound material, a substrate, 4-methylumbelliferyl
phosphate is added to the matrix and the fluorescent product is measured by
MEIA optical assembly.
8- The presence or absence of HBeAg is determined by comparing the rate of
formation of fluorescent product to the cutoff which is calculated from the IMx
HBe2 MODE I Calibrator rate. The IMx HBe2 MODE I Calibrator consists of
recalcified human plasma nonreactive for HBsAg, anti-HBs, anti-HBc, anti-HCV,
anti-HIV-IIHIV-2, antiHBe, HBeAg and HIV Ag.
Interpretation of HBe2 results:
The IMx HBe2 assay calculates a ratio of the sample rate to the MODE I Calibrator rate
SIN = sample rate/MODEl calibrator rate. SIN rates were interpreted according to the
manufacturer's recommendations as follows:
1- Samples with rates less than the cutoff «2.1) are nonreactive by the criteria of the
IMx HBe2 assay.
2- Samples with rates equal to or greater than the cutoff rate (>2.1) are considered
initially reactive by the criteria of the IMx HBe2 assay. Initially reactive samples
must be centrifuged at 8000 RCF for 10minutes and retested in duplicate.
3- If repeat testing shows both assay values to be less than the cutoff, the sample was
classified as nonreactive.
4- If either of the repeat assay values was greater than or equal to the cutoff the
sample was classified repeatedly reactive.
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5- Samples found to be repeatedly reactive are positive for HBeAg by the criteria of
the IMx HBe 2 assay.
6- Samples with SIN values less than 0.000 are invalid and must be repeated.
3.3.5 AbbottlIMx AUSAB kit (No. 2262-21):
The IMx AUSAB assay is a MEIA for the qualitative and quantitative determination of
anti-HBs. It is intended for the measurement of anti-HBs following HBV infection or
vaccination (Abbott, 1998).
The AUSAB assay kit consists of IMx AUSAB Reagent Pack, IMx AUSAB MODE 1
Calibrator, and 100 reaction cells developed by Abbott Laboratories Diagnostics
Division, USA, for use on the IMx System (Abbott, 1998).
In addition to the AUSAB Kit, performing the AUSAB assay requires the IMx AUSAB
Calibrators, IMx AUSAB Controls, IMx AUSAB Specimen Diluent, and IMx Probe
Cleaning Solution.
The principles of the procedure are as follows (Abbott, 1998):
1- Initially, a probe delivers recombinant hepatitis B surface antigen (rDNA HBsAg)
coated microparticles to the reaction cell, followed by the serum sample.
2- The anti-HBs in the sample binds to the microparticles forming an antibody-
antigen complex.
3- An aliquot of the reaction mixture is transferred onto a glass fibre matrix, onto
which microparticles bind irreversibly to the matrix.
4- Biotinylated rDNA HBsAg is then added to the matrix forming an antigen-
antibody-antigen complex.
5- An anti-biotin: alkaline phosphate conjugate is dispensed onto the matrix and
binds to the antigen-anti body-antigen complex.
6- After washing unbound materials, a substrate, 4-methylumbelliferyl phosphate is
added to the matrix and the fluorescent product is measured by the MEIA optical
assembly.
7- The presence or absence of anti-HBs in the specimen is determined by comparing
the rate of formation of fluorescent product to the cutoff rate, which is calculated
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from the IMx AUSAB Calibrator A or MODE 1 adjusted calibrator A rate. The
IMx AUSAB MODE 1 calibrator consists of recalcified human plasma
nonreactive for anti-HIV-lIHIV-2, anti-HCV, HBsAg and HIV-1 Ag, containing
anti-HBs at 100 mIU/ml. The IMx AUSAB calibrator A is nonreactive for anti-
HBs, while calibrators B, C, D, E and F have an anti-HBs concentration of 10, 50,
100,500 and 100 mIU/mL, respectively.
Interpretation of AUSAB results:
Specimens and controls in the IMx AUSAB assay are determined to be reactive or
nonreactive based only on the cutoff rate. The IMx AUSAB assay calculates a ratio of the
sample to the MODE 1 adjusted cutoff rate. This was interpreted according to the
manufacturer's recommendations as follows:
1- Samples with rates less than the cutoff «1.000) rate are nonreactive by the IMx
AUSAB assay and need not be further tested.
2- Specimens whose rates are greater than or equal to the MODE 1 adjusted
Calibrator A rate (> 1.000) are reactive.
3- Specimens with anti-HBs < 10 mIU/mL are not immune to HBV following
vaccination.
4- Specimens with anti-HBs > 10 mIU/mL are considered Immune to HBV
following vaccination.
3.3.6 Serological kits:
The codes, Lot numbers and expiry dates of the MEIA kits used to perform serological
analysis of HBV infection markers amongst the participants in this survey are presented
in table 3.3.6.
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Table 3.3.6
MEIA reagents used in the analysis of HBV infection
amongst participants in the survey
Serological Kit Kit Code Manufacturer Lot. Numberls Expiry Date/s
IMx HBsAg (V2) 2228-22 Abbott 78155LU02 07/12/2001
Laboratories 80279LUOI 08/02/2002
81277LUOO 16/01/2002
81277LUOI 16/01/2002
82182LUOI 04/03/2002
IMx Core 2259-20 Abbott 81237LUOO 20103/2002
Laboratories 81237LU03 20103/2002
IMx Core-M 2260-66 Abbott 78547M200 07/05/2002
Laboratories
IMx HBe2 4B14-66 Abbott 80232M300 23103/2002
Laboratories
IMxAUSAB 2262-21 Abbott 81207LUOO 07/05/2002
Laboratories
IMx HBsAg Control 2228-12 Abbott 82271LUOO 02/0312002
Laboratories
IMx Core Control 2259-10 Abbott 78621MOO 03/04/2002
Laboratories
IMx Core-M Control 2260-10 Abbott
Laboratories
IMx HBe 2 Control 4B 14-10 Abbott
Laboratories
IMxAUSAB 2262-10 Abbott 82603HPOO 17/07/2002
Control Laboratories
IMx AUSAB 2262-01 Abbott 82601HPOO 08/07/2002
Calibrator Laboratories
3.4 Laboratory quality control procedures:
There were three main quality control procedures that were implemented throughout the
laboratory analysis of serum specimens collected during the survey in order to ensure
valid, accurate and reliable laboratory results. Two of these procedures, referred to below
as internal and external quality control, were procedures required and applied specifically
for the laboratory analysis of serum specimens collected during this survey and were
under the supervision of the primary study investigator. The third, referred to below as
routine laboratory quality control procedures, were standard and routine quality control
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procedures implemented by the laboratories performing the MEIA assays and were not
procedures specifically introduced for the analysis of the specimens of this survey.
3.4.1 Internal quality control:
1- In accordance with manufacturer's recommendations a calibration was performed
each time a reagent pack with a new lot number was used and if the IMx HBsAgi
Core/Core-MlHBe2/AUSAB control or IMx HBsAgiCore/HBe2/AUSAB MODE
1 Calibrator value was out of its specified range.
2- In accordance with every IMx HBsAgiCore/Core-MlHBe21 AUSAB calibration,
the corresponding positive and negative IMx HBsAgiCore/Core-
MlHBe2/AUSAB control was processed as a means of evaluating the calibration.
3- A minimum of one positive and negative IMx HBsAgiCore/Core-
MIHBe2/AUSAB control was run with every 50 serum samples processed.
4- In accordance with manufacturer's recommendations at least one IMx
HBsAgiCore/Core-MlHBe2 positive control was run per 8 hour shift.
5- In accordance with manufacturer's recommendations at least one IMx AUSAB
positive control was run per IMx AUSAB MODE 1 assay.
6- The characteristics, values, and normal range of the IMx HBsAgiCore/Core-
MlHBe2/AUSAB positive and negative controls and AUSAB calibrators are
summarised in table 3.4.1. All the results for the positive and negative controls in
the kits were within the specified control range.
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Table 3.4.1
Characteristics of IMx HBsAg/Core/Core-M/HBe21 AUSAB
Abbott MEIA control kits
Control Kit Kit Serology Colour Concentration of Control Range
Number Markerl
Minimum Titre
IMx HBsAg 2228-12 HBsAg Positive Blue 4-15 nglmL* 25 -140 SIN
HBsAg Negative Natural On~mL 0.5 -1.5 SIN
IMx Core 2259-10 anti-HBc Positive Blue 0.5- 2 PEl unitlmL ** 0.05 - 0.8 S/CD
anti-HBc Negative Natural OPEl unitlmL 1.7 - 2.3 S/CD
IMx Core-M 2260- 10 IgM anti-HBc +ve Blue 1:1.5 > 1.5
IgM anti-HBc -ve Natural 0 <0.4
IMx HBe2 4B14-10 HBeAg Positive Blue 1:2 15 - 100 SIN
HBeAg Negative Natural 0 0.5 - 1.5 SIN
IMxAUSAB 2262-10 anti-HBs Positive Blue 80 mIU/mL*** 60 - 100
anti-HBs Negative Natural 0 0
IMxAUSAB 2262-01 A 0 mIU/mL
Calibrator B 10 mlU/mL
(6 bottles A- C 50 mIU/mL
F) D 100 mIU/mL
E 500 mIU/mL
F 1000 mIU/mL
* nanogram per millilitre.
** Concentration of anti-HBc standardised against the Reference Standard of the Paul-Ehrlich-
Institut, Langen, Germany.
* * * Concentration of anti -HBs standardised against the World Health Organisation Reference
Standard.
3.4.2 External quality control:
All serum samples that were initially reactive or repeatedly reactive for HBsAg and
HBeAg in the laboratory carrying out the initial serological testing in the survey were
retested at a confirmatory laboratory by MEIA using the same laboratory methods and
assays described above and implementing at minimum the same internal quality control
measures described above. The results of these confirmatory laboratory tests were
consistent with the results of the initial laboratory.
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3.4.3 Routine laboratory quality control procedures:
In addition to the internal and external quality control procedures described above that
were implemented throughout the analysis the laboratory performing the serological
assays routinely carried out the following quality control procedures:
1- A positive and negative control was included with every new kit or lot number of
MEIA.
2- A positive and negative control was included with every MEIA calibration
performed.
3- As external quality control known positive and negative samples sent from a
reference laboratory were tested in the laboratory once every three months.
4- The laboratory had its own known positive and negative HBsAg/anti-HBc
samples that were included with every 100 MEIA tests.
3.5 Definitions of HBV infection and chronic carrier status:
The definition of the different HBV infection status according to the laboratory results for
HBV serological markers was as follows:
3.5.1 Perinatally infected HBV chronic carrier child:
A child 1-3 years old was considered a perinatally infected HBV chronic carrier if
repeatedly HBsAg positive, IgM anti-HBc negative, anti-HBc positive, and was born
from a repeatedly HBsAg positive mother.
3.5.2 Childhood infected HBV chronic carrier child:
A child 1-3 years old was considered a HBV chronic carrier infected by childhood
transmission if repeatedly HBsAg positive, IgM anti-HBc negative, anti-HBc positive,
and was born from a HBsAg negative mother.
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3.5.3 Child with ongoing or previous HBV infection:
A child was considered HBV infected (anti-HBc positive), whether ongoing or previous,
if repeatedly positive for anti-HBc.
3.5.4 Child seronegative for HBV infection:
A child was considered negative for HBV infection if negative for HBsAg and anti-HBc
(total).
3.5.5 HBV chronic carrier mother:
A mother was considered a HBV chronic carrier if repeatedly HBsAg positive.
3.5.6 HBeAg positive HBV chronic carrier mother:
A HBV chronic carrier mother was considered a HBeAg positive chronic carrier mother
if repeatedly HBeAg positive.
3.5.7 Mother with ongoing or previous HBV infection:
A mother was considered HBV infected (anti-HBc positive), whether ongomg or
previous, if repeatedly positive for anti-HBc.
3.5.8 Mother seronegative for HBV infection:
A mother was considered negative for HBV infection if negative for HBsAg and anti-
HBc (total).
3.5.9 Child successfully vaccinated with hepatitis B vaccine:
A child was considered successfully vaccinated (immune) with hepatitis B vaccine if the
child had an anti-HBs concentration greater than 10 mIU/mL after receiving all three
doses of hepatitis B vaccine.
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Chapter 4: Data Management, Methods of Analysis and
Description of the Data
This chapter consists of four main sections. In the first section (4.1) the databases created
in the survey are described and data management is presented. The second section (4.2)
describes the statistical techniques and methods applied in the analysis. The third section
(4.3) defines the dependent and independent variables in the survey. Finally, the fourth
section (4.4), describes the data contained in the databases (mainly of children aged 1-3)
and focuses on describing, examining, analysing and reducing the independent variables
included in the analysis of HBV infection and hepatitis B vaccine coverage amongst
study participants.
4.1 Database description and data management:
There were a total of seven Epi-info database files created in the survey. These database
files were designed, constructed, and managed by the primary study investigator, who
also functioned as one of the data-entry clerks who entered data from the questionnaires
into their corresponding databases. The database files were as follows:
1- Database file 1 containing data from questionnaire of children aged 1-3 and their
mothers (questionnaire 1, annex 1).
2- Database file 2 containing data from questionnaire of children aged 4-9
(questionnaire 2, annex 2).
3- Database file 3 containing laboratory results of children aged 1-3.
4- Database file 4 containing laboratory results of mothers of children aged 1-3.
5- Database file 5 containing laboratory results of children aged 4-9.
Data entered into database files 1 to 5 was double-entered, checked, validated, and
corrected as necessary. After the databases above were completed two more databases
were created by the primary study investigator as follows:
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6- Database file 6 containing data from questionnaire of children aged 1-3 and their
mothers, together with their corresponding laboratory results.
7- Database file 7 containing data from questionnaire of children aged 4-9 and their
corresponding laboratory results.
There were 1285 completed questionnaires of children aged 1-3 and their mothers with
their corresponding children's and mother's blood sample results, and 467 completed
questionnaires of children aged 4-9 with their corresponding blood sample results.
Database file 1 had 74 fields, and database file 2 had 66 fields, with each field
corresponding to a field in questionnaires 1 and 2, respectively. Database files 1 and 2
had a similar format and structure, except for 8 fields focusing on birth history of the
child that were not present in database 2 because these were not originally part of
questionnaire 2.
Data from these questionnaires was entered into their corresponding databases in Sanaa
during the months of September, October, and November 2001. The data was entered by
two different data entry clerks, into two different database files. The database files were
compared and differences were rectified by referring to the original questionnaires and
the data was adjusted in the database accordingly. This was repeated until the data
contained in both databases was identical, resulting in final checked and validated
database files 1 and 2.
In both database files 1 and 2 the fields were set where appropriate, with checks, legal
values, must enter format, minimum and maximum values, unique value, and skips. For
example, field (or question) two in database files 1 and 2, which is the child's
identification number, was a must enter field, with a unique value and within a specific
range. In other words, this field could not be left empty, the value entered must lie within
the range of 1001 to 2286, and only one record could be given this identification number.
Another example is field 27 in database 1, which is "Have you breastfed this child?"
This was a must enter field, with legal values of 1 or 2, corresponding to yes or no, and
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had a skip option to skip the following field 28, which was "For how long have you
breastfed this child?" if the answer to this question was no, which was not applicable in
this case.
Three database files were constructed for the laboratory results. One of these was for
children aged 1-3 (database file 3), one for mothers of the children aged 1-3 (database file
4), and one for children aged 4-9 (database file 5). Laboratory results were entered twice
on different occasions, for each of the three database files, over a period extending from
November 2001 until February 2002. The two database files were compared and although
no differences were found, these would have been rectified by referring to the original
laboratory results provided by the laboratory and adjusting the database accordingly.
The laboratory database files were also set with the appropriate checks and legal values.
Finally, database file 1 was merged with database files 3 and 4, producing database file 6
containing data from the questionnaire of children aged 1-3 and their mothers together
with their corresponding laboratory results. Similarly, database file 2 was merged with
database file 5, producing database file 7 containing data from the questionnaire of
children aged 4-9 with their corresponding laboratory results.
Database files 6 and 7 were transformed from Epi-info files to Stata files using the
programme Stat-Transfer version 6.
These Stata files were set using the appropriate commands in the statistical software Stata
7 to adjust for the stratification, clustering, and sample weights resulting from the survey
design. This avoids biased results when computing point estimates, standard error, and
95% confidence intervals (explained in methods of analysis).
These database files were used for subsequent analysis and were further developed by
creating new variables as and when needed.
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4.2 Statistical techniques and methods of analysis:
All the statistical analysis was performed using the statistical software Stata 7.
Because the survey had a multistage sampling design and the sampling was not carried
out by simple random sampling, the stratification, clustering, and probability of being
selected (probability/sampling weights) resulting from the survey design had to be
accounted for in order to avoid biased estimates. In other words, adjustments had to be
made in the data analysis to account for the stratification, clustering, and probability
weights involved in the survey design. This is essential in order to obtain the correct point
estimates, standard errors, 95% confidence intervals and test statistics (StataCorp (A),
2001). In the survey, there were a total of 5 strata with each province constituting one
stratum and 25 clusters or primary sampling units (PSU) with each district constituting
one cluster. The sampling (probability) weight is equal or proportional to the inverse of
the probability of being selected (StataCorp (A), 2001). This was calculated for all the
study participants of each district by dividing the total population size of the districts
province by the number sampled from that district. Data on stratification, clustering and
sampling weights was held in the database in the variables "stratum", "psuid", and
"finalwg4", respectively.
The statistical software Stata 7 has a group of survey commands, specifically developed
for the analysis of survey data that all start with the prefix "svy" (short for survey). These
make the necessary adjustments in the analysis to account for clustering, probability
weights and stratification in the design. Before using the survey commands (e.g. svylogit,
svytab) the dataset in Stata 7 had to be survey set (setting the dataset so that the statistical
survey commands make the necessary adjustments in the analysis), which basically
requires the specification of variables containing data on sampling weights, strata, and
cluster identifier variables. In both combined datasets 6 and 7, probability weight was
specified to be "finalwg4", strata was specified to be "stratum", and cluster was specified
to be "psuid". Once these were set, the survey commands automatically used these design
specifications in all subsequent survey command estimations unless they were cleared or
changed (StataCorp (B), 2001).
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Once the data had been survey set, the survey estimation commands (e.g. svylogit) were
used in the same manner as the non-survey version of the command (e.g. logit). All the
analysis and computations mentioned were performed using survey estimation commands
unless indicated otherwise. Similarly all the percentages, proportions, prevalence
estimates, odds ratios (OR), 95% confidence intervals (95% Cl) were weighted estimates
that took into account the survey design unless indicated otherwise. It should be noted
that the Stata user's guide explains that the "likelihood" in the output for weighted and
cluster designs is not a true likelihood (pseudo likelihood), that is, the likelihood is not the
distribution of the sample and that the point estimates are from a weighted "ordinary"
maximum-likelihood estimator. The consequence of this pseudo-likelihood means that
the standard likelihood tests are no longer valid and cannot be performed (StataCorp (A),
2001).
A socioeconomic index was constructed for this survey by performing a multiple
correspondence analysis (MCA) (Van Kerm, 1998). Correspondence analysis is a method
for deriving a set of coordinate values representing the row and column categories of a
contingency table, allowing the associations in the table to be displayed graphically.
MCA actually conducts an adjusted simple correspondence analysis on the Burt matrix
constructed with a list of variables, which is a matrix of frequency counts resulting from
all two-way cross-tabulations of the variables in the list including cross-tabulations of
each variable with itself (Van Kerm, 1998).
The MCA was done in Stata using a Stata command developed by Philippe Van Kerm at
the Boston College Department of Economics. The command MCA produces numerical
results and graphical representations for MCA (Van Kerm, 1998). This allowed
identification of all the variables that corresponded well with the remaining variables and
with itself. In other words, variables with subcomponents or categories that were clearly
demarcated from each other and that were closely linked with the subcomponents or
categories of the remaining variables. These variables were then combined together
forming the socioeconomic index. Variables that did not correspond well were excluded
from the index. All of the variables included in the MCA were and must be categorical
variables for the MCA to be performed. The socioeconomic index allowed the
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classification of study participants into low, middle and upper socioeconomic classes
based on a group of variables identified in the MCA effectively representing household
characteristics, household possessions, as well as educational and social status of the
mother and father. The variables identified in the MCA representing household
characteristics were household ownership, type of household, what the household was
built of, availability of an electricity supply, source of water supply, and the crowding
index of the household. Variables representing household possessions were ownership of
a fridge/freezer, television, home telephone, mobile telephone, motorbike, radio and car.
Variables representing educational and social status were educational status of the
mother, educational status of the father and employment status of the mother. Different
cut-off points for the index and the significance of the difference between the cut-off
points of the index was examined. Finally, study participants that had a socioeconomic
index of 1-9 (39.4%) were classified as low socioeconomic status, those with an index of
10-13 (39.6%) were classified as middle socioeconomic status, and those with an index
of 14-19 (21%) were classified as upper socioeconomic status.
Following data entry and after the data was checked, verified and cleaned a data analysis
was performed using survey command cross-tabulations. These tables have the same cell
frequencies as standard tables, but the proportions, percentages, and confidence intervals
are adjusted according to the study design. They were produced for area of residence for
all variables such as baseline information on the child's age, birth order, personal and
vaccination history, mother's characteristics, father's characteristics, and the household's
characteristics and possessions. Where appropriate, variables were examined for
percentage and cumulative distribution, minimum and maximum values, mean, median,
and were reduced to categorical variables.
The first objectives of the survey to be measured were the prevalence objectives. These
were measuring the prevalence of anti-HBc positivity and HBV chronic carrier status
amongst children aged 1-3, mother's of children aged 1-3 (women of childbearing age),
children aged 4-9, and hepatitis B vaccine coverage amongst children aged 1-3
participating in the survey. This was performed using survey cross-tabulations for each
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outcome of interest (dependent variable) in the dataset by the relevant independent
variables. These computed the weighted prevalence of each outcome of interest by the
relevant independent variables, 95% Cl of the prevalence estimates, number of
observations, adjusted design-based Pearson chi square test of significance with Rao and
Scott second order correction, and p-values. The adjusted design-based Pearson chi
square test of significance with Rao and Scott second order correction is the
recommended test of significance for cross-tabulations using survey commands
(StataCorp (A), 2001). Examining the output from the survey cross-tabulations and their
design-based adjusted Pearson chi square values allowed the identification of variables
potentially associated with the outcomes of interest that may be significant in the
univariable and multivariable analysis.
Secondly, a univariable analysis was done to estimate the association of each dependent
variable in the analysis with the explanatory variables under investigation in the survey.
This was performed using survey logistic regression which computed crude odds ratios
(OR), 95% confidence intervals (Cl), standard errors (SE), adjusted Wald tests and
p-values. These were computed as log OR, 95% Cl, and SE and by using an option in the
regression model these estimates were anti-logged and transformed back to the normal
scale. In the case of binary explanatory variables the univariable analysis was performed
directly. In the case of categorical explanatory variables, where appropriate (such as in
the case of ordered categorical variables), the linear OR (OR per one unit increase in the
variable), its 95% Cl, SE, adjusted Wald tests were computed, and the p-value of the
linear OR was indicative of the significance of the association with the dependent
variable. When it was not appropriate to use a linear OR, such as type of household
where the categories of the variable cannot be ordered, an adjusted Wald test (survey test)
was performed to compute the significance of association of joint effect of the categories
of this variable with the dependent variable.
After completing the univariable analysis the explanatory variables were ordered
according to the p-value, which was considered indicative of the significance of their
association with the dependent variable. A p-value less than or equal to 0.05 was
considered indicative of evidence of a significant association between the explanatory
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variable and the outcome of interest. Nevertheless, variables with a p-value less than 0.2
were taken forward to be included in the multivariable model in order to avoid missing
any statistically significant associations that may have been confounded by other
explanatory variables.
A few explanatory variables were treated as a priori variables and it was decided to take
these variables forward to the multivariable analysis and include them in the final model
regardless of the significance of their association with the outcome of interest. This was
done either because of evidence suggesting an association of these variables with the
dependent variable under investigation or the importance of obtaining information about
these variables. These a priori variables were age-group, sex, area of residence, and
mothers educational status ..
Thirdly, a multi variable analysis was done using multiple logistic regression to
investigate the association of the dependent variables with independent variables
adjusting for the remaining independent variables in the model. Explanatory variables
associated with the dependent variable identified in the univariable analysis with a
p-value less than 0.2 were added to the multivariable model, one at a time, starting with
the variable with the most significant association (smallest p-value) with the dependent
variable in the univariable analysis. This process was repeated until all explanatory
variables with p-values less than 0.2 were added to the model (forward fitting). The a
priori variables were also fitted to the model according to the significance of their
association with the dependent variable. All the independent variables in the
multi variable model were then tested for their significance in the model and variables
with a p-value greater than 0.05 were removed from the model one at a time, starting with
the least significantly associated independent variable (largest p-value) with the
dependent variable until only significantly associated independent variables remained in
the model. If a priori variables were removed during the process of removing variables
according to their p-value, these were added back to the final model at the end of the
process.
After completing the forward fitting multi variable modelling a backward fitting
multivariable model was done to compare results obtained by the two methods. This was
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done by adding the explanatory variables identified in the univariable analysis with a p-
value less than 0.2 all in one go. Independent variables were then removed from the
model, one at a time, starting with the variable with the least significant association
(largest p-value) until only significantly associated variables remained in the model. If
a priori variables were removed during the process, these were added back to the final
model. If an independent variable was found to be statistically significantly associated
with anti-HBc positivity or HBV chronic infection in the final multivariable model of
either of these two dependent variables, this independent variable was added to the final
multi variable model of the other dependent variable, regardless of the strength of its
association, resulting in two models, one for anti-HBc positivity and one for HBV
chronic infection, with identical independent variables in them.
In order to examine the association of the socioeconomic status variable with anti-HBc
positivity and HBV chronic infection the exact process of the multivariable analysis
described above conducted on all the variables was repeated using the socioeconomic
status variable alone with the remaining variables but excluding all the socioeconomic
indicator variables that contributed to and were included in the socioeconomic status
variable (household characteristics, household possessions, and mothers and fathers
educational status).
The multiple logistic regression computed adjusted OR, 95% Cl, SE, adjusted Wald tests
and p-values. These were computed as log OR, 95% Cl, and SE and were anti-logged and
transformed back to the normal scale.
Finally, the effectiveness of hepatitis B vaccination in preventing anti-HBc positivity and
HBV chronic infection amongst children aged 1-3 was measured using the formula,
vaccine effectiveness = 1 - relative risk. Since anti-HBc positivity was found to be a rare
disease in Yemen, and in rare diseases the risk ratio approximates the odds ratio and rate
ratio, the odds ratio was used to estimate vaccine effectiveness. Vaccine effectiveness
was estimated by comparing completely vaccinated to unvaccinated children.
The OR of anti-HBc positivity by hepatitis B vaccination status was computed using
logistic univariable analysis and this OR was used to estimate the effectiveness of
hepatitis B vaccination in preventing anti-HBc positivity using the formula described
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above. When it was attempted to estimate the effectiveness of hepatitis B vaccine in
preventing HBV chronic infection it could not be estimated using logistic univariable
analysis because no OR or 95% confidence intervals could be computed since there were
no cases of HBV chronic infection amongst vaccinated children and this group predicted
perfect failure. Therefore, the OR was computed using survey cross-tabulations of HBV
chronic infection by vaccination status (comparing completely vaccinated with
unvaccinated children) using the weighted percentages of the number of observations in
the cells. The validity and reliability of this method was tested by comparing the
effectiveness of hepatitis B vaccination in preventing anti-HBc positivity computed by
logistic univariable analysis and survey cross-tabulations, and it was found that both
methods produced the same results. The vaccine effectiveness computed by this
technique is equivalent to the prevented fraction amongst exposed group computed by the
epi-tab table for epidemiologists from cross-sectional or case-control studies, but in this
case it was adjusted for design effect.
4.3 Definition of dependent and independent variables:
4.3.1 Dependent variables:
1- Hepatitis B surface antigenaemia amongst mothers (MsAg3).
2- Hepatitis B surface antigenaemia amongst children aged 1-3 (CsAg3).
3- Hepatitis B surface antigenaemia amongst children aged 4-9 (sAg3).
4- Hepatitis B core antibody amongst mothers (mcab 1).
5- Hepatitis B core antibody amongst children aged 1-3 (ccabl).
6- Hepatitis B core antibody amongst children aged 4-9 (cab 1).
7- Hepatitis B surface antibody amongst children aged 1-3 (csabl).
8- Hepatitis B e antigen (MeAg2) amongst chronic carrier mothers.
9- Immunoglobulin-M hepatitis B core antibody (IgM anti-HBc) amongst children.
10-Vaccination status of the children (vacstat 1).
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4.3.2 Independent (explanatory) variables:
The main independent variables in the survey were:
1- Age of mother, age of child 1-3, and age of child 4-9.
2- Sex of child aged 1-3 and sex of child aged 4-9.
3- Province and area of residence.
4- Qualifications of the person managing delivery of the child.
5- Setting in which the child was delivered.
6- Type of delivery.
7- Antenatal care during pregnancy.
8- Breastfeeding.
9- Birth order of mother, child aged 1-3 and child aged 4-9.
10-Knowing of hepatitis B vaccine.
11-Mothers education.
12-Mothers employment.
13- Fathers education.
14- Fathers employment.
15-Household ownership.
16-Type of household.
17- Availability of an electricity supply.
18-Household source of water supply.
19-Crowding index in the household.
20- Television, refrigerator/freezer, radio, telephone, mobile telephone, motorcycle,
and bicycle ownership.
21- Schooling of child aged 4-9.
22- Number of doses of hepatitis B vaccine.
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4.4 Data description:
4.4.1 Database of children aged 1-3 (Database 1):
The final dataset contained 1285 records with each record representing one child aged
1-3 and the child's mother participating in the survey. The dataset had 74 fields,
representing the fields in questionnaire 1 (annex 1). The dataset consisted of data on the
child and mother. It contained baseline information such as identification number,
province, district, city or village, street, household and area of sampling. It also consisted
of information on the child's personal and vaccination history, mother, father, and the
household's characteristics and indicators of socioeconomic status.
Child and mother identification numbers:
Each record had two unique identification numbers one for the child aged 1-3 starting
with 1001 and ending with 2286, and another for the mother starting with 4001 and
ending with 5286. Mothers starting with 4xxx had the same last three digits as their
children aged 1-3 starting with lxxx, and mothers starting with 5xxx had the same last
three digits as their children aged 1-3 starting with 2xxx.
One record had missing data on anti-HBc status of the child. Because this was one of the
principal outcomes under investigation, record number 247 (child identification number
1247 and consequently mother identification number 4247) was dropped from the
analysis.
Province, district, street, city or village, household and area:
These recorded the province, district, and city or village from which the study participant
was sampled, as well as street name and household number where appropriate.
The variable "area" classified areas in the survey into urban or rural, and each study
subject was recorded as either being sampled from an urban or rural area.
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Interview time and date, interviewer, and person interviewed:
These recorded the date and time the interview was started. The name and identification
code of the study investigator completing the interviewer administered questionnaire was
recorded, as well as the name of the person interviewed and the relationship of this
person to the child. However, the name of the person interviewed as well as study
participant was not entered to the database to ensure confidentiality and anonymity of
study participants. The mother or father of the child was the target person to be
interviewed and this was fulfilled in 95% of the interviews with study participants. If this
was not possible the aunt, uncle, grandfather or grandmother of the child was
interviewed.
Age of child, date of birth and source of child age:
The first question attempting to determine the age of the child was the date of birth of the
child. The date of birth of the child was known for only 45% of children aged 1-3
participating in the survey, in which case the source of the date of birth was determined
by a birth certificate, vaccination card, or parents memory or records.
Parents were then directly asked for the age of their child in months (12 to 36 months). If
the date of birth was known, this was used to compute the age of the child in months. If
the date of birth was not known the age was recorded after asking the parents a series of
questions in order to determine the age of their child as accurately as possible. These
aimed to determine when during the year the child was born (e.g. summer, winter) or to
link the birth of the child to a memorable date during the year (for example Eid Alfitr,
Eid Al Adha, Ramadan).
The mean age of children participating in the survey was 23.7 months (95% Cl 23.1 to
24.4) ranging from 12 to 36 months. After examining the percentage and cumulative
distribution, and minimum and maximum values of age, this was reduced to the
categorical variable age-group that was initially divided into 8 and finally 4 categories,
ensuring that the baseline group was large enough to avoid generating wide confidence
intervals (table 4.4.1 A).
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Table 4.4.1 A
Age-group of children participating in survey of children aged 1-3
No Age-group Frequency Percent Cumulative
Percentage
Age-group in months
(8 categories)
12 to 14 139 10.8 10.8
15 to 17 130 10.1 20.9
18 to 20 225 17.5 38.4
21 to 23 159 12.4 50.8
24 to 26 187 14.6 65.4
27 to 29 88 6.9 72.2
30 to 32 165 12.8 85.1
33 to 36 192 14.9 100
Total 1285 100
Age-group in months
(4 categories)
12 to 17 269 20.9 20.9
18 to 23 384 29.9 50.8
24 to 29 275 21.4 72.2
30 to 36 357 27.8 100
Total 1285 100
The source of the child's age was recorded as an indicator of the accuracy of the reported
age of the child (table 4.4.1 B).
Table 4.4.1 B
Source of age for children participating in survey of children aged 1-3
No. Source Frequency Percent
1 Approximate 132 13.4
2 Health records 422 28.5
3 Birth certificate 61 3.9
4 Parents memory 645 51.9
5 Parents records 22 1.9
6 ID card or passport 3 0.3
Total 1285 100
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When the source of the child's age was a birth certificate, health record (e.g. vaccination
card), parents records, or identification card or passport, and evidence of the child's age
was verified by one of the study investigators the age of the child was considered
accurately determined. Parents memory was recorded when either one of the parents
remembered the month of birth of the child, or linked the birth of their child to a
memorable event but no evidence of the child's age was seen by the study investigator.
Approximate was recorded when no evidence of age or date of birth was seen by the
study investigator and neither of the parents could confidently specify when their child
was born. This was estimated by linking the birth of the child to a memorable event, for
example, asking when in the year the child was born (summer or winter), or relating the
birth of the child to memorable events such as Eid celebrations or Ramadan.
Sex of the child:
This recorded whether the child was male or female. 52% of the children aged 1-3
participating in the survey were male and 48% were female.
Place of birth of child:
Approximately 19% of children participating in the survey were born in a health setting
and 81% in a home setting. Table 4.4.1 C shows the place of birth of children aged 1-3
participating in the survey.
Table 4.4.1 C
Place of birth of child participating in survey of children aged 1-3
No. Place of delivery of Urban % (no) Rural % (no) Total % (no)
child
1 General hospital 41.0 (235) 4.7 (57) 16.2 (292)
2 Private hospital 4.4 (19) 1.8 (13) 2.6 (32)
3 Health centre 0.6 (2) 0.3 (4) 0.4 (6)
4 Father/mother home 44.5 (200) 75.7 (565) 65.8 (765)
5 Grand Parents home 8.3 (46) 13.4 (92) 11.8 (138)
6 Other 1.3 (7) 4.1 (45) 3.2 (52)
Total 100 (509) 100 (776) 100 (1285)
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There were significant differences in place of delivery by area of residence. While 45%
of urban deliveries took place in the home of the father/mother of the child, 76% of rural
deliveries took place in the home of the father/mother of the child. On the other hand,
while 41% of deliveries in urban areas took place in a general hospital, only 5% of rural
deliveries took place in a general hospital (p<O.OOOl).Differences also existed in place of
delivery between the two urban areas in the survey where 35% of deliveries in Sanaa
took place in a health setting compared to 69% of deliveries in Aden (p=0.003).
Who delivered child and type of delivery:
Approximately 39% of deliveries of children aged 1-3 participating in the survey were
attended by a medically qualified individual (doctor, nurse, or midwife), and the
remaining 61% were attended by a relative or traditional birth attendant (table 4.4.1 D).
Table 4.4.1 D
Person delivering child participating in survey of children aged -3
No. Person who delivered the Urban % (no) Rural % (no) Total % (no)
child
1 Doctor 49.3 (263) 9.4 (99) 21.9 (362)
2 Nurse 5.6 (30) 5.7 (44) 5.7 (74)
3 Midwife 8.3 (48) 11.2 (75) 10.3 (123)
4 Traditional birth attendant 8.5 (45) 20.5 (123) 16.7 (168)
5 Relative 22.7 (102) 49.5 (401) 41.0 (503)
6 Alone or with husband 3.5 (13) 1.8 (21) 2.4 (34)
7 Other 1.9 (8) 2.1 (13) 2.0 (21)
Total 100 (509) 100 (7761 100 (1285)
The person who delivered the child varied by area. While 63% of urban deliveries were
attended by a medically qualified individual, only 26% of rural deliveries were attended
by a medically qualified individual (p<0.0001). Differences also existed between the two
urban provinces in the survey. Whilst 54% of deliveries in Sanaa were attended by a
medically qualified individual, 82% of deliveries in Aden were attended by a medically
qualified individual (p=0.005).
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Overall, 98% (124911285) of the children participating in the survey were delivered by
normal vaginal delivery and the remaining 2% (3611285) by caesarean section. 92%
(34/36) of caesarean sections were carried out in urban areas, where health care facilities
and qualified staff are available, compared to the remaining 8% of sections done in rural
areas (p<O.OOOl). Only one woman in Taiz and one woman in Shabwa underwent
caesarean sections. No women in Hodeidah underwent caesarean sections. It is unknown
if women undergoing caesarean sections in Sanaa and Aden (urban areas) included
women from other provinces whom were transported to urban areas due to complications
during labour and were consequently delivered by caesarean section. Another possibility
is that availability of facilities for caesarean section may have tempted health care
providers to perform a caesarean section for a child who would have been delivered by
normal vaginal delivery had they not intervened with the normal course of labour. There
was no evidence suggesting that caesarean section was more common in private
hospitals, which may be indicative of supplier induced demand.
Antenatal care during pregnancy:
A woman was considered to have received antenatal care if she came into contact with a
qualified health care provider at any time during her pregnancy with her child aged 1-3
involved in this survey before the onset of labour. Overall, 45.2% of women participating
in the survey received antenatal care during their pregnancy, 54.7% did not, and 0.1%
could not recall if they received antenatal care (table 4.4.1 E).
Table 4.4.1 E
Antenatal care during pregnancy for mothers of children aged 1-3
No. Received antenatal care Urban % (no) Rural % (no) Total % (no)
1 Yes 65.0 (350) 36.1 (269) 45.2 (619)
2 No 34.7 (157) 63.9 (504) 54.7 (661)
3 Don't know 0.3 (2) 0.1 (1) 0.1 (3)
Total 100 (509) 100 (774) 100 (1283)
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There were marked differences in receiving antenatal care between provinces. 65% of
women in urban areas reported having received antenatal care at anytime during their
pregnancy compared to 36% of women in rural areas (p<0.0001). Differences also
existed in receiving antenatal care between the two urban areas in the survey. 56% of
women in Sanaa received antenatal care during pregnancy compared to 82% of women in
Aden (p=0.003). Records 678 and 682 had missing data on whether they received
antenatal care or not.
Breastfeeding and its duration:
98.6% (1262/1284) of mothers breastfed their child aged 1-3 participating in the survey
and 1.4% (2211284) of mothers did not breastfeed their child. Record number 711 had
missing data on whether the child was breastfed or not. Out of the 1262 mothers whom
breastfed their child aged 1-3 participating in the survey, there was missing data from
three mothers (record numbers 357, 581 and 709), leaving 1259 mothers with data on
duration they breastfed their child.
The mean duration of breast feeding was 16.2 months (95% Cl 15.4 to 16.9) ranging
from 1 to 36 months. After examining the percentage and cumulative distribution, and
minimum and maximum values of duration of breastfeeding, this was reduced to a
categorical variable and was divided into 3 categories, up to 1 year, 1 to 2 years, and 2 to
3 years breastfeeding (table 4.4.1 F).
Table 4.4.1 F
Duration breastfeeding of children aged 1-3 participating in the survey
No. Duration breastfeeding Urban % (no) Rural % (no) Total % (no)
1 Up to 1 year 41.5 (209) 31.6 (262) 34.7 (471)
2 1 to 2 years 51.6 (250) 58.0 (436) 56.0 (686)
3 2 to 3 years 6.8 (35) 10.5 (67) 9.3 (102)
Total 100 (494) 100 (765) 100 (1259)
Approximately 91% of women participating in the survey breastfed their child aged 1-3
. up to 2 years. A higher proportion of rural women breastfed their children for 1 to 2
years, and 2 to 3 years than urban women (p=0.009).
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Child birth order:
The mean number of deliveries by mothers of the children aged 1-3 participating in the
survey was 4.6 (95% Cl 4.4 to 4.8) ranging from 1 to 18. The mean birth order of
children aged 1-3 participating in the survey was 4.5 (95% Cl 4.2 to 4.8) ranging from
1 to 18. After examining the distribution of child birth order, and its minimum and
maximum values, child birth order was reduced to a categorical variable and was divided
into 6 categories, with birth order's 6, 7 up to 18 combined into one category 6 to 18
(table 4.4.1 G).
Table 4.4.1 G
Birth order of children aged 1-3 participating in the survey
No. Childs birth order Urban % (no) Rural % (no) Total % (no)
1 1 25.4 (130) 14.2 (111) 17.7 (241)
2 2 18.1 (97) 16.5 (113) 17.0 (210)
3 3 15.2 (84) 13.5 (114) 14.0 (198)
4 4 13.4 (71) 8.0 (70) 9.7 (141)
5 5 8.7 (42) 9.5 (81) 9.3 (123)
6 6 to 18 19.2 (85) 38.3 (287) 32.2 (372)
Total 100 (509) 100 (776) 100 (1285)
Approximately 50% of children aged 1-3 participating in the survey were one of the first
three children in birth order. 32% of children aged 1-3 participating in the survey were
between the 6th to is" child in birth order. A higher proportion of the children aged 1-3
born in urban areas were the 1", 2nd, 3rd, or 4th in birth order, whereas a higher proportion
of children born in rural areas were the 5thor 6th to 18th in birth order (p<0.0001). This
meant that children aged 1-3 living in rural areas were more likely to have older siblings
than children living in urban areas.
Vaccination card:
84% (1109/1285) of parents of children aged 1-3 participating in the survey said their
child aged 1-3 had a vaccination card. There was no evidence of a significant difference
in the proportion of parents saying their child had a vaccination card in urban areas (90%)
compared to rural areas (81%) (p=0.06) (table 4.4.1 H).
115
Table 4.4.1 H
Having a vaccination card amongst children aged 1-3 participating in the survey
No. Has vaccination card Urban % (no) Rural % (no) Total % (no)
1 Yes 89.6 (467) 81.3 (642) 83.9 (1109)
2 No 10.4 (42) 18.7 (134) 16.1 (176)
Total 100 (509) 100 (776) 100 (1285)
When study participants who said their child had a vaccination card were asked to show
it to the study investigator only 54% (596/1108) had the vaccination card available and
46% (512/1108) did not. There was no significant difference in vaccination card
availability by area (p=O.4). There was one record (record number 643) that had missing
data on vaccine availability amongst those reporting having a vaccination card.
Knowledge of hepatitis B vaccine:
Overall, approximately 78% of study participants claimed to know of hepatitis B vaccine,
22% claimed they did not know of hepatitis B vaccine and less than 0.5% could not
determine whether they knew of the vaccine or not (table 4.4.1 J)
Table 4.4.1 I
Knowledge of hepatitis B vaccine amongst parents of children aged 1-3
participating in the survey
No. Know of hepatitis B Urban % (no) Rural % (no) Total % (no)
vaccine
1 Yes 92.1 (468) 71.3 (504) 77.8 (972)
2 No 7.5 (39) 28.4 (266) 21.8 (305)
3 Undetermined 0.4 (2) 0.3 (7) 0.4 (7)
Total 100 (509) 100 (775) 100 (1284)
There were significant differences in knowledge of hepatitis B vaccine by area. 92% of
urban participants claimed to know of hepatitis B vaccine compared to 71% of rural
participants (p<0.0001). There was no significant difference in knowledge of hepatitis B
vaccine between the urban provinces in the survey, Sanaa and Aden, where the
proportion of respondents who claimed to know of hepatitis B vaccine were 93 and 91%,
respectively (p=0.7). Similarly, there was no significant difference in knowledge of
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hepatitis B vaccine between the rural provinces, Taiz, Shabwa, and Hodeidah, included in
the survey (p=O.l).
Been vaccinated with hepatitis B vaccine and number of doses:
Although 78% of parents interviewed claimed to know of hepatitis B vaccine only 32%
of parents interviewed said their child aged 1-3 was vaccinated with hepatitis B vaccine,
66% said their child did not receive the vaccine and 2% did not know whether their child
aged 1-3 received the vaccine or not (table 4.4.l J).
Table 4.4.1 J
Parent's response whether their child aged 1-3 participating in the survey
received hepatitis B vaccine
No. Child was vaccinated with Urban % (no) Rural % (no) Total % (no)
hepatitis B vaccine
1 Yes 43.9 (239) 26.4 (174) 31.9 (413)
2 No 52.9 (251) 72.2 (589) 66.1 (840)
3 Don't know 3.2 (19) 1.5 (12) 2.0 (31)
Total 100 (509) 100 (775) 100 (1284)
44% of urban participants said that their child aged 1-3 received hepatitis B vaccine
compared to 26% of rural participants. On the other hand, although 72% of rural
participants said their child did not receive hepatitis B vaccine compared to 53% of urban
participants, this difference was not statistically significant (p=0.06). Record number 643
had missing data on parent's response whether their child aged 1-3 was vaccinated.
Differences existed between the two urban provinces in the survey. 37% of participants in
Sanaa said their child received hepatitis B vaccine compared to 57% of participants in
Aden (p=0.02). There was no evidence of a significant difference in parents response
regarding their child's vaccination between rural provinces (p=0.6).
Out of the study participants who said that their child received hepatitis B vaccine, 31%
(107/414) said their child received one dose, 29% (118/414) said their child received two
doses, and 39% (187/414) said their child received three doses. The number of doses of
hepatitis B vaccine received by the children who had a vaccination card was copied from
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the card whatever the person interviewed reported (table 4.4.1 K). If the vaccination card
had three doses recorded on it the child was classified as completely vaccinated. If the
card had one or two doses recorded on it the child was recorded as incompletely
vaccinated. Children were classified as unvaccinated if the child was reported to be
unvaccinated by the parents or vaccinated by the parents but their vaccination card
showed them to be unvaccinated. Children were classified as unknown vaccination status
if they were reported to be vaccinated but did not have evidence of their vaccination to
show the study investigator or if the parents did not know their child's vaccination status.
The vaccination status of 112411285 children aged 1-3 was accurately determined, and
13% (16111285) of children had an unknown vaccination status.
Table 4.4.1 K
Hepatitis B vaccination status amongst children aged 1-3 participating in the survey
No. Number of doses Frequency Percent
1 Zero 840 65.9
2 One 66 6.3
3 Two 81 6.2
4 Three 137 8.6
5 Unknown 161 13.0
Total 1285 100
Hepatitis B vaccination status was determined by study investigators by checking the
source of the child's vaccination status. 44% of children's vaccination status was
determined by a vaccination card and 56% of children's vaccination status was
determined by parent's memory.
After verifying hepatitis B vaccination status by study investigators, 21% of children
participating in the survey received at least one dose of hepatitis B vaccine, and 8.6%
received all three doses of vaccine. There was a significant difference in vaccination
status by area. 17.3% of children in urban areas were completely vaccinated compared to
4.6% of children in rural areas (p=0.05). Moreover, there was a significantly higher
proportion of completely vaccinated children in Aden (34.27%) compared to Sanaa
(8.5%) (p=0.002).
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Mother's age, place of birth and birth order:
Three questions were asked before directly asking about the mother's age. These were the
age of the mother at her first marriage, age of the mother's oldest child, and how long
after marriage she delivered her first child. The years of these questions were added to
give an approximate idea of the age of the mother. After this the mother was asked what
her age was. This allowed evaluation of the reliability of the reported age of the mother.
The mean age of mothers of children aged 1-3 participating in the survey was 28.5 years
(95% Cl 28.1 to 28.9) ranging from 15 to 49 years. Less than 5% of mothers were
younger than 20 years and just over 5% of the mothers were older than 40 years. After
examining the percentage and cumulative distribution, and minimum and maximum
values of mothers age, this was reduced to the categorical variable mothers age-group
that was initially divided into 7 and finally 5 categories, ensuring that the baseline group
was large enough to avoid generating wide confidence intervals (table 4.4.1 L).
Table 4.4.1 L
Age-group of mothers participating in survey of children aged 1-3
No Mothers age-group Frequency Percent Cumulative Percentage
1 Age-group in years
(7 categories)
15 to 19 46 3.6 3.6
20 to 24 354 27.6 31.1
25 to 29 349 27.2 58.3
30 to 34 268 20.9 79.1
35 to 39 177 13.8 92.9
40 to 44 79 6.2 99.1
45 to 49 12 0.9 100
Total 1285 100
2 Age-group in years
(5 categories)
15 to 24 400 31.1 31.1
25 to 29 349 27.2 58.3
30 to 34 268 20.9 79.1
35 to 39 177 13.8 92.9
40 to 49 91 7.1 100
Total 1285 100
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88% of mothers age was approximately estimated (i.e. the mother did not know the date,
month, or year she was born), 8% was obtained from family records, 3% from an
identification card (ID) or passport, and 1% from a birth certificate.
Having an ID card or passport as source of age does not necessarily mean that the age
recorded is accurate. Mothers or their relatives may have guessed their age and recorded
it in the passport or ID card. Nevertheless, 3% of mothers age was determined by ID card
or passport whereas a lower proportion 0.3% of children's age was determined by
passport or ID indicating that with increasing age individuals are more likely to have an
ID card or passport particularly amongst males.
Out of the mothers participating in the survey 35% were born in Taiz, 28% in Hodeidah,
9% in Sanaa, 8% in Aden, 6% in Shabwa, and 14% in provinces other than the five
targeted in the survey. Over 90% of women sampled from Taiz, Hodeidah, and Shabwa
were born in these provinces. On the other hand, only 41% of women sampled from
Sanaa were born there. 42% of women sampled in Sanaa were born in provinces other
than those targeted in the survey, 11% in Taiz, 4% in Hodeidah, and 2% in Aden.
Similarly, 70% of women sampled from Aden were born there, 21% were born in
provinces other than those targeted in the survey, 7% were born in Taiz, 1% in Hodeidah
and 1% were born in Shabwa.
The mean number of siblings per mothers was 7.2 (95% Cl 7.0 to 7.4) ranging from 0 to
20. The mean birth order of mothers participating in the survey was 3.9 (95% Cl 3.8 to
4.1) ranging from 1 to 19. After examining the distribution, minimum and maximum
values of mothers birth order it was reduced to 6 categories with birth order 6 and above
combined into one category 6 to 19 (table 4.4.1 M).
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Table 4.4.1 M
Birth order of mothers participating in survey of children aged 1-3
No. Mothers birth order Urban % (no) Rural % (no) Total % (no)
1 1 22.1 (109) 22.5 (169) 22.4 (278)
2 2 15.9 (80) 15.3 (123) 15.5 (203)
3 3 16.0 (80) 16.7 (124) 16.5 (204)
4 4 13.6 (67) 12.1 (93) 12.6 (160)
5 5 12.2 (61) 9.0 (71) 10.0 (132)
6 6 to 19 20.2 (112) 24.5 (196) 23.1 (308)
Total 100 (509) 100 (776) 100 (1285)
Over 50% of mothers participating in the survey were one of the first three of their
siblings in birth order. 23% of mothers participating in the survey were between the 6th to
19th child in birth order. There was no evidence of a significant difference in mothers
birth order by area (p=0.3).
Mothers educational and employment status:
Overall, 37% (95% Cl 29.9 to 44.1) of mothers participating in the survey claimed to be
educated compared to 63% (95% Cl 55.91 to 70.07) who were uneducated. The
proportion of mothers completing schooling and university was significantly higher in
urban areas compared to rural areas (p<0.0001). 29%, 14%, and 5% of mothers
participating in the survey claimed to have completed primary school, secondary school
and university or college, respectively, in urban areas compared to 9%, 4% and 0.6% of
mothers in rural areas (table 4.4.1 N).
Table 4.4.1 N
Educational status of mothers participating in survey of children aged 1-3
No. Educational status Urban % (no) Rural %_(no) Total % (no)
1 Uneducated 37.0 (158) 75.4 (580) 63.3 (738)
2 Read and write (Basic) 15.0 (70) 10.7 (109) 12.1 (179)
3 Completed primary 28.7 (159) 9.4 (62) 15.5 (221)
4 Completed secondary 14.3 (91) 3.9 (22) 7.2 (113)
5 Completed university 4.9 (31) 0.6 (3) 1.9 (34)
Total 100 (509) 100 (776) 100 (1285)
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97% of mothers participating in the survey were not employed with only 3% (55/1285) of
mothers participating in the survey in paid employment. Approximately 8% of urban
women participating in the survey were in paid employment compared to 1.4% of rural
women (p=0.003). Approximately 50% of women in paid employment worked as
teachers, 25% as secretaries in the public and private sector, and the remaining 25%
worked for example in factories, ministries, or as cleaners.
Household ownership, type and characteristics:
Overall, 85% of households in the survey were owned and 15% were rented. 63% of
urban households were owned compared to 96% of rural households. In other words,
only 4% of rural households were rented compared to 37% of urban households
(p<O.OOOI). Apartments constituted 36% of urban residences and 1.4% of rural
residences. 17% and 81% of rural households were shacks (ill defined households built
of wood, corrugated steel sheets or non-specific mixed materials and with no concrete
roof) and houses, respectively, compared to 3% and 60% of urban households
(p<O.OOOI).
Rural households were more likely to be built of stone, mud or clay, and mixed materials
compared to urban households, which were more likely to be built of cement (p=0.007).
The mean number of rooms per household was 2.8 (95% Cl 2.5 to 3.2) ranging from 1 to
25. Approximately 90% of households had 1 to 7 rooms. The mean number of people per
household was 8.9 (95% Cl 8.4 to 9.3) ranging from 2 to 60.
The crowding index was calculated by dividing the number of people by the number of
rooms per household, giving the average number of individuals per room. The mean
crowding index overall, was 4.1 (95% Cl 3.7 to 4.5) individuals per room, ranging from 1
to 18 individuals per room. After examining its percentage distribution, minimum and
maximum values, crowding index was reduced to a categorical variable of six categories
with indexes 6 to 18 combined into one category (table 4.4.1 0).
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Table 4.4.1 0
Crowding index in households of children aged 1-3 participating in the survey
No Crowding index Urban % (no) Rural % (no) Total % (no)
1 One 6.7 (35) 4.9 (65) 5.5 (100)
2 Two 33.6 (165) 14.1 (158) 20.2 (323)
3 Three 31.0(155) 18.3 (157) 22.3 (312)
4 Four 15.9 (78) 20.8 (143) 19.2 (221)
5 Five 6.9 (39) 14.5 (87) 12.1 (126)
6 Six to eighteen 6.0 (37) 27.6 (166) 20.7 (203)
Total 100 (509) 100 (776) 100 (1285)
Crowding indexes 1, 2 and 3 were more common in urban areas, and crowding indexes 4,
5, and 6 to 18 were more common in rural areas (p<O.OOOl), indicating that rural
residents were living in more crowded households compared to their urban counterparts.
The mean number of individuals sleeping in the same room as the child aged 1-3
participating in the survey was 5.3 (95% Cl 5.1 to 5.6) ranging from 2 to 17.
Out of all the households participating in the survey 56% had an electricity supply. 98%
of urban households had an electricity supply compared to 37% of rural households
(p<O.OOOl). Out of the households that had an electricity supply, 99.7% of urban
households had an electricity supply all the time (excluding power failures), whereas only
61% of the rural households that had an electricity supply had it all the time and the
remaining 35% of rural households that had an electricity supply had it after sunset
(p=0.0008). 28% of households in the survey had a governmental water supply, 29% a
local project, 9% were supplied by car trucks, and 34% collected water using buckets
(table 4.4.1 P).
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Table 4.4.1 P
Source of water in households of children aged 1-3 participating in the survey
No. Source of water supply Urban % (no) Rural % (no) Total % (no)
1 Governmental 68.8 (384) 8.6 (52) 27.6 (436)
2 Local project 2.3 (9) 41.2 (434) 28.9 (443)
3 Car truck 23.9 (96) 2.5 (26) 9.2 (122)
4 Buckets 4.9 (19) 47.5 (263) 34.1 (282)
5 Other 0.2 (1) 0.2 (1) 0.2 (2)
Total 100 (509) 100 (776) 100 (1285)
There was a significant difference in source of water according to area of residence
(p<O.OOO1). Governmental water supply was more characteristic of urban areas, whereas
local projects, established by local inhabitants and supported by the government and
external donors, were more common in rural areas. Both these methods delivered tapped
water directly to the household. 69% of urban households had a governmental water
supply compared to 9% of rural households. On the other hand, 41% of rural households
had a local project water supply compared to 2% of urban households. Inurban areas, the
main alternative source of water was car truck where 24% of urban households obtained
water this way. In rural areas, the main alternative source of water was using buckets to
collect water from a water source where 48% of rural households obtained water this
way.
Fathers level of education and employment:
27% of fathers in the survey were uneducated and 73% of fathers claimed they could read
and write, regardless of their level of education (table 4.4.1 Q).
Table 4.4.1 Q
Educational status of fathers of children participating in survey of children aged 1-3
No. Fathers level of education Urban % (no) Rural % (no) Total % (no)
1 Uneducated 13.1 (51) 33.8 (219) 27.3 (270)
2 Read and write 14.3 (63) 18.5 (152) 17.2 (215)
3 Completed primary school 27.6 (147) 20.2 (193) 22.5 (340)
4 Completed secondary school 23.1 (136) 17.0 (148) 19.0 (284)
5 Completed university/college 21.9 (112) 10.5 (64) 14.1 (176)
Total 100 (509) 100 (776) 100 (1285)
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28%, 23%, and 22% of urban men claimed they had completed primary school,
secondary school and university or college, respectively, compared to 20%, 17% and
11% of their rural counterparts (p=0.0009).
The fathers of the children aged 1-3 in the survey had the following occupations: 30%
government employees, 39% manual labourers, 7% farmers, 5% private sector
employees, 3.8% shop owners, 3.6% worked overseas, 3% drivers, 1% professionals
(doctor, lawyer, engineers, academic staff at universities), 0.5% businessmen, 1%
students, 4.5% were unemployed and 1% were dead. Manual labourers worked for
example as builders, painters, or as carpenters. Individuals working overseas were mainly
in Saudi Arabia and the United Arab Emirates. Individuals in these countries worked as
manual labourers, cooks or waiters in restaurants, textile shops, sales assistants, and to a
lesser extent businessmen.
Household possessions:
Overall, approximately 30% of households of study participants had a fridge/freezer,
59% had a television, 65% a radio, 16% a home telephone, 4% a mobile telephone, 19%
a car, 5% a motorcycle, and 9% a bicycle (table 4.4.1 R). A significantly higher
proportion of households in urban areas had the household possessions listed in table
4.4.1 R except for motorcycle, which was more common in rural areas, and particularly
in Hodeidah province.
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Table 4.4.1 R
Household possessions of participants in the survey of children aged 1-3
No. Urban % (no) Rural % (no) Total % (no) P value
1 Freezer
Yes 64.0 (361) 14.8 (229) 30.3 (590)
No 36.1 (148) 85.2 (547) 69.7 (695) <0.0001
100 (509) 100 (776) 100 (1285)
2 Television
Yes 89.9 (468) 44.5 (404) 58.8 (872)
No 10.2 (41) 55.5 (372) 41.2 (413) <0.0001
100 (509) 100 (776) 100 (1285)
3 Radio
Yes 76.5 (407) 60.1 (914) 65.3 (914)
No 23.5 (102) 39.9 (269) 34.7 (371) 0.03
100 (509) 100 (776) 100 (1285)
4 Home telephone
Yes 41.9 (240) 3.4 (25) 15.6 (265)
No 58.1 (269) 96.6 (751) 84.5 (1020) <0.0001
100 (509) 100 (776) 100 (1285)
5 Mobile phone
Yes 9.6 (51) 1.5 (9) 4.0 (60)
No 90.4 (458) 98.6 (767) 96.0 (1225) 0.0008
100 (509) 100 (776) 100 (1285)
6 Car
Yes 26.0 (135) 15.1 (182) 18.6 (317)
No 74.0 (594) 84.9 (594) 81.4 (968) 0.0006
100 (509) 100 (776) 100 (1285)
7 Motor Cycle
Yes 2.7 (11) 6.5 (42) 5.3 (53)
No 97.3 (498) 93.5 (734) 94.7 (1232) 0.019
100 (509) 100 (776) 100 (1285)
8 Bicycle
Yes 13.2 (55) 6.7 (80) 8.8 (135)
No 86.8 (454) 93.3 (696) 91.2 (1150) 0.03
100 (509) 100 (776) 100 (1285)
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4.4.2 Database of children aged 4-9 (Database 2):
The final dataset contained 467 records with each record representing one child aged 4-9
participating in the survey. The dataset had 68 fields representing the fields in
questionnaire 2 (annex 2). The fields in database 2 were identical to the fields in database
1 of children aged 1-3 except for not having a few questions in database 1 that
investigated the setting in which the child was delivered (health versus home), the
qualifications of the person managing delivery of the child, the type of delivery, receiving
antenatal care during pregnancy, as well as breastfeeding and its duration.
Otherwise database 2 consisted of data on the child aged 4-9 and the child's mother, and
similar to database 1 it contained baseline information such as identification number,
province, district, city or village, street, household and area of sampling. It also consisted
of information on the child's personal and vaccination history, mother, father, and the
household's characteristics and indicators of socioeconomic status.
76% (356/467) of children aged 4-9 participating in the survey were the older siblings of
participants in the survey of children aged 1-3 and the data and results produced by this
dataset were similar to that produced by dataset 1. Therefore the results produced by the
variables and questions in this dataset will not be repeated except for variables that were
either unique to dataset 2 or that were noticeably different from those resulting from
dataset 1.
Child aged 4-9, mothers and sibling aged 1-3 identification numbers:
Each record had a unique identification number for the child aged 4-9 starting with 7001
and ending with 7469. If the child was the older sibling of a child aged 1-3 included in
database 1, two fields recorded the mothers and child aged 1-3 identification numbers,
which allowed linking children in database 1 with children in database 2.
Two records had missing data on anti-HBc status of the child and because this was one of
the principal outcomes under investigation, record numbers 98 and 113 (child
identification numbers 7098 and 7113) were dropped from the analysis.
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Age of child, date of birth and source of child age:
The date of birth was known for 41% of children aged 4-9 participating in the survey.
The mean age of children aged 4-9 participating in the survey was 6.5 years (95% Cl 5.9
to 7.1) ranging from 4 to 9 years. The source of the child's age was recorded as an
indicator of the accuracy of the reported age of the child (table 4.4.2 A). A higher
proportion of children in this dataset had their age approximately determined and a lower
proportion had their age determined by health records than children participating in the
survey of children aged 1-3.
Table 4.4.2 A
Source of age for children participating in survey of children aged 4-9
No. Source Frequency Percent
1 Approximate 101 26.2
2 Health records 96 14.9
3 Birth certificate 34 4.4
4 Parents memory 224 53.4
5 Parents records 10 1.0
6 ID card or passport 2 0.2
Total 467 100
Sex of the child:
43% of the children aged 4-9 participating in the survey were male and 57% were female.
Child birth order:
The mean birth order of children aged 4-9 participating in the survey was
3.2 (95% Cl 3.0 to 3.4) ranging from 1 to 6, which was lower than the mean birth order
4.5 (95% Cl 4.2 to 4.8) of children aged 1-3 participating in the survey. Record number
212 (child identification number 7212) had missing data on the birth order of the child.
After examining the distribution of child birth order, and its minimum and maximum
values, child birth order was reduced to a categorical variable and was divided into 6
categories, with birth order's 6, 7 up to 15 combined into one category 6 to 15 (table
4.4.2 B).
128
Table 4.4.2 B
Birth order of children aged 4-9 participating in the survey
No. Child birth order Urban % (no) Rural % (no) Total % (no)
1 1 33.5 (76) 24.3 (53) 27.2 (129)
2 2 26.1 (61) 16.9 (40) 19.8 (101)
3 3 12.8 (35) 11.1 (30) 11.7 (65)
4 4 7.7 (21) 12.5 (25) 11.0 (46)
5 5 8.4 (15) 12.0 (25) 10.9 (40)
6 6 to 15 11.6 (33) 23.1 (52) 19.5 (85)
Total 100 (241) 100 (225) 100 (466)
47% of children aged 4-9 participating in the survey were one of the first two children in
birth order. 19% of children aged 1-3 participating in the survey were between the 6th to
is" child in birth order.
Vaccination card:
71% (346/467) of parents of children aged 4-9 participating in the survey said their
children had a vaccination card compared to 84% of parents of children aged 1-3. There
was no evidence of a significant difference in the number of parents saying their child
had a vaccination card between urban (79%) and rural areas (67%) (p=0.08)
(table 4.4.2 C).
Table 4.4.2 C
Having a vaccination card amongst children aged 4-9 participating in the survey
No. Has vaccination card Urban % (no) Rural % (no) Total % (no)
1 Yes 79.4 (194) 67.0 (152) 70.9 (346)
2 No 20.6 (47) 33.0 (74) 29.1 (121)
Total 100 (241) 100 (226) 100 (467)
When study participants who said their child had a vaccination card were asked to present
it only 33% (139/346) had the vaccination card available to show the study investigator.
Amongst those who said their child had a vaccination card, there was evidence
suggesting a significantly (p=0.03) higher availability of vaccination cards in urban areas
(46%) compared to rural areas (26%).
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Been vaccinated with hepatitis B vaccine and number of doses:
Although 78% of parents interviewed knew of hepatitis B vaccine only 10% of parents
interviewed said their child aged 4-9 was vaccinated with hepatitis B vaccine, 88% said
their child was not vaccinated and less than 2% did not know (table 4.4.2 D).
Table 4.4.2 D
Parent's response whether their child aged 4-9 participating in the survey
received hepatitis B vaccine
No. Vaccinated with hepatitis B Urban % (no) Rural % (no) Total % (no)
vaccine
1 Yes 16.5 (36) 7.2 (12) 10.1 (48)
2 No 81.3 (199) 91.6 (211) 88.3 (410)
3 Don't know 2.2 (6) 1.3 (3) 1.6 (9)
Total 100 (241) 100 (226) 100 (467)
There was no evidence of a significant difference in parents response whether the child
received hepatitis B vaccine between urban and rural residents (p=0.06). Nevertheless,
differences did exist between the two urban provinces in the survey. 22% of participants
in Sanaa said their child aged 4-9 participating in the survey received hepatitis B vaccine
compared to 7% of participants in Aden (p=0.03). There was no evidence of a significant
difference in parents response regarding their child's vaccination between rural provinces
Taiz, Shabwa and Hodeidah, where 2.5%, 6.6% and 12.8%, respectively, of parents said
their child was vaccinated with hepatitis B vaccine (p=0.2).
The number of doses received by children who had a vaccination card was taken from the
card whatever the person interviewed reported (table 4.4.2 E). The vaccination status of
90% (419/467) of children aged 4-9 was determined and 10% (48/467) of children had an
unknown vaccination status. This was determined by the study investigators checking the
source of the child's vaccination status.
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Table 4.4.2 E
Hepatitis B vaccination status amongst children aged 4-9 participating in the survey
No. Number of doses Frequency Percent
1 Zero 410 88.3
2 One 2 0.2
3 Two 3 1.3
4 Three 4 0.5
5 Unknown 48 9.8
Total 467 100
Twenty one percent of children's vaccination status was determined by a vaccination card
and 79% of children's vaccination status was determined by the parent's memory.
Overall, 1.9% of children aged 4-9 participating in the survey received at least one dose
of hepatitis B vaccine, and 0.5% received all three doses of vaccine. This low vaccine
coverage amongst children aged 4-9 is because these children are not targeted for
hepatitis B vaccination in the first place, and the low percentage of these children that
were vaccinated were done so by their parents own initiative.
There was a significant difference in vaccination status by area. 1.5% of children aged
4-9 living in urban areas were completely vaccinated compared to 0% of children in rural
areas. Similarly, 4.3% of children aged 4-9 in urban areas received one or two doses of
hepatitis B vaccine compared to 0.1% of children in rural areas (p=0.004).
Schooling:
This recorded whether the child aged 4-9 participating in the survey attended school.
Overall, 48% of children participating in the survey of the children aged 4-9 went to
school. There was no evidence of a significant difference in school attendance between
children in urban areas (54%) and rural areas (45%) (p=0.5). The odds ratio for attending
school was 2.4 (95% Cl 2.l to 2.6) per one year increase in the age of the child.
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4.4.3 Database oflaboratory results of children aged 1-3 (Database 3):
The final dataset had 12 fields containing 1285 records with each record representing the
laboratory results of one child aged 1-3 participating in the survey.
The dataset contained laboratory results of all children aged 1-3 for hepatitis B surface
antigen (HBsAg) with SIN ratio, hepatitis B core antibody (anti-HBc) with SIN ratio,
immunoglobulin M hepatitis B core antibody (IgM anti-HBc) with SIN ratio, and
hepatitis B surface antibody (anti-HBs) with SIN ratio. On data entry results were coded
as 1 if the test result was positive and 0 if the result was negative.
One record had missing data on anti-HBc status of the child and because this was one of
the principal outcomes under investigation, record number 247 (child identification
number 1247 and consequently mother identification number 4247) was dropped from
the analysis.
4.4.4 Database of laboratory results of mothers (Database 4):
The final dataset had 12 fields containing 1285 records with one record representing the
laboratory results of the mother of each child aged 1-3 participating in the survey.
The dataset contained laboratory results of mothers of all children aged 1-3 participating
in the survey for hepatitis B surface antigen (HBsAg) with SIN ratio, hepatitis B core
antibody (anti-HBc) with SIN ratio, and hepatitis B e antigen (HBeAg) with SIN ratio. On
data entry results were coded as 1 if the test result was positive and 0 if the result was
negative.
One record (mother identification number 4247) was dropped from the analysis because
the child of this mother did not have anti-HBc results, and the objectives would not be
fulfilled by looking at the mothers results alone.
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4.4.5 Database of laboratory results of children aged 4-9 (Database 5):
The final dataset had 9 fields containing 467 records with each record representing the
laboratory results of one child aged 4-9 participating in the survey.
The dataset contained the laboratory results of children aged 4-9 participating in the
survey tested for the same serological markers of children aged 1-3, and the results were
coded similarly.
Two records 98 and 113 were dropped (child identification number 7098 and 7113)
because the child did not have anti-HBc results.
4.4.6 Combined database of children aged 1-3, their mothers, and laboratory results
(Database 6):
This database contained data from the questionnaire of children aged 1-3 and their
mothers (database 1), together with the corresponding laboratory results of children aged
1-3 (database 3) and laboratory results of mothers of children aged 1-3 (database 4).
This database was created by merging database files 1, 3 and 4 using unique identifier
variables, which were the child's and mothers identification numbers which were unique
to each study participant.
4.4.7 Combined database of children aged 4-9 and their laboratory results
(Database 7):
This database contained data from questionnaire of children aged 4-9 (database 2) and
their corresponding laboratory results (database 5).
This database was created by merging database files 2 and 5 using a unique identifier
variable, which was the child's identification number that was unique to each study
participant.
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Chapter 5: Results Women of Childbearing Age:
In this chapter the results of the prevalence, univariable analysis, and multivariable
analysis ofHBV infection and chronic carrier status amongst women of childbearing age
(mothers of the children aged 1-3 participating in the survey) are presented. The terms
mothers and women of childbearing age will be used interchangeably.
HBV Infection:
5.1 Prevalence of mothers hepatitis B core antibody (anti-HBc positive):
The overall prevalence of anti-HBc amongst women of childbearing age in Yemen was
24.4% (95% Cl 17.48 to 32.97). A total of 299 out of the 1285 women participating in
the survey were anti-HBc positive. There was a statistically significant difference in the
prevalence of anti-HBc amongst mothers by age, area of residence, socioeconomic status,
and educational status. There was a clear increase in the prevalence of anti-HBc amongst
mothers with increasing age (p<0.0001). The prevalence ofanti-HBc was lowest amongst
mothers aged 15 to 24 (16.87%) and highest amongst mothers aged 40 to 49 (40.1%).
Figure 5.1.1 shows the prevalence of anti -HBc amongst mothers by age.
Figure 5.1.1
Prevalence of anti-HBc amongst mothers by age
60
i 50
:cl
l 40
U
III
:I:
.J.. 30-c:
III
~!?..
20
8
c:
JI
~ 10
I!!
D-
O
..
l
->
~
.«:
~
..
15 to 24 25 to 29 30t034
Mothers age in years
bars =95%CI
35t039 4Oto 49
134
The prevalence of anti-HBc amongst mothers living in urban areas (16.99%) was lower
than the prevalence of anti-HBc amongst mothers living in rural areas (27.83%) and this
difference unadjusted for age was statistically significant (p=0.04). When the prevalence
of anti-HBc amongst mothers was compared by urban versus rural area of birth of mother
the results were similar to that by area of residence of the mother. The prevalence of anti-
HBc was 15% (411293) amongst mothers born in urban areas and 27% (215/793)
amongst mothers born in rural areas, and this difference was also statistically significant
(p=0.04). The prevalence of anti-HBc amongst uneducated women (29.41%) was nearly
double the prevalence of anti-HBc amongst women claiming to have any level of
education (15.77%) and this difference was statistically significant (p=0.0005). Despite
this there was no evidence of a statistically significant difference in the prevalence of
anti-HBc by mothers level of education (p=0.68). The prevalence of anti-HBc amongst
mothers claiming to have attended University or College was 8.98%, which was lower
than the prevalence of anti-HBc amongst mothers claiming that they could read and
write, completed primary school, or completed secondary school, which was 15.87%,
16.47%, and 15.93%, respectively. The prevalence of anti-HBc was 30.81% amongst
mothers of low socioeconomic status, 21.22% amongst women of middle socioeconomic
status, and 10.04% amongst women of upper socioeconomic status unadjusted for age
and this was statistically significant (p=0.002). Figure 5.1.2 shows the prevalence of anti-
HBc amongst mothers by socioeconomic status.
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Figure 5.1.2
Prevalence of anti-HBc amongst mothers by socioeconomic status
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The prevalence of anti-HBc was lower amongst mothers in paid employment (18.19%)
compared to mothers who were not in paid employment (24.62%), however there was no
evidence of a statistically significant difference in the prevalence of anti-HBc according
to the employment status of the mother (p=O.35). The prevalence of anti-HBc amongst
mothers was 19.28% in Sanaa, 28.34% in Taiz, 12.57% in Aden, 28.64% in Shabwa, and
27.03% in Hodeidah. There was no evidence ofa statistically significant difference in the
prevalence of anti-HBc when comparing all five provinces (p=O.58), the three rural
provinces (p=0.97), or the two urban provinces (p=O.13) in the survey. Table 5.1.1 shows
the prevalence of anti-HBc amongst mothers by mothers demographic and educational
characteristics.
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Table 5.1.1
Prevalence of anti-HBc positive mothers by women's
demographic and educational characteristics
Number Prevalence 95%CI 95%CI p-value
Prevalence anti-HBc positive of (weighted) Lower Upper (Pearson
Mothers % Limit Limit design-based)
anti-HBc
Overall 299/1285 24.40 17.48 32.97
Area
Urban 82/509 16.99 13.60 21.02
Rural 217/776 27.83 18.06 40.27 0.04
Province
Sanaa 51/262 19.28 15.03 24.39
Taiz 72/252 28.34 12.53 52.19
Aden 31/247 12.57 7.67 19.92
Shabwa 76/268 28.64 12.87 52.16
Hodeidah 69/256 27.03 17.36 39.53 0.41
Mother's Age
15 to 24 60/400 16.87 10.23 26.55
25 to 29 71/349 20.16 13.20 29.54
30 to 34 73/268 27.15 17.94 38.85
35 to 39 62/177 38.81 29.62 48.86
40 to 49 33/91 40.10 31.82 48.98 <0.0001
Mother's Educational Status
Educated 81/547 15.77 10.64 22.76
Uneducated 218/733 29.41 20.67 39.99 0.0005
Mother's Level of Education
Read and Write 28/179 15.87 8.02 28.99
Completed Primary School 33/221 16.47 11.85 22.44
Completed Secondary School 16/113 15.93 9.54 25.40
Completed University or College 4/34 8.98 4.04 18.78 0.68
Mother's Employment
Employed 11/55 18.19 9.77 31.36
Not employed 288/1230 24.62 17.48 33.50 0.35
Socioeconomic Status
Low 158/506 30.81 20.03 44.18
Middle 110/508 21.22 15.95 27.66
Upper 31/270 10.04 6.55 15.09 0.002
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5.2 Mothers anti-HBc univariable analysis:
The univariable analysis of the association of anti-HBc positivity amongst women of
childbearing age with exposure variables are here classified into three types of results.
The first had an OR that was statistically significantly different from 1. The second type
of result had notably increased or decreased OR by more or less than 30% but these were
not statistically significant. The third type of result neither had notably increased nor
decreased OR. These results are shown in tables 5.2.1 and 5.2.2.
Overall, the exposure variables that had a statistically significant association with anti-
HBc positivity amongst mothers by univariable analysis were age of the mother, area of
residence, mothers educational status, socioeconomic status, ownership of the household,
source of water in the household, and the availability of electricity, television,
fridge/freezer, and home telephone in the household.
The age of the mother in years was the exposure variable with the most significant
association with mothers anti-HBc positivity. There was an increase in the odds of
mothers anti-HBc positivity with increasing age of the mother (p=0.0001) with a
significant difference in the odds of anti-HBc positivity across mothers age-groups. The
OR of anti-HBc positivity was 2.22 amongst uneducated mothers and this was
statistically significantly higher than anti-HBc positivity amongst mothers claiming to be
educated (p=0.001). The OR ofanti-HBc positivity (OR=1.88) amongst mothers living in
rural areas was statistically significantly higher than mothers living in urban areas
(p=0.04). The OR of being anti-HBc positive was statistically significantly lower
amongst mothers of middle (OR=0.6) and upper (OR=0.25) socioeconomic status
compared to mothers of low socioeconomic status (p=0.003). Fridge/freezer, television,
and home telephone were the three household commodities that were statistically
significantly associated with anti-HBc positivity amongst women of childbearing age.
The OR of being anti-HBc positive was 2.35 amongst women living in households
without a fridge/freezer (p=0.003), 1.99 amongst mothers living in households without a
television (p=0.04) and 2.9 amongst mothers living in households without a home
telephone (p=0.002). The OR of being anti-HBc positive was 1.7 amongst mothers living
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in households without an electricity supply (p=0.05) and 0.58 amongst mothers living in
rented households (p=0.03). There was an association between mothers anti-HBc
positivity and the households source of water (p=0.008), with a higher odds of mothers
being anti-HBc positive in households that obtained water through a local project or
bucket. Table 5.2.1 shows the results of the univariable analysis of the association of
mothers demographic characteristics with anti-HBc positivity amongst mothers in
Yemen.
Table 5.2.1
Association of anti-HBc positivity amongst mothers
with women's demographic characteristics
Variable Number Number OR p value 95% C.I.
Controls Cases
Age of mother 15 to 24 340 60 1
(in years) 25 to 29 278 71 1.24 0.26 0.84 - 1.84
30 to 34 195 73 1.84 < 0.001 1.37 - 2.47
35 to 39 115 62 3.13 < 0.001 2.10 -4.64
40 to 49 58 33 3.30 0.001 1.73 - 6.29
Joint significance 0.0001
Linear trend OR 1.41 < 0.001 1.24 -1.60
Province Sanaa 211 51 1
Taiz 180 72 1.66 0.33 0.57 -4.78
Aden 216 31 0.60 0.11 0.32 - 1.12
Shabwa 192 76 1.68 0.31 0.59 -4.77
Hodeidah 187 69 1.55 0.17 0.82 -2.95
Joint significance 0.18
Area Urban 427 82 1
Rural 559 217 1.88 0.04 1.02 - 3.49
Mothers Birth 1 205 73 1
Order 2 159 44 0.65 0.26 0.30 - 1.40
3 163 41 0.64 0.004 0.47 - 0.85
4 113 47 1.06 0.86 0.53 - 2.14
5 104 28 0.63 0.1 0.35 - 1.11
6 to 18 242 66 0.66 0.24 0.33 -1.35
Joint significance 0.07
Linear Trend OR 0.95 0.36 0.83 - 1.07
Mothers Educated 466 81 1
Education Uneducated 520 218 2.22 0.001 1.47 - 3.36
Mothers Unemployed 942 288 1
Employment Employed 44 11 0.68 0.36 0.29 - 1.59
Husbands Educated 799 216 1
Education Uneducated 187 83 1.45 0.11 0.91- 2.32
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Exposure variables that had notably increased or decreased OR by more or less than 30%
but were not statistically significantly associated with anti-HBc positivity amongst
mothers were province of sampling, employment status of the mother, husbands
educational status, type of household, crowding index of the household, and mothers
birth order.
The OR of mothers being anti-HBc positive was 1.66, 1.68, 1.55 and 0.60 in Taiz,
Shabwa, Hodeidah, and Aden, respectively, compared to Sanaa (p=O.l8). Women in paid
employment appeared to have a lower odds of being anti-HBc positive (OR=0.68)
compared to women who were not in paid employment (p=0.36). Women with an
uneducated husband had a higher odds of being anti-HBc positive (OR=1.45) than
women with an educated husband (p=O.ll). The odds of anti-HBc positivity amongst
women living in apartments or shacks appeared to be lower than women living in houses
(p=O.l5). The OR of mothers anti-HBc positivity associated with crowding index of the
household did not follow a clear trend but households with higher crowding indexes
appeared to have a higher odds of being anti-HBc positive (p=0.09). Likewise, the OR of
anti-HBc positivity associated with mothers birth order was not significant and did not
follow a clear trend (p=0.07). Table 5.2.2 shows the results of the univariable analysis of
the association of household characteristics and possessions with anti-HBc positivity
amongst mothers in Yemen.
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Table 5.2.2
Association of anti-HBc positivity amongst mothers
with household characteristics and possessions
Variable Number Number OR p value 95% C.I.
Controls Cases
Household Owned 829 269 1
Ownership Rented 157 30 0.58 0.03 0.36 -0.93
Household House 707 241 1
Type Apartment 188 33 0.54 0.05 0.29 - 0.99
Shack 90 25 0.74 0.51 0.29 - 1.90
Joint sig_nificance 0.15
Household Stone 289 85 1
Construction Block 457 127 0.99 0.99 0.57 - 1.75
Mud or Clay 141 49 1.04 0.95 0.32 - 3.39
Mixed 99 38 1.12 0.79 0.47 - 2.67
Joint significance 0.99
Crowding 1 77 23 1
Index 2 270 53 0.91 0.81 0.42 - 1.97
3 244 68 1.26 0.53 0.59 - 2.73
4 155 66 2.12 0.05 0.99 -4.55
5 97 29 1.47 0.37 0.61 - 3.52
6 to 18 143 60 2.39 0.02 1.21 - 4.74
Joint significance 0.09
Linear Trend OR 1.22 0.003 1.08 - 1.39
Electricity Yes 724 180 1
Supply No 262 119 1.7 0.05 0.99 -2.94
Source of Governmental 374 62 1
Water Local Project 321 122 2.43 0.002 1.46 - 4.03
Water Truck 94 28 1.50 0.35 0.62 - 3.66
Buckets 195 87 2.70 0.048 1.01 -7.2
Joint significance 0.008
Freezer Yes 498 92 1
No 488 207 2.35 0.003 1.38 - 4.01
Television Yes 707 165 1
No 279 134 1.99 0.04 1.05 - 3.79
Radio Yes 714 200 1
No 272 99 1.27 0.25 0.83 - 1.94
Home Phone Yes 233 32 1
No 753 267 2.90 0.002 1.58 - 5.31
Mobile Phone Yes 51 9 1
No 935 290 1.97 0.09 0.88 -4.37
Car Yes 244 73 1
No 742 226 1.07 0.74 0.70 -1.63
Socioeconomic Low 348 158 1
Status Middle 398 110 0.6 0.07 0.35 -1.04
Upper 239 31 0.25 0.001 0.12-0.51
Joint significance 0.003
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Exposure variables that neither showed notable increased or decreased OR nor evidence
of a statistically significant association with anti-HBc positivity amongst mothers were
ownership of a radio (p=0.25) or car (p=0.74), and the material used in the construction
of the household (p=0.99).
5.3 Mothers anti-HBc multivariable analysis:
The independent variables that had a statistically significant association with anti-HBc
positivity amongst women of childbearing age in the multiple logistic regression analysis
after adjusting for the remaining variables in the model were age of the mother,
ownership of a fridge/freezer, and ownership of a home telephone.
There was an increase in the adjusted OR of anti-HBc positivity amongst mothers with
increasing age of the mother (p=O.OOOl).The OR of being anti-HBc positive was 1.29,
1.83, 3.15, and 2.99 amongst women aged 25 to 29, 30 to 34, 35 to 39, and 40 to 49,
respectively. The adjusted OR of anti-HBc positivity was 1.76 (95% Cl 1.04 to 2.97)
amongst mothers who did not have a fridge or freezer in their household and 1.59 (95%
Cl 1.03 - 2.46) amongst mothers living in households that did not have a home
telephone. The adjusted OR of anti-HBc positivity associated with area of residence was
1.12 (95% Cl 0.58 to 2.14) amongst mothers living in rural areas and this was not
significant (p=O.72) after adjusting for the remaining variables in the model, although in
the univariable analysis the odds of anti-HBc positivity amongst women living in rural
areas was double the odds of anti-HBc positivity amongst women living in urban areas.
Mothers birth order (p=0.11) and educational status (p=0.19) did not show evidence of a
statistically significant association with anti-HBc positivity amongst mothers, however,
they were found to be significantly associated with HBV chronic infection (HBsAg
chronic carrier status) amongst mothers. Therefore, they were added to the final
multivariable model of mothers anti-HBc positivity resulting in two models, one for
mothers anti-HBc positivity and the other for mothers HBV chronic infection, both
including identical independent variables. There was no evidence of interaction between
the independent variables in the multi variable model. Table 5.3.1 shows the results of the
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multivariable analysis of the association of independent variables with anti-HBc
positivity amongst mothers in Yemen.
Table 5.3.1
Adjusted logistic regression of the association of anti-HBc positivity
amongst mothers with independent exposure variables
iVariable OR* p value** 95% C.I.***
Mothers Age 15 to 24 1
(in years) 25 to 29 1.29 0.231 0.84 - 1.98
30 to 34 1.83 <0.001 1.37 - 2.44
35 to 39 3.15 <0.001 2.13 - 4.66
40 to 49 2.99 0.002 1.55 - 5.75
Jointsignij7cance **** 0.0001
Mothers Birth 1 1
Order 2 0.64 0.25 0.29 - 1.41
3 0.65 0.02 0.46 - 0.91
4 1.13 0.73 0.55 - 2.34
5 0.73 0.26 0.41 - 1.29
6 to 18 0.69 0.31 0.32 - 1.46
Jointsignij7cance 0.23
Area Urban 1
Rural 1.12 0.72 0.58 - 2.14
Mothers Educated 1
Educational Status Uneducated 1.37 0.19 0.84 - 2.22
Fridge/Freezer Yes 1
Ownership No 1.76 0.04 1.04 - 2.97
Home Telephone Yes 1
Ownership No 1.59 0.04 1.03 - 2.46
* adjusted OR computed by survey logistic regression multivariable analysis.
** p-value of the adjusted Wald test statistic.
*** 95% Confidence Intervals.
**** p-value of the adjusted survey Wald test statistic of the significance of the joint
effect of the categories of the independent variable on the dependent variable.
The multivariable analysis of variables associated with anti-HBc positivity amongst
mothers was repeated excluding the socioeconomic variables that contributed to the
socioeconomic index constructed in the survey and substituting them with this single
socioeconomic status variable. The OR and p-values of anti-HBc positivity associated
with mothers age and birth order were extremely similar in this model as in table 5.3.1.
The adjusted OR of anti-HBc positivity associated with residing in a rural area increased
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from 1.12 to 1.41 (p=O.2). Socioeconomic status, on the other hand, was significantly
associated with anti-HBc positivity, and there was a clear decrease in the OR of anti-HBc
positivity associated with increasing socioeconomic status. Table 5.3.2 shows the results
of the multi variable analysis of the association of independent variables and the
socioeconomic status variable with anti-HBc positivity amongst mothers participating in
the survey.
Table 5.3.2
Adjusted logistic regression of the association of anti-HBc positivity
amongst mothers with independent exposure variables and socioeconomic status
lVariable OR* p value** 95% C.I.***
Mothers Age 15 to 24 1
(in years) 25 to 29 1.29 0.24 0.84 - 1.98
30 to 34 1.79 0.001 1.29 - 2.48
35 to 39 3.08 <0.001 2.09 -4.54
40 to 49 2.91 0.003 1.49 - 5.68
Jointsign~ance **** 0.0005
Mothers Birth 1 1
Order 2 0.62 0.20 0.29 - 1.32
3 0.65 0.01 0.47 - 0.91
4 1.07 0.83 0.54 - 2.14
5 0.69 0.18 0.40 - 1.21
6 to 18 0.64 0.23 0.31 - 1.35
Joint significance 0.23
Area Urban 1
Rural 1.41 0.20 0.82 - 2.44
Socioeconomic Low 1
Status Middle 0.73 0.21 0.44 -1.22
Upper 0.32 0.001 0.17-0.58
Joint significance 0.004
* adjusted OR computed by survey logistic regression multi variable analysis.
** p-value of the adjusted Wald test statistic.
*** 95% Confidence Intervals.
**** p-value of the adjusted survey Wald test statistic of the significance of the joint
effect of the categories of the independent variable on the dependent variable.
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HBV Chronic Infection (HBsAg chronic carrier):
5.4 Prevalence of mothers HBV chronic infection:
The overall prevalence of HBV chronic infection amongst women of childbearing age in
Yemen was 5.08% (95% Cl 3.56 to 7.20).59 out of the 1285 women participating in the
survey were chronic carriers of HBV (HBsAg positive). The prevalence of hepatitis B e
antigenaemia was 12.84% (95% Cl 6.12 to 24.99) amongst these HBV chronically
infected women with 8 out of 59 HBV chronic carrier women being hepatitis B e antigen
positive. There was a statistically significant difference in the prevalence of HBV chronic
infection amongst mothers by area of residence, socioeconomic status, and educational
status.
The prevalence of HBV chronic infection was lowest amongst women aged 15 to 24
years (4.03%) and highest amongst women aged 40 to 49 years (6.49%). However, there
was no evidence of a statistically significant difference in the prevalence of HBV chronic
infection by mothers age (p=0.78) nor was there a clear pattern of increasing prevalence
ofHBV chronic infection with increasing mothers age. Figure 5.4.1 shows the prevalence
of HBV infection amongst mothers by age.
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Figure 5.4.1
Prevalence of HBV infection amongst mothers by age
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The prevalence ofHBV chronic infection amongst mothers in urban areas (3.08%) was
half the prevalence of HBV chronic infection amongst mothers in rural areas (6%) and
this difference unadjusted for age was statistically significant (p=0.05). When the
prevalence of HBV chronic infection amongst mothers was compared by urban versus
rural area of birth of mother the results were similar to what was found by area of
residence of the mother. The prevalence of HBV chronic infection was 2.9% (7/293)
amongst mothers born in urban areas and 5.9010 (45/793) amongst mothers born in rural
areas (p=0.06). The prevalence of HBV chronic infection amongst uneducated women
(7.2%) was higher than the prevalence of HBV chronic infection amongst women
claiming to have any level of education (1.43%) and this difference was statistically
significant (p=O.OOI). However, there was no evidence of a statistically significant
difference in the prevalence of HBV chronic infection by mothers level of education
(p=O.13).There were only 7 cases ofHBV chronic infection amongst women claiming to
have any level of education. There were no cases (0/34) of HBV chronic infection
amongst women claiming to have completed University or College. lout of 113 (0.62%)
women claiming to have completed secondary school was a HBV chronic carrier, 4 out
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of 221 (2.78%) women claiming to have completed primary school were HBV chronic
carriers, and 2 out of 179 (0.4%) women claiming they could read and write were HBV
chronic carriers. The prevalence ofHBV chronic infection was 6.89% amongst women of
low socioeconomic status, 4.03% amongst women of middle socioeconomic status, and
1.34% amongst women of upper socioeconomic status and this was statistically
significant (p=0.004). Figure 5.4.2 shows the prevalence of HBV chronic infection
amongst mothers by socioeconomic status.
Figure 5.4.2
Prevalence of HBV chronic infection amongst mothers
by socioeconomic status
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The prevalence of HBV chronic infection was slightly lower amongst women in paid
employment (4.62%) compared to women who were not in paid employment (5.1%) but
this difference was not statistically significant (p=0.91). The prevalence ofHBV chronic
infection amongst mothers was 4.04% in Sanaa, 4.62% in Taiz, 1.23% in Aden, 5% in
Shabwa, and 7.85% in Hodeidah. There was no evidence of a statistically significant
difference in the prevalence ofHBV chronic infection when comparing all five provinces
(p=0.13), the three rural provinces (p=0.33), or the two urban provinces (p=O.12) in the
survey. Table 5.4.1 shows the prevalence ofHBV chronic infection amongst mothers by
mothers demographic and educational characteristics.
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Table 5.4.1
Prevalence of HBV chronic infection (HBsAg positive) amongst mothers
by women's demographic and educational characteristics
Prevalence 95%CI 95%CI p-valueHBV Chronic Infection Number of (weighted) Lower Upper (Pearson(HBsAg positive) Prevalence Mothers % Limit Limit design-based)
HBsAg
Overall 59/1285 5.08 3.56 7.20
HBeAgl HBsAg positive
Positive 8/59 12.84 6.12 24.99
Negative 51/59 87.16 75.01 93.88
Area
Urban 14/509 3.08 1.78 5.28
Rural 45/776 6.00 3.94 9.04 0.05
Province
Sanaa 11/262 4.04 2.22 7.22
Taiz 12/252 4.62 1.81 11.29
Aden 3/247 1.23 0.30 4.91
Shabwa 13/268 5.00 2.70 9.10
Hodeidah 20/256 7.85 5.12 11.84 0.13
Mother's Age (in years)
15 to 24 14/400 4.03 1.85 8.55
25 to 29 19/349 5.85 3.41 9.87
30 to 34 14/268 5.56 2.94 10.25
35 to 39 8/177 4.75 2.41 9.12
40 to 49, 4/91 6.49 2.11 18.30 0.78
Mother's Educational Status
Educated 7/547 1.43 0.60 3.37
Uneducated 52/738 7.20 5.01 10.24 0.001
Mother's Level of Education
Read and Write 2/179 0.40 0.05 3.17
Completed 1ry 4/221 2.78 1.04 7.23
Completed 2ry 1/113 0.62 0.08 4.77
Completed Univ. 0/34 0.00 0.13
Mother's Employment
Employed 2/55 4.62 0.87 21.09
Not Employed 57/1230 5.10 3.50 7.35 0.91
Socioeconomic Status
Low 34/506 6.89 4.63 10.12
Medium 21/508 4.03 2.48 6.47
Upper 4/270 1.34 0.46 3.88 0.004
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5.5 Mothers HBV chronic infection univariable analysis:
Similar to the univariable analysis of HBV infection, the univariable analysis of the
association of HBV chronic infection amongst women of childbearing age with exposure
variables are also classified into three types of results. The first had an OR that were
statistically significantly different from 1. The second type of result had notably
increased or decreased OR by more or less than 30% but these were not statistically
significant. The third type of result neither had notable increased or decreased OR. These
results are shown in tables 5.5.1 and 5.5.2.
Overall, the exposure variables statistically significantly associated with mothers HBV
chronic infection by univariable analysis were educational status, area of residence,
mothers birth order, type and crowding index of the household, socioeconomic status,
and the availability of television and freezer in the household.
Mothers educational status was the exposure variable with the most significant
association with mothers HBV chronic infection. The OR of HBV chronic infection was
5.36 amongst uneducated women and this was statistically significantly higher than HBV
chronic infection amongst women claiming to be educated (p=0.002). The OR of HBV
chronic infection (OR=2) amongst women living in rural areas was statistically
significantly higher than women living in urban areas (p=0.05). The OR of HBV chronic
infection was statistically significantly lower amongst women of middle (OR=0.57) and
upper (OR=0.18) socioeconomic status compared to women of low socioeconomic status
(p=O.OI). Fridge/freezer and television were the two household commodities that were
statistically significantly associated with HBV chronic infection amongst women of
childbearing age. The OR of HBV chronic infection was 3.65 amongst women living in
households without a fridge/freezer (p=O.OOl) and 2.22 amongst mothers living in
households without a television (p=0.01). The OR of HBV chronic infection was 0.12
amongst mothers living in apartments compared to mothers living in houses (p=0.003).
The odds of mothers HBV chronic infection appeared to be higher in households with a
crowding index of 4 and above (p=0.05). HBV chronic infection was significantly
associated with mothers birth order but did not follow a clear trend (p=0.04). Table 5.5.1
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shows the results of the univariable analysis of the association of mothers demographic
characteristics with HBV chronic infection amongst mothers in Yemen.
Table 5.5.1
Association of HBV chronic infection (HBsAg positive) amongst mothers
with women's demographic characteristics
Variable Number Number OR p value 95% C.I.
Controls Cases
Age of mother 15 to 24 386 14 1
(in years) 25 to 29 330 19 1.48 0.38 0.60 - 3.65
30 to 34 254 14 1.40 0.41 0.61 - 3.22
35 to 39 169 8 1.19 0.75 0.39 - 3.61
40 to 49 87 4 1.65 0.52 0.33 - 8.3
Joint significance 0.92
Linear trend OR 1.09 0.51 0.84 - 1.41
Province Sanaa 251 11 1
Taiz 240 12 1.15 0.8 0.37 - 3.62
Aden 244 3 0.30 0.12 0.06 - 1.40
Shabwa 255 13 1.25 0.6 0.51- 3.05
Hodeidah 236 20 2.02 0.07 0.94 -4.35
Joint significance 0.13
Area Urban 495 14 1
Rural 731 45 2.00 0.05 0.98 - 4.12
Mothers Birth 1 267 11 1
Order 2 195 8 0.7 0.45 0.27 - 1.82
3 197 7 0.83 0.6 0.40 - 1.73
4 147 13 2.19 0.02 1.18 - 4.07
5 126 6 1.14 0.72 0.53 - 2.49
6 to 18 294 14 1.08 0.88 0.39 - 3.00
Joint significance 0.04
Linear Trend OR 1.06 0.5 0.89 - 1.28
Mothers Educated 540 7 1
Education Uneducated 686 52 5.36 0.002 2.01- 14.3
Mothers Unemployed 1173 57 1
Employment Employed 53 2 0.9 0.91 0.14 - 5.64
Husbands Educated 974 41 1
Education Uneducated 252 18 1.55 0.29 0.67 - 3.61
Exposure variables that had notably increased or decreased OR by more or less than 30%
but were not statistically significantly associated with HBV chronic infection amongst
mothers were province of sampling, husbands educational status, household ownership
and construction, household source of water, availability of an electricity supply, home
telephone, and mobile telephone in the household.
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The OR ofHBV chronic infection amongst women was 1.15, 1.25,2.02 and 0.3 in Taiz,
Shabwa, Hodeidah and Aden, respectively, compared to Sanaa (p=0.13). Women with an
uneducated husband had a higher odds ofHBV chronic infection (OR=1.55) than women
with an educated husband (p=0.29). The OR of HBV chronic infection was 0.36 amongst
mothers living in rented households compared to mothers living in owned houses
(p=0.15). The odds of HBV chronic infection was 1.33, 1.65, and 2.04 amongst women
living in households built of block, mud/clay, or mixed material, respectively (p=0.69).
There was a higher odds of mothers HBV chronic infection in households that obtained
water through a local project, bucket, or truck when compared to households with a
governmental water supply (p=0.2). The OR of HBV chronic infection was 2.36 amongst
mothers living in households without a home telephone (p=0.11), 2.27 amongst mothers
living in households without a mobile telephone (p=0.42), and 1.91 amongst mothers
living in households without an electricity supply (p=0.08). Table 5.5.2 shows the results
of the univariable analysis of the association of household characteristics and possessions
with HBV chronic infection amongst mothers in Yemen.
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Table 5.5.2
Association of HBV chronic infection amongst mothers
with household characteristics and possessions
Variable Number Number OR p value 95% C.I.
Controls Cases
Household Owned 1043 55 1
Ownership Rented 183 4 0.36 0.15 0.08 - 1.51
Household House 898 50 1
Type Apartment 219 2 0.12 0.003 0.03 - 0.43
Shack 108 7 1.08 0.9 0.31- 3.78
Jointsignij7cance 0.01
Household Stone 359 15 1
Construction Block 561 23 1.33 0.39 0.67 -2.63
Mud or Clay 179 11 1.65 0.34 0.56 -4.84
Mixed 127 10 2.04 0.26 0.57 -7.34
Joint significance 0.69
Crowding 1 96 4 1
Index 2 312 11 0.91 1.13 0.30 -4.28
3 302 10 1.26 0.78 0.14 - 4.31
4 208 13 2.12 1.91 0.45 - 8.07
5 119 7 1.47 2.15 0.46 -10.04
6 to 18 189 14 2.39 2.37 0.53 - 10.55
Joint sig_niJk:ance 0.05
Linear Trend OR 1.25 0.03 1.03 - 1.53
Electricity Yes 872 32 1
Supply No 354 27 1.91 0.08 0.92 - 3.95
Source of Governmental 425 11 1
Water Local Project 418 25 2.48 0.03 1.10 - 5.61
Water Truck 116 6 1.70 0.35 0.54 - 5.30
Buckets 265 17 2.36 0.09 0.86 - 6.46
Jointsignij7cance 0.2
Freezer Yes 576 14 1
No 650 45 3.65 0.001 1.81-7.36
Television Yes 841 31 1
No 385 28 2.22 0.01 1.21- 4.06
Radio Yes 876 38 1
No 350 21 1.01 0.97 0.55 -1.87
Home Phone Yes 259 6 1
No 967 53 2.36 0.11 0.82 - 6.85
Mobile Phone Yes 59 1 1
No 1167 58 2.27 0.42 0.29 - 17.92
Car Yes 305 12 1
No 921 47 1.17 0.57 0.66- 2.07
Socioeconomic Low 472 34 1
Status Middle 487 21 0.57 0.07 0.31 - 1.04
Upper 266 4 0.18 0.004 0.06 - 0.55
Joint significance 0.01
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Exposure variables that neither showed notable increased or decreased OR nor evidence
of a statistically significant association with HBV chronic infection amongst mothers
were age of the mother (p=0.92), mothers employment (p=0.91), and the ownership of a
radio (p=0.97) or car (p=0.57).
5.6 Mothers HBV chronic infection multivariable analysis:
The independent variables that had a statistically significant association with HBV
chronic infection amongst women of childbearing age in the multiple logistic regression
analysis after adjusting for the remaining variables in the model were mothers birth order,
educational status of the mother and the ownership of a fridge/freezer.
The association between mothers birth order and mothers HBV chronic infection did not
follow a clear pattern, however, mothers birth order was significant in the multivariable
model (p=O.OI). The OR ofHBV chronic infection was 2.5 amongst mothers 4th in birth
order (p=0.004) and women of higher birth order appeared to have a higher odds ofHBV
chronic infection. The adjusted OR of HBV chronic infection amongst women claiming
to be uneducated was 4.5 (95% Cl 1.47 to 13.7). Similar to findings with anti-HBc
positivity amongst mothers, the adjusted OR of HBV chronic infection was 2.5 (95% Cl
1.20 to 5.15) amongst mothers living in households that did not have a fridge/freezer
(p=0.02). The adjusted OR of HBV chronic infection associated with living in a rural area
of residence was 1.04 (95% Cl 0.52 to 2.08) amongst mothers and this was not significant
(p=0.9) after adjusting for the remaining variables in the model, although in the
univariable analysis the odds of HBV chronic infection amongst women living in rural
areas was double the odds of HBV chronic infection amongst women living in urban
areas. Age of the mother and ownership of a home telephone did not show evidence of a
statistically significant association with mothers HBV chronic infection, however, they
were associated with mothers being anti-HBc positive. Therefore, these were added to the
final multi variable model of mothers HBV chronic infection resulting in two models one
for anti-HBc positivity and the other for HBV chronic infection both including identical
independent variables. There was no evidence of interaction between the independent
variables in the multivariable model. Table 5.6.1 shows the results of the multivariable
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analysis of the association of the independent variables with HBV chronic infection
amongst mothers in Yemen.
Table 5.6.1
Adjusted logistic regression of the association of HBV chronic infection
amongst mothers with independent exposure variables
Variable OR* p value** 95% C.I.***
Mothers Age 15 to 24 1
(in years) 25 to 29 1.54 0.33 0.62 - 3.85
30 to 34 1.30 0.54 0.54 - 3.11
35 to 39 0.98 0.98 0.34 - 2.89
40 to 49 1.27 0.76 0.26- 6.12
Joint significance **** 0.68
Mothers Birth 1 1
Order 2 0.79 0.61 0.31- 2.05
3 0.85 0.64 0.41- 1.74
4 2.53 0.004 1.38 - 4.64
5 1.32 0.48 0.59 - 2.98
6 to 18 1.10 0.85 0.41 - 2.94
Joint significance 0.01
Area Urban 1
Rural 1.04 0.9 0.52 - 2.08
Mothers Educated 1
Educational Status Uneducated 4.49 0.01 1.47 - 13.7
FridgelFreezer Yes 1
Ownership No 2.48 0.02 1.20 - 5.15
Home Telephone Yes 1
Ownership No 0.75 0.65 0.20 - 2.78
* adjusted OR computed by survey logistic regression multi variable analysis.
** p-value of the adjusted wald test statistic.
*** 95% Confidence Intervals.
**** p-value of the adjusted survey wald test statistic of the significance of the joint
effect of the categories of the independent variable on the dependent variable.
The multivariable analysis of the association of variables with HBV chronic infection
amongst mothers was repeated excluding the socioeconomic variables that contributed to
the socioeconomic index constructed in the survey and substituting these variables with
the single socioeconomic status variable. The OR and p-values of HBV chronic infection
associated with mothers age and birth order were extremely similar in this model as in
table 5.6.1. The adjusted OR of HBV chronic infection associated with residing in a rural
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area increased from 1.04 to 1.44 (p=0.31). Socioeconomic status, on the other hand, was
significantly associated with HBV chronic infection, and there was a clear decline in the
OR of HBV chronic infection with increasing socioeconomic status. Table 5.6.2 presents
the results of the multi variable analysis of the association of independent variables and
the socioeconomic status variable with HBV chronic infection amongst mothers
participating in the survey.
Table 5.6.2
Adjusted logistic regression of the association of HBV chronic infection
amongst mothers with independent exposure variables and socioeconomic status
Variable OR* p value** 95% C.I.***
Mothers Age 15 to 24 1
(in years) 25 to 29 1.49 0.39 0.58 - 3.79
30 to 34 1.31 0.52 0.56 - 3.09
35 to 39 1.09 0.86 0.36- 3.32
40 to 49 1.42 0.65 0.29 - 6.96
Joint significance **** 0.88
Mothers Birth 1 1
Order 2 0.74 0.51 0.29 - 1.87
3 0.86 0.66 0.42 - 1.75
4 2.26 0.01 1.20 -4.27
5 1.22 0.62 0.54 - 2.76
6 to 18 1.05 0.92 0.39 - 2.83
Joint significance 0.03
Area Urban 1
Rural 1.44 0.31 0.70 - 2.95
Socioeconomic Low 1
Status Middle 0.60 0.14 0.31-l.l9
Upper 0.22 0.004 0.09 - 0.59
Joint significance 0.01
* adjusted OR computed by survey logistic regression multi variable analysis.
** p-value of the adjusted Wald test statistic.
*** 95% Confidence Intervals.
**** p-value of the adjusted survey Wald test statistic of the significance of the joint
effect of the categories of the independent variable on the dependent variable.
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5.7 Discussion:
There are no previous community-based seroepidemiological surveys investigating HBV
infection in Yemen. This is the first study to focus on the prevalence of HBV infection
amongst women of childbearing age as a specific age-group in the Republic of Yemen.
The overall prevalence of anti-HBc positivity (24.4%) and HBsAg chronic carriers
(5.1%) amongst women of childbearing age participating in this household
seroepidemiological survey was lower than initially expected compared to earlier studies
in Yemen and neighbouring Middle Eastern countries. Rather than obtaining an estimated
570 anti-HBc positive and 190 HBsAg positive chronic carrier mothers as was expected
based on the prevalence of HBV infection reported from previous studies conducted in
Yemen, the survey generated 299 anti-HBc positive and 59 HBsAg positive chronic
carrier mothers. Earlier studies have shown the prevalence of anti-HBc positivity to range
from 45% to 60% and HBV chronic infection to range from 13% to 19% amongst adults
in hospital populations, and the prevalence of HBV chronic infection to range from
12.5% to 16.6% amongst women of childbearing age attending hospitals in Yemen (EI-
Guneid et al.,1993; Scott et al., 1990; Abdul Raheem et al., 1991). Unfortunately, there is
no information on age-specific prevalence of anti-HBc positivity and HBV chronic
infection amongst women participating in these earlier studies. Similarly, studies in
neighbouring countries in the Middle-East have shown that these countries have an
intermediate to high endemicity of HBV infection. Noteworthy to mention is that anti-
HBc positivity is a crude marker of HBV infection as anti-HBc positive mothers may
have been infected many years earlier or during childhood with anti-HBc positivity being
the only indicator of previous or past exposure to HBV infection.
The prevalence ofHBV chronic infection [5.08% (95% Cl 3.56 to 7.2)] amongst mothers
participating in this survey barely places Yemen amongst the group of countries highly
endemic with HBV infection. Actually, this prevalence estimate of HBV chronic
infection amongst mothers in Yemen makes the endemicity of HBV infection in Yemen
more consistent with the endemicity of HBV infection in other Middle-Eastern countries
in the region such as Saudi Arabia, Kuwait, Lebanon, Tunisia and Iran (Al-Nakib et al.,
1986; Amini et al., 1993; Basalamah et al., 1984; Coursaget et al., 1994; Nabulski et al.,
1997; Ramia et al., 1984). This is contrary to earlier studies conducted in Yemen, which
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suggested that HBV infection is hyperendemic in Yemen and much higher than other
countries in the region.
Why were the prevalence estimates of anti-HBc positivity and HBsAg chronic carriers
amongst mothers participating in this survey much lower than the prevalence estimates
from previous studies in Yemen? The difference between the prevalence of anti-HBc
positivity and HBV chronic infection amongst mothers participating in this survey and
previous studies is not expected to be the result of the effect of time (cohort effect) on the
prevalence of anti-HBc positivity and HBV chronic infection amongst mothers. This is
mainly because there is no significant decline in the prevalence of HBV chronic infection
amongst the youngest mothers (15 to 24 years) compared to the oldest mothers (40 to 49
years) participating in the survey, similar to what was observed with anti-HBc positivity
amongst mothers. The difference between the prevalence estimates is also not expected to
be due to differences in measurement technique or serological assay which is another
potential explanation for the difference between the prevalence estimates. The most likely
explanation for the difference in the prevalence of HBV infection amongst mothers
participating in this survey and earlier studies is due to the mothers in this survey and the
mothers in previous studies being drawn from two totally different populations. The
prevalence estimates of this survey are based on a community-based household
seroepidemiological survey with mothers randomly selected from the general population
across' the country based on probability proportional to size, whereas the prevalence
estimates of the previous studies were based on hospital-based serosurveys in major cities
with study participants representing a specific subgroup of the population. Not everyone
in the general population has an equal chance of being included in a hospital-based
sample, and therefore, the sample can only be considered representative of the hospital
population or the community that it serves. The prevalence estimates of community-
based surveys, on the other hand, are more generalisable, accurate, reliable and
representative of the general population than those of hospital-based serosurveys. In
Yemen, the results of these earlier hospital-based surveys are commonly and incorrectly
reported by unqualified individuals as the prevalence estimates of HBV chronic infection
in the general population. This results in an exaggerated and overestimated prevalence of
HBV chronic infection amongst adults in the general population in Yemen with the
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widespread belief that 15% to 20% of the general population is chronically infected with
HBV.
One of the most important findings of this survey was the low infectiousness of HBV
chronic carrier mothers in Yemen. Infectiousness of HBV chronic carrier mothers is
determined by their HBeAg status, which correlates with HBV DNA levels with HBeAg
positive chronic carriers being highly infectious (Hall, 1994; Hwang et al., 1985). Out of
the 59 HBV chronic carrier mothers identified in this survey, 12.8% (8/59) were HBeAg
positive, which is lower than the prevalence of HBeAg (31%) amongst chronic carrier
women reported by El-Guneid et al (El-Guneid et al., 1993), but similar to the prevalence
of HBeAg amongst HBV chronic carriers reported by Scott et al in Yemen (Scott et al.,
1990), and similar to the prevalence of HBeAg amongst HBV chronic carrier women of
childbearing age reported by many other studies in Middle-Eastern countries (Al-Nakib
et al., 1986; Amini et al., 1993; Basalamah et al., 1984; Coursaget et al., 1994; Nabulski
et al., 1997; Ramia et al., 1984). This reduces the prevalence of HBeAg positive chronic
carrier mothers in Yemen by approximately two-thirds, and consequently the prevalence
of potentially highly infectious HBV chronic carrier women, and thereby the risk of
perinatal transmission of HBV infection in Yemen. The number of HBeAg positive
mothers was too small to allow examination of HBeAg status by age of mother.
Another important finding was the clear increase in the prevalence of anti-HBc positivity
with increasing age of the mother (p=0.0001). As the age of the mother increases the
more likely she is to be exposed to HBV regardless of means or setting. The adjusted OR
of anti-HBc positivity was 1.29, 1.83,3.15, and 2.99 amongst women aged 25 to 29, 30
to 34, 35 to 39, and 40 to 49, respectively (p=O.OOOI).This association was demonstrated
in an earlier study in Yemen which showed that after adjusting for other variables age
was highly significantly associated with being seropositive (adjusted OR 1.51), and is
consistent with findings of numerous international studies as well as other studies in the
region (Scott et al., 1990). On the other hand, the relatively stable prevalence of HBV
chronic infection from young to older mothers, and the apparently low risk of perinatal
transmission of HBV infection suggests that mothers with HBV chronic infection were
most likely infected by child-to-child transmission during childhood, which has been
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suggested to be the major mode of transmission of HBV infection in the Middle East
(Toukan et al., 1990).
There was approximately a 50% decline in the prevalence of anti-HBc positivity (p=0.04)
and HBV chronic infection (p=0.05) amongst mothers living in urban areas compared to
mothers living in rural areas unadjusting for age. Nevertheless, this difference did not
remain significant in the multivariable analysis after adjusting for the remaining variables
in the model. It is suspected that the difference in the prevalence of HBV infection by
area of residence may be attributed to socioeconomic factors including mother's
educational status. It has already been shown in chapter 1 that numerous studies in the
Middle-East have demonstrated the prevalence of anti-HBc positivity and HBV chronic
infection to be inversely related to socioeconomic status. International research as well as
studies in Middle-Eastern countries, most commonly in Jordan and Saudi Arabia, show
the prevalence of anti-HBc positivity and HBV chronic infection amongst individuals of
upper socioeconomic status to be lower than the prevalence of anti-HBc positivity and
HBV chronic infection amongst individuals of middle and low socioeconomic status
(Awidi et al., 1984; Ghaffar et al., 1989; Toukan et al., 1990; Toukan, 1996; WHO,
1995). Similarly, the socioeconomic classification in this survey demonstrated a clear and
statistically significant decline in the prevalence and OR of anti-HBc positivity and HBV
chronic infection with increasing socioeconomic status by univariable and multivariable
analysis. According to the socioeconomic index of this survey study participants were
divided into low, middle, and upper socioeconomic status. This was based on a number
of household characteristics, household possessions, and levels of educational attainment
of mother and father. Fridge/freezer ownership was one of the household possessions
contributing to the socioeconomic index constructed in the survey that was statistically
significantly associated with anti-HBc positivity and HBV chronic infection amongst
mothers in Yemen in the multi variable analysis after adjusting for the remaining variables
in the model. There was also a statistically significant increase in fridge/freezer
ownership with increasing socioeconomic status (p<0.0001), mothers educational status
(p<O.OOOI),and fathers educational status (p<0.0001), as well as in urban areas of
residence (p<0.0001). Home telephone ownership was another household possession
contributing to the socioeconomic index constructed in the survey that was statistically
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significantly associated with anti-HBc positivity in the multivariable analysis [OR 1.59
(95% Cl 1.03 to 2.46)]. There was a statistically significant increase in home telephone
availability with increasing socioeconomic status (p<O.OOO1) as well as a statistically
significant difference in home telephone availability by area of residence with only 3% of
rural households having a home telephone compared to 42% of urban households
(p<O.OOOI).However, area of residence was not statistically significantly associated with
being anti-HBc positive or HBV chronic infection in the multivariable analysis in this
survey, which is similar to findings observed in an earlier study in Yemen (Scott et al.,
1990).
Mothers educational status, another variable contributing to the socioeconomic index
constructed in the survey, was also statistically significantly associated with HBV chronic
infection amongst mothers in Yemen. Being an uneducated mother had a highly
significant association with HBV chronic infection in the multivariable analysis [adjusted
OR 4.49 (95% Cl 1.47 to 13.7)] (p=0.01). The adjusted OR of being anti-HBc positive
amongst uneducated women was also increased in the multi variable analysis but did not
reach statistical significance [OR 1.37 (95% Cl 0.84 to 2.22)] (p=0.19). Female education
is a well established determinant of health. It has been demonstrated that women who
received even one to three years of schooling acquired greater knowledge and learnt
better health practices which were enough to reduce child mortality by 15% (Abel-Smith,
1998).
Women of higher birth order had an increased adjusted OR of HBV chronic infection in
the multi variable analysis than women of relatively lower birth order. This suggested that
women of higher birth order had a greater risk of becoming infected with HBV by their
older siblings during childhood and indicates that childhood transmission was occurring
and contributed to the pool ofHBV chronic carrier women in Yemen. Family size, on the
other hand, which takes into account the number of younger siblings, as opposed to child
birth order which only takes into account the number of older siblings, was not
significantly associated with HBV chronic infection nor did it alter the OR of HBV
chronic infection amongst mothers associated with mothers birth order indicating that
mothers were not at risk of becoming infected with HBV from their younger siblings.
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The prevalence estimates of anti-HBc positivity and chronic infection amongst mothers
participating in this survey are the first estimates obtained from this age-group through a
random population-based household seroepidemiological survey in Yemen. The reason
for selecting this age-group was to measure the prevalence of HBV chronic infection
amongst women of childbearing age and the proportion of these women HBeAg positive,
which would allow assessing the infectiousness of these women and thereby the risk of
perinatal transmission of HBV infection from these women to their children. It is
believed that these results are reliable, accurate, and based on a representative sample
taken for the general population. It is not suspected that these results are biased and a
general discussion of the possible effect of bias or confounding on these results will be
presented in chapter 9.
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Chapter 6: Results Children Aged 1-3:
In this chapter the results of the prevalence, univariable analysis, and multivariable
analysis of anti-HBc positivity and HBsAg chronic carrier status amongst children aged
1-3 participating in the survey will be presented.
HBV Infection:
6.1 Prevalence of hepatitis B core antibody (anti-HBc):
The overall prevalence of anti-HBc positive children aged 1-3 participating in the survey
in Yemen was 2.38% (95% Cl 1.25 to 4.49). The prevalence of anti-HBc positive
children aged 1-3 participating in the survey was statistically significantly different
according to mothers HBV infection status, sex of the child, qualifications of the person
managing delivery of the child, and socioeconomic status.
The prevalence of anti-HBc positivity was 9.86% amongst children born from HBV
chronic carrier mothers, 5.09% amongst children born from anti-HBc positive mothers,
and 1.19% amongst children born from uninfected mothers (p=O.OOOI).When examining
the risk of the child being anti-HBc positive by hepatitis B e antigen (HBeAg) status of
HBV chronic carrier mothers, 2/8 (21%) of children born from HBeAg positive chronic
carrier mothers were anti-HBc positive compared to 3/51 (8.2%) of children born from
HBeAg negative chronic carrier mothers, however, this difference was not statistically
significant probably due to the small number of HBeAg positive chronic carrier mothers
(p=0.45).
The prevalence ofanti-HBc positivity amongst males (3.16%) was twice as high as it was
amongst females (1.54%) (p=0.05). The prevalence of anti-HBc positivity amongst
children whose delivery was managed by a medically qualified individual (1.02%) was
statistically significantly lower than the prevalence of anti-HBc positivity amongst
children whose delivery was managed by an unqualified individual (3.32%) (p=0.02).
Similarly, the prevalence of anti-HBc positivity amongst children delivered in a health
setting (0.87%) was significantly lower than the prevalence of anti-HBc positivity
amongst children delivered in a home setting (2.71%) (p=0.06). There was a significant
difference in the prevalence of anti-HBc positivity between the three socioeconomic
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classes in the survey (p=0.01). The prevalence ofanti-HBc positivity was 3.61% amongst
children of low socioeconomic status, 0.92% amongst children of middle socioeconomic
status, and 1.43% amongst children of upper socioeconomic status. The higher
prevalence of anti-HBc positivity amongst children of upper socioeconomic status
compared to children of middle socioeconomic status was not statistically significant
(p=0.52). Table 6.1.1 shows the prevalence of anti-HBc positivity amongst children aged
1-3 by personal and health care characteristics.
The prevalence of anti-HBc positivity was lower amongst completely vaccinated (0.5%)
compared to unvaccinated (2.95%), and partially vaccinated (3.17%) children (p=0.34).
When completely vaccinated children were compared to unvaccinated children alone the
p-value became smaller (p=0.06). The prevalence of anti-HBc positivity amongst
children aged 1-3 in urban areas (1.46%) was nearly half the prevalence of anti-HBc
positivity in rural areas (2.79%) but this difference was not statistically significant
(p=0.26). When anti-HBc positivity was compared by urban/rural area of birth of child
the prevalence of anti-HBc positivity was 1.1% (5/454) amongst children born in urban
areas and 2.8% (201755) amongst children born in rural areas (p=0.07). There was no
evidence of a statistically significant difference in the prevalence of anti-HBc positivity
between all five provinces (p=0.58), urban provinces (p=0.31), or rural provinces
(p=0.o8) in the survey. Table 6.1.2 shows the prevalence of anti-HBc positivity amongst
children aged 1-3 by characteristics of the mother.
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Table 6.1.1
Prevalence of anti-HBc positive children aged 1-3
by demographic and health care characteristics
Number Prevalence p-value
Prevalence anti-HBc positive of (weighted) 95%CI 95%CI (Pearson
Children % LL UL design-
based)
Overall 27/1285 2.38 1.25 4.49
Sex
Male 19/652 3.16 1.71 5.79
Female 8/633 1.54 0.62 3.79 0.05
Age (in months)
12 to 17 5/269 2.02 0.48 8.18
18 to 23 8/384 2.24 0.74 6.59
24 to 29 3/275 1.07 0.29 3.82
30 to 36 11/357 3.80 1.96 7.24 0.33
Province
Sanaa 5/262 1.84 0.68 4.91
Taiz 6/252 2.36 0.65 8.18
Aden 2/247 0.81 0.22 2.87
Shabwa 5/268 1.84 0.49 6.62
Hodeidah 9/256 3.53 1.20 9.92 0.58
Area
Urban 7/509 1.49 0.64 3.44
Rural 20/776 2.79 1.29 5.97 0.26
Vaccination Status
Not Vaccinated 22/840 2.95 1.44 5.92
Completely Vaccinated 1/137 0.50 0.06 3.78
Partially Vaccinated 4/147 3.17 1.02 9.47 0.34
Person Managing Delivery
Medically Qualified Personnel 6/559 1.02 0.48 2.18
Unqualified Personnel 21/705 3.32 1.57 6.87 0.02
Setting of Delivery
Health Setting 4/330 0.87 0.31 2.43
Home Setting 22/903 2.71 1.35 5.38 0.06
Antenatal Care
Yes 9/619 1.91 0.85 4.24
No 18/661 2.78 1.28 5.90 0.42
Socioeconomic Status
Low 17/506 3.61 1.92 6.69
Middle 6/508 0.92 0.29 2.87
Upper 4/270 1.43 0.48 4.17 0.01
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Table 6.1.2
Prevalence of anti-HBc positive children aged 1-3
by characteristics of the mother
Number Prevalence p-value
Prevalence anti-HBc positive of (weighted) 95%CI 95%CI (Pearson
Children % LL UL design-based)
Mothers HBV Status
Mother Chronic Carrier 5/59 9.86 5.35 17.47
Mother anti-HBc positive 12/240 5.09 2.45 10.28
Mother Uninfected 10/986 1.19 0.56 2.50 0.0001
Mothers HBeAg Status
Positive 2/8 21.14 2.40 74.51
Negative 3/51 8.20 2.97 20.68 0.45
Mothers Age (In years)
15 to 24 12/400 3.17 1.60 6.16
25 to 29 6/349 2.30 0.68 7.49
30 to 34 5/268 1.65 0.56 4.76
35 to 39 2/177 1.14 0.20 6.29
40 to 49 2/91 3.44 0.74 14.58 0.61
Mother's Educational Status
Educated 9/547 1.61 0.68 3.77
Uneducated 18/738 2.83 1.49 5.32 0.12
Mother's Level of Education
Read and Write 5/179 2.28 0.62 8.06
Primary School 3/221 1.75 0.48 6.21
Secondary School 0/113 0.00
University or College 1/34 2.22 0.22 19.06 0.61
Mother's Employment
Employed 1/55 1.27 0.13 11.28
Not Employed 26/1230 2.42 1.26 4.60 0.56
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6.2 Children's anti-BBc univariable analysis:
The variables statistically significantly associated with children aged 1-3 being anti-HBc
positive by univariable analysis were HBV infection status of the mother, qualifications
of the person managing delivery of the child, availability of electricity in the household,
television ownership, fridge/freezer ownership, and socioeconomic status.
The HBV infection status of the mother was the independent variable with the most
significant association with children being anti-HBc positive. The OR of being anti-HBc
positive amongst children aged 1-3 associated with having an anti-HBc positive mother
was 4.47 (95% Cl 1.62 to 12.33) and the OR associated with having a HBV chronic
carrier mother was 9.11 (95% Cl 4.29 to 19.36) compared to children born from
uninfected mothers (p<0.001). The OR of being anti-HBc positive was 3.32 (95% Cl 1.19
to 9.22) amongst children whose delivery was managed by an unqualified individual
which was statistically significantly higher than children whose delivery was managed by
a medically qualified individual (p=0.02). The OR of being anti-HBc positive was
significantly lower amongst children of middle (OR=0.25) and upper (OR=0.39)
socioeconomic status compared to children of low socioeconomic status (p=0.03).
Fridge/freezer and television were the two household commodities that were statistically
significantly associated with children aged 1-3 being anti-HBc positive. The OR of being
anti-HBc positive was 2.95 (95% Cl 1.04 to 8.37) amongst children who did not have a
fridge/freezer in their household (p=0.04), 4.17 (95% Cl 1.35 to 12.84) amongst children
who did not have a television in their household (p=0.02) and 3.55 (95% Cl 1.04 to
12.12) amongst children living in households that did not have an electricity supply
(p=0.04). Table 6.2.1 shows the results of the univariable analysis of the association of
demographic and health care variables with anti-HBc positivity amongst children aged
1-3.
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Table 6.2.1
Association of anti-HBc positivity amongst children aged 1-3
with demographic and health care characteristics
Variable Number Number OR p value 95% C.I.
Controls Cases
Sex Male 633 19 1
Female 625 8 0.48 0.06 0.23 - 1.02
Age of child 12 to 17 264 5 1
(in months) 18 to 23 376 8 1.11 0.88 0.27 -4.52
24 to 29 272 3 0.52 0.52 0.07 -4.01
30 to 36 346 11 1.91 0.39 0.41 - 8.84
Joint significance 0.25
Linear trend OR 1.24 0.42 0.72 - 2.11
Province Sanaa 257 5 1
Taiz 246 6 1.29 0.75 0.25 - 6.72
Aden 245 2 0.43 0.3 0.08 -2.24
Shabwa 263 5 0.99 1 0.19 - 5.32
Hodeidah 247 9 1.95 0.36 0.44 - 8.72
Joint significance 0.57
Area Urban 502 7 1
Rural 756 20 1.90 0.26 0.59 - 6.11
Child Birth Order 1 235 6 1
2 208 2 0.51 0.55 0.05 - 5.32
3 195 3 0.99 0.99 0.33 - 3.02
4 135 6 2.72 0.16 0.65 - 11.46
5 120 3 1.73 0.57 0.24 - 12.43
6 to 18 365 7 0.80 0.7 0.24 -2.66
Joint significance 0.29
Linear Trend OR 1.03 0.78 0.82 - 1.3
Duration Up to 1 year 462 9 1
Breastfed 1 to 2 years 670 16 2.34 0.12 0.78 -7.04
More than 2 yrs 100 2 1.68 0.49 0.37 -7.64
Joint significance 0.31
Vaccination Unvaccinated 818 22 1
Status Partially 143 4 1.08 0.9 0.29 -4.01
Completely 136 1 0.17 0.09 0.02 -1.42
Joint significance 0.24
Person Managing Qualified Medic 553 6 1
Delivery Unqualified 684 21 3.32 0.02 1.19 - 9.22
Setting of Health Setting 326 4 1
Delivery Home Setting 881 22 3.12 0.08 0.88 - 11.43
Variables that had notably increased or decreased OR by more or less than 30% but not
found to be statistically significantly associated with anti-HBc positivity amongst
children aged 1-3 were age and sex of the child, area and province of residence,
vaccination status of the child, breastfeeding, setting of delivery, mothers and fathers
167
educational status, mothers employment, household crowding index, ownership of a car
or home telephone, and household ownership, type and construction. These are all
presented in tables 6.2.1, 6.2.2 and 6.2.3. Some of the most notable findings were the OR
of anti-HBc positivity was 0.17 amongst completely vaccinated children compared to
unvaccinated children (p=0.09), the odds of anti-HBc positivity was 0.43 amongst
children aged 1-3 in Aden compared to children in Sanaa (p=O.3), the odds of anti-HBc
positivity amongst children aged 30 to 36 months was 1.91 compared to children aged 12
to 17 months (p=0.39), and children living in households with high crowding indexes
appeared to have a higher odds of being anti-HBc positive (p=0.06). Table 6.2.2 shows
the results of the univariable analysis of the association of mothers and fathers
characteristics with anti-HBc positivity amongst children aged 1-3.
Table 6.2.2
Association of anti-HBc positivity amongst children aged 1-3
with mothers and fathers characteristics
Variable Number Number OR P 95% C.I.
Controls Cases value
MotherHBV Uninfected 976 10 1
Status anti-HBc positive 228 12 4.47 0.006 1.62 - 12.33
Chronic carrier 54 5 9.11 <0.001 4.29 - 19.36
Jointsignij1cance <0.001
Mothers Age 15 to 24 388 12 1
(in years) 25 to 29 343 6 0.72 0.53 0.24-2.12
30 to 34 263 5 0.51 0.35 0.12-2.18
35 to 39 175 2 0.35 0.22 0.06 - 1.95
40 to 49 89 2 1.09 0.9 0.27 -4.35
Joint significance 0.48
Linear Trend OR 0.86 0.44 0.58 - 1.27
Mothers Educated 538 9 1
Education Uneducated 720 18 1.78 0.12 0.85 - 3.76
Mothers 1 277 1 1
Birth Order 2 200 3 2.86 0.41 0.21 - 38.54
3 198 6 9.85 0.07 0.82 - 118
4 155 5 7.25 0.12 0.59 - 88.79
5 129 3 9.14 0.07 0.79 - 105
6 to 19 299 9 6.71 0.06 0.91-49.19
Joint significance 0.13
Linear Trend OR 1.24 0.01
Mothers Unemployed 1204 26 1
Employment Employed 54 1 0.52 0.57 0.05 - 5.6
Fathers Educated 998 17 1
Education Uneducated 260 10 2.02 0.2 0.66 - 6.15
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Variables that neither showed notably increased or decreased OR nor evidence of a
statistically significant association with anti-HBc positivity amongst children aged 1-3
participating in the survey were ownership of mobile telephone (p=O.99), radio (p=O.94),
or household source of water (p=O.ll). Likewise the OR of anti-HBc positivity amongst
children aged 1-3 associated with child birth order (p=O.29), mothers birth order (p=O.13)
and mothers age (p=O.12) was not significant and did not follow a clear trend (see tables
6.2.1, 6.2.2, 6.2.3). Table 6.2.3 shows the association of anti-HBc positivity amongst
children aged 1-3 with household characteristics and possessions.
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Table 6.2.3
Association of anti-HBc positivity amongst children aged 1-3
with household characteristics and possessions
Variable Number Number OR P 95% C.I.
Controls Cases value
Household Owned 1073 25 1
Ownership Rented 185 2 0.45 0.25 0.11- 1.81
Household Type House 928 20 1
Apartment 218 3 0.9 0.86 0.26-3.14
Shack 111 4 1.7 0.33 0.56 - 5.01
Jointsignij7cance 0.57
Household Stone 368 6 1
Construction Block 571 13 1.83 0.26 0.62 - 5.41
Mud or Clay 187 3 0.85 0.88 0.08 - 8.6
Mixed 132 5 2.61 0.22 0.54 - 12.67
Joint significance 0.59
Crowding Index 1 99 1 1
2 317 6 3.7 0.23 0.41 - 33.09
3 310 2 1.03 0.98 0.08 - 14.1
4 213 8 10.16 0.04 1.11 - 93.27
5 124 2 3 0.38 0.23 - 38.69
6 to 18 195 8 11.04 0.03 1.27 - 95.85
Joint significance 0.06
Linear Trend OR 1.41 0.009 1.1-1.81
Electricity Yes 892 12 1
Supply No 366 15 3.55 0.04 1.04-12.12
Source of Water Governmental 431 5 1
Local Project 434 9 2.3 0.21 0.61- 8.69
Water Truck 117 5 3.16 0.03 1.13 - 8.86
Buckets 274 8 2.56 0.14 0.71 - 9.22
Joint significance 0.11
FridgelFreezer Yes 583 7 1
No 675 20 2.95 0.04 1.04 - 8.37
Television Yes 861 11 1
No 397 16 4.17 0.02 1.35 - 12.84
Radio Yes 894 20 1
No 364 7 0.98 0.94 0.53 - 1.79
Home Phone Yes 261 4 1
No 997 23 1.66 0.37 0.53 - 5.24
Mobile Phone Yes 59 1 1
No 1199 26 0.99 0.99 0.13 - 7.48
Car Yes 312 5 1
No 946 22 1.71 0.49 0.35 - 8.42
Socioeconomic Low 489 17 1
Status Middle 502 6 0.25 0.01 0.08 -0.73
Upper 266 4 0.39 0.11 0.12 -1.27
Jointsignij7cance 0.03
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6.3 Children's anti-HBc multivariable analysis:
After adjusting for the remaining variables included in the multivariable analysis, the
only variables found to have a statistically significant association with anti-HBc
positivity amongst children aged 1-3 were HBV infection status of the mother and the
ownership of a television.
The adjusted OR of anti-HBc positivity amongst children aged 1-3 born from anti-HBc
positive mothers was 3.97 (95% Cl 1.38 to 11.43) and increased to 7.84 (95% Cl 3.78 to
16.25) amongst children aged 1-3 born from HBV chronic carrier mothers.
The adjusted OR of anti-HBc positivity amongst children aged 1-3 born from families
that did not own a television in their household was 3.34 (95% Cl 1.07 to 10.41)
compared to families that owned a television (p=0.04). Adding television ownership to
the multivariable model changed the adjusted OR of anti-HBc positivity amongst
children aged 1-3 living in rural areas from 1.6 (p=0.5) in the model without television
ownership to 0.78 (p=0.68) in the model including television ownership. Age, sex, and
area of residence did not show evidence of a statistically significant association with anti-
HBc positivity amongst children aged 1-3, but because these were a priori variables, they
were added to the final model at the end of the multivariable modelling.
The adjusted OR of the qualifications of the person managing delivery of the child
associated with anti-HBc positivity amongst children aged 1-3 was 2.5 (95% Cl 0.8 to
7.82)' but showed no evidence of a statistically significant association (p=O.l1).
Nevertheless, because qualifications of the person managing delivery of the child was
significantly associated with HBV chronic infection it was added to the final
multivariable model of anti-HBc positivity, regardless of the significance of its
association with anti-HBc positivity, resulting in two models, one for anti-HBc positivity
and the other for HBV chronic infection, both including identical independent variables.
There was no evidence of interaction between the independent variables in the model.
Table 6.3.1 shows the results of the multivariable analysis of the association of the
independent variables with anti-HBc positivity amongst children aged 1-3.
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Table 6.3.1
Adjusted logistic regression of the association of anti-HBc positivity
amongst children aged 1-3 with independent exposure variables
~ariable OR* p value** 95% C.I.***
MotherHBV Uninfected 1
Status anti-HBc positive 3.97 0.01 1.38 - 11.43
Chronic Carrier 7.84 <0.001 3.78 - 16.25
Joint significance **** <0.0001
Sex Male 1
Female 0.52 0.13 0.22 - 1.22
Age of Child 12 to 17 1
(in months) 18 to 23 1.18 0.78 0.36 - 3.90
24 to 29 0.45 0.43 0.06 - 3.57
30 to 36 1.88 0.4 0.41 - 8.66
Joint significance 0.33
Area Urban 1
Rural 0.61 0.46 0.16 - 2.38
Person Managing Qualified Medic 1
Delivery Unqualified 2.5 0.11 0.80 -7.82
Television Yes 1
Ownership No 3.34 0.04 1.07 - 10.41
* adjusted OR computed by survey logistic regression multivariable analysis.
** p-value of the adjusted Wald test statistic.
*** 95% Confidence Intervals.
**** p-value of the adjusted survey Wald test statistic of the significance of the joint
effect of the categories of the independent variable on the dependent variable.
The multivariable analysis of variables associated with anti-HBc positivity amongst
children aged 1-3 was repeated excluding all the socioeconomic variables and after
substituting them with the single socioeconomic status variable. The OR and p-values of
anti-HBc positivity associated with age and sex of the child aged 1-3, as well as mothers
HBV infection status, were similar in the model including the socioeconomic status
variable as the model including all the socioeconomic variables. The adjusted OR of anti-
HBc positivity associated with residing in a rural area in the model including the
socioeconomic status variable changed from 0.61 to 0.92 (p=0.2). Socioeconomic status,
on the other hand, was not significantly associated with anti-HBc positivity amongst
children aged 1-3 (p=0.25). Table 6.3.2 shows the results of the multivariable analysis of
the association of independent variables and the socioeconomic status variable with anti-
HBc positivity amongst children aged 1-3 participating in the survey.
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Table 6.3.2
Adjusted logistic regression of the association of anti-HBc positivity amongst
children aged 1-3 with independent exposure variables and socioeconomic status
~ariable OR* p value** 95% C.I.***
MotherHBV Uninfected 1
Status anti-HBc positive 4.14 0.01 1.39 - 12.34
Chronic Carrier 8.62 <0.001 3.91 - 19.01
Joint significance **** <0.0001
Sex Male 1
Female 0.51 0.12 0.22 - 1.17
Age of Child 12 to 17 1
(in months) 18 to 23 1.21 0.74 0.36 -4.07
24 to 29 0.47 0.45 0.06 - 3.54
30 to 36 1.72 0.46 0.39-7.55
Joint significance 0.38
Area Urban 1
Rural 0.92 0.90 0.24 - 3.57
Person Managing Qualified Medic 1
Delivery Unqualified 2.82 0.08 0.87 - 9.16
Socioeconomic Low 1
Status Middle 0.37 0.12 0.11- 1.28
Upper 0.88 0.83 0.25 - 3.05
Joint significance 0.25
* adjusted OR computed by survey logistic regression multivariable analysis.
** p-value of the adjusted Wald test statistic.
*** 95% Confidence Intervals.
**** p-value of the adjusted survey Wald test statistic of the significance of the joint
effect of the categories of the independent variable on the dependent variable.
As well as being one of the important factors under investigation in the survey, hepatitis
B vaccination was an important factor determining the HBV infection status of the child.
In the univariable analysis, the OR of being anti-HBc positive was 0.17 amongst
completely vaccinated children compared to unvaccinated children (p=0.09). Therefore,
even though vaccination status was dropped from the multiple logistic regression model,
it was added to the final model in order to examine the effect of vaccination status of the
child on the remaining variables in the model. Vaccination status was not statistically
significant in the final model (p=0.65). Adding vaccination status to the multivariable
model of anti-HBc positivity amongst children aged 1-3 had a minor effect on the OR
and p-values. It reduced the OR of anti-HBc positivity associated with not owning a
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television in the household from 3.34 to 2.9 and its statistical significance from 0.04 to
0.08. Table 6.3.3 shows the results of the multivariable analysis of the association of the
independent variables including hepatitis B vaccination status with anti-HBc positivity
amongst children aged 1-3.
Table 6.3.3
Adjusted logistic regression of the association of anti-HBc positivity
amongst children aged 1-3 with independent exposure variables
including vaccination status of the child
Variable OR* p value** 95% C.I.***
MotherHBV Uninfected 1
Status anti-HBc positive 4.03 0.01 1.38 - 11.78
Chronic Carrier 7.57 <0.001 3.83 - 14.94
Joint significance **** <0.0001
Sex Male 1
Female 0.54 0.12 0.24 -1.20
Age of Child 12 to 17 1
(in months) 18 to 23 1.17 0.79 0.35 - 3.92
24 to 29 0.47 0.44 0.06 - 3.47
30 to 36 1.97 0.37 0.43-9.12
Joint significance 0.29
Area Urban 1
Rural 0.53 0.34 0.14 - 2.06
Person Managing Qualified Medic 1
Delivery Unqualified 2.29 0.17 0.69 -7.65
Television Yes 1
Ownership No 2.86 0.08 0.86 - 9.47
Vaccination Unvaccinated 1
status One Dose 1.82 0.46 0.34 - 9.73
Two Doses 0.65 0.67 0.08 - 5.15
Three Doses 0.34 0.32 0.04 - 3.08
Joint significance 0.65
* adjusted OR computed by survey logistic regression multivariable analysis.
** p-value of the adjusted Wald test statistic.
*** 95% Confidence Intervals.
**** p-value of the adjusted survey Wald test statistic of the significance of the joint
effect of the categories of the independent variable on the dependent variable.
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HBV Chronic Infection:
6.4 Prevalence of HBV chronic infection (HBsAg positive):
The prevalence of HBV chronic infection amongst children aged 1-3 participating in the
survey in Yemen was 0.99% (95% Cl 0.35 to 2.76). Only 11 out of 1285 children tested
were positive for HBsAg, all of whom were negative for IgM anti-HBc, indicating that
these children did not have acute HBV infection and were chronically infected with HBV
(infected for longer than six months). All of these chronically infected children were a
subset of children aged 1-3 positive for anti-HBc. There was evidence of a statistically
significant difference in the prevalence of HBV chronic infection amongst children aged
1-3 by mothers HBV infection and HBeAg status, qualifications of the person managing
delivery of the child, setting in which the child was delivered, and socioeconomic status.
The prevalence of HBV chronic infection was 2.72% amongst children born from HBV
chronic carrier mothers, 3.85% amongst children born from anti-HBc positive mothers,
and 0.14% amongst children born from uninfected mothers (p=0.0002). 89% of HBV
chronic carrier children and 62% of anti-HBc positive children were born from HBV
infected/chronic carrier mothers. When examining the risk of the child developing HBV
chronic infection by HBeAg status of HBV chronic carrier mothers, 2/8 (21%) of
children born from HBeAg positive chronic carrier mothers were chronically infected
with HBV compared to 0/51 (0%) of children born from HBeAg negative chronic carrier
mothers (p=0.02).
The prevalence of HBV chronic infection amongst children whose delivery was managed
by a medically qualified individual (0.06%) was statistically significantly lower than the
prevalence of HBV chronic infection amongst children whose delivery was managed by
an unqualified individual (3.32%) (p=0.0003). Similarly, the prevalence of HBV chronic
infection amongst children delivered in a health setting (0.12%) was statistically
significantly lower than the prevalence of HBV chronic infection amongst children
delivered in a home setting (1.25%) (p=0.02). The prevalence of HBV chronic infection
was 1.6% amongst children of low socioeconomic status, 0.15% amongst children of
middle socioeconomic status, and 0.78% amongst children of upper socioeconomic status
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(p=0.04). Similar to findings with anti-HBc positivity amongst children aged 1-3 the
higher prevalence of HBV chronic infection amongst children of upper socioeconomic
status compared to children of middle socioeconomic status was not statistically
significant (p=0.07). Table 6.4.1 shows the prevalence ofHBV chronic infection amongst
children aged 1-3 by demographic and health care characteristics.
All HBV chronic carrier children participating in the survey were unvaccinated and the
prevalence of HBV chronic carriers amongst unvaccinated children was 1.5% (95% Cl
0.53 to 4.16). There were no HBV chronic carriers amongst the 284 completely or
partially vaccinated children. However, there was no evidence of a statistically significant
difference in the prevalence of HBV chronic carriers between completely vaccinated,
partially vaccinated and unvaccinated children (p=0.58). Likewise, there was no evidence
of a statistically significant difference in the prevalence of HBV chronic carriers between
vaccinated children (completely and partially combined) and unvaccinated children
(p=0.28). Similarly, there was no evidence of a statistically significant difference in the
prevalence of HBV chronic carriers between completely vaccinated and unvaccinated
children (p=0.5). Similar to findings with anti-HBc positivity amongst children aged 1-3
the prevalence of HBV chronic infection amongst children aged 1-3 in urban areas
(0.61%) was nearly half the prevalence of HBV chronic infection in rural areas (1.17%)
but this difference was not statistically significant (p=0.58). When HBV chronic infection
was compared by urban/rural area of birth of child the prevalence of HBV chronic
infection was 0.3% (1/459) amongst children born in urban areas and 1.17% (9/775)
amongst children born in rural areas (p=0.26). Table 6.4.2 shows the prevalence of HBV
chronic infection amongst children aged 1-3 by characteristics of the mother.
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Table 6.4.1
Prevalence of HBV chronically infected children aged 1-3
by demographic and health care characteristics
Number Prevalence p-value
Prevalence HBsAg Positive of (weighted) 95%CI 95%CI (Pearson
Children % II Ul design-based)
Overall 11/1285 0.99 0.35 2.76
Sex
Male 6/652 1.00 0.31 3.20
Female 5/633 0.99 0.37 2.60 0.98
Age (In months)
12 to 17 1/269 0.63 0.08 4.93
18 to 23 3/384 0.92 0.24 3.47
24 to 29 2/275 0.56 0.10 3.01
30 to 36 5/357 1.67 0.52 5.17 0.43
Province
Sanaa 2/262 0.93 0.11 7.16
Taiz 3/252 1.18 0.14 8.95
Aden 0/247 0.00
Shabwa 3/268 1.10 0.28 4.25
Hodeidah 3/256 1.17 0.29 4.56 0.90
Area
Urban 2/509 0.61 0.08 4.79
Rural 9/776 1.17 0.36 3.75 0.58
Vaccination Status
Not Vaccinated 11/840 1.50 0.53 4.16
Completely Vaccinated 0/137 0.00
Partially Vaccinated 0/147 0.00 0.58
Person Managing Delivery
Medically Qualified Personnel 1/559 0.06 0.01 0.52
Unqualified Personnel 101705 1.61 0.55 4.65 0.0003
Setting of Delivery
Health Setting 1/330 0.12 0.02 1.02
Home Setting 10/903 1.25 0.42 3.60 0.02
Antenatal Care
Yes 3/619 0.79 0.16 3.86
No 8/661 1.16 0.46 2.90 0.55
Socioeconomic Status
Low 7/506 1.60 0.53 4.73
Middle 2/508 0.15 0.04 0.56
Upper 2/270 0.78 0.14 4.34 0.04
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Table 6.4.2
Prevalence of HBV chronically infected children aged 1-3
by characteristics of the mother
Number Prevalence p-value
Prevalence HBsAg Positive of (weighted) 95%CI 95%CI (Pearson
Children % LL UL deslgn-based)
Mothers HBV Status
Mother Chronic Carrier 2/59 2.72 0.53 12.76
Mother anti-HBc Positive 8/240 3.85 1.37 10.33
Mother Uninfected 1/986 0.14 0.02 1.18 0.0002
Mothers HBeAg Status
Positive 2/8 21.14 2.40 74.51
Negative 0/51 0.00 0.02
Mothers Age (in years)
15 to 24 6/400 1.71 0.63 4.59
25 to 29 2/349 0.51 0.09 2.86
30 to 34 1/268 0.13 0.02 1.03
35 to 39 1/177 0.96 0.12 7.03
40 to 49 1/91 1.83 0.21 14.38 0.21
Mother's Educational Status
Educated 3/547 0.40 0.09 1.69
Uneducated 8/738 1.34 0.43 4.04 0.11
Mother's Level of Education
Read and Write 2/179 0.41 0.11 1.54
Primary School 1/221 0.63 0.08 4.90
Secondary School 0/113 0.00
University or College 0/34 0.00 0.78
Mother's Employment
Employed 0/55 0.00
Not Employed 11/1230 1.03 0.36 2.86 0.68
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6.5 Children's HBV chronic infection univariable analysis:
The variables that showed evidence of a statistically significant association with HBV
chronic infection amongst children aged 1-3 by univariable analysis were HBV infection
status of the mother, qualifications of the person managing delivery of the child, mother's
age, birth order of the child, duration breastfeeding, car ownership and socioeconomic
status.
The HBV infection status of the mother had the most significant association with
children's HBV chronic infection. The OR of HBV chronic infection amongst children
aged 1-3 associated with having an anti-HBc positive mother was 27.6 (95% Cl 3.37 to
226) and the OR associated with having a HBV chronic carrier mother was 19.2 (95% Cl
1 to 385) compared to children born from uninfected mothers (p=O.OOOl).Also similar to
findings with anti-HBc positivity amongst children aged 1-3, children whose delivery
was managed by an unqualified individual had an OR of 25.95 (95% Cl 2.43 to 277) for
HBV chronic infection and this was statistically significantly higher than children whose
delivery was managed by a medically qualified individual (p=O.OI). Children breastfed
for more than 1 year (OR=2.45) or more than 2 years (OR=4.91) had a significantly
higher odds ofHBV chronic infection than children breastfed up to 1 year (p=O.05).
The OR of HBV chronic infection was significantly lower amongst children of middle
(OR=O.09) and upper (OR=0.49) socioeconomic status compared to children of low
socioeconomic status (p=O.03). The OR of HBV chronic infection was 9.32 amongst
children living in households without a car (p=O.05). The birth order of the child was
significantly associated with HBV chronic infection (p=O.OI) but did not follow a clear
pattern. Children fourth in birth order had the highest OR of HBV chronic infection
(OR=30) (95% Cl 3 to 292). Likewise, the association between children's HBV chronic
infection and mothers age did not follow an obvious pattern but generally appeared to
decline with increasing age of the mother (p=O.007). Table 6.5.1 shows the results of the
univariable analysis of the association of demographic and health care variables with
HBV chronic infection amongst children aged 1-3.
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Table 6.5.1
Association of HBV chronic infection amongst children aged 1-3
with demographic and health care characteristics
Variable Number Number OR p value 95% C.I.
Controls Cases
Sex Male 646 6 1
Female 628 5 0.99 0.98 0.51 - 1.93
Age of child 12 to 17 268 1 1
(in months) 18 to 23 381 3 1.45 0.55 0.4 - 5.27
24 to 29 273 2 0.88 0.92 0.06 - 13.3
30 to 36 352 5 2.66 0.28 0.43 - 16.55
Joint significance 0.3
Linear trend OR 1.36 0.38 0.67 -2.78
Province Sanaa 260 2 1
Taiz 249 3 1.27 0.87 0.06 - 26.24
Aden 247 0 - - -
Shabwa 265 3 1.18 0.89 0.09 - 15.33
Hodeidah 253 3 1.26 0.85 0.1 - 16.42
Joint significance 0.99
Area Urban 507 2 1
Rural 767 9 1.91 0.58 0.17 - 21.4
Child Birth Order 1 240 1 1
2 208 2 8.52 0.15 0.44 - 164
3 198 0 - - -
4 137 4 29.97 0.01 3.08 - 292
5 122 1 8.87 0.13 0.49 - 161
6 to 18 369 3 6.64 0.19 0.36 - 121
Joint significance 0.01
Linear Trend OR 1.14 0.45 0.79 - 1.68
Duration Up to 1 year 468 3 1
Breastfed 1 to 2 years 680 6 2.45 0.39 0.29 - 20.9
More than 2 yrs 100 2 4.91 0.02 1.42 - 17
Joint significance 0.05
Vaccination Unvaccinated 829 11 1
Status Partially 137 0 - - -
Completely 147 0 - - -
Person Managing Qualified med 558 1 1
Delivery Unqualified 695 10 25.95 0.01 2.43 - 277
Setting of Health setting 329 1 1
Delivery Home setting 893 10 10.13 0.06 0.94-108
Variables that had an OR associated with HBV chronic infection amongst children aged
1-3 that was increased or decreased by more or less than 30% but failed to reach
statistical significance were age of the child, area of residence, setting of delivery,
mothers and fathers educational status, household crowding index, ownership of a home
telephone, mobile telephone, fridge/freezer and television, household electricity and
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water supply, as well as household ownership, type and construction. These are presented
in tables 6.2.1, 6.2.2, and 6.2.3. Notable findings are that there were no cases of HBV
chronic infection amongst completely or partially vaccinated children, the OR of HBV
chronic infection amongst children born from an uneducated mother was 3.38 (p=0.12),
and the odds of HBV chronic infection amongst children aged 30 to 36 months
(OR=2.66) was more than double the odds of HBV chronic infection amongst children
aged 12 to 17 months, however, there was no evidence of a statistically significant
difference in the odds ofHBV chronic infection amongst children aged 1-3 by age of the
child (p=0.3). Table 6.5.2 shows the results of the univariable analysis of the association
of mother and father characteristics with HBV chronic infection amongst children aged 1-
3.
Table 6.5.2
Association of HBV chronic infection amongst children aged 1-3
with mothers and fathers characteristics
Variable Number Number OR p value 95% C.I.
Controls Cases
Mother HBV Status Uninfected 985 1 1
anti-HBc positive 232 8 27.58 0.004 3.37 -226
Chronic carrier 57 2 19.22 0.05 1- 385
Joint significance 0.0001
Mothers age 15 to 24 394 6 1
(in years) 25 to 29 347 2 0.3 0.15 0.24-2.12
30 to 34 267 1 0.07 0.03 0.12 - 2.18
35 to 39 176 1 0.56 0.52 0.06 -1.95
40 to 49 90 1 1.07 0.94 0.27 -4.35
Joint significance 0.007
Linear Trend OR 0.85 0.69 0.36 -1.98
Mothers Education Educated 544 3 1
Uneducated 730 8 3.38 0.12 0.66 - 17.3
Mothers Birth 1 277 1 1
Order 2 202 1 0.36 0.48 0.21 - 38.54
3 201 3 5.3 0.22 0.82-118
4 158 2 2.5 0.5 0.59 - 88.79
5 131 1 2.65 0.5 0.79 - 105
6 to 19 305 3 2.53 0.29 0.91-49.19
Joint significance 0.59
Linear Trend OR 1.15 0.02
Mothers Unemployed 1219 11
employment Employed 55 0 - - -
Fathers Education Educated 1007 8 1
Uneducated 267 3 0.81 0.76 0.18-3.51
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Variables that neither showed notable increased or decreased OR nor were they
associated with HBV chronic infection amongst children aged 1-3 were sex of the child
(p=O.98), province of sampling in the survey (p=O.99) and ownership of a radio (p=O.98).
Likewise the OR of HBV chronic infection amongst children aged 1-3 associated with
mothers birth order (p=O.S9) was not significant and did not follow a clear trend. Table
6.5.3 shows the association of HBV chronic infection amongst children aged 1-3 with
household characteristics and possessions.
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Table 6.5.3
Association of HBV chronic infection amongst children aged 1-3
with household characteristics and possessions
Variable Number Number OR p value 95% C.I.
Controls Cases
Household Owned 1088 10 1
Ownership Rented 186 1 0.63 0.65 0.07 - 5.24
Household Type House 941 7 1
Apartment 219 2 2.21 0.39 0.34 - 14.5
Shack 113 2 2.32 0.4 0.3 -17.9
Jointsi~nificance 0.67
Household Stone 371 3 1
Construction Block 581 3 0.89 0.88 0.16-4.91
Mud or Clay 188 2 1.03 0.98 0.06 - 17.23
Mixed 134 3 2.68 0.41 0.23 - 31.31
Joint significance 0.75
Crowding Index 1 99 1 I
2 320 3 2.48 0.48 0.41 - 33.09
3 312 0 - - -
4 217 4 4.54 0.23 1.11 - 93.27
5 125 1 2.17 0.58 0.23 - 38.69
6 to 18 201 2 2.9 0.45 1.27 - 95.85
Joint significance 0.84
Linear Trend OR 1.17 0.54 0.68 - 2.03
Electricity Yes 899 5 1
Supply No 375 6 3.55 0.22 0.45 - 28.12
Source of Water Governmental 435 1 1
Local Project 439 4 2.65 0.45 0.19 - 37.86
Water Truck 120 2 3.82 0.01 1.41- 10.35
Buckets 278 4 4.28 0.27 0.3 - 61.76
Jointsignij1cance 0.08
FridgelFreezer Yes 587 3 1
No 687 8 2.57 0.26 0.47 -14
Television Yes 867 5 1
No 407 6 3.92 0.16 0.56 - 27.4
Radio Yes 906 8 1
No 368 3 0.99 0.98 0.3 - 3.23
Home Phone Yes 264 I 1
No 1010 10 1.71 0.61 0.2 - 14.51
Mobile Phone Yes 59 1 I
No 1215 10 0.38 0.33 0.05 - 2.86
Car Yes 316 I 1
No 958 10 9.32 0.05 0.96 - 90.7
Socioeconomic Low 499 7 I
Status Middle 506 2 0.09 0.01 0.02 - 0.51
Upper 268 2 0.49 0.42 0.08 - 3.06
Joint significance 0.03
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6.6 Children's HBV chronic infection multivariable analysis:
Following the adjustment for the remaining variables, independent variables significantly
associated with HBV chronic infection amongst children aged 1-3 in the multivariable
analysis were mothers HBV infection status and qualifications of the person managing
delivery of the child.
The adjusted OR of HBV chronic infection amongst children born from anti-HBc
positive mothers was 27.3 (95% Cl 3.15 to 237), and the OR of HBV chronic infection
amongst children aged 1-3 born from mothers chronically infected with HBV was 15.6
(95% Cl 0.65 to 378). The adjusted OR of HBV chronic infection amongst children aged
1-3 whose delivery was managed by an unqualified individual was 25.5 (95% Cl 1.79 to
362), indicating that children whose delivery was attended by an unqualified individual
had a 25 times higher odds of developing HBV chronic infection compared to children
whose delivery was managed by a medically qualified individual after adjusting for the
remaining independent variables in the model. Age, sex, and area of residence did not
show evidence of a significant association with HBV chronic infection of children aged
1-3, however, being a priori variables these were added to the final model. The adjusted
OR of HBV chronic infection amongst children aged 1-3 associated with not owning a
television [2.8 (95% Cl 0.85 to 9.17)] was not statistically significant (p=0.09), however,
because it was associated with anti-HBc positivity it was added to the multivariable
model of HBV chronic infection in order to have two models both including identical
independent variables. There was no interaction between the independent variables in the
model. Table 6.6.1 shows the results of the multi variable analysis of the association of
the independent variables with HBV chronic infection amongst children aged 1-3.
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Table 6.6.1
Adjusted logistic regression of the association of HBV chronic infection
amongst children aged 1-3 with independent exposure variables
Variable OR* p value** 95% C.I.***
MotherHBV Uninfected 1
Status anti-HBc positive 27.3 0.005 3.15 - 237
Chronic Carrier 15.64 0.09 0.65 - 378
Jointsignij7cance **** 0.02
Sex Male 1
Female 1.14 0.7 0.57 - 2.28
Age of child 12 to 17 1
(in months) 18 to 23 1.4 0.4 0.62 - 3.18
24 to 29 0.65 0.73 0.05 - 8.27
30 to 36 2.29 0.38 0.34 - 15.49
Jointsignij7cance 0.35
Area Urban 1
Rural 0.41 0.43 0.04 -4.11
Person Managing Qualified Medic 1
Delivery Unqualified 25.45 0.02 1.79 - 362
Television Yes 1
No 2.79 0.09 0.85 - 9.17
* adjusted OR computed by survey logistic regression multivariable analysis.
** p-value of the adjusted Wald test statistic.
*** 95% Confidence Intervals.
**** p-value of the adjusted survey Wald test statistic of the significance of the joint
effect of the categories of the independent variable on the dependent variable.
The multivariable analysis of variables associated with HBV chronic infection amongst
children aged 1-3 was repeated excluding the socioeconomic variables and substituting
these variables with the single socioeconomic status variable. The OR and p-values of
HBV chronic infection associated with age and sex of the child aged 1-3, as well as
mothers HBV infection status, were similar in the model including the socioeconomic
status variable as the model including all the socioeconomic variables. The adjusted OR
of HBV chronic infection associated with residing in a rural area in the model including
the socioeconomic status variable changed from 0.4 to 0.6 (p=0.09). Socioeconomic
status, on the other hand, was not significantly associated with HBV chronic infection
amongst children aged 1-3 (p=0.07) as none of the socioeconomic variables were directly
significantly associated with HBV chronic infection amongst children aged 1-3. Table
6.3.2 shows the results of the multivariable analysis of the association of independent
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variables and the socioeconomic status variable with HBV chronic infection amongst
children aged 1-3 participating in the survey.
Table 6.6.2
Adjusted logistic regression of the association of HBV chronic infection amongst
children aged 1-3 with independent exposure variables and socioeconomic status
~ariable OR* pvalue** 95% C.I.***
MotherHBV Uninfected 1
Status anti-HBc positive 27.6 0.01 2.94 - 259
Chronic Carrier 17.7 0.08 0.69 - 451
Joint significance **** 0.02
Sex Male 1
Female 1.11 0.75 0.57 - 2.15
Age of Child 12 to 17 1
(in months) 18 to 23 1.35 0.42 0.63 - 2.88
24 to 29 0.62 0.70 0.05 -7.54
30 to 36 1.80 0.52 0.28 - 11.8
Joint sign ij7cance 0.52
Area Urban 1
Rural 0.60 0.69 0.04 - 8.48
Person Managing Qualified Medic 1
Delivery Unqualified 26.6 0.02 1.88 - 378
Socioeconomic Low 1
Status Middle 0.15 0.04 0.03 - 0.90
Upper 1.64 0.45 0.43 - 6.32
Joint significance 0.07
* adjusted OR computed by survey logistic regression multivariable analysis.
** p-value of the adjusted Wald test statistic.
*** 95% Confidence Intervals.
**** p-value of the adjusted survey Wald test statistic of the significance ofthe joint
effect of the categories of the independent variable on the dependent variable.
As well as being one of the important variables investigated in the survey, hepatitis B
vaccination was an important factor determining the HBV infection status of the child. In
the univariable analysis, no OR of HBV chronic infection by vaccination status was
computed because there were no cases of HBV chronic infection amongst completely and
partially vaccinated children. Therefore, vaccination status was not added to the final
multiple logistic regression model to examine the effect of vaccination status on the
remaining variables in the model.
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6.7 Discussion:
There was no previous data or information on the prevalence of HBV infection amongst
children in the Republic of Yemen before this survey was conducted. The overall
prevalence of anti-HBc and HBsAg positivity amongst children aged 1-3 participating in
this household seroepidemiological survey was 2.4% and 0.99%, respectively, which was
lower than initially expected. A recent study published in 2002 conducted amongst
individuals presenting at Sanaa central health laboratory in response to a campaign to
control HBV infection, as described by its authors, found the prevalence of HBV chronic
infection amongst children aged less than 5 years to be 2.2% (Ragaa et al., 2002). The
prevalence of HBV chronic infection amongst children aged 1-3 participating in this
survey was expected to be approximately 5% based on a number of factors. Firstly, the
few studies conducted in Yemen reported a high prevalence of HBV chronic infection
amongst adults in the general population as well as women of childbearing age and all
concluded that HBV infection is either highly endemic or hyperendemic in Yemen.
Secondly, the studies that included women of childbearing age found a high prevalence
of HBeAg amongst HBV chronic carrier women of childbearing age which indicates a
potentially high rate of perinatal transmission of HBV infection in Yemen. Finally,
studies conducted in the Middle-East and more specifically neighbouring countries of
Yemen, described in preceding chapters, showed a high prevalence ofanti-HBc positivity
and HBV chronic infection amongst children and suggested childhood and perinatal
transmission as the major contributors to the pool of HBV chronic carriers in these
countries. According to these factors it was expected that the majority of HBV chronic
infections in Yemen would be the result of childhood and perinatal transmission, and
consequently, there would be a large proportion of anti-HBc and HBsAg positive
children. Nevertheless, rather than obtaining an estimated 120 anti-HBc positive and 60
HBsAg positive children based on the expected prevalence, the survey generated 27 anti-
HBc positive and 11 HBsAg positive children. This had important consequences on the
power of the study and one major concern resulting from the unexpected small number of
anti-HBc positive and HBV chronic carrier children in the survey was the possibility of
an insufficient power to detect a statistically significant difference or association even if
this existed. This was despite the fact that there was overachievement in the sampling
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process and the total actual sample size (1285 children aged 1-3) exceeded the total
planned sample size (1100 children aged 1-3) by 17%. For example, hepatitis B
vaccination is well known to be effective in preventing anti-HBc positivity and HBV
chronic infection. The prevalence of anti-HBc positivity amongst unvaccinated children
in the survey was 2.95% (22/840) and this was higher than the prevalence of anti-HBc
positivity amongst completely vaccinated children which was 0.5% (11137), however,
this difference was not statistically significant (p=0.6). Similarly, there were no cases of
HBV chronic infection amongst completely vaccinated children (0/137) with all cases of
HBV chronic infection occurring amongst unvaccinated children (111840), however, this
difference did not reach statistical significance (p=0.5). Moreover, even though the
prevalence of anti-HBc positivity and chronic infection amongst children in urban areas
was half the prevalence in rural areas this did not reach statistical significance.
Nevertheless, it would be incorrect to conclude that the results obtained from this survey
did not reflect true differences or associations because these differences or associations
failed to reach statistical significance when this may be the result of an insufficient power
of the study to yield a statistically significant result. Systematically repeating such an
error would bias the results of this study towards the null.
One of the major findings of the survey was the decline in the prevalence of anti-HBc
positivity (p=0.0001) and HBV chronic infection (p=0.0002) amongst children aged 1-3
according to the HBV infection status of the mother. It is well established that children
born from HBV chronic carrier mothers have the highest risk of becoming infected with
HBV. The multivariable analysis showed a clear increase in the adjusted OR of anti-HBc
positivity amongst children born from anti-HBc positive mothers [OR=3.97 (95% Cl 1.38
to 11.43)] and mothers chronically infected with HBV [OR=7.84 (95% Cl 3.78 to
16.25)], which provided strong evidence of the association between HBV infection
amongst children aged 1-3 and the HBV infection status of mothers. Similarly,
multivariable analysis showed a statistically significant association between HBV chronic
infection amongst children aged 1-3 and HBV infection status of the mother.
The risk of children becoming infected with HBV from a HBV chronic carrier mother is
highly dependent on the mothers HBeAg status, with HBeAg positive mothers being
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more infectious than HBeAg negative mothers. In this survey, there was evidence that the
prevalence of HBV chronic infection was statistically significantly higher amongst
children born to HBeAg positive chronic carrier mothers (21%) compared to HBeAg
negative chronic carrier mothers (0%) (p=0.02). The same rate ofHBV transmission from
HBsAg positive mothers (21%) was observed in Tunisia, which had the same rate of
HBeAg (9.6%) amongst HBV chronic carrier mothers (Coursaget et al., 1994). The
proportion of children born from HBeAg positive chronic carrier mothers developing
HBV chronic infection (21%) in this survey was much lower than 70% - 90% of children
reported from numerous international studies (Hwang et al., 1985; Hall AJ, 1994), or an
earlier study in Yemen which suggested that 50% of HBsAg chronic carrier mothers
transmitted HBV chronic infection to their children although they did not measure the
HBeAg status of the mothers (Abdul Raheem at al., 1991). Such differences in the risk of
transmission of HBV infection to children of HBeAg positive mothers have been
previously attributed to differences in HBV DNA levels between women in Africa and
South-East Asia (Hall AJ, 1994).
The low prevalence of HBV chronic infection amongst children aged 1-3, the low
prevalence of HBeAg amongst chronic carrier mothers, and the low transmission of HBV
infection from HBeAg positive chronic carrier mothers to their children in this survey
provides evidence that Yemen follows the pattern of studies suggesting that perinatal
transmission is unlikely to be an important mode of transmission of HBV infection in the
Middle East (Basalamah et al., 1984; Coursaget et al., 1994; Toukan, 1996) or a major
contributor to the pool of HBV chronic carriers in Yemen. Childhood transmission, on
the other hand, cannot be ruled out, which is supported by the increasing prevalence of
HBV chronic infection amongst children aged 4-9 included in this survey presented in
chapter 7. The importance of childhood transmission has been supported by other studies
in the Middle East (Amini et al., 1993; Arya et al., 1985; Ramia, 1990).
In this survey 21% (2/8) of children born from HBeAg positive chronic carrier mothers
became anti-HBc positive compared to 8% (3/51) of children born from HBeAg negative
chronic carrier mothers, however, this difference did not reach statistical significance
(p=0.5). It should be noted that mothers lose their HBeAg positive status over time and
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that a few of the HBV chronic carrier mothers who were HBeAg negative at the time of
the survey may have been HBeAg positive 1 to 3 years earlier at the time of delivery of
their child aged 1-3 participating in the survey. Therefore, these women may have been
highly infectious and actually infected their child at the time of delivery. Such changes in
the HBV serological status of the mother (HBsAg/HBeAg) over time make it difficult to
interpret the exact relationship between the child and the mothers HBV infection status.
This may result in underestimating the risk of HBV infection amongst children born to
HBeAg positive chronic carrier mothers, and therefore, the importance of HBeAg
positivity amongst mothers in determining perinatal transmission will be underestimated.
Moreover, due to the cross-sectional nature of the survey a causal relationship between
mothers HBV infection and the child's HBV infection cannot be firmly established based
on the results of this survey alone, as both the child's and mothers serological markers
were measured at the same point of time and, theoretically, it is not known for sure if the
mothers HBV infection proceeded her child's infection or vice versa (temporal
relationship). Nevertheless, the prevalence of anti-HBc positivity and chronic infection
amongst mothers is much higher than children and many of the Bradford Hill criteria still
hold such as plausibility, consistency, and the strength of relationship.
Another important finding was the lower prevalence of anti-HBc positivity (p=O.02) and
HBV. chronic infection (p=O.00003) amongst children aged 1-3 whose delivery was
managed by medically qualified personnel compared to unqualified persons. In
multivariable analysis, there was an increased OR of anti-HBc positivity (OR=2.5) and
HBV chronic infection (OR=25) amongst children aged 1-3 delivered by an unqualified
person but only the latter of the two reached statistical significance (p=O.02). This may be
due to qualified medical personnel using sterilised equipment and conducting adequate
procedures during management of labour in proper settings (which reduces the risk of
infecting the child), or a better chance of children receiving hepatitis B vaccine, or more
hazardous procedures carried-out by unqualified personnel. De La Hoz found a similar
association between anti-HBc positivity and qualifications of the person delivering the
child in Colombia, and suggested that practices at the time of birth carried-out by
unqualified persons such as cutting the umbilical cord may increase the child's risk of
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HBV infection (De La Hoz, 2002). This survey also found a significantly lower
prevalence of HBV chronic infection (p=0.02) and anti-HBc positivity (p=0.06) amongst
children aged 1-3 delivered in a health setting compared to a home setting in Yemen.
Parents of children delivered by medically qualified personnel or in a health setting are
likely to have better health awareness or access to health services, and whether on their
own or according to medical personnel's recommendations are more likely to visit health
centres to vaccinate their child thereby reducing the child's risk ofHBV infection.
It has already been demonstrated in chapter 1 that many studies in the Middle East have
shown the prevalence of HBV chronic infection to be inversely related to socioeconomic
status. International research and studies from neighbouring countries show that the
prevalence of HBV infection declines with improving socioeconomic status. The
socioeconomic classification of this survey also showed a decline in the prevalence of
anti-HBc positivity (p=O.Ol) and HBV chronic infection (p=0.04) amongst children with
increasing socioeconomic status. However, unexpected was the higher prevalence of anti-
HBc positivity and HBV chronic infection amongst children of upper socioeconomic
status compared to children of middle socioeconomic status. It was suspected that the
higher prevalence of anti-HBc positivity and HBV chronic infection amongst children of
upper socioeconomic status compared to children of middle socioeconomic status may
have.resulted from design and the cut-off points in the construction of the socioeconomic
status variable, however, this was not the case when anti-HBc positivity and HBV
chronic infection amongst mothers was analysed. When investigating the difference in
prevalence of anti-HBc positivity (p=0.52) and HBV chronic infection (p=0.07) between
children of upper and middle socioeconomic status this was not statistically significant.
The independent variables that were statistically significantly associated with anti-HBc
positivity amongst children aged 1-3 in the multivariable analysis after adjusting for the
remaining variables in the model were mothers HBV infection status and television
ownership. The nature of the association between anti-HBc positivity amongst children
aged 1-3 and not owning a television in the household is unexplained [OR = 3.34 (1.07 to
10.41)]. The adjusted OR of the association between HBV chronic infection amongst
children and not owning a television was also increased [OR=2.79 (95% Cl 0.85 to 9.17)]
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although it did not reach statistical significance. The most likely explanation is that
television ownership is an indicator of financial wellbeing and socioeconomic status.
When the socioeconomic status variable was included in the multivariable analysis it
showed a decreased OR of anti-HBc positivity and HBV chronic infection amongst
children of middle and upper socioeconomic status compared to children of low
socioeconomic status but neither of these associations reached statistical significance.
Television ownership was highly dependent on the availability of an electricity supply in
the household. In this survey, 88% of households that had an electricity supply had a
television whereas only 21% of households without an electricity supply had a television
in the household (p<O.OOOl).The availability of electricity supply, on the other hand, is
highly dependent on area of residence. 98% of urban households had an electricity supply
compared to 37% of rural households (p<0.0001). Noteworthy to mention is that 30% of
rural households participating in the survey that had a television did not have electricity
but used alternative sources such as batteries to power their television sets. Interestingly,
after television ownership was added to the multiple logistic regression model it reversed
the odds of anti-HBc positivity amongst children aged 1-3 associated with living in a
rural area from 1.6 to 0.78. On the other hand, adding the socioeconomic status variable
to the multiple logistic regression model did not have such a profound effect on the odds
of anti-HBc positivity associated with living in a rural area. Why this occurred is not fully
understood but a possible explanation is the highly significant difference (p<O.OOOl)in
the prevalence of television ownership by area of residence (table 6.7.1).While 90% of
urban households owned televisions less than half (45%) of rural households owned a
television. Moreover, 92% of households that did not own a television were in rural
areas, whereas only 8% of households that did not own a television were in urban areas.
Table 6.7.1
Television Ownership by Area
Area of Residence
Television Ownership Urban % (no) Rural % (no)
Yes 89.9 (468) 44.5 (404)
No 10.2 (41) 55.52 (372)
Total 100 (509) 100 (776)
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This suggests that there may have been positive correlation between television ownership
and area of residence. It is already known that pooling dissimilar subsets (in this case
with reference to television ownership) in an analysis can suggest a difference or
association where one does not exist, or even suggest an association or difference the
opposite way around to one which does exist (Kirkwood, 1997) . This might be a possible
explanation for the reversal of the odds of anti-HBc positivity associated with living in a
rural area after adding television ownership to the multi variable model.
The results of the prevalence of anti-HBc positivity and HBV chronic infection amongst
children aged 1-3 participating in this survey are the first results obtained from this age-
group in Yemen. The reason for selecting this age-group was in order to confidently
determine cases of HBV chronic infection resulting from perinatal transmission based on
serological markers of the child and mother. At this age it was expected that the parents
or guardians of these children would have the children's vaccination records of the type
and dates of vaccines received. It is believed that these results are reliable and true
findings based on a representative sample taken from the general population. It is
unlikely that these results are biased and a general discussion of the possible effect of
bias or confounding on these results is presented in chapter 9.
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Chapter 7: Results Children Aged 4-9:
This chapter presents the results of the prevalence, univariable analysis, and multi variable
analysis of HBV infection amongst children aged 4-9 participating in the survey in
Yemen. These children were surveyed to simply provide a baseline measure of the
prevalence of HBV infection amongst children in Yemen prior to the effect of hepatitis B
vaccination on the prevalence of HBV infection amongst these children. These children
were not included to examine factors associated with HBV infection.
HBV Infection:
7.1 Prevalence of hepatitis B core antibody (anti-HBcl:
The prevalence of anti-HBc positive children aged 4-9 participating in the survey in
Yemen was 4.75% (95% Cl 2.34 to 9.41). Out of the 467 children aged 4-9 participating
in the survey, 19 were anti-HBc positive.
Amongst the children aged 4-9 participating in the survey there was only evidence of a
statistically significant difference in the prevalence of anti-HBc positivity by
socioeconomic status and educational status of the mother. The prevalence of anti-HBc
positive children aged 4-9 participating in the survey born to uneducated women (6.59%)
was higher than the prevalence of anti-HBc positive children born to women claiming to
have any level of education (1.55%) and this difference was statistically significant
(p=0.02). There were no anti-HBc positive children aged 4-9 participating in the survey
born from women who completed secondary school, attended college/university, or who
were in paid employment. There was a significant difference in the prevalence of anti-
HBc positivity between the three socioeconomic classes in the survey (p=0.002). The
prevalence of anti-HBc positivity was 7.82% amongst children of low socioeconomic
status, 0.83% amongst children of middle socioeconomic status, and 1.49% amongst
children of upper socioeconomic status. The higher prevalence of anti-HBc positivity
amongst children of upper socioeconomic status compared to children of middle
socioeconomic status was not statistically significant (p=0.55). There was an increase in
the prevalence of anti-HBc positive children with increasing age across the six age-
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groups of children participating in the survey of children aged 4-9 but this did not reach
statistical significance (p=O.72). Figure 7.1.1 shows the distribution of anti-HBc
positivity amongst children aged 4-9 participating in the survey by age of the child.
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Table 7.1.1 shows the prevalence of anti-HBc positivity amongst children aged 4-9
participating in the survey by demographic characteristics.
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Table 7.1.1
Prevalence of anti-HBc positive children aged 4-9
by children's demographic characteristics
Number Prevalence p-value
Prevalence anti-HBc positive of (weighted) 95%CI 95%CI (Pearson
Children % LL UL design-based)
Overall 19/467 4.75 2.34 9.41
Sex
Male 10/232 3.36 1.04 10.33
Female 9/235 5.82 2.67 12.20 0.37
Age (in years)
4 3/91 2.95 0.83 9.91
5 3/97 2.57 0.74 8.54
6 3/74 3.51 0.85 13.38
7 4/78 5.20 1.42 17.26
8 3/72 8.54 1.66 34.10
9 3/55 5.73 0.74 33.24 0.72
Province
Sanaa 8/151 8.74 3.01 22.82
Taiz 3/66 4.33 1.39 12.63
Aden 1/90 1.11 0.14 8.48
Shabwa 3/75 5.07 1.24 18.59
Hodeidah 4/85 3.64 0.43 24.74 0.55
Area of residence
Urban 9/241 6.14 2.26 15.58
Rural 10/226 4.11 1.54 10.55 0.55
Vaccination Status
Not Vaccinated 18/410 5.22 2.47 10.68
Completely Vaccinated 0/4 0.00
Partially Vaccinated 0/5 0.00 0.83
School Attendance
Yes 8/198 4.15 1.38 11.79
No 11/268 5.32 2.25 12.04 0.69
Socioeconomic Status
Low 14/200 7.82 3.64 16.03
Middle 3/161 0.83 0.18 3.69
Upper 2/106 1.49 0.38 5.61 0.002
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Only 9 of the 467 children aged 4-9 participating in the survey claimed and had evidence
of receiving at least one dose of hepatitis B vaccine and none of these children had
evidence of being exposed to HBV infection (i.e. these children were anti-HBc negative).
The prevalence of anti-HBc positive children aged 4-9 appeared to be lower amongst
males than females and lower in rural than urban areas but neither of these was
statistically significant. There was no evidence of a statistically significant difference in
the prevalence of anti-HBc positive children aged 4-9 between the five provinces
(p=O.55) or rural provinces (p=O.93) in the survey, however, there appeared to be a
difference between the urban provinces, with the prevalence of anti-HBc positive
children aged 4-9 living in Sanaa (8.74%) higher than children living in Aden (1.11%)
(p=O.06). Table 7.1.2 shows the prevalence of anti-HBc positivity amongst children aged
4-9 by mothers characteristics.
Table 7.1.2
Prevalence of anti-BBc positive children aged 4-9
by mother's characteristics
Number Prevalence
p-value
Prevalence antl-HBc positive of (weighted)
95%CI 95%CI (Pearson
Children %
LL UL design-
based)
Mothers Age (in years)
18 to.24 5/81 11.01 2.76 35.09
25 to 29 5/131 2.45 0.88 6.63
30 to 34 4/127 4.10 1.05 14.70
35 to 39 4/88 5.79 1.59 18.96
40 to 52 1/40 2.29 0.28 16.40 0.31
Mother's Educational Status
Educated 5/200 1.55 0.65 3.69
Uneducated 14/267 6.59 3.02 13.77 0.02
Mother's Level of Education
Read and Write 2/64 1.57 0.20 11.30
Primary School 3/86 2.97 0.87 9.66
Secondary School 0/37 0.00
University or College 0/13 0.00 0.67
Mother's Employment
Employed 0/25 0.00
Not Employed 19/442 5.02 2.51 9.81 0.50
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7.2 Anti-HBc univariable analysis:
The univariable analysis of the association of anti-HBc positivity amongst children aged
4-9 with exposure variables produced three types of results. The first of these had OR
statistically significantly different from 1. The second had notably increased or decreased
OR, by more or less than 30%, but these were not statistically significant. The third type
neither had notably increased or decreased OR nor were these statistically significant.
These results are presented in tables 7.2.1, 7.2.2 and 7.2.3.
Out of all the variables analysed those that had a statistically significant association with
anti-HBc positivity amongst children aged 4-9 by univariable analysis were educational
status of the mother and father, socioeconomic status and ownership of a fridge/freezer.
The OR of anti-HBc positivity amongst children aged 4-9 born to an uneducated mother
was 4.47 (95% Cl 1.19 to 16.78), and the OR of anti-HBc positivity amongst children
aged 4-9 born to an uneducated father was 6.14 (95% Cl 1.67 to 22.57). The OR of anti-
HBc positivity was 4.13 (95% Cl 1.11 to 15.3) amongst children aged 4-9 who did not
have a fridge/freezer in their household (p=0.04). There was a decline in the odds of anti-
HBc positivity amongst children aged 4-9 with increasing socioeconomic status. The OR
of anti-HBc positivity was significantly lower amongst children of middle (OR=O.I) and
upper (OR=0.18) socioeconomic status compared to children of low socioeconomic
status (p=0.03). Table 7.2.1 shows the results of the univariable analysis of the
association of demographic variables with anti-HBc positivity amongst children aged 4-9.
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Table 7.2.1
Association of anti-HBc positivity amongst children aged 4-9
with children's demographic characteristics
Variable Number Number OR p value 95% C.I.
Controls Cases
Sex Male 222 10 1
Female 226 9 1.77 0.38 0.47 - 6.69
Age of child 4 88 3 1
(in months) 5 94 3 0.87 0.86 0.17 -4.38
6 71 3 1.20 0.79 0.29 -4.95
7 74 4 1.81 0.37 0.48 - 6.84
8 69 3 3.08 0.32 0.30 - 31.33
9 52 3 2.00 0.53 0.21- 19.53
Joint significance 0.80
Linear trend OR 1.24 0.25 0.85 - 1.82
Province Sanaa 143 8 1
Taiz 63 3 0.47 0.35 0.09 - 2.38
Aden 89 1 0.12 0.08 0.01- 1.28
Shabwa 72 3 0.56 0.52 0.09 - 3.51
Hodeidah 81 4 0.39 0.44 0.03 -4.52
Joint significance 0.55
Area Urban 232 9 1
Rural 216 10 0.66 0.55 0.15 - 2.79
Child Birth Order 1 123 6 1
2 99 2 0.12 0.04 0.02 -0.85
3 61 4 0.64 0.61 0.11-3.83
4 44 2 0.45 0.40 0.07 - 2.67
5 37 3 0.95 0.96 0.15 - 6.00
6 to 15 84 1 0.15 0.12 0.01-1.67
Joint significance 0.16
Linear Trend OR 0.84 0.36 0.57 - 1.24
Vaccination Unvaccinated 392 18 1
Status Partially 5 0 -
Completely 4 0 -
Variables that had increased or decreased OR by more or less than 30% but were not
statistically significantly associated with anti-HBc positivity amongst children aged 4-9
were age of the child, area and province of residence, household ownership, type,
construction and source of water, availability of an electricity supply, ownership of a
television and home telephone, as well as birth order of the child and mother, and age of
the mother. These are presented in tables 7.2.1, 7.2.2, and 7.2.3. There appeared to be an
increasing odds of anti-HBc positivity amongst children aged 4-9 with increasing age of
the child with children aged 7, 8 and 9 having an higher odds of anti-HBc positivity than
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children aged 4,5, and 6 (p=0.8). Table 7.2.2 shows the results of the univariable analysis
of the association of mothers and fathers characteristics with anti-HBc positivity amongst
children aged 4-9.
Table 7.2.2
Association of anti-HBc positivity amongst children aged 4-9
with mothers and fathers characteristics
Variable Number Number OR p value 95% C.I.
Controls Cases
MothersAge 18to 24 76 5 1
(in years) 25 to 29 126 5 0.2 0.12 0.03 - 1.44
30 to 34 123 4 0.35 0.28 0.05 - 2.57
35 to 39 84 4 0.5 0,46 0.07 - 3.38
40 to 52 39 1 0.19 0.21 0.01 = 2.73
Joint significance 0.31
Linear Trend OR 0.78 0,42 0,41 - 1.47
Mothers Educated 195 5 1
Education Uneducated 253 14 4,47 0.03 1.19-16.78
Mothers 1 79 5 1
Birth Order 2 85 1 0.12 0.1 0.01 - 1.61
3 71 5 2.56 0.27 0,45 - 14.57
4 62 1 0.36 0.39 0.03 -4.02
5 55 2 0.77 0.78 0.11 - 5.22
6 to 13 96 5 1,48 0.65 0.24- 9.02
Joint significance 0.3
Linear Trend OR 1.08 0.62 0.77 - 1.53
Mothers Unemployed 423 19 1
Employment Employed 25 0 -
Fathers Educated 363 II 1
Education Uneducated 85 8 6.14 0.009 1.67- 22.57
There were no anti-HBc positive children amongst children receiving any number of
doses of hepatitis B vaccine, born from mothers in paid employment, living in
households with a crowding index of 1, or living in households with a mobile telephone,
and therefore no OR were computed for these variables in the univariable analysis.
Variables that did not show an increase or decrease in their OR by more or less than 30%
nor evidence of a statistically significant association with anti-HBc positivity amongst
children aged 4-9 were ownership of a car (p=0.86) and radio (p=0.99). Table 7.2.3
shows the association of anti-HBc positivity amongst children aged 4-9 with household
characteristics and possessions.
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Table 7.2.3
Association of anti-HBc positivity amongst children aged 4-9
with household characteristics and possessions
Variable Number Number OR p value 95% C.I.
Controls Cases
Household Owned 358 15 1
Ownership Rented 90 4 3.24 0.28 0.36 - 29.22
Household Type House 303 12 1
Apartment 99 3 0.55 0.47 0.10-3.02
Shack 46 4 0.99 0.99 0.28 - 3.55
Joint significance 0.77
Household Stone 113 3 1
Construction Block 226 10 1.7 0.58 0.24-12.15
Mud or Clay 58 2 0.71 0.78 0.06- 8.38
Mixed 51 4 1.21 0.84 0.18 - 8.26
Joint significance 0.85
Crowding Index 1 30 0 -
2 113 4
3 118 6
4 74 3
5 41 2
6 to 15 72 4
Electricity Yes 334 12 1
Supply No 114 7 1.42 0.59 0.37 - 5.39
Source of Water Governmental 156 4 1
Local Project 132 3 0.16 0.08 0.02 - 1.22
Water Truck 67 6 2.73 0.25 0.46 - 16.27
Buckets 93 6 0.82 0.82 0.14 -4.84
Joint significance 0.08
Freezer Yes 232 5 1
No 216 14 4.13 0.04 1.11-15.30
Television Yes 317 9 1
No 131 10 2.47 0.25 0.50-12.16
Radio Yes 308 9 1
No 140 10 0.99 0.99 0.26 - 3.72
Home Phone Yes 106 2 1
No 342 17 3.11 0.18 0.56 - 17.23
Mobile Phone Yes 34 0 -
No 414 19
Car Yes 129 4 1
No 319 15 0.86 0.86 0.14 - 5.24
Socioeconomic Lower 186 14 1
Status Middle 158 3 0.1 0.01 0.02- 0.56
Upper 104 2 0.18 0.05 0.03 - 1.02
Joint significance 0.03
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7.3 Anti-HBc multivariable analysis:
The independent variable statistically significantly associated with anti-HBc positivity
amongst children aged 4-9 in the multivariable analysis was father's educational status.
The adjusted OR of being anti-HBc positive amongst children aged 4-9 born from fathers
who were uneducated was 7.89 (95% Cl 1.55 to 40.17) compared to children born from
fathers claiming to be educated. Age, sex, and area of residence did not show evidence of
a statistically significant association with anti-HBc positivity amongst children aged 4-9,
but being a priori variables they were added to the final model at the end of the process.
The OR of anti-HBc positivity increased with increasing age of the child, and the OR of
anti-HBc positivity appeared to be lower amongst children living in rural areas of
residence, but neither of these was statistically significant. There was no evidence of
interaction between the independent variables in the model. Table 7.3.1 shows the results
of the multivariable analysis of the association of the independent variables with anti-
HBc positivity amongst children aged 4-9.
Table 7.3.1
Adjusted logistic regression of the association of anti-HBc positivity
amongst children aged 4-9 with independent exposure variables
iVariable OR* p value** 95% C.I.***
Age of Child 4 1
(in years) 5 0.89 0.90 0.14 - 5.54
6 1.53 0.57 0.33-7.11
7 1.98 0.34 0.46 - 8.44
8 2.65 0.35 0.32 - 22.29
9 2.57 0.42 0.23 -28.32
Joint significance **** 0.73
Sex Male 1
Female 1.35 0.58 0.45 -4.09
Area Urban 1
Rural 0.38 0.24 0.07 -2.03
Fathers Educated 1
Educational Uneducated 7.89 0.02 1.55 - 40.17
Status
• adjusted OR computed by survey logistic regression multivariable analysis .
•• p-value of the adjusted wald test statistic .
••• 95% Confidence Intervals .
•••• p-value of the adjusted survey wald test statistic of the significance of the joint
effect of the categories of the independent variable on the dependent variable.
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The multivariable analysis of variables associated with anti-HBc positivity amongst
children aged 4-9 was repeated excluding the socioeconomic variables and substituting
them with the single socioeconomic status variable. The adjusted OR of being anti-HBc
positive amongst children aged 4-9 was significantly lower amongst children of middle
(OR=O.06) and upper (OR=O.l) socioeconomic status compared to children of low
socioeconomic status (p=O.02). The OR and p-values of anti-HBc positivity associated
with sex of the child aged 4-9 and area of residence were similar in the model including
the socioeconomic status variable as the model including all the socioeconomic variables.
The OR of anti-HBc positivity associated with increasing age of the child in the model
including the socioeconomic status variable was slightly higher and is shown in table
7.3.2. Table 7.3.2 shows the results of the multivariable analysis of the association of
independent variables and the socioeconomic status variable with anti-HBc positivity
amongst children aged 4-9 participating in the survey.
Table 7.3.2
Adjusted logistic regression of the association of anti-HBc positivity amongst
children aged 4-9 with independent exposure variables and socioeconomic status
Variable OR* p value** 95% C.I.***
Age of Child 4 1
(in years) 5 0.98 0.98 0.16-6.11
6 1.48 0.59 0.34 - 6.45
7 1.85 0.38 0.44-7.72
8 4.23 0.15 0.58 - 30.70
9 3.49 0.29 0.31- 39.00
Joint significance **** 0.45
Sex Male 1
Female 1.33 0.65 0.37 -4.80
Area Urban 1
Rural 0.36 0.14 0.09 - 1.41
Socioeconomic Low 1
Status Middle 0.06 0.01 0.01 - 0.38
Upper 0.10 0.04 0.01- 0.88
Jointsignij7cance 0.02
* adjusted OR computed by survey logistic regression multivariable analysis.
** p-value of the adjusted wald test statistic.
*** 95% Confidence Intervals.
**** p-value of the adjusted survey wald test statistic of the significance ofthe joint
effect of the categories of the independent variable on the dependent variable.
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HBV Chronic Infection:
7.4 Prevalence of HBV chronic infection:
The prevalence of HBV chronic infection amongst children aged 4-9 participating in the
survey in Yemen was 3.08% (95% CI1.10 to 8.32). Out of the 467 children participating
in the survey only 9 were HBV chronic carriers.
There was no evidence of a statistically significant difference in the prevalence of HBV
chronic infection amongst children aged 4-9 by any of the variables under investigation.
The prevalence of HBV chronic infection amongst children aged 4-9 participating in the
survey born to uneducated women (4.35%) was higher than the prevalence of HBV
chronic infection amongst children born to women claiming to have any level of
education (0.89%) (p=0.07). There were no HBV chronic carrier children aged 4-9
participating in the survey born from women who completed secondary school, college or
university, or women in paid employment. The prevalence of HBV chronic infection
declined with increasing socioeconomic status (p=0.12). The prevalence of HBV chronic
infection was 5.46% amongst children of low socioeconomic status, 0% amongst children
of middle socioeconomic status, and 0.65% amongst children of upper socioeconomic
status. The higher prevalence of HBV chronic infection amongst children of upper
compared to middle socioeconomic status was not statistically significant (p=0.23). There
appeared to be an increase in the prevalence of HBV chronic infection with increasing
age across the six age-groups of children participating in the survey (p=0.72). Figure
7.4.1 shows the distribution of HBV chronic infection amongst children aged 4-9 by age-
group amongst children participating in the survey.
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Figure 7.4.1
Prevalence of HBV chronic infection amongst children aged 4-9
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Table 7.4.1 shows the prevalence ofHBV chronic infection amongst children aged 4-9 by
demographic characteristics.
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Table 7.4.1
Prevalence of HBV chronic infection amongst children aged 4-9
by children's demographic characteristics
Number Prevalence p-valueHBV Chronic Infection of (weighted) 95%CI 95%CI (PearsonPrevalence Children % LL UL design-
based)
Overall 9/467 3.08 1.10 8.32
Sex
Male 5/232 1.94 0.49 7.42
Female 4/235 3.96 1.19 12.40 0.37
Age (in years)
4 1/091 0.64 0.08 4.74
5 1/097 0.64 0.08 4.86
6 1/074 1.99 0.27 13.38
7 3/078 3.25 0.60 15.85
8 2/072 7.08 1.04 35.63
9 1/055 5.02 0.51 35.09 0.44
Province
Sanaa 5/151 7.10 1.69 25.34
Taiz 1/066 2.50 0.30 17.89
Aden 0/90 0.00
Shabwa 0/75 0.00
Hodeidah 3/085 2.73 0.33 19.31 0.51
Area of residence
Urban 5/241 4.68 1.13 17.34
Rural 4/226 2.35 0.53 9.84 0.48
Vaccination Status
Not Vaccinated 9/410 3.49 1.24 9.43
Completely Vaccinated 0/4 0.00
Partially Vaccinated 0/5 0.00 0.88
School Attendance
Yes 4/198 3.16 0.79 11.82
No 5/268 3.03 0.80 10.77 0.96
Socioeconomic Status
Low 8/200 5.46 1.89 14.75
Middle 0/161 0.00
Upper 1/106 0.65 0.08 5.37 0.12
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Out of the 9 children aged 4-9 participating in the survey whom received at least one dose
of hepatitis B vaccine none was a HBV chronic carrier. The prevalence of HBV chronic
infection amongst children aged 4-9 appeared to be lower amongst males than females
and lower amongst children aged 4-9 living in rural areas than children living in urban
areas but these were not statistically significant. There was no evidence of a statistically
significant difference in the prevalence of HBV chronic infection amongst children aged
4-9 between the five provinces (p=O.51), rural provinces (p=O.88), or urban provinces
(p=O.29) in the survey. Table 7.4.2 shows the prevalence of HBV chronic infection
amongst children aged 4-9 by mother's characteristics.
Table 7.4.2
Prevalence of HBV chronic infection amongst children
aged 4-9 by mothers characteristics
Number Prevalence p-valueHBV Chronic Infection of (weighted) 95%CI 95%CI (PearsonPrevalence LL UL design-Children % based)
Mothers Age (in years)
18 to 24 3/081 8.48 1.48 36.39
25 to 29 3/131 1.62 0.41 6.12
30 to 34 1/127 2.78 0.35 18.76
35 to 39 2/088 3.17 0.43 19.98
40 to 52 01040 0.00 0.48
Mother's Educational Status
Educated 3/200 0.89 0.21 3.64
Uneducated 6/267 4.35 1.42 12.56 0.07
Mother's Level of Education
Read and Write 1/064 0.79 0.10 5.85
Primary School 2/086 1.81 0.22 13.28
Secondary School 01037 0.00
University or College 01013 0.00 0.78
Mother's Employment
Employed 01025 0.00
Not Employed 9/442 3.26 1.18 8.69 0.61
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7.5 HBV chronic infection univariable analysis:
The univariable analysis of the association of HBV chronic infection amongst children
aged 4-9 with exposure variables produced three types of results. The first had OR that
were statistically significantly different from 1. The second had OR that were increased
or decreased by more or less than 30%, but did not reach statistical significance. The
third neither had increased or decreased OR nor did they reach statistical significance.
These results are shown in tables 7.5.1, 7.5.2 and 7.5.3.
In the univariabe analysis the variables that had a statistically significant association with
HBV chronic infection amongst children aged 4-9 were educational status of the father
and ownership of a fridge/freezer. The OR of HBV chronic infection amongst children
aged 4-9 born to an uneducated father was 12.67 (95% Cl 1.67 to 22.57) and the OR of
HBV chronic infection was 12.51 (95% Cl 1.17 to 133.4) amongst children aged 4-9 who
did not have a fridge/freezer in their household (p=0.04). Table 7.5.1 shows the results of
the univariable analysis of the association of demographic variables with HBV chronic
infection amongst children aged 4-9.
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Table 7.5.1
Association of HBV chronic infection amongst children aged 4-9
with children's demographic characteristics
Variable Number Number OR p value 95% C.I
Controls Cases
Sex Male 227 5 1
Female 231 4 2.09 0.38 0.38 - 11.32
Age of child 4 90 1 1
(in years) 5 96 1 0.99 0.94 0.72 - 1.36
6 73 1 3.13 0.43 0.17 - 58.09
7 75 3 5.19 0.22 0.34 - 80.48
8 70 2 11.78 0.1 0.60 - 231.7
9 54 1 8.17 0.16 0.42 - 160.4
Jointsignij7cance 0.34
Linear trend OR 1.57 0.08 0.94 - 2.63
Province Sanaa 146 5 1
Taiz 65 1 0.34 0.4 0.02 - 5.12
Aden 90 0 -
Shabwa 75 0 -
Hodeidah 82 3 0.37 0.44 0.02 - 5.62
Joint significance 0.63
Area Urban 236 5 1
Rural 222 4 0.49 0.49 0.06 - 3.99
Child Birth Order 1 125 4 1
2 100 1 0.1 0.07 0.01-1.23
3 64 1 0.14 0.16 0.01 - 2.36
4 45 1 0.41 0.43 0.04-4.27
5 39 1 0.41 0.47 0.03 - 5.14
6 to 15 85 0 -
Joint significance 0.4
Linear Trend OR 0.63 0.23 0.29 - 1.37
Vaccination Unvaccinated 401 9 1
Status Partially 5 0 -
Completely 4 0 -
Variables with increased or decreased OR associated with HBV chronic infection
amongst children aged 4-9 failing to reach statistical significance were age and sex of the
child, area and province of residence, mothers educational status, socioeconomic status,
household ownership, type, construction and source of water, availability of an electricity
supply, ownership of a television, home telephone, car and radio, as well as birth order of
the child and mother, and age of the mother. These are presented in tables 7.5.1, 7.5.2 and
7.5.3. There appeared to be an increase in the OR of HBV chronic infection amongst
children aged 4-9 with increasing age of the child with children aged 7, 8 and 9 having an
higher OR of HBV chronic infection than children aged 4, 5, and 6 (p=O.34). Children
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born to uneducated women appeared to have a higher OR ofHBV chronic infection [5.07
(95% Cl 0.72 to 35.69)] but this was not statistically significant (p=O.l). Table 7.5.2
shows the results of the univariable analysis of the association of mothers and fathers
characteristics with HBV chronic infection amongst children aged 4-9.
Table 7.5.2
Association of HBV chronic infection amongst children aged 4-9
with mothers and fathers characteristics
Variable Number Number OR P 95% C.I.
Controls Cases value
Mothers Age 18 to 24 78 3 1
(in years) 25 to 29 128 3 0.18 0.16 0.01-2.14
30 to 34 126 1 0.31 0.38 0.02 -4.69
35 to 39 86 2 0.35 0.46 0.02 - 6.09
40 to 52 40 0 -
Joint significance 0.25
Linear Trend OR 0.62 0.37 0.21- 1.81
Mothers Educated 197 3 1
Education Uneducated 261 6 5.07 0.1 0.72 - 35.69
Mothers Birth 1 5 1
Order 2 1 0.12 0.1 0.03 - 1.61
3 5 2.56 0.27 0.45 - 14.57
4 1 0.36 0.39 0.03 -4.02
5 2 0.77 0.78 0.11 - 5.22
6 to 13 5 1.48 0.65 0.24 - 9.02
Joint significance 0.3
Linear Trend OR 1.08 0.62 0.77 -1.531-:-:--.
Unemployed 423 19 1Mothers
Employment Employed 25 0 -
Fathers Educated 363 11 1
Education Uneducated 85 8 12.67 0.005 2.41 - 66.52
There were no cases of HBV chronic infection amongst children receiving any number of
doses of hepatitis B vaccine, born from mothers in paid employment, living in
households with a crowding index of 1, living in households with a mobile telephone, or
in Aden and Shabwa provinces, and therefore no OR were computed for these variables
in the univariable analysis. Table 7.5.3 shows the association of HBV chronic infection
amongst children aged 4-9 with household characteristics and possessions.
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Table 7.5.3
Association of HBV chronic infection amongst children aged 4-9
with household characteristics and possessions
Variable Number Number OR p value 95% C.I.
Controls Cases
Household Owned 367 6 1
Ownership Rented 91 3 5.64 0.17 0.45 -71.5
Household Type House 309 6 1
Apartment 100 2 0.48 0.52 0.05 -4.96
Shack 49 1 0.19 0.18 0.02 - 2.23
Joint significance 0.37
Household Stone 115 1 1
Construction Block 229 7 1.89 0.61 0.14 - 24.97
Mud or Clay 60 0 -
Mixed 54 1 0.24 0.32 0.01 - 4.25
Joint significance 0.33
Crowding Index 1 30 0 -
2 115 2
3 122 2
4 75 2
5 43 0
6 to 15 73 3
Electricity Yes 341 5 1
Supply No 117 4 1.41 0.73 0.19 - 10.57
Source of Water Governmental 158 2 1
Local Project 135 0 -
Water Truck 69 4 2.82 0.33 0.31 - 26.12
Buckets 96 3 0.47 0.54 0.04 - 6.11
Joint significance 0.36
Fre2zer Yes 236 1 1
No 222 8 12.51 0.04 1.17 - 133.4
Television Yes 322 4 1
No 136 5 1.92 0.56 0.20 - 18.8
Radio Yes 312 5 1
No 146 4 0.45 0.33 0.08 - 2.39
Horne Phone Yes 107 1 1
No 351 8 4.65 0.21 0.4 - 53.49
Mobile Phone Yes 34 0 -
No 424 9
Car Yes 131 2 1
No 327 7 0.66 0.7 0.07 - 5.95
Socioeconomic Lower 192 8 1
Status Middle 161 0 -
Upper 105 1 0.11 0.08 0.01 - 1.34
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7.6 HBV chronic infection multivariable analysis:
The independent variable statistically significantly associated with HBV chronic
infection amongst children aged 4-9 in the multivariable analysis was father's educational
status. The adjusted OR of HBV chronic infection amongst children aged 4-9 born from
uneducated fathers was 23.1 (95% Cl 1.99 to 269) compared to children born from
fathers claiming to be educated. There were no cases of HBV chronic infection amongst
children of upper and middle socioeconomic status and therefore this variable was
dropped from the multivariable analysis and a model was not fitted substituting the
remaining socioeconomic variables with the socioeconomic status variable. Age, sex, and
area of residence did not show evidence of a statistically significant association with
HBV chronic infection amongst children aged 4-9, but being a priori variables, they were
added to the final model. There was no interaction between the independent variables in
the model. Table 7.6.1 shows the results of the multivariable analysis of the association
of independent variables with HBV chronic infection amongst children aged 4-9.
Table 7.6.1
Adj usted logistic regression of the association of HBV chronic infection
amongst children aged 4-9 with independent exposure variables
!Variable OR* p value** 95% C.I.***
Age of Child 4 I
(in years) 5 1.04 0.88 0.62 - 1.74
6 4.75 0.3 0.22 - 103
7 6.35 0.21 0.33 - 121
8 10.01 0.1 0.63 - 159
9 14.42 0.12 0.49 -428
Joint significance 0.45
Sex Male 1
Female 1.41 0.64 0.31 - 6.29
Area Urban 1
Rural 0.2 0.18 0.02-2.18
Fathers Educated 1
Educational Uneducated 23.1 0.02 1.99 - 269
Status
* adjusted OR computed by survey logistic regression multivariable analysis.
** p-value of the adjusted wald test statistic.
*** 95% Confidence Intervals.
**** p-value of the adjusted survey wald test statistic of the significance of the joint
effect of the categories of the independent variable on the dependent variable.
212
7.7 Discussion:
The reason this age-group of children aged 4-9 years was targeted in the survey was in
order to obtain a baseline measure of the prevalence of HBV infection amongst an
unvaccinated cohort of children aged 4-9 prior to the effect of universal hepatitis B
vaccination on the prevalence of HBV infection amongst these children. Such an estimate
will allow the evaluation of the impact of routine hepatitis B vaccination following its
introduction to the Yemeni EPI on the prevalence of HBV infection amongst children
aged 4-9 in the future when it is compared to the baseline measure obtained in this
survey. It has already been discussed in previous chapters that no surveys have been
conducted to investigate the prevalence of HBV infection amongst children, and therefore
there is a lack of data and information on the epidemiology of HBV infection amongst
children in the Republic of Yemen. When the children aged 4-9 participating in this
survey were recruited there was no intention or plan to perform an analysis of factors
associated with HBV infection amongst these children. Nevertheless, because data was
already collected from these children it was decided to perform a case-control analysis to
investigate factors associated with anti-HBc positivity and HBV chronic infection
amongst these children to add more strength to information resulting from the analysis of
factors associated with anti-HBc positivity and chronic infection amongst children aged
1-3.
The overall prevalence of anti-HBc positivity (4.75%) and HBV chronic infection
(3.08%) amongst children aged 4-9 participating in the survey was lower than expected.
The prevalence of HBV chronic infection amongst children aged 4-9 was expected to be
5% to 10% based on a few factors. First of all, the majority of studies conducted in
neighbouring countries in the region have suggested that most of HBV chronic infections
occur during childhood in the Middle-East. Secondly, previous studies conducted in
Yemen have reported a high prevalence of HBV chronic infection amongst adults in the
general population and it is expected that these are mainly the result of childhood
transmission. Thirdly, earlier studies have reported a high prevalence of HBV chronic
infection as well as a high HBeAg positivity amongst HBV chronic carrier women of
childbearing age in Yemen suggesting a potentially high rate of perinatal transmission of
HBV infection. Taking these factors into consideration it was expected that the survey
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would obtain at least 47 anti-HBc positive and 23 HBV chronic carrier children aged 4-9.
Nevertheless, contrary to expectations, what the survey did obtain was 19 anti-HBc
positive and 9 HBV chronic carrier children aged 4-9, which is less than half the number
that was expected. Obviously, one of the limitations resulting from the small number of
anti-HBc and HBsAg positive children aged 4-9 would be an insufficient power to detect
a statistically significant difference or association even if one existed. This was despite
the successful sampling process that resulted in a total actual sample size (467 children
aged 4-9) exceeding the total planned sample size (420 children aged 4-9) by over 10%.
Nevertheless, this was not of major concern because the main objective of sampling
children aged 4-9 in the first place, as mentioned above, was to examine the pattern of
HBV infection and provide a baseline measure of the prevalence of HBV infection
amongst children aged 4-9, not to investigate associations by performing univariable and
multivariable analyses.
This survey demonstrated an increase m the prevalence of anti-HBc and HBsAg
positivity amongst children aged 4-9 with increasing age of the child. The prevalence of
anti-HBc positivity was 3%, 2.6%, 3.5%, 5.2%, 8.5% and 5.7% amongst children aged 4,
5, 6, 7, 8 and 9 years, respectively (p=O.72), whereas, the prevalence of HBV chronic
infection was 0.64%, 0.64%, 1.99%,3.25%, 7.08%, and 5.02% amongst children aged 4,
5, 6, 7, 8 and 9 years, respectively (p=0.44). In the multivariable analysis there was a
clear increasing OR of anti-HBc positivity and HBV chronic infection with increasing
age of the child from 4 to 9 years, although these did not reach statistical significance.
Failure of these associations to reach statistical significance does not mean that these
associations are not true but only, as mentioned above, that the power of the study may
have been insufficient to provide evidence of a statistically significant association. The
increasing prevalence of anti-HBc positivity and HBV chronic infection with increasing
age across the age-groups of children aged 4-9 suggests that these children are becoming
infected with HBV through childhood transmission, regardless of the initial extent or
magnitude of perinatal transmission of HBV infection amongst these children. This is
supported by the higher prevalence of HBV chronic infection throughout childhood
above the baseline prevalence of 1% HBV chronic infection amongst children aged 1-3
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years, which is likely to be the result of mother-to-child transmission. Nevertheless, it has
already been discussed that the low prevalence of HBV infection amongst children aged
1-3 and the low prevalence of HBeAg positive chronic carrier women of childbearing age
provides evidence that mother-to-child transmission of HBV infection is not a major
problem in Yemen.
Similar to findings with anti-HBc positivity amongst children aged 1-3 there was a
significant decline in the prevalence of anti-HBc positivity amongst children aged 4-9
with increasing socioeconomic status (p=O.002) and amongst children aged 4-9 born from
women claiming to be educated (1.55%) compared to uneducated (6.59%) mothers
(p=0.02). The association between socioeconomic status and anti-HBc positivity amongst
children aged 4-9 was also statistically significant in the multi variable analysis and
showed a decline in anti-HBc positivity with increasing socioeconomic status. There
were also differences in the prevalence of HBV chronic infection amongst children aged
4-9 years by mothers educational and socioeconomic status but these did not reach
statistical significance, probably due to the small number of HBV chronic carrier children
aged 4-9. There were no cases of HBV chronic infection amongst children of middle and
upper socioeconomic status, and therefore, the socioeconomic status variable was not
added to the multivariable analysis model of HBV chronic infection amongst children
aged 4-9. An interesting association not found in the multivariable analysis of anti-HBc
and HBsAg positivity amongst children aged 1-3 years was the statistically significant
association of fathers educational status with anti-HBc and HBsAg positivity in the
multivariable analysis of children aged 4-9. There was a higher adjusted OR of being
anti-HBc positive [OR=4.1 (95% Cl 1.05 to 15.96)] and HBV chronically infected
[OR=23.1 (95% Cl 1.99 to 269)] amongst children of uneducated fathers compared to
children of fathers claiming to be educated. Although this was not consistent with
findings amongst children aged 1-3 it confirms the significance of the association of
educational status specifically and socioeconomic variables in general with HBV
infection.
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An unexplainable finding was the higher prevalence of HBV infection amongst children
aged 4-9 living in urban areas and females. This was contrary to what was expected and
found amongst children aged 1-3 participating in the survey. This may be due to the small
number of anti-HBc positive and HBV chronic carrier children in the survey resulting in
inaccurate prevalence estimates as demonstrated by their wide 95% confidence intervals.
Not only did Sanaa, one of the two urban provinces in the survey, have a higher
prevalence of anti-HBc positivity (8.74%) amongst children aged 4-9 than Aden (1.11%)
(p=0.06), it also had the highest prevalence of anti-HBc positive and HBV chronic carrier
children aged 4-9 compared to all the provinces in the survey. This might be the result of
the sampling process of children aged 4-9 participating in the survey. It was initially
planned to sample an equal number of children from all age-groups extending from 4-9
and five provinces in the survey, however, with children aged 4-9 being a secondary
objective this was not strictly adhered to during the survey. Actually, the sample size of
children aged 4-9 from Sanaa was greater than the sample size of children from the
remaining provinces in the survey. Table 7.7.1 shows the governorate sampling
distribution of children aged 4-9 participating in the survey. While this should have
produced more accurate point estimates with narrower confidence intervals it may have
also obtained more cases ofHBV infection in Sanaa.
Table 7.7.1
Governorate sampling distribution of children aged 4-9 participating in the
cross-sectional household sero-epidemiological survey
Province (Survey Domain) Planned Sample Size Actual Sample Size (%)
Sanaa 84 151 (32%)
Aden 84 66 (14%)
Taiz 84 90 (20%)
Shabwa 84 75 (16%)
Hodeidah 84 85 (18%)
Total 420 467 (100%)
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It is expected that the prevalence estimates of anti-HBc positivity and HBV chronic
infection amongst children aged 4-9 in Yemen participating in this survey are reliable
estimates obtained from a representative sample of the general population. All children
aged 4-9 participating in the survey were selected from within the same households of
participants in the survey of children aged 1-3. Seventy-six percent (356/467) of the
children aged 4-9 were older siblings of children aged 1-3 years participating in the
survey. The remaining 24% were either relatives or were living in the same household.
Considering all children participating in the survey of children aged 1-3 were randomly
selected, which gave all children aged 1-3 and consequently all children aged 4-9 in the
population an equal chance of being selected, this makes selection bias unlikely. A group
of children aged 4-9 at risk of not being selected or included in the sample population are
children that did not have a child aged 1-3 living in their household. However, there is no
apparent reason such children differ from children who did have a child aged 1-3 living
in their household. Another group of children aged 4-9 at risk of not being selected are
children living away from home or those at school. Nevertheless, it is uncommon for
young children aged 4-9 to live away from home or their parents, and considering that
households were visited during the morning and afternoon this should give children
attending schools an equal chance of being selected. Finally, a more general discussion of
the possible effect and sources of bias or confounding follows in chapter 9.
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Chapter 8: Results Vaccine Coverage and Effectiveness:
In this chapter the results of the prevalence, univariable analysis, and multivariable
analysis of hepatitis B vaccine coverage as well as the effectiveness of hepatitis B
vaccination in preventing HBV infection amongst children aged 1-3 participating in the
survey are presented. It is important to note that in all subsequent comparisons of the
prevalence of hepatitis B vaccination coverage, as well as factors associated with
hepatitis B vaccination coverage investigated by univariable and multivariable analysis,
the two comparison groups examined were hepatitis B vaccinated and unvaccinated
children, with hepatitis B vaccinated children referring to all vaccinated children
regardless of number of doses received. When analysing vaccine effectiveness the two
comparison groups were completely vaccinated and unvaccinated children, whereas, all
children of unknown vaccination status were excluded from the analysis.
Hepatitis B Vaccine Coverage:
8.1 Prevalence of hepatitis B vaccination coverage:
The overall prevalence of hepatitis B vaccine coverage, with at least one dose of hepatitis
B vaccine, amongst children aged 1-3 participating in the survey was 21.1% (95% Cl
15.81 to 27.58). The classification of the vaccination status of children aged 1-3
participating in the survey was carried out primarily according to what their vaccination
card records showed their hepatitis B vaccination status to be, and/or secondarily
according to the response of their parents to questions specifically asking about the
vaccination status of their child. Children who had evidence of receiving three doses of
hepatitis B vaccine were classified as completely vaccinated, children who had evidence
of receiving one or two doses of hepatitis B vaccine were classified as partially
vaccinated, and children who had vaccination records showing they did not receive any
doses of hepatitis B vaccine or whose parents confidently confirmed that their child did
not receive hepatitis B vaccine were classified as unvaccinated. Finally, children whose
vaccination status was unknown by their parents or children who were reported to have
received hepatitis B vaccine but did not have documentary evidence supporting this were
classified as unknown vaccination status. Out of all the children aged 1-3 participating in
the survey 8.63% (95% Cl 5.1 to 14.24) were completely vaccinated with hepatitis B
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vaccine, 12.47% (95% Cl 9.72 to 15.85) were partially vaccinated with hepatitis B
vaccine, 65.94% (95% Cl 54.32 to 75.92) were unvaccinated with hepatitis B vaccine,
and 12.96% (95% Cl 8.09 to 20.11) were of unknown hepatitis B vaccination status. As
for the number of doses of hepatitis B vaccine received by children aged 1-3 participating
in the survey 8.63% (95% Cl 5.1 to 14.24) received all three doses, 6.2% (95% Cl 4.51 to
8.48) received two doses, 6.27% (95% Cl 4.34 to 8.98) received one dose, 65.94% (95%
Cl 54.32 to 75.92) did not receive any doses, and 12.96% (95% Cl 8.09 to 20.11) had an
unknown dose status.
There was a statistically significant difference in the prevalence of hepatitis B vaccination
coverage amongst children aged 1-3 by demographic, health care, and educational
characteristics.
Demographic characteristics showing a significant difference in the prevalence of
hepatitis B vaccination amongst children aged 1-3 were sex, age, province, area of
residence, and socioeconomic status. The prevalence of hepatitis B vaccination was
26.28% amongst males aged 1-3 and 22.02% amongst females (p=0.04). There was a
decline in hepatitis B vaccine coverage with increasing age of the child. The prevalence
of hepatitis B vaccination was lowest amongst children aged 30 to 36 months (15.43%)
and highest amongst children aged 18 to 23 months (33.37%) (p=0.0009). The prevalence
of hepatitis B vaccination amongst children aged 1-2 (30.32%) was significantly higher
than' children aged 2-3 (17.85%) (p=0.0007). Figure 8.1.1 shows the prevalence of
hepatitis B vaccination coverage amongst children aged 1-3 by age.
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Figure 8.1.1
Prevalence of hepatitis B vaccination amongst children aged 1-3
by age (unadjusted)
45
40
j 35
~ 30.~
25>
e!
20
~c
J! 15
~
I!:! 10
0..
5
0
-----i<,~ ~
<,
1-2l11 ------- 11\4~
12 to 17 months 18 to 23 months 24 to 29 months 30 to 36 months
Age of the child in months
bars = 95% Cl
There was a statistically significant difference in the prevalence of hepatitis B vaccine
coverage amongst children aged 1-3 living in the five provinces of the survey (p=0.04).
Hepatitis B vaccine coverage was highest in Aden (56.44%), one of the two urban
provinces, and lowest in Shabwa (7.48%), one of the three rural provinces in the survey.
There was also evidence of a statistically significant difference in the prevalence of
hepatitis B vaccination between the two urban provinces in the survey. Hepatitis B
vaccine coverage was 23.48% (95% Cl 15.79 to 33.44) in Sanaa and 56.44 (95% Cl
41.85 to 69.99) in Aden (p=0.002). On the other hand, there was no evidence of a
statistically significant difference in the prevalence of hepatitis B vaccination between the
three rural provinces in the survey (p=0.41). The prevalence of hepatitis B vaccine
coverage amongst children aged 1-3 living in urban areas (35.33%) was higher than
children living in rural areas (19.53%) and this was statistically significantly different
(p=O.03). When the prevalence of hepatitis B vaccine coverage was compared by urban
versus rural area of birth of child aged 1-3 the vaccination results were similar to those
found according to area of residence of the child. The prevalence of hepatitis B
vaccination was 36.93% (156/380) amongst children aged 1-3 born in urban areas and
18.96% (113/704) amongst children aged 1-3 born in rural areas, and this difference was
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also statistically significant (p=O.009). Figure 8,1.2 shows the prevalence of hepatitis B
vaccination coverage amongst children aged 1-3 by province unadjusted for age or sex.
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Figure 8.1.2
Prevalence of hepatitis B vaccination amongst children aged 1-3 by province (unadjusted)
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There was a statistically significant difference in the prevalence of hepatitis B vaccine
coverage amongst children aged 1-3 between the three socioeconomic classes in the
survey (p<O.OOOI).The prevalence of hepatitis B vaccination coverage was positively
related to socioeconomic status. In other words, there was an increase in the prevalence
of hepatitis B vaccination coverage with increasing socioeconomic status. Figure 8.1.3
shows the prevalence of hepatitis B vaccination coverage amongst children aged 1-3
according to socioeconomic status.
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Figure 8.1.3
Hepatitis B vaccination amongst children aged 1-3 by socioeconomic status
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Table 8.1.1 shows the prevalence of hepatitis B vaccination coverage amongst children
aged 1-3 by level of vaccination and number of doses according to demographic
characteristics of children aged 1-3 participating in the survey.
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Table 8.1.1
Hepatitis B vaccine coverage amongst children aged 1-3
by children's demographic characteristics
Number Prevalence p-valueHepatitis B Vaccine Coverage
of (weighted) 95%CI 95%CI (PearsonAmongst Children Aged 1-3 LL UL design-Children %
based)
Vaccinated vs. unvaccinated children
Vaccinated (1, 2, or 3 doses) 284/1285 21.10 15.81 27.58
Unvaccinated (zero doses) 840/1285 65.94 54.32 75.92
Unknown Vaccination Status 161/1285 12.96 8.09 20.11
By Level of Vaccination
Completely Vaccinated (3 doses) 137/1285 8.63 5.10 14.24
Partially Vaccinated (1 or 2 doses) 147/1285 12.47 9.72 15.85
Unvaccinated (No doses) 840/1285 65.94 54.32 75.92
Unknown Vaccination Status 161/1285 12.96 8.09 20.11
By Number of Doses of Vaccine
Completely Vaccinated (3 doses) 137/1285 8.63 5.10 14.24
Partially Vaccinated (2 Doses) 81/1285 6.20 4.51 8.48
Partially Vaccinated (1 Dose) 66/1285 6.27 4.34 8.98
Unvaccinated (No doses) 840/1285 65.94 54.32 75.92
Unknown Vaccination Status 161/1285 12.96 8.09 20.11
Sex
Male 155/570 26.28 19.01 35.12
Female 129/554 22.02 14.76 31.53 0.04
Age-group (In months)
12 to 17 months 67/241 26.00 18.20 35.69
18 to 23 months 111/346 33.37 25.17 42.71
24 to 29 months 54/230 21.11 12.79 32.79
30 to 36 months 52/307 15.43 8.69 25.93 0.0009
Province
Sanaa 48/207 23.48 16.42 32.40
Taiz 39/215 17.87 5.32 45.75
Aden 121/214 56.44 43.22 68.80
Shabwa 19/251 7.48 2.94 17.73
Hodeidah 57/237 24.18 14.50 37.48 0.04
Area
Urban 169/421 35.33 28.29 43.07
Rural 115/703 19.53 10.95 32.38 0.03
Socioeconomic Status
Low 66/471 14.88 8.59 24.55
Middle 127/439 31.41 23.47 40.60
Upper 91/213 46.59 33.78 59.85 <0.0001
223
Health care characteristics showing a statistically significant difference in the prevalence
of hepatitis B vaccination coverage amongst children aged 1-3 were qualifications of the
person managing delivery of the child, setting of delivery, receiving antenatal care during
pregnancy, type of delivery, and parental knowledge of hepatitis B vaccine.
The prevalence of hepatitis B vaccination amongst children whose delivery was managed
by a medically qualified individual (36.65%) was twice as high as the prevalence of
hepatitis B vaccination amongst children whose delivery was managed by an unqualified
individual (17.52%) (p<O.OOOI).Similarly, the prevalence of hepatitis B vaccination
amongst children delivered in a health setting (43.19%) was twice as high as the
prevalence of hepatitis B vaccination amongst children delivered in a home setting
(19.89%) (p<O.OOOI). A significantly higher percentage of children delivered by
caesarean section (41.64%) were vaccinated than children delivered by normal delivery
(23.9%) (p=O.006). Children whose mothers received antenatal care during their
pregnancy (35.93%) had a higher prevalence of hepatitis B vaccination than children
whose mothers did not (15.84%) (p<O.OOOI).Less than 1% of children of parents who
did not know of hepatitis B vaccine were vaccinated compared to 32% of children of
parents who knew of hepatitis B vaccine (p<O.OOOI).Table 8.1.2 shows the prevalence of
hepatitis B vaccination coverage amongst children aged 1-3 by children's health care
characteristics.
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Table 8.1.2
Hepatitis B vaccination coverage amongst children aged 1-3
by children's health care characteristics
Number Prevalence
p-value
Hepatitis B Vaccination Coverage of (weighted)
95%CI 95%CI (Pearson
Amongst Children Aged 1-3 Children % LL
UL design-
based)
Person Managing Delivery
Medically Qualified Personnel 179/465 36.65 26.27 48.45
Unqualified Personnel 103/638 17.52 11.67 25.44 <0.0001
Setting of Delivery
Health Setting 123/277 43.19 33.54 53.38
Home Setting 152/802 19.89 13.26 28.73 <0.0001
Type of Delivery
Normal 270/1094 23.90 16.71 32.95
Caesarian 14/30 41.64 31.60 52.41 0.006
Antenatal Care During Pregnancy
Yes 192/506 35.93 26.32 46.82
No 90/614 15.84 10.28 23.62 <0.0001
Parents Know of Vaccine
Yes 283/819 32.14 23.78 41.82
No 1/299 0.52 0.06 4.19 <0.0001
The prevalence of hepatitis B vaccination amongst children aged 1-3 born from women
claiming to be educated (39.59%) was more than double the prevalence amongst children
born from uneducated women (16.69%) (p=O.OOOI).Likewise, the prevalence of hepatitis
B vaccination amongst children aged 1-3 whose fathers claimed to be educated (27.88%)
was nearly double the prevalence of vaccination amongst children aged 1-3 of
uneducated fathers (15.29%) (p=O.003). There was a statistically significant difference in
the prevalence of hepatitis B vaccine coverage amongst children aged 1-3 by the level of
mothers (p=O.OOOI) or fathers (p=O.003) education. The prevalence of hepatitis B
vaccination amongst children aged 1-3 born to women or fathers claiming to have
attended University/College or secondary school was higher than the prevalence of
hepatitis B vaccination amongst children aged 1-3 born to women or fathers claiming to
have completed primary school, which was higher than the prevalence of hepatitis B
vaccination amongst children aged 1-3 born to women or fathers claiming they could
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read and write. The prevalence of hepatitis B vaccination amongst children aged 1-3 born
from women in paid employment (54.13%) was higher than the prevalence of hepatitis B
vaccination amongst children aged 1-3 born from women who were not in paid
employment (23.45%) (p=O.0004). Table 8.1.3 shows the prevalence of hepatitis B
vaccine coverage amongst children aged 1-3 by mothers and fathers characteristics.
Table 8.1.3
Hepatitis B vaccination coverage amongst children aged 1-3
by mother's and father's characteristics
Number Prevalence p-valueHepatitis B Vaccination Coverage
of (weighted) 95%CI 95%CI (PearsonAmongst Children Aged 1-3 LL UL design-Children %
basedl
Mothers Age
15 to 24 years 91/341 25.55 18.39 34.33
25 to 29 years 86/302 27.94 19.60 38.16
30 to 34 years 51/241 19.74 12.09 30.56
35 to 39 years 38/158 23.86 14.06 37.49
40 to 49 years 18/82 18.29 9.54 32.20 0.16
Mothers Educational Status
Reads and Writes 178/445 39.59 30.51 49.45
Does not Read and Write 106/679 16.69 10.37 25.77 0.0001
Mothers Level of Education
Reads and Writes 33/151 25.44 19.21 32.88
Completed Primary School 79/180 39.24 26.86 53.18
Completed Secondary School 53/91 61.17 48.11 72.80
Completed University or College 13/23 61.68 44.66 76.24 0.0001
Mother's Employment
Employed 23/41 54.13 38.70 68.80
Unemployed 261/1083 23.45 16.29 32.53 0.0004
Father's Educational Status
Reads and Writes 250/873 27.88 20.34 36.92
Does not Read and Write 34/251 15.29 8.49 25.99 0.003
Father's Level of Education
Reads and Writes 38/195 18.88 13.61 25.58
Completed Primary School 80/295 27.00 18.55 37.53
Completed Secondary School 75/238 32.16 21.39 45.23
Completed University or College 57/145 35.78 21.11 53.71 0.05
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8.2 Hepatitis B vaccination coverage univariable analysis:
The univariable analysis of the association of hepatitis B vaccination amongst children
aged 1-3 participating in the survey with exposure variables produced results that were
classified into three categories. The first of these had OR that were statistically
significantly different from 1. The second category had notably increased or decreased
OR, by more or less than 30%, but these were not statistically significant. The third
category consisted of results that neither had notable increased or decreased OR nor were
these significant. These results of the univariable analysis are presented in tables 8.2.1,
8.2.2 and 8.2.3.
The demographic and health care variables of children aged 1-3 (table 8.2.1) that had a
statistically significant association with hepatitis B vaccination of children aged 1-3 in the
univariable analysis were sex and age of child, province and area of residence, birth order
of child, qualifications of the person managing delivery, setting and type of delivery, and
having received antenatal care during pregnancy. Mother's and father's variables that had
a statistically significant association with hepatitis B vaccination of children aged 1-3
(table 8.2.2) by univariable analysis were mothers education, mothers employment,
fathers education, and parents knowledge of hepatitis B vaccine. Household
characteristics and possessions that had a statistically significant association with
hepatitis B vaccination of children aged 1-3 (table 8.2.3) by univariable analysis were
type of household, material used in the construction of household, availability of an
electricity supply, household source of water, socioeconomic status, and the ownership of
a fridge/freezer, television, home telephone, mobile telephone, and radio.
Starting with demographic and health care variables females aged 1-3 were significantly
less likely be vaccinated with hepatitis B vaccine [OR=0.79 (95% Cl 0.64 to 0.98)]
compared to males aged 1-3 participating in the survey. Children aged 12 to 17 (OR=I)
and 18 to 23 months (OR=1.43) had a higher OR of receiving hepatitis B vaccine than
children aged 24 to 29 (OR=0.76) and 30 to 36 months (OR=0.52) (p=0.0004). Province
of residence was significantly associated with having received hepatitis B vaccine
(p=O.OOI).Children aged 1-3 living in Aden (OR=4.22) were four times more likely to
have received hepatitis B vaccine than children in Sanaa (p<O.OOI). Children living in
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rural areas [OR=0.44 (95% Cl 0.21 to 0.94)] had less than half the odds of being
vaccinated compared to children living in urban areas. Child birth order was significantly
associated with hepatitis B vaccination (p=0.02) and there was a decline in the odds of
being vaccinated with increasing birth order of the child.
Children whose delivery was managed by an unqualified individual [OR=0.37 (95% Cl
0.25 to 0.53)], children delivered in a home setting [OR=0.33 (95% Cl 0.22 to 0.48)], or
children whose mothers did not receive antenatal care during pregnancy [OR =0.34 (95%
I 0.23 to 0.48)] had a statistically significantly lower odds of receiving hepatitis B
vaccine. On the other hand, children delivered by caesarean section [OR=2.27 (95% Cl
1.29 to 4)] had a higher odds of receiving hepatitis B vaccine than children delivered by
normal vaginal delivery. Table 8.2.1 shows the results of the univariable analysis of the
association of demographic and health care characteristics with hepatitis B vaccination
coverage amongst children aged 1-3.
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Table 8.2.1
Association of hepatitis B vaccination coverage amongst children aged 1-3
with demographic and health care characteristics
Variable Number Number OR p value 95% C.I.
Controls Cases
Sex Male 415 155 1
Female 425 129 0.79 0.04 0.64 - 0.98
Age of child 12 to 17 174 67 1
(in months) 18 to 23 235 111 1.43 0.008 1.11 - 1.83
24 to 29 176 54 0.76 0.32 0.43 - 1.34
30 to 36 255 52 0.52 0.02 0.30 - 0.89
Joint significance 0.0004
Linear trend OR 0.77 0.003 0.65 -0.90
Province Sanaa 159 48 1
Taiz 176 39 0.71 0.62 0.17 - 2.95
Aden 93 121 4.22 <0.001 2.11 - 8.45
Shabwa 232 19 0.26 0.02 0.09 - 0.77
Hodeidah 180 57 1.04 0.92 0.48 - 2.25
Joint significance 0.001
Area Urban 252 169 1
Rural 588 115 0.44 0.04 0.21- 0.94
Child Birth Order 1 115 81 1
2 132 47 0.49 0.005 0.30 - 0.78
3 122 46 0.60 0.06 0.35 - 1.02
4 93 31 0.44 0.02 0.22 - 0.86
5 94 23 0.39 0.002 0.23 - 0.67
6 to 18 284 56 0.32 <0.001 0.18 - 0.56
Joint significance 0.02
Linear Trend OR 0.82 0.001 0.74- 0.91
Brcastfed Yes 830 274 1
No 9 10 2.49 0.17 0.66 - 9.33
Duration Up to 1 year 304 110 1
Breastfed 1 to 2 years 452 147 1.00 0.99 0.70 - 1.44
More than 2 yrs 71 17 0.57 0.09 0.30 - 1.09
Joint significance 0.23
Person Managing Qualified Medic 286 179 1
Delivery Unqualified 535 103 0.37 <0.001 0.25 - 0.53
Setting of Health Setting 154 123 1
Delivery Home Setting 650 152 0.33 <0.001 0.22 - 0.48
Type of Delivery Normal 824 270 1
Caesarian 16 14 2.27 0.007 1.29 - 4.00
Antenatal Care Yes 314 192 1
During No 524 90 0.34 <0.001 0.23 - 0.48
Pregnancy
With reference to mother's and father's characteristics, knowledge of hepatitis B vaccine
by either parent of the child aged 1-3 was strongly associated with being vaccinated with
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hepatitis B vaccine. Children whose parents did not know of hepatitis B vaccine
[OR=O.Ol (95% Cl 0.001 to 0.08)] were extremely unlikely to be vaccinated with
hepatitis B vaccine compared to children of parents who did know of the vaccine.
Children aged 1-3 born to uneducated mothers [OR=0.31 (95% Cl 0.18 to 0.51)] and
uneducated fathers [OR=0.47 (95% Cl 0.29 to 0.76)] experienced a 70% and 50%
reduction, respectively, in the odds of being vaccinated with hepatitis B vaccine
compared to children of mothers and fathers claiming to be educated. On the other hand,
children of women in paid employment were nearly four times more likely [OR=3.85
(95% Cl 1.88 to 7.88)] to be vaccinated with hepatitis B vaccine than children of women
who were not employed. Table 8.2.2 shows the results of the univariable analysis of the
association of mothers and fathers characteristics with hepatitis B vaccination coverage
amongst children aged 1-3.
Table 8.2.2
Association of hepatitis B vaccination coverage
amongst children aged 1-3 with mothers and fathers characteristics
Variable Number Number OR p value 95% C.I.
Controls Cases
Mothers Age 15 to 24 250 91 1
(in years) 25 to 29 216 86 1.13 0.40 0.84 - 1.52
30 to 34 190 51 0.72 0.1 0.48 - 1.07
35 to 39 120 38 0.91 0.71 0.55 - 1.51
40 to 49 64 18 0.65 0.23 0.32 - 1.35
Joint significance 0.25
Linear Trend OR 0.91 0.14 0.80 -1.04
Mothers Educated 267 178 1
Education Uneducated 573 106 0.31 <0.001 0.18-0.51
Mothers Birth 1 188 58 1
Order 2 137 37 1.18 0.56 0.65-2.16
3 126 52 1.57 0.12 0.89 -2.77
4 104 35 1.20 0.57 0.62 - 2.33
5 86 23 0.88 0.57 0.56 - 1.39
6 to 19 199 79 1.33 0.17 0.88 -2.03
Joint significance 0.24
Linear Trend OR 1.03 0.46 0.95 - 1.11
Mothers Unemployed 822 261 1
Employment Employed 18 23 3.85 0.001 1.88 -7.88
Fathers Educated 623 250 1
Education Uneducated 217 34 0.47 0.004 0.29 - 0.76
Parents know Yes 536 283 1
of Vaccine No 298 1 0.01 <0.001 0.001 -0.08
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When exammmg socioeconomic variables, children of upper socioeconomic status
[OR=4.99 (95% Cl 2.71 to 9.19)] and middle socioeconomic status [OR=2.62 (95% Cl
1.44 to 4.75), were 5 times and 2.5 times, respectively, more likely to receive hepatitis B
vaccine than children of low socioeconomic status (p=0.0002). Children aged 1-3 living
in households that did not have an electricity supply [OR=0.3 (95% Cl 0.14 to 0.62)],
fridge/freezer [OR=0.39 (95% Cl 0.22 to 0.69)], radio [OR=0.43 (95% Cl 0.27 to 0.68)],
home telephone [OR=0.34 (95% Cl 0.19 to 0.6)], or mobile telephone [OR=0.32 (95% Cl
0.12 to 0.86)] in their household had a statistically significantly lower odds of receiving
hepatitis B vaccine than children aged 1-3 who did have these commodities in their
household. Children living in apartments had a higher odds [OR=2.76 (95% Cl 1.59 to
4.77)] and children living in shacks had a lower odds [OR=0.29 (95% Cl 0.18 to 0.45)] of
receiving hepatitis B vaccine than children living in houses. Children living in
households built of mud/clay [OR=0.38 (95% Cl 0.13 to 1.14)] or mixed materials
[OR=0.23 (95% Cl 0.1 to 0.51)] had a lower odds of receiving hepatitis B vaccine than
children living in households built of stone. Children living in households obtaining
water through by a local project (OR=0.34), water truck (OR=0.37), or buckets
(OR=0.23) had a statistically significantly lower odds of receiving hepatitis B vaccine
than children obtaining water by a governmental water supply (p=0.0003). Table 8.2.3
shows the association of household characteristics and possessions with hepatitis B
vaccination coverage amongst children aged 1-3.
231
Table 8.2.3
Association of hepatitis B vaccination coverage amongst children aged 1-3
with household characteristics and possessions
Variable Number Number OR p value 95% C.I.
Controls Cases
Household Owned 736 240 1
Ownership Rented 104 44 1.23 0.39 0.75 - 2.03
Household Type House 644 184 1
Apartment 91 91 2.76 0.001 1.59 - 4.77
Shack 104 9 0.29 <0.001 0.18 - 0.45
Joint significance <0.0001
Household Stone 215 85 1
Construction Block 346 170 1.16 0.71 0.51 - 2.59
Mud or Clay 157 19 0.38 0.08 0.13 - 1.14
Mixed 122 10 0.23 0.001 0.10-0.51
Joint significance <0.0001
Crowding Index 1 60 18 1
2 197 75 1.26 0.38 0.74 - 2.12
3 192 81 1.04 0.91 0.48 - 2.24
4 153 48 0.79 0.48 0.41 - 1.55
5 83 32 0.86 0.77 0.31 - 2.39
6 to 18 155 30 0.45 0.04 0.21 - 0.96
Joint significance 0.12
Linear Trend OR 0.82 0.03 0.69 -0.98
Electricity Yes 526 238 1
Supply No 314 46 0.30 0.002 0.14 - 0.62
Source of Water Governmental 200 167 1
Local Project 343 60 0.34 0.005 0.17 - 0.70
Water Truck 73 19 0.37 <0.001 0.23 - 0.60
Buckets 223 38 0.23 0.001 0.10 - 0.49
Joint significance 0.0003
Freezer Yes 321 177 1
No 519 107 0.39 0.003 0.22 -0.69
Television Yes 502 234 1
No 338 50 0.35 0.006 0.17-0.72
Radio Yes 551 231 1
No 289 53 0.43 0.001 0.27 - 0.68
Home Phone Yes 114 101 1
No 726 183 0.34 0.001 0.19 - 0.60
Mobile Phone Yes 20 24 1
No 820 260 0.32 0.03 0.12 - 0.86
Car Yes 191 71 1
No 649 213 0.75 0.14 0.51-1.11
Socioeconomic Lower 405 66 1
Status Middle 312 127 2.62 0.003 1.44 - 4.75
Upper 122 91 4.99 <0.001 2.71 - 9.19
Joint significance 0.0002
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Variables that had notably increased or decreased OR, by more or less than 30%, but
were not statistically significantly associated with hepatitis B vaccination amongst
children were having breastfed the child aged 1-3 and duration of breastfeeding (table
8.2.1). Variables that neither showed notably increased or decreased OR nor evidence of
a statistically significant association with hepatitis B vaccination amongst children aged
1-3 were age of the child's mother, birth order of the child's mother, household
ownership, household crowding index and the ownership of a car.
8.3 Hepatitis B vaccination coverage multivariable analysis:
The independent variables that had a statistically significant association with hepatitis B
vaccination coverage amongst children aged 1-3 in the multivariable analysis were age of
the child, parents knowledge of hepatitis B vaccine, having received antenatal care during
pregnancy, mothers educational status, and ownership of a radio.
The adjusted OR of hepatitis B vaccination amongst children aged 1-3 born from families
that did not know of hepatitis B vaccine was 0.01 (95% Cl 0.002 to 0.11) indicating that
it is extremely unlikely for children born in families that do not know of hepatitis B
vaccine to be vaccinated. Children born from women who did not receive antenatal care
during their pregnancy with the child aged 1-3 participating in the survey had half the
odds (OR= 0.5) of being vaccinated with hepatitis B vaccine after adjusting for the
remaining variables in the model (p=0.001). Similarly, children born from uneducated
women had half the odds (OR=0.55) of receiving hepatitis B vaccine compared to women
claiming to be educated (p=0.02). The adjusted OR of hepatitis B vaccination was 0.67
amongst children living in households that did not have a radio indicating that children
living in households without a radio had an approximately 30% lower likelihood of being
vaccinated compared to children living in households that did have a radio (p=0.02). Age
of the child was statistically significantly associated with hepatitis B vaccination after
adjusting for the remaining significant variables in the model (p=0.02). There was a
significant difference in the odds of receiving hepatitis B vaccine according to age.
Children aged 12 to 17 months and 18 to 23 months had a higher odds of receiving
hepatitis B vaccine compared to children aged 24 to 29 and 30 to 36 months (p=0.006).
Female children (OR=0.81) and children living in rural areas (OR=0.91) aged 1-3 had a
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lower odds of receiving hepatitis B vaccine but sex and area of residence did not show
evidence of a statistically significant association with hepatitis B vaccination amongst
children aged 1-3, but because these were a priori explanatory variables these were added
to the model at the end of the process. There was no evidence of interaction between the
independent variables in the model. Table 8.3.1 shows the results of the multivariable
analysis of the association of the independent variables with hepatitis B vaccination
coverage amongst children aged 1-3.
Table 8.3.1
Adjusted logistic regression of the association of hepatitis B vaccination
amongst children aged 1-3 with independent exposure variables
lVariable OR* p value** 95% C.I.***
Age of Child 12 to 17 1
(in months) 18 to 23 1.51 0.06 0.98 -2.32
24 to 29 0.79 0.5 0.38 -1.62
30 to 36 0.51 0.02 0.29 - 0.90
Joint significance 0.02
Sex Male 1
Female 0.81 0.09 0.63 - 1.04
Area Urban 1
Rural 0.91 0.81 0.42 - 1.99
Parents know of Yes 1
hepatitis B vaccine No 0.01 <0.001 0.002 - 0.11
Antenatal care Yes 1
during pregnancy No 0.5 0.001 0.34 - 0.74
Mothers Educated 1
Educational Status Uneducated 0.55 0.02 0.34 - 0.89
Radio Ownership Yes 1
No 0.67 0.02 0.48 - 0.94
* adjusted OR computed by survey logistic regression multivariable analysis.
** p-value of the adjusted wald test statistic.
*** 95% Confidence Intervals.
**** p-value of the adjusted survey wald test statistic of the significance of the joint
effect of the categories of the independent variable on the dependent variable.
The multivariable analysis was repeated excluding all the socioeconomic variables that
contributed to the socioeconomic index constructed in the survey and substituting them
with the single socioeconomic status variable. The OR and p-values of the age of the
child, sex, and area of residence associated with hepatitis B vaccination were extremely
similar in this model in table 8.3.1 ending up with mothers educational status and radio
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ownership, expect for the p-value of sex, which changed from 0.09 to 0.05.
Socioeconomic status, on the other hand, was significantly associated with hepatitis B
vaccine coverage, and there was a clear increased OR of hepatitis B vaccination
associated with increasing socioeconomic status. Table 8.3.2 shows the results of the
multivariable analysis of the association of independent variables and socioeconomic
status with hepatitis B vaccination coverage amongst children aged 1-3.
Table 8.3.2
Adjusted logistic regression of association of hepatitis B vaccination amongst
children aged 1-3 with exposure variables including socioeconomic status
Variable OR* p value** 95% C.I.***
Age of Child 12 to 17 1
(in months) 18 to 23 1.50 0.05 0.98 - 2.32
24 to 29 0.78 0.47 0.38 -1.62
30 to 36 0.50 0.02 0.29 - 0.90
Joint significance 0.01
Sex Male I
Female 0.78 0.05 0.61- 1.00
Area Urban 1
Rural 0.94 0.87 0.43 - 2.04
Parents know of Yes 1
hepatitis B vaccine No 0.01 <0.001 0.001 - 0.11
Antenatal care Yes 1
during pregnancy No 0.5 0.001 0.34 - 0.71
Socioeconomic Low I
Status Middle 1.72 0.07 0.95 to 3.09
Upper 2.53 0.004 1.39 to 4.59
Joint significance 0.02
* adjusted OR computed by survey logistic regression multivariable analysis.
** p-value of the adjusted wald test statistic.
*** 95% Confidence Intervals.
**** p-value of the adjusted survey wald test statistic of the significance of the joint
effect of the categories of the independent variable on the dependent variable.
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Hepatitis B Vaccine Effectiveness:
8.4 Hepatitis B vaccine immunoe;enicity:
The immunogenicity of hepatitis B vaccine amongst children aged 1-3 participating in the
survey was measured in terms of the ability of hepatitis B vaccine to stimulate an
immune response amongst vaccinated children resulting in hepatitis B surface antibody
(anti-HBs) concentrations greater than 10 milli-international units per litre (MiU/L).
Children with anti-HBs concentrations> 10 MiU/L were classified as anti-HBs positive
and were considered protected against HBV infection.
Out of 1285 children aged 1-3 participating in the survey, 284 children received one, two
or three doses of hepatitis B vaccine, as discussed in section 8.1. Six out of these 284
children were excluded from the analysis ofimmunogenicity. One of these 6 children had
insufficient serum samples to test for anti-HBs. The remaining five children excluded
from the analysis were anti-HBc positive indicating that they were exposed to HBV, and
were excluded with the intention of removing the effect of HBV infection in inducing
natural immunity amongst these 5 children (because it was not known if they responded
to vaccination). The final analysis of the immunogenicity of hepatitis B vaccine included
278 vaccinated children aged 1-3. Overall, 77.03% (95% Cl 67.16 to 84.62) of vaccinated
children (completely and partially) were anti-HBs positive. However, this varied
significantly according to the number of doses of hepatitis B vaccine given to the child.
Table 8.4.1 shows vaccine induced immunity amongst children aged 1-3 according to
number of doses of hepatitis B vaccine.
Table 8.4.1
Vaccine induced immunity amongst children aged 1-3
by number of doses of hepatitis B vaccine
Number of Doses of % anti-HBs Positive Number 95%CI 95%CI p-value
Hepatitis B Vaccine (anti-HBs > 10 miu/L) LL UL
Weighted
1 Dose 44.24 29/63 29.53 60.64
2 Doses 82.56 66/80 70.39 90.41
3 Doses 95.85 130/135 91.62 97.99 <0.0001
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There was a clear increase in the proportion of anti-HBs positive children with increasing
number of doses of hepatitis B vaccine received and this difference was statistically
significant (p<O.0001). Figure 8.4.1 shows the increase in anti-HBs positivity amongst
vaccinated children aged 1-3 by number of doses of hepatitis B vaccine received.
Figure 8.4.1
Anti-HBs positivity (> 10 Miu/L) amongst children aged 1-3
by number of doses of hepatitis B vaccine
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Similar to the increasing proportion of anti-HBs positive children with an increase in the
number of doses of hepatitis B vaccine, there was also an increase in the anti-HBs
geometric mean concentration with an increase in number of doses hepatitis B vaccine
received by children aged 1-3 participating in the survey. Figure 8.4.2 shows the
geometric mean concentration of anti-HBs amongst children aged 1-3 by number of
doses of hepatitis B vaccine.
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Figure 8.4.2
Anti-HBs Geometric Mean Concentration (GMC) amongst children aged 1-3
(anti-HBc-/anti-HBs+) by number of doses of hepatitis B vaccine
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8.5 Hepatitis B vaccine effectiveness:
When examining hepatitis B vaccine effectiveness the two comparison groups were the
l37 completely vaccinated children receiving all three doses of hepatitis B vaccine
regardless of vaccine schedule and dose intervals, and the 840 unvaccinated children
aged 1-3 participating in the survey. Two aspects of vaccine effectiveness were
examined, one was the effectiveness of hepatitis B vaccine in preventing anti-Hfsc
positivity and the other was the effectiveness of hepatitis B vaccine in preventing HBV
chronic infection.
Overall, 27 of the 1285 children aged 1-3 participating in the survey were anti-HBc
positive. 81.6% (22/27) of these anti-Hfsc positive children were unvaccinated with
hepatitis B vaccine, 14.3% (3/27) received one dose, 2.4% (1/27) received two doses, and
1.8% (1127) received all three doses of hepatitis B vaccine.
The prevalence of anti-BBc positivity was 2.95% (95% Cl 1.45 to 5.92) amongst children
unvaccinated with hepatitis B vaccine compared to 0.5% (95% Cl 0.06 to 3.78) amongst
children completely vaccinated with hepatitis B vaccine (p=O.06). There was a decline in
the prevalence of anti-Hfsc positivity according to the number of doses of hepatitis B
vaccine given to children aged 1-3 participating in the survey. Table 8.5.1 shows the
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prevalence of anti-HBc positivity amongst children aged 1-3 according to the number of
doses of hepatitis B vaccine received by children aged 1-3 participating in the survey.
Table 8.5.1
Prevalence of anti-HBc positivity amongst children aged 1-3
by number of doses of hepatitis B vaccine
Number of doses of Number anti-HBc 95%CI 95%CI p-value
hepatitis B vaccine of Positive LL UL (Pearson
Children Prevalence design-
(Weighted) % based)
o Doses 22/840 2.95 1.45 5.92
1 Dose 3/66 5.42 1.70 15.98
2 Doses 1/81 0.91 0.11 6.96
3 Doses 1/137 0.50 0.06 3.78 0.06
On the other hand, 11 out of the 1285 children aged 1-3 participating in the survey were
HBV chronic carriers. All of these HBV chronic carrier children were unvaccinated with
hepatitis B vaccine and there were no HBV chronic carriers amongst children receiving
one, two or three doses of hepatitis B vaccine. The prevalence of HBV chronic infection
was 1.5% (95% Cl 0.53 to 4.12) amongst children unvaccinated with hepatitis B vaccine.
Table 8.5.2 shows the prevalence of HBV chronic infection amongst children aged 1-3
according to the number of doses of hepatitis B vaccine received by children aged 1-3
participating in the survey.
Table 8.5.2
Prevalence of HBV chronic infection amongst children aged 1-3
by number of doses of hepatitis B vaccine
Number of doses of Number HBV Chronic 95%CI 95%CI p-value
hepatitis B vaccine of Infection LL UL (Pearson
Children Prevalence design-
(Weighted) % based)
o Doses 11/840 1.5 0.53 4.16
1 Dose 0/66 0
2 Doses 0/81 0
3 Doses 0/137 0 0.69
The OR of anti-HBc positivity amongst children aged 1-3 completely vaccinated with
hepatitis B vaccine compared to unvaccinated children was 0.17 (95% Cl 0.03 to 1.09).
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This OR suggests an 80% reduction in anti-HBc positivity amongst children receiving all
three doses of hepatitis B vaccine (p=0.06). There were no cases of HBV chronic
infection amongst children completely vaccinated with hepatitis B vaccine. Consequently
the OR ofHBV chronic infection amongst children aged 1-3 completely vaccinated with
hepatitis B vaccine compared to unvaccinated was O. Vaccine effectiveness (VE) is
computed as 1 - relative risk. It is well established that in rare diseases the risk ratio
approximates the odds ratio and rate ratio. HBV infection amongst children aged 1-3 in
Yemen was clearly found to be a rare disease, therefore, vaccine effectiveness was
computed as VE = 1 - OR. Accordingly, hepatitis B vaccine had a vaccine effectiveness
of 83% (95% Cl -9 to 97) in preventing anti-HBc positivity and a vaccine effectiveness
of 100% (95% Cl 97% lower limit) in preventing HBV chronic infection amongst
completely vaccinated children aged 1-3 participating in the survey. Table 8.5.3 shows
hepatitis B vaccine effectiveness in preventing anti-HBc positivity and HBV chronic
infection amongst completely vaccinated children aged 1-3 participating in the survey.
Table 8.5.3
Hepatitis B vaccine effectiveness in preventing HBV infection
amongst completely vaccinated children aged 1-3
Completely vaccinated OR (95% Cl) p-value Vaccine Effectiveness
versus unvaccinated (Pearson (95% Cl)
children aged 1-3 design-
based)
Anti-HBc positivity 0.17 (0.03to 1.09) 0.06 83% (-9 to 97%)
HBV Chronic Infection o (0.03 Upper Limit) 0.50 100% (97% Lower Limit)
8.6 Discussion:
Overall, the percentage of children aged 1-3 participating in this survey receiving at least
one dose of hepatitis B vaccine in Yemen was 21.1% (95% Cl 15.81 to 27.58). Out of all
children aged 1-3 participating in the survey 8.63% (95% Cl 5.1 to 14.24) were
completely vaccinated (received 3 doses), 12.47% (95% Cl 9.72 to 15.85) were partially
vaccinated (received 1 or 2 doses), and 65.94% (95% Cl 54.32 to 75.92) did not receive
any dose of hepatitis B vaccine. The percentage of children aged 1-3 with unknown
hepatitis B vaccination status was 12.96% (95% Cl 8.09 to 20.11) and the potential effect
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of this proportion of children on the hepatitis B vaccine coverage prevalence estimates of
this survey will be discussed later in this section.
These are the first independent estimates of hepatitis B vaccine coverage in Yemen. The
prevalence estimates of this survey show hepatitis B vaccine coverage to be much lower
than initially expected and much lower than vaccine coverage with the remaining routine
EPI vaccines in Yemen. These estimates of hepatitis B vaccine coverage are also much
lower than hepatitis B vaccine coverage in the majority of Middle-Eastern countries
which are presented in Chapter 1.
The EPI reports that vaccine coverage with BCG, DPT (3 doses), OPV (3 doses),
measles and hepatitis B vaccine (3 doses) was 78.2%, 72.8%, 72.8%, 71.4% and 14.8%,
respectively, by one year of age (MOPHP(B), 2001). Hepatitis B vaccine coverage with
three doses of hepatitis B vaccine was reported to be 9% in 1999 (MOPHP(A), 2001)
which when compared to vaccine coverage in 2001 indicates that the proportion of
children completely vaccinated with hepatitis B vaccine is increasing. The EPI in Yemen
reports that 42% of children under the age of 1 year receive at least one dose of hepatitis
B vaccine but this figure has been occasionally incorrectly reported as the prevalence of
hepatitis B vaccine coverage with all three doses of hepatitis B vaccine by the age of 1
year.
The estimates of hepatitis B vaccine coverage amongst children aged 1-3 obtained from
this' survey are expected to be more reliable than those reported by the EPI at the MOPHP
in Yemen. It is unknown how the EPI obtained its estimate of hepatitis B vaccine
coverage but being responsible for the vaccination programme in Yemen the EPI may
have provided biased high vaccine coverage estimates. This survey, on the other hand, is
independent of the EPI and MOPHP, and there is no motive or reason for study
investigators to underestimate or overestimate hepatitis B vaccine coverage. It is
noteworthy to mention that the reported high coverage with BCG vaccine should be
encouraging had it been proven that a birth dose of hepatitis B vaccine was necessary
These results of low hepatitis B vaccine coverage are not encouraging, especially when
78% of parents claimed to have knowledge of hepatitis B vaccine and 32% of parents
said their child received hepatitis B vaccine. Nevertheless, this survey did not investigate
the attitude and practice of parents toward hepatitis B vaccination and it is unknown if
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parents of unvaccinated children were willing but unable to have their child vaccinated or
if they refused to do so.
The only independent variables that remained statistically significantly associated with
hepatitis B vaccine coverage amongst children aged 1-3 in the multivariable analysis after
adjusting for the remaining variables in the model were age of the child, receiving
antenatal care during pregnancy, parents knowledge of hepatitis B vaccine, mothers
educational status, and the ownership of a radio. All of these variables, except for age of
the child, are related to health awareness, health attitudes and practices, and
socioeconomic status.
The OR of receiving hepatitis B vaccine was 0.5 amongst children aged 2-3 compared to
children aged 1-2 (p=O.OOl), indicating that children aged 2-3 had half the odds of being
vaccinated with hepatitis B vaccine compared to children aged 1-2. The higher
prevalence of hepatitis B vaccine coverage amongst children aged 1-2 (30.32%)
compared to children aged 2-3 (17.85%) (p=0.0007) is probably because the hepatitis B
vaccination programme was gradually introduced (phased introduction) starting with
central health centres in 1998 targeting children less than 1 year old, and then extended to
peripheral health centres and units. Initially children older than 1 year could pay for
hepatitis B vaccine but this was discontinued later due to legal constraints on selling
childhood vaccines by the rolling fund established by the MOPHP for this purpose. This
meant that younger cohorts of children at the time the survey was carried out in 2001 had
a better chance of receiving the vaccine and consequently higher hepatitis B vaccine
coverage.
Knowledge of hepatitis B vaccine by either parent had the most significant association
with hepatitis B vaccine coverage [OR=0.01 (95% Cl 0.002 to 0.11)] and it was
extremely unlikely for children born to parents who had no knowledge of hepatitis B
vaccine to be vaccinated. Nevertheless, it is not known for sure if being vaccinated is the
result of knowledge of hepatitis B vaccine or vice versa (reverse causality). Actually,
having a child vaccinated with hepatitis B vaccine may have resulted in the parents
becoming more knowledgeable about hepatitis B vaccine. In this survey the parents of
only 1 child out of 284 children receiving hepatitis B vaccine did not know of it.
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However, due to the cross-sectional nature of this survey it is difficult to establish a
causal link between parents knowledge and receiving hepatitis B vaccine.
There was a 50% reduction in hepatitis B vaccine coverage amongst children aged 1-3
born from uneducated mothers [adjusted OR=0.55 (95% Cl 0.34 to 0.89)] compared to
educated mothers. The risk in investigating the association between mother's educational
status as an exposure and hepatitis B vaccine coverage as an outcome is the potential for
misclassification of mother's educational status. Mother's educational status was
recorded when completing the interviewer administered questionnaire and later in the
database according to the response of the person interviewed. 63% of mothers
participating in this survey were uneducated and the remaining 37% claiming to be
educated did not show the study investigators evidence of their educational status.
Moreover, 75% of women claiming to be educated could only read or write or had
completed primary school at the best. It may have been difficult for mothers to recall
precisely the number of years spent in education and this was not verified because they
were not requested to show study investigators evidence of educational attainment. As a
result mothers may have underestimated or overestimated their educational status with
study investigators unable to validate their claims to educational status and attainment.
This is of concern because educational differences are commonly reported to be
associated with low vaccination coverage, and therefore it is important to obtain
information on educational status as precisely and accurately as possible. There was also
a lower OR [adjusted OR=0.67 (95% Cl 0.48 - 0.94)] of receiving hepatitis B vaccine
amongst children living in households that did not have a radio compared to households
that had a radio. The association of radio ownership and mothers educational status with
hepatitis B vaccine coverage is most probably explained by these being indicators of
socioeconomic status. In the second multivariable model (table 8.2.2), where radio
ownership, mothers educational status, and all other socioeconomic variables were
substituted with socioeconomic status, this variable was significantly associated with
hepatitis B vaccine coverage (p=0.02) and showed an increased odds of vaccine coverage
with increasing socioeconomic status.
The odds of hepatitis B vaccine coverage was significantly lower amongst children aged
1-3 of mothers who did not receive antenatal care during their pregnancy [adjusted
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OR=0.5 (95% Cl 0.34 to 0.74)] compared to mothers who received antenatal care during
their pregnancy. There was also lower prevalence of hepatitis B vaccine coverage
according to availability of health care factors. Children receiving better health care as
suggested by delivery managed by a qualified medical individual, a hospital-based
delivery, or caesarean section (which was most likely to be done by a qualified individual
in a hospital setting) had approximately twice as high hepatitis B vaccine coverage
compared to children who did not receive this health care. Parents of children delivered
by medically qualified personnel, in health settings, or receiving antenatal care, are likely
to be of a higher educational status, socioeconomic status, and have better health
awareness or access to health services. Such parents come into close contact with health
care professionals allowing them to receive better health education and whether on their
own or according to medical personnel's recommendations are more likely to
subsequently visit health centres for postnatal checkups and to vaccinate their child and
follow up on their children's vaccination schedule.
Hepatitis B vaccine coverage was not the same in the provinces and areas of residence in
the survey. Children living in rural areas had a 50% lower hepatitis B vaccine coverage
(unadjusted OR= 0.44) than children living in urban areas (p=0.04). The higher vaccine
coverage amongst children aged 1-3 living in urban areas compared to children living in
rural areas suggests better availability of hepatitis B vaccine and accessibility to health
services and health care in urban areas, which is in accordance with the phased
introduction of hepatitis B vaccination starting with central health centres. Nevertheless,
when the two urban provinces, Sanaa and Aden, were compared, children living in Aden
were four times more likely (OR=4.22) to receive hepatitis B vaccine than children living
in Sanaa (p=O.OOI), and children aged 1-3 in Aden (56.44%) had more than double the
hepatitis B vaccine coverage than children in Sanaa (23.48%) (p=0.002). This cannot be
explained by health service factors alone such as better availability of vaccine or
accessibility to health services, but is likely to be influenced by individual factors such as
socioeconomic status, higher educational status of mother and father, better attitude and
practice by parents, and better compliance with health care advice. An important finding
supporting this was the significant increase in the prevalence of hepatitis B vaccine
coverage with increasing socioeconomic status (p<0.0001). In accordance, there was a
244
significantly higher proportion of study participants of upper socioeconomic status in
Aden than Sanaa (p=0.01). InAden, 91% of mothers claimed to be educated compared to
49% of mothers in Sanaa (p<0.0001) and 98% of fathers in Aden claimed to be educated
compared to 81% of fathers in Sanaa (p<0.0008). It is noteworthy to mention that female
children appeared to have lower hepatitis B vaccination coverage (22%) compared to
male children (26%) (p=0.04). The adjusted OR of being vaccinated amongst females
aged 1-3 was 0.81 (95% Cl 0.63 to 1.04) indicating a 20% reduction in hepatitis B
vaccine coverage amongst females compared to males. This did not reach statistical
significance but may suggest a bias towards vaccinating males or a bias towards taking
more males to health centres than females increasing their chance of being vaccinated.
Hepatitis B vaccine was highly immunogenic and there was an increase in anti-HBs
positivity and anti-HBs geometric mean concentrations with an increase in the number of
doses of hepatitis B vaccine received. The study investigators did not ask every study
participant about the site hepatitis B vaccine was administered on the body but it was
assumed that all the children received the vaccine on the antero-lateral aspect of the thigh
or biceps muscle. The vaccine effectiveness estimates lead to the conclusion that hepatitis
B vaccination was highly effective in preventing anti-HBc positivity and HBV chronic
infection amongst completely vaccinated children aged 1-3 participating in the survey.
Only one of the completely vaccinated children became anti-HBc positive [0.5% (95% Cl
0.06 to 3.78)] and the OR of becoming anti-HBc positive amongst completely vaccinated
children was 0.17 (95% Cl 0.03 to 1.09) compared to unvaccinated children, which
suggests a highly significant reduction (80%) in anti-HBc positivity indicating that
hepatitis B vaccine is highly effective in preventing HBV infection [VE=83% (95% Cl -
9% to 97%)] even though this barely reached statistical significance (p=0.06). There were
no cases of HBV chronic infection amongst completely vaccinated children which is
suggestive of a vaccine effectiveness of 100%, given the assumption that this protection
was the result of hepatitis B vaccination and that this was not the result of the small
number of HBV chronically infected children found in the survey. This was not
demonstrated in the multivariable case-control analysis of HBV chronic infection
amongst children aged 1-3 because none of the HBV chomic carrier children received
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hepatitis B vaccine, and consequently no odds ratio could be computed to compare them
with the controls. Nevertheless, the high vaccine immunogencitiy and the increasing anti-
HBc GMC with increasing number of doses received is consistent with previous
knowledge and reassuring of hepatitis B vaccine effectiveness. This survey did not
address the time interval been hepatitis B vaccine doses or adherence to the EPI routine
vaccination schedule and its effect on hepatitis B vaccine effectiveness. Actually, vaccine
effectiveness may have been higher than what this survey found if the vaccine schedule
had been strictly adhered to. This survey also did not investigate causes of delayed or
incompletely vaccinated children such as hepatitis B vaccine availability and accessibility
to health services.
An important factor that may have biased the estimate of hepatitis B vaccine coverage in
this survey is the number of children aged 1-3 participating in the survey with no vaccine
information available, especially when vaccine information was related to the
independent variable being examined, which was hepatitis B vaccine coverage. Out of all
the children aged 1-3 participating in the survey 12.96% (16111285) were of unknown
hepatitis B vaccination status. These were children of parents who did not know if their
child participating in the survey received hepatitis B vaccine and did not have a
vaccination card, or children of parents who said that their child did receive hepatitis B
vaccine but did not have written documentation to show the study investigators to
confirm this. To avoid misc1assification of hepatitis B vaccination status, children
reported to have an unknown hepatitis B vaccination status were left as a separate
category in the prevalence estimates presented in section 8.1 of this chapter, and were
excluded from the univariable and multivariable analysis of hepatitis B vaccine coverage.
If, in the unlikely event, a large proportion of these children are hepatitis B vaccinated,
this may result in the survey underestimating hepatitis B vaccine coverage. If on the other
hand, most of these children are unvaccinated against HBV infection this may result in
the survey overestimating hepatitis B vaccine coverage.
Other potential sources of error in the survey estimates of hepatitis B vaccine coverage
may be mistakes in vaccination cards or in parent's memory and response to their child's
hepatitis B vaccination status. At the time of conducting the survey attempts were made
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to keep these errors minimal by combining all children with and unknown or
unconfirmed vaccination status in a separate category (children of unknown vaccination
status) and excluding such children from the univariable and multivariable analysis, and
the analysis of hepatitis B vaccination coverage and effectiveness. In order to assess the
extent of mistakes occurring in vaccination cards, on some occasions, these were verified
by referring to the vaccinating health centre. In a few districts in the survey the
vaccination status of children participating in the survey with doubtful vaccination cards
was checked and compared to their vaccination records in their vaccinating health
centres. The finding of this exercise were reassuring. Recall and interviewer bias was
unlikely considering study participants and investigators were blind regarding the child's
HBV infection status at the time of completing the interviewer administered
questionnaire. Moreover, the consistency in the immunologic response (anti-HBs
positivity) amongst vaccinated children according to the number of doses of hepatitis B
vaccine received is highly reassuring with regard to the correct classification of study
participants according to number of doses of vaccine received as well as serological assay
predictability.
Given the hepatitis B vaccination coverage estimates of this survey it is concluded that
hepatitis B vaccine coverage in Yemen is low. A few factors have been found to be
significantly associated with hepatitis B vaccine coverage and it is important that these
factors are taken into consideration by the Yemeni MOPHP in its necessary attempt to
increase vaccination coverage. Firstly, the MOPHP must acknowledge and voice that the
low educational status of women is an obstacle hindering high hepatitis B vaccine
coverage and emphasise the importance of improving the educational status of women in
Yemen if vaccine coverage is to be increased. This is an extremely difficult task which is
not directly under the control and influence of the MOPHP, and requires political
commitment and multi-sectoral governmental collaboration. Secondly, health education
programmes and messages must have two main objectives; increasing awareness about
vaccines generally and hepatitis B vaccine specifically, and increasing antenatal visits
and the proportion of women attending for antenatal care during pregnancy (currently
45%), with an emphasis on rural areas, and targeting these women with the appropriate
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health care and education programmes ensuring that they understand the importance of
hepatitis B vaccination so that they return after delivery to vaccinate their children.
Thirdly, when designing any health education programmes or messages the educational
status and attainment of the target population must be taken into consideration in order to
design messages appropriate to the target population. Additionally, health education
programmes must utilise the appropriate method, which in this case is radio broadcasting,
to convey its message to the target population. There was 33% lower hepatitis B vaccine
coverage in households that did not have a radio [adjusted OR=0.67 (95% Cl 0.48 to
0.94)]. With over 65% of all households and 60% of rural households possessing a radio
in Yemen, this is a highly attractive way of conveying messages to the population which
is dispersed over 65,000 rural villages and hamlets. Finally, all of this will not have a
sustainable impact unless the MOPHP ensures a continuous supply of hepatitis B vaccine
in all its health centres. Availability and accessibility to health centres with an equitable
distribution for the general population is essential. This survey was not conducted with
the intention of analysing health care infrastructure, provision, or accessibility to health
services in Yemen nor is there an intention to claim that it did. With regard to the target
population for hepatitis B vaccination, the MOPHP must reconsider its objective of
vaccinating children under 1 year because by not offering the vaccine to older children
the MOPHP is missing out on the opportunity of vaccinating children who did not visit
health centres when they were less than 1 year old but did visit later in childhood. This
will have financial implications but the feasibility of this should be investigated.
Recently, the MOPHP decided to introduce a new pentavalent vaccine to its routine
immunisation programme which will result in changing the current hepatitis B
vaccination schedule. Considering the pentavalent vaccine will reduce the number of
injections given to a child during each visit, this new vaccine is likely to increase parental
acceptance and uptake and consequently vaccine coverage. This will depend on the
availability of a sustainable supply of vaccines, minimal side effects of the vaccine, and
no widely publicised vaccine scares, such as what happened previously with hepatitis B
vaccine. If the introduction of the pentavalent vaccine is successful, due to health service
and population factors, this is likely to increase hepatitis B vaccine and haemophilus
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influenzae vaccine coverage to the same level of vaccine coverage as DPT, if not
increasing overall vaccine coverage to levels better than current levels. If, on the other
hand, introduction is not successful this may compromise the existing vaccines provided
in the routine EPI. This indicates the importance of careful planning, preparation and
campaigning for the introduction of the pentavalent vaccine to the EPI in Yemen.
Currently, there is already a delay in introducing the vaccine because there is a delay in
provision of the pentavalent vaccine by the manufacturer unti12004.
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Chapter 9: Discussion and Recommendations:
This chapter starts with a discussion of the methodological issues in the study. This is
followed by a discussion of the most important research findings of this survey, their
interpretation and implications. A summary of the research findings is presented,
fulfilling the research objectives. Finally a number of recommendations are made based
on the research findings in the context of national and international evidence.
9.1 Discussion:
This is the first community-based household seroepidemiological survey to investigate
HBV infection in Yemen. Previous studies investigating HBV infection in Yemen were
mainly hospital-based surveys conducted in urban areas of the country. This is also the
first survey of its nature to estimate hepatitis B vaccine coverage and vaccine
effectiveness amongst children in Yemen.
This survey also investigated the association of demographic factors and variables with
anti-HBc positivity and HBV chronic infection with the intention of providing a better
understanding of the epidemiology of HBV infection in Yemen, information that is
essential for guiding health policy formulation. Some of the factors that were
investigated, for example, educational status, age, and socioeconomic status, were found
associated with HBV infection, which was consistent with research findings carried out
in the Middle East. Other well-recognized risk factors associated with HBV infection
identified in previous studies amongst hospital populations in Yemen, and internationally,
such as history of blood transfusion or surgery, injection practices, haemodialysis, and
history of jaundice were not investigated in this survey because these are more specific to
high risk groups and less relevant to the general population especially children.
It is expected that the estimates of anti-HBc positivity and HBV chronic infection
amongst children aged 1-3, children aged 4-9, and women of childbearing age obtained
from this survey in Yemen are reliable, accurate, valid, and generalisable. There is no
reason to believe that the results of this study are biased. Selection bias is expected to be
minimal considering all children participating in the survey were randomly selected
based on probability proportional to size giving all children of the population an equal
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chance of being selected. All women of childbearing age participating in the survey were
mothers of children aged 1-3 participating in the survey. There were two categories of
women who could not be included in the sample population of this survey. The first
category were women without a child aged 1-3 and the second were women with a child
aged 1-3 but who could not be recruited because they or their child were not present at
home at the time the study investigators visited their household. The main reason women
might not have a child is infertility. This could be related to a history of sexually
transmitted infection and thus might be associated with hepatitis B infection. However,
this would not produce a major selection bias. The second category of women, women
absent from home on the day their household was surveyed, were uncommon, probably
due to the small number of women in paid employment. Throughout the survey study
investigators only came across a few households within this category. The women who
were not in their households at the time their household was surveyed were either visiting
neighbours, were shortly gone shopping or on errands, or farming. Study investigators
waited while household members went to call mothers/children visiting neighbouring
households, or marked and visited households of women away on errands or farming
later on that day. Study investigators did come across a few households where mothers
and their children travelled away to attend a wedding or visit relatives, and households
where there was a child aged 1-3 whose mother had unfortunately died, and
consequently, these could not be included in the survey, but this was uncommon. Other
factors contributing to minimising selection bias were the high response rate attained
(over 80%), comprehensive training of study investigators on household sampling
methodology, and the blindness of study investigators to the HBV infection status of
potential study participants.
On the other hand, self-selection bias was avoided because study participants were
randomly included in the survey based on probability proportional to size, and not
according to potential study participants wishes. Study investigators did come across
potential study participants who refused to participate in the survey for various reasons
such as suspecting that study investigators intended to sell their blood after it was
collected, suspecting the injections used to withdraw the blood samples caused infertility,
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or not wanting to give personal information or details of their household and possessions
to an unknown person. Nevertheless, the presence of local facilitators, health workers and
pre-arrangements with local leaders minimized refusal in rural areas whereas higher
educational attainment helped minimize refusal in urban areas.
Strict laboratory procedures and quality control minimised measurement bias. Two other
potential sources of bias in this survey were information and recall bias. Interviewer bias
was minimized because before carrying out the survey study investigators were trained in
conducting and interpreting responses to an interviewer administered questionnaire.
Throughout the interview study investigators, systematically asked identical questions.
Recall and interviewer bias with reference to the HBV infection estimates of the survey
were avoided because both interviewer and respondent were blind to the HBV infection
status of the study participant. Recall and interviewer bias resulting in misclassification
with reference to hepatitis B vaccine coverage were avoided because data on vaccination
status was only based on what was recorded on vaccination cards not on what
respondents reported. An important factor that may have biased the estimate of hepatitis
B vaccine coverage in this survey is that 13% of children aged 1-3 participating in the
survey had no vaccine information available. If, in the unlikely event, a large proportion
of these children had received hepatitis B vaccine, this would result in the survey
underestimating hepatitis B vaccine coverage. If on the other hand, most of these children
did not receive hepatitis B vaccine this may result in the survey overestimating hepatitis
B vaccine coverage.
A major concern, as described previously, was the reduction in the study's power to
detect statistically significant differences or associations even when there were increased
or decreased odds ratios. This was the result of the much lower number of anti-HBc
positive and HBV chronically infected study participants amongst children aged 1-3 and
children aged 4-9 participating in the survey than was initially expected.
Another important concern was potential HBV chronic carrier misclassification. This
resulted from a few cases (three cases) of repeatedly reactive HBsAg samples that were
simultaneously repeatedly anti-HBc negative. These were considered non-specific
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reactive false HBsAg positives and were classified HBsAg negative in subsequent
analysis. This was based on information from Abbott Laboratories, the low SIN ratio of
these samples, and advice from Professor Richard Tedder virologist at University College
London. Another source for potential misclassification was in measuring mothers and
fathers educational status and level of education. Mothers and fathers level of education
was recorded according to what they claimed their level of education to be. Study
investigators did not request study participants to show them their educational certificates
or evidence of their educational attainment. If there was a tendency for study participants
to misinform study investigators this may have passed unnoticed. However, parents with
high educational attainment were clearly noticed during interviews and study
investigators carefully investigated parents claims to their level of education or
educational status if they appeared to be less or more educated during the interview than
they claimed to be.
Representative controls were included in the analysis of anti-HBc positivity and HBV
chronic infection amongst children aged 1-3, children aged 4-9, and mother's. The
controls in the case-control univariable and multivariable analysis of anti-HBc positivity
and HBV chronic infection were all children or mothers uninfected with HBV
participating in the survey, and thus a subset of the sample population. These are unlikely
to differ from the cases considering they were selected at the same time, from the same
population, and based on the same criteria as children and mothers who were
subsequently diagnosed as anti-HBc positive or HBV chronic carrier women and
therefore are considered an appropriate comparative group.
A potential weakness resulting from the cross-sectional nature of this survey is that
associations found in the case-control analysis between outcome variables and exposure
variables were measured at the same point in time. This potentially led to
misinterpretation of the causal relationship between exposure and outcome. For example,
mothers HBV infection status and HBV infection amongst children aged 1-3 were
measured at the same time, and based on the association between these two variables the
proportion of childhood infections arising from the mother was determined.
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Generally speaking, and relative to pre-survey expectations, the results of this study are
encouraging with regard to the prevalence of anti-HBc positivity and HBV chronic
infection amongst all three age-groups investigated in the study but disappointing with
regard to hepatitis B vaccine coverage.
The prevalence estimate of HBV chronic infection amongst women of childbearing age
participating in the survey is considered representative of the prevalence of HBV chronic
infection amongst adults in the general population. This prevalence estimate is much
lower than estimates from previous hospital-based studies in Yemen showing the
prevalence of HBV chronic infection to range from 12.5% to 16.6% amongst pregnant
women (Abdul Raheem et al., 1991; El-Guneid et al., 1993; Scott et al., 1990). However,
these results are not surprising when considering that the population targeted in this
community-based survey is different from the hospital-based populations targeted in
previous surveys in Yemen who may have a higher risk of HBV infection than the
general population, as well as laboratory quality control procedures that may have
differed between this survey and the earlier surveys in Yemen. Based on the results of
this survey it cannot be ruled out, however, that some pocket populations such as the
African community in Sanaa or inhabitants of Socotra island did not have a higher
prevalence of HBV infection, and therefore, may require specific vaccination policies.
This surveys prevalence estimate barely places Yemen amongst the group of countries
with a high endemicity of HBV infection. This is contrary to earlier estimates suggesting
Yemen is amongst the group of countries in the upper range of highly endemic or
hyperendemic for HBV infection (El-Guneid et al., 1993; Scott et al., 1990). In fact, this
prevalence estimate of HBV chronic infection amongst mothers in Yemen makes the
endemicity of HBV infection in Yemen consistent with the endemicity of HBV infection
in other Middle-Eastern countries in the region such as Saudi Arabia, Kuwait, Lebanon,
Tunisia and Iran (Al-Nakib et al., 1986; Amini et al., 1993; Basalamah et al., 1984;
Coursaget et al., 1994; Nabulski et al., 1997; Ramia et al., 1984).
The prevalence estimates of anti-HBc positivity and HBV chronic infection amongst the
three groups of study participants show an increasing risk of exposure to HBV infection
with increasing age. It is not possible in this cross sectional survey to know whether this
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is due to a fall in childhood infection with time (a birth cohort effect) or evidence of
increasing infection with age. However the fact that HBV chronic infection is reasonably
constant by age in women whilst cumulative infection increases suggests that it is an
effect of continuing exposure to the virus in adult life. Regardless of the initial extent of
perinatal transmission of HBV infection amongst children aged 1-3, there appears to be
childhood transmission of HBV infection occurring amongst the children aged 4-9, as
indicated by the higher prevalence amongst this age-group of children relative to the
baseline prevalence amongst children aged 1-3, and by the increasing prevalence ofHBV
infection across the age-groups extending from 4-9. The importance of childhood
transmission has been supported by other studies in the Middle East (Amini et al., 1993;
Arya et al., 1985; Ramia, 1990). The higher prevalence of HBV infection amongst
mothers relative to children aged 4-9 suggests that there is transmission of HBV infection
during adult life. The mode of transmission of HBV infection in adult life is not known.
This may be through sexual transmission between married couples, at the time of
childbirth through contaminated equipment (e.g. used razors to cut umbilical cord) used
by unqualified individuals in non-health setting, or unsafe injection practices. Anecdotal
evidence suggests that health facilities do not incinerate waste products posing a health
and safety haphazard, especially to children living near health facilities. For example, in
one health centre visited exposed used needles were seen on the ground outside the
windows of health centre consulting rooms. No further comments can be made about the
extent of sexual and parenteral transmission based on this survey because it was not
initially designed to investigate these modes of transmission. It is recommended that
studies be undertaken to investigate these modes of transmission as well as emphasising
on the importance of enforcing the basic health and safety guidelines to prevent them.
The prevalence of anti-HBc positivity and HBV chronic infection amongst children aged
1-3, children aged 4-9, and mothers in Yemen is shown in figure 9.1.1.
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Figure 9.1.1
Prevalence of anti-HBc positivity and HBV chronic infection amongst children aged 1-3,
children aged 4-9, and mothers in Yemen
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The low prevalence of HBV chronic infection (0.99%) amongst children aged 1-3
participating in this survey suggests that perinatal transmission is unlikely to be a major
mode of HBV transmission in Yemen. This is contrary to earlier studies suggesting that
perinatal transmission may play an important role in HBV transmission in Yemen (Abdul
Raheem et al., 1991; El-Guneid et al., 1993). The low rate of perinatal transmission of
HBV infection is mainly the result of both the low prevalence of HBV chronic infection
amongst women of childbearing age and the low prevalence of HBeAg positivity
amongst these HBV chronic carrier women (i.e. HBV chronic carrier women with low
infectivity). In this survey, 5.08% of mothers were HBV chronic carriers (only one-third
the prevalence suggested by earlier studies), which clearly reduces the prevalence of
HBV chronic carrier mothers in Yemen. Moreover, only 12.84% (95% Cl 6.12 to 24.99)
of HBV chronic carrier mothers were HBeAg positive, which reduces the pool of highly
infectious HBV chronic carrier mothers in Yemen to one-third of what was previously
reported (El-Guneid et al., 1993). Additionally, only 21% (2/8) of HBeAg positive
chronic carrier mothers had HBV infected children confirming a low rate of perinatal
transmission of HBV infection from these mothers. This is in contrast to HBeAg positive
mothers in Southeast Asia where 70 - 90% of children born to these women became
HBV chronic carriers (CDC, 1991; Hall, 1994; Hwang et al., 1985). This lower risk of
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transmitting HBV infection to the offspring of HBeAg positive women in Yemen follows
a pattern similar that observed amongst HBeAg positive African women (Hall, 1994),
however, this survey did not measure HBV DNA concentrations amongst the HBeAg
positive women because this test was not available in Yemen. The low prevalence HBV
chronic infection amongst mothers, the low prevalence of HBeAg positive chronic carrier
mothers, and the low transmission ofHBV infection from HBeAg positive chronic carrier
mothers to their children (21%) in this survey provides evidence that Yemen follows the
pattern of studies suggesting that perinatal transmission is not a major mode of
transmission of HBV infection in the Middle East (Basalamah et al., 1984; Coursaget et
al., 1994; Ramia et al., 1988; Toukan, 1996), and that perinatal transmission is not a
major contributor to the pool of HBV chronic carriers in Yemen. This is further
supported by the low prevalence ofHBV chronic infection amongst children aged 1-3.
This indicates there is no need to introduce an additional birth dose of hepatitis B vaccine
or hepatitis B immunogloblulin (HBIG) nor is there need to amend the current schedule
of hepatitis B vaccine administered in the EPI in order to prevent perinatal transmission
ofHBV infection. This solves for the MOPHP the problem of having to provide the funds
and logistics involved in introducing a birth dose of hepatitis B vaccine or HBIG, and
avoids the incremental cost resulting from the introduction of a fourth dose of hepatitis B
vaccine. The Yemeni EPI states in its plan for the introduction of hepatitis Band
Haemophilus influenzae type b vaccines to its routine vaccination schedule that it is
unknown if a birth dose of hepatitis B vaccine is necessary to prevent perinatal
transmission of HBV infection (MOPHP(A), 2001). It also states that if it is proven that a
birth dose is needed this will be extremely difficult to implement considering only 16 out
of every 100 children are delivered at a health facility. This makes it extremely difficult
to ensure a birth dose of hepatitis B vaccine for children delivered at home within 24
hours of delivery to prevent mother-to-child transmission of HBV infection. In this plan it
was recommended that a study needed to be done to investigate perinatal transmission of
HBV infection. Considering that this survey has already been conducted and has
answered the questions needed for the MOPHP to make an evidence-based policy
decision, it is no longer necessary for the MOPHP to conduct such a survey.
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The prevalence of anti-HBc positivity amongst males was higher than females aged 1-3
but this was not significant, whereas, the prevalence of HBV chronic infection was
similar amongst males and females aged 1-3. On the other hand, there was a higher
prevalence of HBV infection amongst females aged 4-9 compared to males but this was
not significant. These observed differences are unlikely to be due to better access to
hepatitis B vaccination by males. First of all, hepatitis B vaccination was not available
when these children received their routine vaccinations, and secondly, there was no
evidence suggesting a major difference in hepatitis B vaccine coverage between males
and females participating in the survey. A similar finding was observed in Colombia
amongst girls older than 10 years and a suggested explanation was that these girls had a
higher exposure to HBV infection as a result of initiating sex early in life (De La Hoz,
2002). This is unlikely to be the explanation in this survey considering the younger age of
the females (aged 4-9) participating in it. This is consistent with results found in a
number of studies reported from Saudi Arabia that did not find significant evidence of
higher anti-HBc positivity or HBV chronic carrier rates amongst males (Al-Faleh., 1992;
El-Hamzi, 1989; Parande et al., 1986). Similarly, a WHO collaborative study in 20
countries did not find a significant difference in the prevalence of HBV chronic infection
by sex (Sobeslavsky, 1980).
This survey did not show evidence of a statistically significant difference in the
prevalence of anti-HBc positivity and HBV chronic infection amongst mothers, children
aged 1-3, and children aged 4-9 when comparing all five provinces, three rural provinces,
or two urban provinces in the survey. This was most probably the result of the small
number of anti-HBc and HBsAg positive study participants, which when divided across
the five provinces diminished the power of the study to detect a statistically significant
difference, not the result of the absence of a true difference. Figure 9.1.2 shows the
prevalence of anti-HBc positivity amongst children aged 1-3, children aged 4-9, and
mothers by province of residence in Yemen. It seems likely that had sample sizes been
greater the rates in Aden would have been statistically significantly lower than other
provinces.
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Figure 9.1.2
Prevalence of anti-HBc positivity amongst children aged 1-3, 4-9, and mothers by province
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There were no cases of HBV chronic infection amongst the 247 children aged 1-3 In
Aden, 90 children aged 4-9 in Aden, or 75 children aged 4-9 in Shabwa. Figure 9.1.3
shows the prevalence ofHBV chronic infection amongst children aged 1-3, children aged
4-9, and mothers by province in Yemen.
Figure 9.1.3
Prevalence of HBV chronic infection amongst children 1-3,4-9, and mothers by province
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Variables found to be statistically significantly associated with HBV infection by
multivariable analysis were the increasing OR of anti-HBc positivity amongst mothers
with increasing age (p=O.OOOI),the increased OR of HBV chronic infection amongst
children aged 1-3 delivered by an unqualified individual, the decreasing OR of HBV
infection amongst children and mothers associated with socioeconomic status, and the
association between HBV infection amongst children aged 1-3 and the HBV infection
status of the mother.
The association between age and HBV infection was discussed earlier in this chapter.
Delivery of a child aged 1-3 by an unqualified individual was a risk factor for HBV
chronic infection. What added to the strength of this finding was that children delivered
in a home setting had an increased risk of HBV infection. A similar association between
the increased OR ofHBV chronic infection and delivery by an unqualified individual was
observed in Colombia, and it was suggested that practices at the time of birth carried-out
by unqualified persons such as cutting the umbilical cord may increase the child's risk of
HBV infection (De La Hoz, 2002). Another possible explanation was that such children
were less likely to receive hepatitis B vaccine. There is room to intervene and reduce the
risk of HBV infection amongst children delivery by unqualified individuals. This can be
reduced by designing massive health education campaigns promoting delivery in health
facilities and by medically qualified personnel (whether this may be at a health or home
setting). This is not expected to have substantial resource requirements or implications
considering that health facilities are already available across the country and are staffed
with medically qualified individuals. This would also serve as an opportunity to educate
parents about the importance of vaccination and enrol their children into routine
vaccination programmes, and with a potential to consequently increase vaccination
coverage. Such a strategy would also make a birth dose of hepatitis B vaccine more
attainable ifthere was evidence that this was needed (e.g. infants of HBV chronic carrier
mothers). Traditional birth attendants, on the other hand, should be invited and
encouraged to attend training courses on sterile, aseptic, and safe delivery methods, and
motivated to do so by issuing them training certificates and reimbursing their travel and
accommodation expenses.
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In the multivariable analysis of HBV infection amongst children aged 1-3 and mothers,
fridge/freezer, home telephone, and television were three household possessions found to
be statistically significantly associated with HBV infection after adjusting for the
remaining variables in the model. Fridge/freezer ownership was significantly associated
with anti-HBc positivity and HBV chronic infection amongst mothers, home telephone
ownership was significantly associated with anti-HBc positivity amongst mothers, and
television ownership was significantly associated with anti-HBc positivity amongst
children aged 1-3. Not owning these household possessions was associated with a
statistically significantly increased OR ofHBV infection. There is no known direct causal
relationship between these three household possessions and HBV infection. Nevertheless,
their association with HBV infection was most probably indirect, by these variables being
indicators of socioeconomic status and well-being. When these variables, as well as the
remaining socioeconomic indicator variables were removed from the multiple logistic
regression analysis and substituted with the socioeconomic status variable, there was a
statistically significant association between this variable and anti-HBc positivity amongst
mothers and children aged 4-9, as well as HBV chronic infection amongst mothers. In
other words, the socioeconomic status variable had a similar association with anti-HBc
positivity and HBV chronic infection amongst mothers and children aged 1-3 as the three
socioeconomic indicator variables mentioned above. Moreover, the socioeconomic status
variable was also found to be significantly associated in the multivariable analysis with
anti-HBc positivity amongst children aged 4-9. Failure of the association between anti-
HBc positivity and HBV chronic infection amongst children aged 1-3, and the
socioeconomic status variable reaching statistical significance was probably due to an
insufficient power to detect a significant association and not due to the absence of a true
association. There were only 11 and 9 HBV chronic carrier children aged 1-3 and 4-9,
respectively, which is less than half the number of cases that were expected to be
identified in the survey. On the other hand, there were 59 HBV chronic carrier mothers,
and this larger number of mothers, relative to the number of HBV chronic carrier
children, provided a power sufficient to detect a statistically significant association of
HBV chronic infection with the socioeconomic status variable. The association found
between hepatitis B vaccination coverage and the socioeconomic status variable
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described later in the discussion adds to the strength and reliability of this variable in
socioeconomic classification. This is consistent with findings from studies conducted in
other Middle East countries that show a clear association between HBV infection and
socioeconomic status (Awidi et al., 1984; Ghaffar et al., 1989 Toukan et al., 1990;
Toukan, 1996; WHO, 1995).
Despite the small number of anti-HBc positive and HBV chronic carrier children aged
1-3 identified in this survey, the study did demonstrate the important and significant
association between HBV infection amongst children aged 1-3 and the HBV infection
status of the mother. The adjusted OR of anti-HBc positivity amongst children aged 1-3
born from anti-HBc positive mothers was 3.97 (95% Cl 1.38 to 11.43) and the OR of
anti-HBc positivity amongst children aged 1-3 born from mothers chronically infected
with HBV was 7.84 (95% Cl 3.78 to 16.25). Preventing HBV infection amongst children
delivered from HBV infected mothers is a more difficult task than reducing the risk of
HBV infection amongst children associated with delivery by unqualified individuals.
First, of all, there is no means of identifying who are the children at risk, at risk children
becoming infected before they are protected, and the extreme difficulty in reaching at risk
children widely dispersed across the country. A possible solution for identifying at risk
children would be to screen all pregnant women for HBV chronic infection. Considering
that less than half the pregnant women receive antenatal care during pregnancy in Yemen
and the enormous costs involved in introducing an antenatal screening programme in a
country with one of the highest fertility rates in the world, a screening programme will
not appear to be an attractive option for the government of Yemen or international
donors. Nevertheless, and regardless of HBV infection, the government of Yemen must
act, quickly and effectively, to reduce the total fertility rate and consequently the
population growth rate that will only put more strain on the already struggling public and
natural resources in the country.
This survey provides the first as well as the only independent estimate of hepatitis B
vaccine coverage in Yemen. The only estimates of hepatitis B vaccine coverage prior to
this survey are those presented by the Yemeni EPI. The EPI reported that 42% of children
below the age of one year received at least one dose of hepatitis B vaccine and 14.8% of
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children were completely vaccinated (MOPHP(B), 2001). The overall prevalence of
children aged 1-3 participating in this survey completely vaccinated with hepatitis B
vaccine [8.63% (95% Cl 5.1 to 14.24)] or receiving at least one dose of hepatitis B
vaccine [21.1% (95% Cl 15.81 to 27.58)] was lower than what was reported and
expected. These estimates are much lower than vaccine coverage with the remaining EPI
vaccines in Yemen (MOPHP(B), 2001), and much lower than hepatitis B vaccine
coverage estimates from other countries in the Middle East (Toukan, 1997).
Also disappointing was the large proportion of incompletely vaccinated children [12.47%
(95% Cl 9.72 to 15.85)], that is, children receiving one or two doses of hepatitis B
vaccine failing to complete their vaccination schedule. If all these children were
completely vaccinated, this would have increased the proportion of completely
vaccinated children to more than double its current level. It is unknown why these
children did not complete their vaccination schedule nor was this survey designed to
investigate this. Possible causes may be divided into health service factors (such as
availability of vaccine and accessibility to health services) and individual factors (such as
knowledge, attitude, and practices). These factors are likely to be responsible for the
observed marked variation in hepatitis B vaccine coverage between the five provinces in
the survey, between the urban versus rural provinces in the survey, and between the two
urban provinces in the survey. The variation in hepatitis B vaccination coverage by
province and area of residence suggests an inequitable distribution, availability or
accessibility to primary health care services in Yemen. It has already been pointed out
that this survey did not investigate health services in Yemen and nor did this survey
investigate the attitude and practice of parents regarding hepatitis B vaccination. For
example, it is not known if parents of unvaccinated children were willing but unable to go
to vaccination centres or if these parents refused to do so because of religious or cultural
beliefs, or otherwise. However, vaccination coverage estimates indicate a bias towards
better provision, or at least uptake, of hepatitis B vaccine, and possibly all EPI services,
in urban areas. After more than four years of hepatitis B vaccination this cannot be
attributed to the phased introduction of hepatitis B vaccination which started with the
major health centres in governorates. Figure 9.1.4 shows hepatitis B vaccine coverage
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with at least one dose of hepatitis B vaccine amongst children aged 1-3 participating in
the survey by province of residence.
Figure9.1.4
Prevalence of hepatitis B vaccination amongst children aged 1-3 by province
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The prevalence of hepatitis B vaccination amongst children aged 2-3 (17.85%) was lower
than vaccine coverage amongst children aged 1-2 (30.32%) (p=0.0007) and is most
probably the result of the EPI policy of providing hepatitis B vaccine free of charge only
to children under 1 year old. This was confirmed in the multivariable analysis which
showed that younger children had a higher odds of being vaccinated with hepatitis B
vaccine (p=0.006). On the other hand, the overall prevalence of hepatitis B vaccine
coverage amongst children aged 4-9 participating in the survey was only 1.91% (95% Cl
0.7 to 5.1) (with at least one dose of hepatitis B vaccine), which is simply explained by
the fact that these children were not targeted or offered hepatitis B vaccine.
The number of children anti-HBs positive and their anti-HBs geometric mean
concentration (GMC) was proportional to the number of doses of hepatitis B vaccine
received. There was a clear increase in the proportion of anti-HBs positive children and
anti-HBs geometric mean concentration with increasing number of doses of hepatitis B
vaccine received. This validates the recording of hepatitis B vaccination doses. It also
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indicates that hepatitis B vaccine was highly immunogenic amongst children aged 1-3
participating in the survey and that there is no need to change the current dose or
schedule of hepatitis B vaccination in Yemen. Figure 9.1.5 shows hepatitis B vaccine
immunogenicity and anti-HBs GMC amongst children aged 1-3 by number of doses of
hepatitis B vaccine.
Figure 9.1.5
Hepatitis B vaccine immunogenicity and anti-HBs GMC amongst children aged 1-3
by number of doses of vaccine
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The effectiveness of hepatitis B vaccine was 83% (95% Cl -9 to 97%) in preventing
anti-HBc positivity and 100% (95% Cl lower limit is 97%) in preventing HBV chronic
infection amongst completely vaccinated children aged 1-3 participating in the survey.
Although this did not reach statistical significance, what is reassuring is the high
immunogenicity of hepatitis B vaccine and GMC presented in figure 9.1.5. This indicates
that the vaccine effectiveness failing to reach statistical significance was the result of the
low number of anti-HBc positive and HBV chronic carrier children not because of
vaccine ineffectiveness. Ideally, this should be repeated on a sample involving a larger
number of vaccinated children, but meanwhile if a high percentage of hepatitis B vaccine
coverage is achieved, the difficulty may then become identifying unvaccinated children
of the same age-group. What this survey did not measure was the effect of dose intervals
or site of administration of vaccine on the immunogenicity and effectiveness of hepatitis
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B vaccine. Figure 9.1.6 shows HBV infection amongst children aged 1-3 participating in
the survey by number of doses of hepatitis B vaccine.
Figure 9.1.6
HBV infection amongst children aged 1-3 by number of
doses of hepatitis B vaccine
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Given the above, the current level of hepatitis B vaccine coverage is unsatisfactory. It is
extremely important to increase hepatitis B vaccine coverage and achieve a pre-specified
target of high vaccine coverage. What is encouraging with regard to increasing hepatitis
B vaccine coverage in the near future is the introduction of the pentavalent vaccine. This
will reduce the number of injections and visits needed for children to receive all three
doses of hepatitis B vaccine. Considering that these children will receive all doses of
hepatitis B vaccine according to the new pentavalent vaccine schedule (6 weeks, 10
weeks and 14 weeks) at the same time as DPT, this should increase coverage with
hepatitis B vaccine to a level similar to coverage with DPT vaccine which is currently
72.8% (MOPHP(A), 2001; MOPHP(B), 2001).
Equally important to increasing vaccination coverage is ensure that once achieved, this
level of coverage is sustainable. This requires strong managerial, financial and political
commitment, all of which are unlikely to be readily available considering the worsening
economic situation in Yemen. The situation will probably be more complicated in the
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future when support provided from the global alliance for vaccines and immunisation
(GAV!) ends unless the MOPHP designs a sound financial sustainability plan well in
advance. Independent variables found to be significantly associated with hepatitis B
vaccine coverage amongst children aged 1-3 after adjusting for the remaining variables
were age of the child, knowledge of hepatitis B vaccine, receiving antenatal care during
pregnancy, mothers educational status, ownership of a radio, and socioeconomic status.
These variables and their associations with hepatitis B vaccine coverage were discussed
in chapter 8 and this will not be repeated. What needs to be said here is that any health
education programmes designed to improve vaccine uptake or increase vaccine coverage
must take these factors/variables into consideration. For example, the increased OR of
vaccine coverage amongst women receiving antenatal care during pregnancy indicates
that more women should be encouraged to receive antenatal care. These women should
then be targeted and encouraged to have their newborn children fully vaccinated. Taking
this one step further, what would be the best way to reach these women? The associations
above suggest that health education programmes utilising the radio should be given
priority over other media considering radio ownership was associated with higher
hepatitis B vaccine coverage whereas television ownership was not. Moreover, 65% of
households participating in the survey had radios whereas 59% of households had a
television. Additionally, only 45% of rural households had a television compared to 60%
or rural households that had a radio. Nevertheless, one must not forget that radio
ownership is also an indicator of socioeconomic status, which showed an increase in
vaccine coverage with increasing socioeconomic status. The strong association between
knowledge of hepatitis B vaccine and vaccine coverage may lead one to believe that the
solution to increase vaccine coverage is increasing knowledge about hepatitis B vaccine.
Why then, although 78% of parents claimed to have knowledge of hepatitis B vaccine
and 32% of parents said their child received hepatitis B vaccine, in reality a lower
percentage of children were really vaccinated. These questions remain unanswered and
qualitative surveys are needed to investigate these issues as well as the health seeking
behaviour of the Yemeni population.
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9.2 Summary:
1- HBV infection in Yemen is not as major a public health problem as was originally
expected. Initially, it was expected that approximately 15% of adults in the
general population would be HBV chronic carriers. There was an increase in the
prevalence of HBV infection with increasing age. The prevalence of HBV chronic
infection amongst adults (women of childbearing age) in the general population
barely places Yemen amongst the group of countries with a high endemicity of
HBV infection (> 5%).
2- There was no evidence of a statistically significant difference in the prevalence of
anti-HBc positivity and HBV chronic infection amongst women of childbearing
age, children aged 1-3, and children aged 4-9 when comparing the five provinces
in the survey.
3- There was evidence that perinatal transmission is not a major mode of
transmitting HBV infection in Yemen. This is mainly the result of both a low
prevalence of HBV chronic infection amongst women of childbearing age, a low
prevalence of HBeAg amongst these HBV chronic carrier women (i.e. chronic
carrier women with low infectivity), and low transmission of HBV infection from
HBeAg positive mothers.
4- Variables associated with HBV infection amongst mothers were age of the mother
and socioeconomic status. Variables associated with HBV infection amongst
children were mothers HBV status, socioeconomic status, and qualifications of
the person managing delivery of the child.
5- The overall level of hepatitis B vaccination coverage amongst children aged 1-3
participating in the survey was low.
6- A high proportion of children were incompletely vaccinated (one or two doses)
and had an unknown vaccination status.
7- There was a significant difference in the prevalence of hepatitis B vaccine
coverage amongst children aged 1-3 between the five provinces and areas of
residence in Yemen. The figures of vaccination coverage suggest an inequitable
distribution, availability or accessibility to primary health care services, with a
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bias towards better provision, or at least uptake, of primary health care services in
urban areas.
8- Hepatitis B vaccine was found to be highly immunogenic amongst children aged
1-3. The number of children anti-HBs positive and their anti-HBs GMC was
proportional to the number of doses of hepatitis B vaccine received.
9- Hepatitis B vaccine had a vaccine effectiveness of 83% (95% Cl -9 to 97%) in
preventing anti-HBc positivity and a vaccine effectiveness of 100% (95% Cl
lower limit is 97%) in preventing HBV chronic infection amongst completely
vaccinated children aged 1-3 participating in the survey.
9.3 Recommendations:
9.3.1 Recommendations to the MOPHP/EPI in Yemen:
Recommendations based on the findings of this survey:
1- The MOPHP should quote the prevalence estimates of HBV infection found in
this survey when presenting estimates of the prevalence of anti-HBc positivity
and HBV chronic infection amongst the general population and children in
Yemen.
2- The MOPHP should disseminate the prevalence estimates of HBV infection and
vaccine coverage found in this survey to the relevant national and international
bodies such as WHO, international organisations and donors, educational
institutions, health care personnel and workers, and health authorities. This can be
achieved through the mass media, MOPHP health education programmes, and
national and international conferences with the objective of updating Yemen's
profile of HBV infection and hepatitis B vaccine coverage, and correcting the
current widespread false belief that 18% of adults in the general population are
chronically infected with HBV.
3- There is no need to introduce a birth dose of hepatitis B vaccine or HBlG
considering the evidence from this survey suggesting that perinatal transmission is
not a major contributor to HBV transmission in Yemen.
4- The EPl should increase its unsatisfactory current hepatitis B vaccine coverage.
The MOPHP should set targets to be achieved as well as process indicators to
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monitor progress towards meeting these targets. The current EPI 5-year-plan set a
target to achieve 90% hepatitis B vaccine coverage by the end of 2006. This
appears to be an optimistic target but may be more realistic following introduction
of the new pentavalent vaccine which is likely to improve hepatitis B vaccine
uptake to levels similar to DPT and OPV, which are currently reported to be over
70%.
5- The EPI should set as a process indicator the objective of increasing the
proportion of children completely vaccinated with hepatitis B vaccine to 60% two
years after introduction of the pentavalent vaccine.
6- Two years after introducing the pentavalent vaccine an independent survey should
be performed on a representative sample of the children in order to estimate
vaccine coverage amongst children by 1 year of age and evaluate progress
towards the final target (assuming this is before 2006).
7- The MOPHP should proceed with introduction of the pentavalent vaccine as soon
as possible. This will reduce the number of injections and time spent per visit,
thereby increasing parents acceptance, as well as improving record keeping at
health centres.
8- The PHC/EPI must ensure that children receive all three doses of hepatitis B
vaccine. Children receiving only one dose of hepatitis B vaccine are a missed
opportunity of becoming completely vaccinated children. EPI staff and health
care workers must be professionally trained to emphasise to parents/guardians the
importance of receiving subsequent vaccine doses and the importance of their
child returning to receive the remaining doses of hepatitis B vaccine according to
the hepatitis B vaccination schedule.
9- There is currently no need for a nationwide immunisation survey to be performed
to estimate hepatitis B vaccine coverage as suggested in the EPI 5-year-plan
considering this survey has already provided the data needed on hepatitis B
vaccine coverage.
10-The PHC/EPI should ensure that every child receives a vaccination card and that
health centre records are up-to-date with children vaccination records. EPIIPHC
health workers should educate parents/guardians about the importance of having
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and retaining vaccination cards in order to have a full vaccination history and for
school entry and registration.
11-The PHCIEPI should ensure equitable distribution, availability, and accessibility
to hepatitis B vaccine in all provinces, with an emphasis on rural regions, in
Yemen. The PHC/EPI should investigate the reasons behind the significant
variation in hepatitis B vaccination coverage between geographic regions m
Yemen.
12-The PHCIEPI should ensure a sufficient supply of hepatitis B vaccine to cover
potential increase in demand for vaccine triggered by the MOPHP health
education programmes.
13- Ideally, hepatitis B vaccine should be provided free of charge to all children
requiring it. The MOPHP ought to revise the current EPI hepatitis B vaccination
policy of providing hepatitis B vaccine free only to children under I-year-old. The
MOPHP needs to consider and evaluate the cost-effectiveness of providing
hepatitis B vaccine to children over l-year-old. Funding and provision of hepatitis
B vaccine should be discussed with international organisations and donors such as
WHO and GAVI. However, due to the low hepatitis B vaccination coverage
amongst children aged 1-3, it is recommended that the implementation of this
should be delayed until hepatitis B vaccine coverage amongst children less than
one-year reaches target levels.
Recommendations based on the findings of this research and for which there have
been previous similar suggestions made to the MOPHP/EPI by its own reports, plans
or consultations but have not yet been implemented (MOPHP(A), 2001; MOPHP(B),
2001; MOPHP(C), 2001):
14-The MOPHP needs to ensure that a realistic financial sustainability plan is
designed and prepared so that immunisation practices continue after support by
GAVI ends.
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15-The MOPHP needs to strengthen its department of statistics and health
information systems in order to have basic data essential for planning activities.
16-The PHCIEPI needs to strengthen its logistic capability with an emphasis on
upgrading its cold chain systems. Issues such as difficulty of storage of hepatitis B
vaccine at the periphery due to lack of electricity and refrigerators need to be
addressed and necessary action must be taken by PHC, EPI and district health
authorities to solve these problems.
17- EPI should reinforcing vaccine management and quality at the district level,
especially with the developing district health systems, and train its staff to
minimise vaccine wastage and monitor vaccine wastage at the central level.
18- The EPI should establish a vaccine adverse events monitoring system and design
the appropriate forms and database for this purpose and ensure that health workers
at the periphery provide this information to the central level.
19- PHC/EPI health care staff need to be trained to educate women of childbearing
age attending health centres for antenatal care or otherwise about the importance
and benefits of early childhood vaccination and encourage them to attend health
centres for postnatal visits.
20- The MOPHP and district health authorities need to ensure that safe injection
practices are implemented and that used materials are safely disposed of and/or
incinerated.
21- The department of reproductive health and the National Population Council need
to act to reduce the total fertility rate by promoting family planning, providing
family planning methods, and encouraging childbirth spacing. The
recommendations set by the second national population conference should be
implemented and progress evaluated.
22- Unplanned building of health units must be stopped as this puts strain on the EPI
to provide equipment and supplies to these units.
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9.3.2 Recommendations requiring multi-sectoral collaboration in Yemen:
1- The health education department in the MOPHP needs to develop Information,
Education, and Communication (lEC) campaigns, mainly utilising radio to
educate the population about the importance and benefits of antenatal care during
pregnancy, vaccination in general, and hepatitis B vaccination specifically. The
MOPHP in collaboration with the Ministry of Information need to select the
prime-time for broadcasting these programmes on television and radio in order to
produce the greatest impact and reach the highest number of the target population.
The MOPHP should review 1 year after instructing the health education
department to do so, how many programmes were developed, frequency of
broadcasting, and evaluate the impact of these programmes and campaigns on
attendance for antenatal care and postnatal vaccination at the same time as when
the vaccination survey is conducted.
2- The MOPHP in collaboration with the Ministry of Education (MOE) needs
emphasise to the cabinet that adult literacy in Yemen is low, with an emphasis on
female education, and the negative impact this low education has on health status
in general, and vaccination coverage specifically. It needs to be clearly
demonstrated that improving educational status has positive externalities on
health, socioeconomic status, and many other demographic characteristics. The
MOPHP and MOE need to present the cabinet with a bilaterally developed project
proposal for improving educational status (with an emphasis on mothers
education), providing a more equitable distribution of schools in Yemen, with an
emphasis on rural areas, and lobby the government and Ministry of Finance to
increase its expenditure on education and health.
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Annex I
Hepatitis B Virus Infection in Yemen
Household Survey Questionnaire
Children Aged 1 - 3 Years Old
Baseline Information:
No Key Code
1. Record Number 0-00-00-
00-00
2. Child's Identification
Number
3. Mother's Identification
Number
4. Province 1-5
5. District 1-5
6. City or Village 1-5
7. Street
8. Household Number 0000
9. Area (Urban or Rural) 1-2
10. Interview Date
11. Interview Time
12. Interviewer
13. Interviewer Code ------------------------------ 1-4
14. Person Interviewed
15: Relation to Child
Characteristics of Individuals from whom blood was drawn:
Child Aged 1-3 years old:
No Question Key Code
16. What is the Child's Name? Tertia!J!_
17. Family Name (Surname)?
18. When was the child born?
(What is the child's DOB?)
19. How old is the child? In months
20. What is the source of the Approximatel y 1 1-7
child's DOB/ Age? Vaccination Records 2
Birth Certificate 3
Parents Memory 4
Parents Records 5
Passport or ID Card 6
Other, specify 7
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21. Is the child male or female? Male 1 1-2
Female 2
22. Inwhat village/city, district Village/City Province
and province was the child District 1-6
born? Province
23. Where was the child Public Hospital 1 1-6
delivered? Private Hospital 2
Health Centre 3
Husbands Home 4
Parents Home 5
Other, specify 6
24. Who delivered the child? Doctor 1 1-7
Nurse 2
Midwife 3
TBA 4
Relative 5
Alone or with husband 6
Other, specify 7
25. What was the type of Vaginal Delivery 1 1-2
delivery? Caesarean Section 2
26. Did you receive antenatal Yes 1
care during your pregnancy No 2
with this child before you Don't Know 3
started delivery?
27~ Have you breastfed this Yes 1 1-2
child? No ___. go to 29 2
28. For how long have you Calculate
breastfed this child? in months
29. How many children have
you ever given birth to
(delivered)?
30. How many of these children Birth
were born before this child? Order
31. How many children other
than your own children live
in the household?
289
Child's Vaccination History
32. Does the child have a Yes 1 1-2
vaccination card? No ----+ go to 34 2
33. Is the vaccination card Yes ----+ request card 1 1-2
available? No 2
(fill in vaccination details)
34. Have you ever heard of Yes 1 1-3
Hepatitis B vaccine? No 2
Don't Know 3
35. Has the child been Yes 1 1-3
vaccinated against HBV? No ----+ Go to 37 2
Don't Know 3
36. How many doses of vaccine One 1 1-5
has the child received? Two 2
Three 3
Four 4
Don't Know 5
37. What is the source of the Vaccination Card 1 1-4
child's vaccination status? Parents Memory 2
Parents Records 3
Other, specify 4
To be filled from vaccination card or record if available
Date BCG DPT OPV MMR HBV
t" dose
Location
200 dose ----------- --------------
Location --------------------------
3rd dose ------------ ------------
Location ----------- ------------
38. Child's hepatitis B Vaccinated 1 1-4
vaccination Status Incompletely Vaccinated 2
Unvaccinated 3
Unknown 4
39. Number of doses received
according to vaccination
card
40. Need to confirm vaccination Yes 1 Check
status at health centre No 2 1-2
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Mother of Child Aged 1-3 Years:
41. What is your name?
42. How old were you when you
first got married?
43. How long after your
marriage did you give birth
to your first child?
44. What is the age of your
oldest child?
45. What is your age? Com.l!_are
46. How do you know your age? Approximate 1 1-6
Birth Certificate 2
Health Records 3
Family Records 4
ID Card or Passport 5
Other, specify 6
47. In what village/city, district Village/city Province
and province were you District 1-6
born? Province
48. How many brothers and
sisters have you ever had?
49. How many of your brothers Birth
and sisters were born before Order
you?
50. Can you read and write? Yes 1 1-2
No -+ go to 52 2
rst. What is your level of Read and write I 1-4
education? Completed try School 2
Completed 2ry School 3
Completed University 4
52. Are you employed? Yes 1 1-2
(Do you work) No • go to 54 2
53. What is your occupation?
Household Characteristics and Socioeconomic Status:
54. Is the household owned or Owned t 1-2
rented? Rented 2
55. What is the type of the House 1 1-3
household? Apartment 2
(filled by investigator) Hut or Shack 3
56. What is the household built Stone t 1-6
of? Brick or Block 2
(filled by investigator) Clay 3
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Mud 4
Mixed 5
Undefined 6
57. What is the number of Count
rooms in the household?
(excluding kitchen and
bath)
58. What is the number of Specify
people living in the Household
household?
59. Crowding Index ~ 58/57
60. What is the number of
individuals sleeping in the
same room as the child?
61. Does the household have Yes 1 1-2
an electrical supply? No _. go to 63 2
62. Excluding electrical Continuously 1 1-3
failures is the electricity After Sunset 2
available? Specific hours only 3
63. What is the house's main Governmental supply 1 1-5
source of water? Local project supply 2
Purchase water truck 3
Buckets local source 4
Other, specify 5
64. Is the father/legal guardian Yes 1 1-2
of the child educated? No _. go to 66 2
65,. What is the level of the Reads and writes 1 1-4
father/legal guardian's Completed lry School 2
education? Completed 2ry School 3
Completed University 4
66. What is the father/legal Farmer 1 1-7
guardian's occupation? Civil Servant 2
Shop Owner 3
Manual Labourer 4
Businessman 5
Professional 6
Other, specify 7
67. Does the household own a Yes 1 1-2
fridge/freezer? No 2
68. Does the household own a Yes 1 1-2
Television? No 2
69. Does the household own a Yes 1 1-2
Radio? No 2
70. Does the household own a Yes 1 1-2
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home telephone? No 2
71. Does the household own a Yes 1 1-2
mobile telephone? No 2
72. Does the household own a Yes I 1-2
Car, Truck or Tractor? No 2
73. Does the household own a Yes 1 1-2
Motorcycle? No 2
74. Does the household own a Yes 1 1-2
Bicycle? No 2
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Annex II
Hepatitis B Virus Infection in Yernen
Household Survey Questionnaire
Children Aged 4 -9 Years Old
Baseline Information:
No Key Code
1. Record Number 0-00-00-
00-00
2. Identification number
3. Province 1-5
4. District 1-5
5. City or Village 1-5
6. Street
7. Household Number 0000
8. Area (Urban or Rural) 1-2
9. Interview Date
10. Interview Time
11. Interviewer
12. Interviewer Code ------------------------------ 1-4
13. Person Interviewed
14. Relation to Child
Characteristics of Individuals from whom blood was drawn:
Child Aged 4-9 years old:
No Question Response Key Code
15. What is the Child's Name? Tertiary
16. Family Name (Surname)?
17. When was the child born?
(What is the child's DOB?)
18. How old is the child? In Years
19. What is the source of the Approximately 1 1-7
child's DOB/ Age? Vaccination Records 2
Birth Certificate 3
Parents Memory 4
Parents Records 5
Passport or ID Card 6
Other, specify 7
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20. Is the child male or female? Male 1 1-2
Female 2
21. In what village/city, district Village/City Province
and province was the child District 1-6
born? Province
22. How many older brothers Birth
and sisters does this child Order
have?
Child's Vaccination History
23. Does the child have a Yes 1 1-2
vaccination card? No ----+- go to 25 2
24. Is the vaccination card Yes----+- request card 1 1-2
available? No 2
25. Have you ever heard of Yes 1 1-3
Hepatitis B vaccine? No 2
Unknown 3
26. Has the child been Yes 1 1-3
vaccinated against HBV? No ----+ Go to 28 2
Don't Know 3
27. How many doses of vaccine One 1 1-5
has the child received? Two 2
Three 3
Four 4
Don't Know 5
28'. What is the source of the Vaccination Card 1 1-4
child's vaccination status? Parents Memory 2
Parents Records 3
Other, specify 4
To be filled from vaccination card or record if available
Date BCG DPT OPV MMR HBV
I" dose
Location
2nd dose ------------------------
Location --------_---------------
3rd dose ------------- --------------
Location ---------- --------------
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29. Child's hepatitis B Vaccinated 1 1-4
vaccination status Incompletely Vaccinated 2
Unvaccinated 3
Unknown 4
30. Number of doses received
according to vaccination
card
31. Need to confirm vaccination Yes 1 Check
status at health centre No 2 1-2
Education of Child Aged 4-9 Years:
1-232. Does the child go to school? Yes
No
IDNO of younger sibling (if applicable):
IDNO of mother (if applicable):
Mother of Child Aged 4-9 Years:
33. What is your name?
34. How old were you when you
first got married?
35. How long after your
marriage did you give birth
to your first child?
36. What is the age of your
oldest child?
37. What is your age? Compare
38. How do you know your age? Approximate 1 1-6
Birth Certificate 2
Health Records 3
Family Records 4
ID Card or Passport 5
Other, specify 6
39. Inwhat village/city, district Village/city Province
and province were you District 1-6
born? Province
40. How many brothers and
sisters have you ever had?
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41. How many of your brothers Birth
and sisters were born before Order
you?
42. Can you read and write? Yes 1 1-2
No ---+ go to 44 2
43. What is your level of Read and write 1 1-4
education? Completed lry School 2
Completed 2ry School 3
Completed University 4
44. Are you employed? Yes 1 1-2
(Do you work) No • go to 46 2
45. What is your occupation?
Household Characteristics and Socioeconomic Status:
46. Is the household owned or Owned 1 1-2
rented? Rented 2
47. What is the type of the House 1 1-3
household? Apartment 2
(filled by investigator) Hut or Shack 3
48. What is the household built Stone 1 1-6
of? Brick or Block 2
(filled by investigator) Clay 3
Mud 4
Mixed 5
Undefined 6
49. What is the number of Count
rooms in the household?
(excluding kitchen and bath)
50. What is the number of Specify
people living in the household
household?
51. Crowding Index XXXXXXXXXX 50149
52. What is the number of
individuals sleeping in the
same room as the child?
53. Does the household have an Yes 1 1-2
electrical supply? No ___. go to 55 2
54. Excluding electrical failures Continuously 1 1-3
is the electricity available? After Sunset 2
Specific hours only 3
55. What is the house's main Governmental supply 1 1-5
source of water? Local project supply 2
Purchase water truck 3
Buckets local source 4
Other, specify 5
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56. Is the father/legal guardian Yes 1 1-2
of the child educated? No -'go to 58 2
57. What is the level of the Reads and writes 1 1-4
father/legal guardian's Completed try School 2
education? Completed 2ry School 3
Completed Universi!Y_ 4
58. What is the father/legal Farmer t 1-7
guardian's occupation? Civil Servant 2
Shop Owner 3
Manual Labourer 4
Businessman 5
Professional 6
Other, specify 7
59. Does the household own a Yes 1 1-2
fridge/freezer? No 2
60. Does the household own a Yes 1 1-2
Television? No 2
61. Does the household own a Yes 1 1-2
Radio? No 2
62. Does the household own a Yes t 1-2
home telephone? No 2
63. Does the household own a Yes 1 1-2
mobile telephone? No 2
64. Does the household own a Yes 1 1-2
Car, Truck or Tractor? No 2
65. Does the household own a Yes 1 1-2
Motorcycle? No 2
66. Does the household own a Yes 1 1-2
Bicycle? No 2
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Annex III
Hepatitis B Virus Infection in Yemen
Governorate Household Survey
Information Sheet
Dear Citizen,
We are currently doing a survey on vaccination and liver diseases (viral hepatitis) in
Yemen. The survey is supervised by the University of London in the United Kingdom,
Taiz University and is approved by the Yemeni Ministry of Public Health.
In this survey we are concentrating on liver diseases (viral hepatitis) and vaccination
amongst children between 1-3 years old and their mothers, and children between 4 - 9
years old.
The survey intends to investigate the extent of spread of this liver disease (viral hepatitis)
in Yemen and its transmission from mother-to-child, the availability of hepatitis B
vaccine provided by the Expanded Programme on Immunisation, and how well hepatitis
B vaccine works in preventing liver disease (hepatitis B virus infection).
For this survey, we are randomly (by chance) choosing people from different
governorates in the country, and from within different cities, towns and villages in these
governorates. Your household has been randomly chosen (chosen by chance) to be part of
the population on which this survey will be carried-out.
All information you provide us with will be very confidential and only the individuals
carrying-out the survey will have access to your personal and household details. All your
personal details and blood samples will be given a secret number and kept in a locked and
safe place. Any information you give us will only be used for this survey. None of your
personal or household details will be given to anybody else unless you allow us to do so.
We encourage you to participate in the survey because the more people participate and
co-operate with the survey, the more the results of the survey become correct, useful and
accurate.
The results of the survey will benefit the country and its citizens and will allow us to
understand and estimate the extent of spread of liver disease (viral hepatitis) in Yemeni
governorates and the chance of mothers passing on this disease to their newborn children.
It will also allow us to know the extent of vaccine availability for infants in the
population and how well it prevents liver disease. This will allow the Ministry of Health
and the Expanded Programme on Immunisation to provide better health services and
prevention programmes against the disease.
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You will also directly benefit from participating in the survey because our survey will be
able to know if the children or mothers in your household have this liver disease. If you
have no objection, we will notify the health authorities of the children's and mother's
results. The health authorities can then let you know these results and can advise you to
have all the close contacts and family members of infected individuals vaccinated against
this liver disease (hepatitis B virus infection).
During our visit to your household we will do two things. First, we will fill in a
questionnaire about the child aged 1-3 years old, mother, and some household
characteristics. Secondly, we will take a blood sample from the child aged 1 - 3 and the
mother, which will be tested in a laboratory. On some occasions we might also fill in a
questionnaire and take a blood sample from a child aged 4 - 9 in the household.
All the equipment used for blood sampling is of the highest standard and the staff
withdrawing the blood samples have excellent experience.
If you have any questions about this surveyor viral hepatitis we are happy to answer
them. You can contact us in Sanaa at Telephone number 203834, or write to us at
Viral Hepatitis in Yemen
PO Box 11351
Sanaa
Republic of Yemen.
Your verbal consent to participate in this survey is very important for the completion of
this survey and for everybody to benefit.
Yours sincerely,
Dr. Naseeb Qirbi
Principal Investigator
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Annex IV
Hepatitis B Virus Infection in Yemen
Population Based Cross Sectional Survey
Household Survey
Study Investigators Manual
Sanaa
Republic of Yemen
May 2001
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Dear study investigator,
It is with great pleasure that I present to you this study investigator manual for the
household survey of hepatitis B virus infection in Yemen you will be participating in.
This is the first household survey investigating hepatitis B virus infection in Yemen.
This Manual provides the necessary information and guidelines that you must study,
understand and practice prior to initiating the survey. All procedures outlined in this
manual should be strictly implemented in the order they appear by study investigators
participating in the household survey. Kindly study this manual carefully and keep it with
you throughout the fieldwork for reference. I am aware that over the years of your
professional experience you will have most probably practised techniques for procedures
such as blood sampling that may differ from the ones outlined in the manual. The basic
principles of blood sampling are universal and whatever technique you have been
implementing is open for discussion during the workshop. However, when you adopt a
blood sampling protocol you should be consistent throughout the survey.
If after reading the manual you have any questions, comments or suggestions I will be
happy to discuss these with you.
Our aim is to conduct research of the highest standard and quality. To achieve this we
must be accurate, punctual, devoted to our work and obsessional throughout its conduct.
During the next few months we are likely to encounter difficulties and obstacles but with
good communication and teamwork we will achieve our targets and goals.
I look forward to working with you and truly believe that by working together we can
ensure a better understanding of this disease in Yemen essential for future health policy
formulation.
Yours sincerely
Dr. Naseeb Qirbi
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Hepatitis B Virus Infection
1 Background:
Hepatitis B virus infection is a major public health problem worldwide. An individual
exposed to hepatitis B virus can either become infected with the virus or become a
chronic carrier. Approximately 2 billion individuals worldwide (a third of the world's
population) have been infected with the hepatitis B virus. Being infected means that an
individual was either previously infected or is currently infected with the virus. It does
not mean that the individual will suffer from liver disease or is a risk for infecting others.
It is estimated that there are over 350 million chronic carriers (an individual who is
positive for a serological marker called the hepatitis B surface antigen HBsAg for longer
than six months) of the hepatitis B virus worldwide. An individual who is a chronic
carrier of the virus is at risk of developing complications and a risk for infecting others.
The course of infection depends on the age at exposure to hepatitis B virus, with age at
infection being the major determinant of whether a person will become a chronic carrier.
The risk of becoming a chronic carrier and consequently developing complications of
hepatitis B virus infection is inversely proportional to age (i.e. the younger the age of the
individual at the time of infection the higher the risk of becoming a chronic carrier).
Approximately 25% of chronic carriers of hepatitis B virus develop the three main
complications of chronic hepatitis B virus infection which are chronic hepatitis, liver
cirrhosis and hepatocellular carcinoma. Hepatocellular carcinoma is the fourth most
common cause of death from cancer and the eighth most common cancer in the world.
The hepatitis B virus is the world's second most common cause of cancer. It is estimated
that 54% - 80% of liver cancers result from chronic hepatitis B virus infection. The
majority of chronic carriers are found in developing countries. Liver cancer is also mainly
a problem of developing countries, which contribute 81% of all deaths resulting from
liver cancer. The global distribution of hepatocellular carcinoma follows the distribution
of hepatitis B virus chronic carriers and occurs predominantly in regions where hepatitis
B virus infection is highly endemic, particularly China and Sub-Saharan Africa ..
2 Epidemiological Classification:
Based on the prevalence of hepatitis B virus chronic carriers (individuals positive for
hepatitis B virus surface antigen HBsAg for longer than six months) amongst adults in
the general population, countries are divided into three main groups. Countries with a
prevalence of chronic carriers less than 2% are classified as countries with a low
endemicity of infection; those with a prevalence of chronic carriers between 2 - 5 % are
classified as having an intermediate endemicity of infection; and countries with a
prevalence of chronic carriers exceeding 5% are classified as having a high endemicity of
infection.
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3 Hepatitis B Virus Infection in the Region:
Hepatitis B virus infection is a major public health problem in the Middle East. Countries
of the region fall into the three groups of low, intermediate and high endemicity of
hepatitis B virus infection. However, the majority of countries in the region have an
intermediate and high endemicity of chronic carriers. Nevertheless, there are marked
geographical differences in the prevalence of HBV chronic carriers within these
countries. In Saudi Arabia, for example, there are significant geographic differences in
the prevalence of chronic carrier females, ranging from 7.3% in Najran to 25% in Jaizan.
4 Hepatitis B Virus Infection in Yemen:
There are a few studies that have investigated hepatitis B virus infection in Yemen. These
studies were mainly hospital-based surveys carried out in the cities of Sanaa, Taiz,
Hodeidah and Hajja. Study subjects were mainly blood donors, pregnant women and
outpatients. All these cities are located in the northern governorates of Yemen. There is a
lack of information on hepatitis B virus infection in southern, eastern, and rural parts of
the country. Whether geographical differences exist between these regions is unknown.
Yemen has a high endemicity of hepatitis B virus infection. Surveys in Yemen show the
prevalence of chronic carriers to range from 12% to 18%. The prevalence of hepatitis B
virus infection ranges from 45% to 60%. It is the prevalence of chronic carriers that is
important not the prevalence of hepatitis B virus infection.
The prevalence of chronic carriers amongst pregnant women in Yemen ranges from 12%
to 17%. This indicates a potentially high rate of mother-to-child transmission of hepatitis
B virus from chronic carrier mothers of hepatitis B virus to their infants.
Hepatitis B virus infection is the most frequent cause of acute viral hepatitis in Yemen,
being responsible for 27% of cases. This is followed by hepatitis E virus responsible for
14% of cases. Hepatitis A virus, hepatitis C virus and hepatitis D virus are each
responsible for 5.1%, 6.4% and 2.6%, respectively, of cases of acute viral hepatitis. These
cases of acute viral hepatitis resulting from hepatitis B virus infection are likely to be
only the tip of the iceberg. In Yemen, the majority of infections occur during childhood
and only 10% of infected children develop symptoms of acute viral hepatitis. 90% of
infected children will have had sub-clinical infections and have no symptoms.
Additionally, only 30 - 40% of infected adults develop symptoms with the remainder
also passing unnoticed.
5 Mode of Transmission:
HBV infection can be transmitted at 3 stages in life; around the time of birth (perinatal),
during childhood, and in adult life. The main modes of transmission are mother-to-child,
child-to-child (horizontal), sexual and parenteral. The role of each of these modes varies
from one country to another. In developed countries (also countries with low endemicity
of hepatitis B virus infection) sexual transmission and intravenous drug abuse in
adolescence and adult life account for the majority of cases of hepatitis B virus
transmission. In developing countries (countries with intermediate and high endemicity
of hepatitis B virus infection), such as Yemen, mother-to-child and child-to-child
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transmission during the early years of life are the major modes of transmission of
hepatitis B virus infection.
Many people in the general population incorrectly believe that hepatitis B virus infection
results from ingesting contaminated water and food. While these are sources of infection
for hepatitis A and E viruses they are not sources of hepatitis B virus infection.
The main factors determining mother-to-child transmission are the mothers serological
status for two markers, hepatitis B surface antigen (HBsAg) and hepatitis B e antigen
(HBeAg). Being positive for hepatitis B surface antigen for longer than six months means
that the mother is a chronic carrier of hepatitis B virus, and can therefore potentially
infect her newborn infant. Being positive for hepatitis B e antigen means that the mother
is highly infectious and indicates that there is a high risk of the infant acquiring a chronic
infection. Approximately 70 - 90% of infants born to mothers who are hepatitis B e
antigen positive become carriers. Determining the role either mode of transmission plays
has important policy implications and may influence vaccination schedules. If mother-to-
child transmission is found to be a common mode of transmitting HBV infection, this
will indicate that vaccinating children against HBV at 6-8 weeks of age with the first
dose of polio/DPT will be too late to prevent mother-to-child infection. Under such
circumstances, one must aim to vaccinate newborns at birth or within 48 hours of
delivery at the latest. In Yemen, where the majority of deliveries occur at home,
introducing such a procedure will encounter numerous obstacles. One of the major
concerns will be the difficulty of delivering vaccines to home deliveries occurring in
remote areas considering that 75% of the Yemeni population lives in rural areas and is
dispersed over approximately 65,000 rural hamlets.
Sexual and parenteral transmission are not major modes of infection in Yemen. Sexual
transmission is probably uncommon due to the conservative culture of the Yemeni
society. The role of parenteral transmission of hepatitis B virus infection in health
institutions is expected to be currently limited as a result of routine screening of blood
products. The number of intravenous drug abusers, in Yemen remains low when
compared to other regions.
6 Factors Associated with HBV Infection:
In Yemen increasing age, a history of jaundice, and a combined history of transfusion and
surgery are associated with hepatitis B virus infection. Other factors found to be
associated with HBV infection and carrier status in the Middle East are large family size,
low socio-economic status, low educational status or contact with a jaundiced person.
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7 Prevention:
The most common methods employed for the control of hepatitis B virus infection in the
Middle East are active immunisation (universal and targeted), routine blood screening for
hepatitis B virus, and ensuring safe injection practices. Due to beliefs that childhood
transmission accounts for the majority of cases of hepatitis B virus infection, its high cost
and the large proportion of household deliveries in many Middle Eastern countries,
passive immunisation using Hepatitis B Immunoglobulin (HBIG) is uncommon in the
Middle East. Due to cultural sensitivity safe sex is not officially promoted in most
countries of the region.
7.1 Active Vaccination:
In 1982, a vaccine was licensed for active vaccination against hepatitis B virus infection.
Hepatitis B vaccine is the first vaccine effective in preventing cancer or a sexually
transmitted disease. Two types of vaccine are currently available, plasma derived and
recombinant hepatitis B vaccine. Both types of vaccine have proven to be safe, highly
effective, recently cost-effective, and available at a cost most countries can afford. As the
success of treatment for hepatitis B virus infection remains low and antiviral therapy
expensive, prevention of infection by vaccinating against hepatitis B virus infection
remains the best option.
In 1991 the World Health Assembly recommended the integration of HBV vaccines to
national immunisation programmes in countries with an intermediate to high endemicity
by 1995, and to all countries by 1997. The main challenge facing developing countries is
reaching highly deprived populations through a primary health care infrastructure that is
in many cases exhausted and short of funds.
Currently recommended and implemented schedules of HBV vaccination vary, but
generally follow a pattern of 2 -3 injections at monthly intervals followed by a booster
dose 6 - 12 months after the initial dose. Immunisation is considered to have occurred if
the concentration of antibody to hepatitis B surface antigen (anti-HBs) is greater than
10mIU/L. Most individuals should remain protected for 5 - 10 years with no need for
booster doses. There is no need to do any post- vaccination tests.
In order to prevent mother-to-child transmission, infants born to carrier mothers should
receive hepatitis B immunoglobulin immediately following delivery or hepatitis B
vaccine as early as possible within the first 48 hours following delivery. Due to high cost,
unavailability and logistical considerations of delivery, Hepatitis B immunoglobulin is
not administered in most developing countries. On the other hand, vaccination at delivery
appears to be an economically attractive option, particularly in developing countries. The
most difficult challenge facing this option is how to identify children at risk and vaccinate
children within 48 hours following delivery in developing countries with a high rate of
mother-to-child transmission where the majority of deliveries occur at home.
The effectiveness of hepatitis B vaccine alone within 48 hours following delivery is
nearly as effective as hepatitis B vaccine with hepatitis B immunoglobulin.
306
7.2 Active Vaccination in Yemen:
In 1998, the Ministry of Public Health introduced plasma derived hepatitis B vaccine then
changed to recombinant vaccine both purchased from Cheil-Jedang Corporation in South
Korea. The vaccine manufacturer Cheil-Jedang recommends giving double the dose to
infants of carrier mothers. However, considering the high chronic carrier rates amongst
women of childbearing age in Yemen and the lack of routine screening for chronic
carriers of hepatitis B virus infection amongst pregnant women allowing the
identification of children at risk, it is highly unlikely that the vaccine manufacturer's
recommendations will be implemented. This leaves infants born to chronic carrier
mothers at potential risk of acquiring perinatal infection.
The first, second and third doses of hepatitis B vaccine, in Yemen, are administered at 2,
3 and 9 months respectively. The first and second doses are administered at the same time
as the first and second doses of DPT/Polio vaccines and the third dose with Measles,
Mumps and Rubella. Ideally the first and second doses of hepatitis B vaccine should be
given one month apart and the third dose given 7 months following the first dose. The
recommendations for dose intervals should be implemented in order maximise vaccine
effectiveness. If a dose is not given by its recommended date (due to parents forgetting,
not going to a vaccination centre, or unavailability of vaccine), it should be given as soon
as possible.
Data available from Yemen suggests that vaccine coverage has reached 42% for the first
dose and 9% for the third dose of hepatitis B vaccine by one year of age. The lower
uptake for the third dose may be due to the later administration of the third dose of
hepatitis B vaccine given with MMR at nine months of age.
307
8 Study Objectives:
8.1 Primary Objectives:
1- Measure the prevalence of hepatitis B virus chronic carriers amongst Yemeni children
aged 1-3 years old and estimate the proportion of these cases resulting from mother-
to-child transmission.
2- Measure the prevalence of hepatitis B virus chronic carriers and highly infectious
chronic carriers amongst Yemeni women of childbearing age and estimate the
potential risk of mother- to-child transmission of hepatitis B virus from these women.
3- Investigate whether the prevalence of hepatitis B virus chronic carriers amongst
children and mothers differs between geographic regions and governorates in Yemen.
8.2 Secondary Objectives:
1- Evaluate the effectiveness of the hepatitis B vaccination programme in preventing
hepatitis B virus infection and carrier status amongst children vaccinated in the
country's Expanded Programme on Immunisation (EPI).
2- Measure hepatitis B vaccination coverage amongst children aged 1-3 years old
participating in the study.
3- Examine the pattern of hepatitis B virus infection and carrier status amongst children
aged 4-9 years old in Yemen prior to the introduction of hepatitis B vaccination to
these age groups and its influence on these cohorts of children.
9 Study Investigators:
This survey will be conducted by four study investigators in Yemen. Dr. Naseeb Qirbi is
the principal study investigator and will be assisted by three other study investigators
(one of which is you).
The study investigators will be divided into two teams during the household survey. Each
team will consist of a qualified medical doctor and a qualified nurse or laboratory
technician. One of the qualified medical doctors is the primary investigator. The second
qualified medical doctor will be recruited based on having a minimum of three years
medical experience and a reasonable relation and background with the governorates and
villages surveyed. A different medical doctor may be selected for each of the
governorates surveyed. Nurses or laboratory technicians will be recruited based on
having a minimum of three years experience in a paediatric ward or active involvement in
withdrawing blood samples from children and infants. A different nurse or laboratory
technician may be selected for each of the governorates and/or primary sampling units
surveyed. Study investigators must be trained on selecting households, filling
questionnaire's, using vaccutainers for blood sampling, and all other aspects of the survey
during a two-week workshop in Sanaa prior to initiating the survey.
The research is supervised by Professor Andy Hall, Head of Infectious Disease
Epidemiology Unit, Department of Infectious and Tropical Diseases, London School of
Hygiene and Tropical Medicine, University of London. Professor Andy Hall will come to
Yemen to attend the first two or three weeks of the survey in order to supervise the
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fieldwork and ensure that it is being conducted as planned. He will also advise on how to
deal with unforeseen difficulties.
10 Study Methodology:
The research will consist of two parts. First, a population based cross-sectional household
seroepidemiological survey of a representative sample of children aged 1-3 and their
mothers. Study subjects participating in the cross-sectional survey will be children aged
1-3 years old and their mothers selected from five governorates representative of the
country's overall population. A total of 1100 children and their mothers will be included
in the sample population. After obtaining informed witnessed verbal consent from study
participants an interviewer administered questionnaire will be completed and both mother
and child will be bled and tested for markers of hepatitis B virus infection. This will
provide information on the prevalence of infection and carrier status amongst children
aged 1-3 and women of childbearing age, mother-to-child transmission of hepatitis B
virus infection, vaccine coverage with hepatitis B vaccine, and geographic distribution of
hepatitis B virus infection and carrier status. An analysis of individuals participating in
the cross sectional survey of children aged 1-3 will evaluate the effectiveness of
Expanded Programme of Immunisation hepatitis B vaccination in preventing hepatitis B
virus infection and carrier status.
Secondly a population based cross sectional survey will be conducted amongst children
aged 4-9 years old, randomly drawn from within the same households of children aged 1-
3 in order to examine the pattern of hepatitis B virus infection and carrier status in
unvaccinated children in Yemen. A total of 420 children will participate in the survey of
the children aged 4-9 years old with 70 children randomly selected from each one of the
six age groups extending from 4-9.
Study Settings:
The survey will be carried out in the following five Yemeni governorates:
1- Sanaa city municipality (political capital).
2- Aden city (economic capital).
3- Taiz governorate (excluding Taiz city).
4- Shabwa governorate.
5- Hodeidah governorate.
These governorates have been selected because they are considered representative of
Yemen's geographic regions, tribes and socio-economic classes; include governorates
from the Southern and Eastern regions of the country, and because of the feasibility of
doing a household survey in these governorates.
Households will be selected from within these five governorates and any child aged 1-3
years old, regardless of sex, meeting the inclusion criteria whose parents witnessed verbal
consent is obtained will be eligible to participate in the study.
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Inclusion criteria for children aged 1 - 3:
All children aged 1-3 years and their mothers willing to participate in the survey from
whom witnessed verbal consent is obtained.
Exclusion criteria for children aged 1 - 3:
1- Children and mothers refusing to participate in the study (children's exclusion will be
based on their guardians refusal to allow them to participate in the study).
2- Seriously ill children.
3- Children and mothers with a history of bleeding disorders.
11 Household Sampling Methodology:
An equal number of children (220 children) will be selected from each one of the five
governorates (see table).
Table
Governorate Sampling Distribution
Governorate Total Sample Size
Sanaa 220
Aden 220
Taiz 220
Shabwa 220
Hodeidah 220
Total 1,100
Sanaa and Aden will represent urban populations whereas Taiz (excluding Taiz city),
Shabwa and Hodeidah (excluding Hodeidah city) will represent rural populations. Within
each governorate, five districts (in rural areas) or enumeration areas (in urban areas) will
be randomly selected as primary sampling units with a fixed number of individuals
selected from each district or enumeration area. Fourty four children aged 1-3 and their
mothers will be randomly selected from each one of the five enumeration areas or
districts in each governorate.
Different procedures will be followed for selecting children aged 1-3 in Sanaa and Aden
(urban populations) than in Taiz, Shabwa and Hodeidah (rural populations).
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11.1 Urban Populations:
In Sanaa City municipality and Aden, which are urban areas and for which maps are
available, five enumeration areas will be randomly selected (based on probability
proportional to size) as primary sampling units with a fixed number of 44 children aged
1-3 and their mothers selected from each enumeration area. Within these enumeration
areas, sampling will be initiated from a street blindly pointed out from a map of this
enumeration area. The first household to be sampled in the street will be selected based
on numbering the households on the street and randomly selecting a household from the
street. If the household is not inhabited by a child aged 1-3 or consent is not obtained (an
eligible household), a coin will be tossed (to determine whether to go right of left) and
every third household will be visited until an eligible household is identified. Once in an
eligible household and after obtaining consent an interviewer administered questionnaire
will be completed and both child aged 1 - 3 years and the mother will be bled and tested
for serological markers of hepatitis B virus infection. Only one child aged 1 - 3 per
mother will be included in the study sample. If more than one child aged 1 -3 per mother
is present in the household, one of these children will be randomly selected, by tossing a
coin, for inclusion to the sample population. If there is more than one mother with a child
aged I -3 in the household, all mothers with a child aged 1 -3 present in the household
will be included in the study sample. Upon the completion of surveying the household,
neighbouring households will be surveyed including to the study population all eligible
consenting households inhabited by a 1 -3 year old child. If no more eligible households
can be identified within the neighbourhood another street in the same enumeration area
will be blindly selected from the map of this enumeration area and the same process of
household selection will be repeated until the target number of 44 children from this
enumeration area has been reached. The same process will be repeated in all five
enumeration areas of each of these urban survey domains (Sanaa City municipality and
Aden).
Procedures for household selection from within enumeration areas in urban
governorates:
1- Randomly select a street from the enumeration area by blindly pointing on a map of
the enumeration area. If an intersection is pointed on randomly select one of these
streets (by giving each street a number and randomly selecting one of these numbers
using a calculator generating random numbers).
2- Number the households on that street starting with the first household on the right
hand side of the street and ending with the first household on the left hand side of the
street (relative to the study investigator standing at the beginning of the street).
3- Randomly select one of these households by using a calculator generating random
numbers within the range of the number of houses on the street.
4- Approach the randomly selected household. After introducing yourselves to
household inhabitants explain why you are there and ask the screening question (if
the household is inhabited by a child aged 1-3 with the child's mother). If the
household is inhabited by a child aged 1-3 and witnessed verbal consent is obtained
take this household as the first household to be sampled. If the household is not
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inhabited by a child aged 1-3 or consent is not given, leave the household, toss a coin
to determine whether to go right or left (heads-right and tails-left) and visit every
third household in that direction until an eligible consenting household inhabited by a
child aged 1-3 is sampled (which will become the first household to be sampled).
5- Within households, only take one child aged 1-3 per mother. If more that one
child aged 1-3 per mother is present, toss a coin to determine which child to include
to the sample (heads-younger child and tails-older child).
6- If there is more than one mother with a child aged 1-3 in the household, sample all
mothers with a child aged 1-3 present in the household.
7- Upon leaving the first household to be sampled, toss a coin to determine whether to
go right or left, and visit neighbouring households in that direction until the target
number of 44 children from that enumeration area has been reached.
8- If the target number of 44 children from that enumeration area (primary sampling
unit) is not reached, blindly select another street from that enumeration area and
repeat steps 1-7 until the target number of children aged 1-3 has been reached.
9- In non-consenting households inhabited by a child aged 1-3 (i.e. eligible but refusing
to participate), always ask and write down the reason for refusal to participate in the
survey.
11.2 Rural Populations:
Once the five districts from each of Taiz, Hodeidah and Shabwa have been randomly
selected (based on probability proportional to size) as primary sampling units, villages
and towns will be randomly selected from within these districts based on probability
proportional to size. Following the selection of a village or town a suitable local
facilitator will be identified and recruited to ensure the co-operation of the village
inhabitants. Within these villages and towns households will be randomly selected. The
first household to be sampled in villages or towns will be selected based on selecting a
central point or street in the village, choosing a random direction from the central point,
numbering households from the central point to the outer boundary of the village and
randomly selecting a household from these numbered households. If the household is not
inhabited by a child aged 1-3 or witnessed verbal consent is not obtained, a coin will be
tossed (to determine whether to go right or left) and every third household in that
direction will be visited until an eligible household is identified. Once in an eligible
household and after obtaining consent an interviewer administered questionnaire will be
completed and children aged 1 - 3 years and their mothers will be bled to test for
serological markers of hepatitis B virus infection. Only one child aged 1 - 3 per mother
will be included to the study sample. If more than one child aged 1 -3 per mother is
present in the household, one of these children will be randomly selected, by tossing a
coin, for inclusion to the sample population. Ifthere is more than one mother with a child
aged 1 -3 in the household, all mothers with a child aged 1 -3 present in the household
will be included in the study sample. Once the first consenting household has been
surveyed all the neighbouring households (starting with the nearest) in the village or town
will be approached until the target number of 44 children and their mothers from this
primary sampling unit has been reached. If village or town maps are available these will
be used to mark surveyed households and streets in the village or town. Otherwise, you
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should draw a map roughly showing surveyed streets and households in the village or
town so that study investigators do not waste time revisiting and surveying households
and streets that have already been surveyed. If the village or town has been completely
surveyed and the targeted sample size from the primary sampling unit has not been
reached, the team will move on to the next village or town selected from within the
primary sampling unit based on probability proportional to size. The same process for
selecting the first and subsequent households for sampling will be repeated in the next
village or town.
Procedures for selection of households from within districts in rural governorates:
1- Go to central point in village. If there is more than one central point in the village
randomly select one of these (by numbering the central points in the village and
randomly selecting one using a calculator generating random numbers).
2- Randomly select a direction from the central point of the village by spinning an
arrow.
3- Number the households in that direction from the central point to the outer boundary
of the village.
4- Randomly select one of these households by using a calculator generating random
numbers.
5- Approach the randomly selected household. After introducing yourselves explain to
household inhabitants why you are there and ask the screening question (if the
household is inhabited by a child aged 1-3 with the child's mother). If the household
is inhabited by a child aged 1-3 and witnessed verbal consent is obtained take this
household as the first household to be sampled. If the household is not inhabited by a
child aged 1-3 or consent is not given, leave the household, toss a coin to determine
whether to go right or left (heads-right and tails-left) and visit every third household
in that direction until an eligible consenting household inhabited by a child aged 1-3
is sampled (which will be the first household to be sampled).
6- Within households, only take one child aged 1-3 per mother. If more that one child
aged 1-3 per mother is present, toss a coin to determine which child to include (heads-
younger child and tails-older child).
7- If there is more than one mother with a child aged 1-3 in the household, sample all
mothers with a child aged 1-3 present in the household.
8- Upon leaving the first household to have been sampled, toss a coin to determine
whether to go right or left, and visit the nearest neighbouring household in that
direction until the target number of 44 children from that village or town has been
reached.
9- If the target number of 44 children from that district is not reached, move on to the
next village or town selected based on probability proportional to size in that district
and repeat the steps from 1-8 until the target number of children aged 1-3 has been
reached.
10- In towns (which are larger than villages) it may not be possible to count the number
of households from the central point of the town (and actually there may be more than
one central point) to the outer boundary of the town. In this case, count the number of
mosques in the town, randomly select one of these (by numbering the mosques and
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randomly selecting one of them using a calculator) to be the central point and repeat
the steps from 1-8.
11- In non-consenting households inhabited by a child aged 1-3 (i.e. eligible but refusing
to participate), always ask and write down the reason for refusal to participate in the
survey.
12 Approaching and Accessing Households:
Upon approaching a household study investigators must first of all state that they are
conducting a survey on hepatitis B virus infection and vaccination of children. They must
then ask if there is a child aged 1-3 living in the household. If there is a child aged 1-3
living in the household the study team must request to meet the parents or guardian of the
child.
Upon identifying and gaining access to a household occupied by a child aged 1-3 years
old the study team (consisting of two individuals) must firstly introduce themselves to the
head of the household and/or the mother of the child. In order to ensure that the same
correct and complete information is given to each study participant, study investigators
must use the information sheet to give the head of the household and/or the mother of the
child a brief explanation that they are conducting a survey on hepatitis B virus infection
and vaccination. They must explain how the household was selected, reassure on
confidentiality and safety issues and encourage household inhabitants to participate in the
survey. Potential study participants must be provided with sufficient information on
potential risks and benefits to enable them to make an informed decision on whether or
not to participate in the study. Study participants must also be informed that the visit to
their household will involve two main procedures. The first is the completion of an
interviewer administered questionnaire. The second is obtaining a blood sample from
both mother and child to test for markers of HBV infection. Following this, household
members should be encouraged to bring forward any questions they may have which
should be answered by the study investigators. Literate parents/ guardians may be given a
copy of the information sheet specifically prepared for the study.
Following the above study participants will be asked for their witnessed verbal consent
for the mothers and child's inclusion in the study population of the survey. They must
also be asked for permission to notify the health authorities of the results of identified
chronic carriers of the virus.
Individuals participating in the survey will be subject to the completion of an interviewer
administered questionnaire and the withdrawal of a blood specimen for investigating
markers of HBV infection and carrier status. The mother should be the target person to be
interviewed. If this is not possible the father or legal guardian of the child should be
interviewed. The questionnaire will be filled by one of the study investigators. The study
investigator will systematically go over the questions reading them out as written and fill
the form according to the response of the person interviewed. Before starting to fill in the
questionnaire the person interviewed should be asked about his/her preferences on the
presence or absence of any individual in the room. During and after filling the
questionnaire strict confidentiality must be ensured for the study participants responses
and details. Completed questionnaires must be labelled with a unique identification
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number for mother and child separately, and kept in a safe and inaccessible place until
returning to base where they will be kept under lock and key.
Once the questionnaire has been completed first the mother and then the child should be
bled aseptically using sterile disposable needles. Samples should be immediately labelled
with the identical identification number that was placed on the questionnaire. The code
number will ensure the anonymity of study participants when samples are transported,
tested for markers of HBV infection, stored, and at the analysis stage.
In some of the households parents will be asked if a child aged 4-9 lives in the household.
Any child 4-9 years old, regardless of sex, whose parents consent is obtained will be
considered eligible to be included in this survey of children aged 4-9 years old. 420
children will be equally selected from the five provinces included in the cross-sectional
survey and from the six age groups extending from 4-9 years (i.e. 70 children from each
of the six age groups extending from 4-9 years).
Procedures upon gaining access to households:
1- When approaching a household state that you are there for the purpose of hepatitis B
virus infection and vaccination.
2- Ask household inhabitants if the household is inhabited by a child aged 1-3 and
mother.
3- Ask for permission to enter the household (for both study investigators in the team).
If there is sensitivity toward entry of a male member of the team to the household the
male member should wait outside.
4- Ask to meet the head of the household, father, or mother of the child.
5- The study investigators must introduce themselves to the head of the household
and/or the parents of the child.
6- Use the information sheet to explain that you are there to survey hepatitis B virus
infection (liver disease) and vaccination, and the survey's objectives.
7- Use the information sheet to explain to the head of the household and/or the mother
or father of the child on how their household was selected.
8- Use the information sheet to reassure the head of the household and/or the mother or
father of the child on confidentiality of their details, responses and results.
9- Use the information sheet to encourage the head of the household and/or the mother
or father of the child to participate in the survey.
10- Use the information sheet to inform the head of the household and/or mother or
father of the child about the general and personal benefits from the study.
11- Use the information sheet to inform study participants that the visit to their
household will involve two main procedures. The first is the completion of an
interviewer administered questionnaire. The second is obtaining a blood sample from
both mother and child to test for markers of HBV infection. Inform study participants
that in some cases you might also fill in a questionnaire and take a blood sample from
a child aged 4 - 9 in the household.
12- If the head of the household and/or parents are literate give them the information
sheet.
13- Encourage household members to ask any questions they may have.
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14- Request witnessed verbal consent for the inclusion of the mother and child aged 1-3
to the study.
15- Request witnessed verbal consent for notifying the health authorities of the results of
identified chronic carriers of the virus.
16- After completing the questionnaire and blood sampling of mother and child 1-3 ask
if there is a child aged 4-9 in the household and request witnessed verbal consent for
the inclusion of this child to the study population.
13 Who to request witnessed verbal consent from:
In order to ensure that the same correct and complete information is given to each study
participant, study investigators must use an information sheet for the procedures above.
Study participants must be asked for their witnessed verbal consent for the mothers and
child's inclusion in the study population of the cross-sectional survey. The reason verbal
consent has been selected is because approximately 75% of the Yemeni population is
illiterate and this is more pronounced in rural areas. Requesting the study participating to
provide written consent will be difficult and impractical.
It must be attempted to obtain the consent of both mother and father of the child. If the
father is not present the mother should be asked if the father is likely to object to their
inclusion in the sample population, in which case an attempt should be made to obtain the
fathers consent. In the event of either parent refusing inclusion of the child and mother in
the study population, efforts should be made to address their concerns and alleviate their
fears. If however, following this either parent refuses to participate in the study, the
household members should not be included in the study population, with subjects
refusing to participate being free to do so at their own wish. However, subjects should be
asked for the reason of their refusal in order to assess if non-participants differ in any
aspects from participants in the study population.
Insome of the households of children aged 1-3, parents 'should be asked if a child aged 4-
9 lives in the household. Any child 4-9 years old, regardless of sex, whose parents
witnessed verbal consent is obtained should be considered eligible to be included in this
survey of children aged 4-9 years old. A total of 420 children will be equally selected
from the five provinces included in the cross-sectional survey and from the six age
groups extending from 4-9 years.
14 Questionnaire:
Individuals participating in the survey of children aged 1-3 will be subject to an
interviewer administered questionnaire. The questionnaire focusing on the child aged 1-3
and the mother asks about the child's details and vaccination history, mother, father, and
the household's characteristics (refer to attached questionnaire for children aged 1-3,
Annex I). It is divided into a section on baseline information, a section on characteristics
of individuals from whom blood was drawn (mother and child), and a section on
household characteristics and socio-economic status. The questionnaire does not include
any sensitive or embarrassing questions.
Individuals participating in the survey of children aged 4-9 will also be subject to an
interviewer administered questionnaire. The questionnaire focuses on the child aged 4-9
and asks about the child's details and vaccination history, mother, father, and the
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household's characteristics (refer to attached questionnaire for children aged 4-9, Annex
II). It is divided into a section on baseline information, a section on characteristics of the
child, and a section on household characteristics and socio-economic status. This
questionnaire also does not include any sensitive or embarrassing questions.
The mother must be the target person to be interviewed. If this is not possible the father
or legal guardian of the child should be interviewed. The interview will be conducted in
the study subjects household and the questionnaire will be administered and filled by one
of the study investigators participating in the survey. During the interview and prior to
filling the questionnaire respondents should be asked about their preferences on the
presence or absence of subjects in the room. No more than two study investigators should
be present in the room at the same time. Whilst the interview is being carried out
individuals present from the study subjects side should be kept to a minimum, unless this
runs contrary to the study subjects wishes. The study investigator must systematically go
over the questions reading them out as written and filling the form according to the
response of the person interviewed. When filling in the questionnaire you must be as
consistent as possible in the way you read out the questions and avoid leading questions.
Completed questionnaires must be labelled with a unique identification number for
mother and child separately (or child alone in the case of children aged 4-9), and kept in a
safe and inaccessible place until returning to base where they will be kept under lock and
key. Strict confidentiality must be ensured for the respondents personal and household
characteristics and details and you must not discuss or reveal any of the study participants
identity, details, characteristics or responses to anyone else other than the study
investigators.
During the workshop prior to the survey you will be trained on how to conduct the
interview and filling the questionnaire. You will receive a full explanation and
description of every question in the questionnaire. If you find anything unclear regarding
the questionnaire please discuss this with the primary investigator.
Procedures for Questionnaire:
1- No more than two study investigators should be present in the room at the same time
(unless the additional person present is the primary investigator or his supervisor).
2- Aim to interview the mother of the child aged 1-3. If this is not possible interview the
father/legal guardian of the child.
3- Before starting to fill in the questionnaire ask the mother about her preferences on the
presence or absence of subjects in the room and take these into consideration.
4- Whilst the interview is being carried out individuals present from the study subjects
side should be kept to a minimum, unless this runs contrary to the study subjects
wishes.
5- Fill in the questionnaire with a black or blue pen. Do not use pencils or red pens to fill
in the questionnaire.
6- Write clearly and neatly on the questionnaire (write numbers in English. Do not
confuse 1 and 7, 4 and 9,6 and 9,2 and Z, 5 and s).
7- Do not write or mark on the coding column on the right of the questionnaire.
8- The study investigator conducting the interviewer administered questionnaire must
systematically go over the questions reading them out as written and fill- in the form
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according to the response of the person interviewed. When filling in the questionnaire
you must be as consistent as possible in the way you read out the questions and avoid
leading questioning unless absolutely necessary.
9- When a questionnaire has been completed it must be labelled with a unique
identification number for child and mother separately. These same identification
numbers will be used to label the child's and mothers blood specimens.
10-After completing the questionnaire revise it and check for any missing information or
skipped questions.
11- Place the questionnaire in the folder for completed questionnaires during fieldwork
and keep it in a safe and inaccessible place until returning to base where
questionnaires will be kept under lock and key.
12- Strict confidentiality must be ensured for the respondents personal and household
characteristics and details and you must not discuss or reveal any of the study
participants identity, details, characteristics or responses to anyone else other than the
study investigators.
13- If more than one mother with a child aged 1-3 is present in the household, do not
allow the other mothers who will be interviewed to attend the interviewer
administered questionnaire with other mothers.
15 Blood Sampling:
Following the completion of the interviewer administered questionnaire both mother and
child aged 1-3 must be bled to test for serological markers of hepatitis B virus infection.
Venesection is the main procedure that may cause discomfort to subjects participating in
the study. This is more likely amongst children than adults. Children will be more likely
to perceive the study investigators in their household as strangers and dislike contact with
them. This is expected to reach its peak when the child is held to obtain the blood sample.
Attempts should be made to minimise this occurring especially whilst the questionnaire is
being completed. During the interview the study team should attempt to be friendly, nice
and playful with the child. Before the blood sample is withdrawn the mother should be
instructed to hold the child giving himlher a sense of security. When withdrawing blood
samples from children both study investigators with the co-operation and permission of
the mother should calmly and friendly hold the child in a secure and fixed position. This
is to prevent injury that may result from sudden movements or attempts by the child to
remove the needle that may occur at the time of blood withdrawal or due to the sting of
the needle.
Procedures for withdrawing the blood sample:
1- 5 millilitre and 2 millilitre vaccutainers, respectively, will be used for obtaining blood
samples from mother and child.
2- If vaccutainers are not used for collecting blood samples, syringes of the same
capacity will be used for collecting the blood specimen, which will then be
transferred into a vaccutainer. 23 gauge needles 15 millimetres in length should be
used in children.
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3- Any venepuncture must be performed usmg a sterile needle or butterfly and
vaccuntainer (or syringe).
4- According to circumstances aim to obtain the first specimen from the mother and the
second specimen from the child.
5- Label vaccutainer (or blood container) with the corresponding patient identification
number (for children ID NO 1001 - 1200, for mothers 4001 - 4200).
6- Attach needle to holder. Push the evacuated tube into the holder, but do not fully
penetrate the rubber seal with the back end of the needle. The front of the needle
should still be sheathed (if using a needle and syringe attach the needle to syringe
with needle still sheathed).
7- Position the patient, sitting or lying comfortably, with one arm outstretched and
supported. The elbow should be fully extended, and the hand should be lower than the
elbow.
8- Before bleeding the child, ask the mother to hold the child in her lap firmly with the
child's facing away from the study investigators and, with one arm outstretched and
supported. The elbow should be fully extended, and the hands should be lower than
the elbow. The other hand and both lower limbs should be held and fixed in position
by the second study investigator not withdrawing the blood sample.
9- Apply the tourniquet just above the bend in the elbow.
10-Locate a vein near the bend in the elbow. It is best to use lateral veins to avoid
injuring the artery or nerve on the medial side of the arm.
11-The vein should be felt not just seen. If veins are not prominent, gently slap, rub or
warm the area of skin over them. This will cause them to stand out. Also, tell the
study participant (if mother) to alternatively close and open her fist until a vein
becomes more prominent. Feel along the path of the vein with your fingers. The
needle should be inserted at the first point (closer to the child's or mothers hand than
to shoulder)) at which the vein can be felt.
12-Once a vein has been located and the site of venepuncture determined, clean the skin
over the vein with an antiseptic swab. Rubbing well with an antiseptic soaked swab
will also make the vein more prominent. Do not touch the area of skin after it has
been disinfected. If that area of skin is touched again (e.g. in order to feel the vein) it
must be wiped again with an antiseptic soaked swab.
13- Leave the disinfected skin to dry for 1minute.
14- Wear disposable gloves.
15- Pick up the needle and vaccutainer (or syringe) and remove the sheath from the
needle. Hold the needle and vaccutainer (or syringe) in one hand. With the other
hand, hold the skin taut just below the vein to prevent the vein from moving.
16- Hold the needle in line with the vein (pointing towards the shoulder) and at a 15
degrees angle with the skin push the needle carefully and directly into the vein (5 - 10
millimetre).
17- Release the tourniquet before withdrawing the blood sample.
18- If using a vaccutainer steady the holder with one hand,and with the other hand push
the vaccutainer all the way into the holder). The tube will automatically fill,
withdrawing a pre-determined volume of blood, when the rubber seal is penetrated by
the back end of the needle. If another tube is to be filled (e.g. EDTA or Heparin
container for mothers), remove the first tube (without removing the needle from the
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vein), and with one hand steady on the holder, push the second tube all the way into
the holder.
19- If using a syringe keep the syringe steady with one hand and slowly (to avoid the
vein collapsing) draw back the plunger with the other hand. Blood will enter the
syringe if the needle is in the vein. Continue to withdraw the plunger until the syringe
has filled (with 5 millilitres of blood in mother and 2 millilitre of blood in children).
20- If you have not already done so, MAKE SURE that you release the tourniquet before
withdrawing the needle from the vein.
21- After collecting the targeted amount of blood slowly withdraw the needle from the
vein, maintaining the same angle with the skin.
22- Firmly apply a clean cotton wool to the site of venepuncture for 3 minutes,
preferably with the blood sampled subjects arm above their head.
23- Ensure that bleeding has stopped from the site of venepuncture and that the
household has not become contaminated with any drops of blood.
24- Apply a bandage to the site of venepuncture if bleeding has not stopped after 3
minutes.
25- If you are not successful at your first attempt of venepuncture, relax and repeat the
attempt once again after 5 minutes (if the child is crying wait until s/he calms down).
Meanwhile reassure the parents, especially the mother.
26- Do not reuse needles, syringes or vaccutainers.
16 Procedures for handling blood sample and sampling equipment in the household:
1- Remove holder from vaccutainer or needle from syringe.
2- Gently handling blood specimens in order to prevent haemolysis.
3- If a syringe has been used, expel the blood into the labelled vaccutainers (labelled
with the study participants identification number) by slowly pushing the plunger into
the syringe (do not squirt blood), and securely put cap on blood container.
4- Dispose of needle, syringe, holder, cotton wool, packaging and all equipment used in
safe disposable box. The disposable box should be taken with the team back to base
and disposed of in the local health centre at the end of each working day.
5- In the case of EDTA or heparin holders for mothers serum mix blood with
anticoagulant by gently inverting the tube several times.
6- Place the blood samples in racks.
7- Place racks in normal temperature transportation box maintaining temperature
between 10 - 40 degrees centigrade for 30 minutes until clotting has occurred (to
protect the stability of immunoglobulins).
8- Transfer the samples into icebox after 30 minutes have passed from the collection of
the blood specimen. If clotting has not occurred yet, leave blood samples in normal
transportation temperature box for another 30 minutes.
9- Count all remaining and make sure that you have not left any equipment in the
household. Under no circumstances should used or unused items used in the blood
sampling process be left in the household.
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17 Vaccinating children and mothers:
1- If vaccine is available and when eligible vaccinate mother and child (children will be
considered eligible if they have not received all three doses of hepatitis B vaccine).
Give priority of vaccination to children.
2- Hepatitis B vaccine should be administered intramuscularly.
3- Mothers receive double the dose of children (mothers receive 3 micrograms and
children receive 1.Smicrograms of hepatitis B vaccine).
4- Mother's should receive the vaccine in the deltoid muscle and children on the lateral
aspect of the thigh.
S- Take hepatitis B vaccine out of the cold-box and make sure it has not frozen.
6- Withdraw the corresponding vaccine dose into the syringe.
7- Before vaccinating the child, ask the mother to hold the child in her lap firmly with
the child facing away from the study investigators and, with the lower limb extended
and supported. The other lower limb and both upper limbs should be held and fixed in
position by the second study investigator not giving the injection (i.e. implement the
same procedures as when withdrawing the blood sample).
8- The lower limb to be injected should be fully exposed.
9- Disinfect the skin at the site of injection using an antiseptic swab.
10-Leave the skin to dry for 1minute.
11-Check that the syringe with the correct dose of vaccine has no air in it.
12- Perpendicular to the surface of the skin, insert the needle 2 centimetres deep into the
muscle.
13-Pull on the plunger slightly, to ensure that the needle in not in a vein. If it is in a vein
blood will appear in the syringe. If this happens, slowly and slightly pull the needle
backwards and pull on the plunger again to ensure that the needle is not in a vein.
14-After ensuring needle is not in a vein push on the plunger to inject the dose of the
vaccine.
lS- Carefully withdraw the needle from the muscle, maintaining the same angle of the
needle with the skin.
16- Firmly apply a clean cotton wool to the site of injection for 1minute.
17- Ensure that bleeding has stopped from the injection site.
18- Apply a bandage to the injection site if bleeding has not stopped.
19- If the child has a vaccination record card available write the date and dose of the
hepatitis B vaccine given to the child. If the child does not have a vaccination record
available s/he should be given one with the date and the number of the dose the child
has been given.
20- Dispose of needle, syringe, cotton wool, packaging and all equipment used in safe
disposable box. The disposable box should be taken with the team back to base and
disposed of in the local health centre at the end of each working day.
21- Count and make sure that you have not left any equipment in the household. Under no
circumstances should used or unused items used in the blood sampling process be left
in the household.
321
18 Procedures for field transportation and field storage of blood:
In order to ensure the safety of study subjects, study investigators and environment the
following measures should be strictly implemented:
1- For transportation, blood samples will be collected in a sealed vaccutainer (or plain
sealed blood container) and/or sealed EDTAlheparin blood container. This will
prevent any spillage, leaking or bacterial contamination of blood.
2- After allowing 30 minutes for blood clotting at temperatures between 10 - 40
degrees centigrade in a normal room temperature storage box, vaccutainers and/or
blood containers should be transferred into pre-cooled iceboxes.
3- If 30 minutes after collection the blood has not clotted, allow another 30 minutes
before transferring to an icebox. Blood should not be refrigerated until a firm clot has
formed.
4- Sealed vaccutainers and/or EDTA blood containers will be held in racks and stored
in a mobile icebox. The lower half of the icebox will be filled with ice.
5- In order to ensure that the blood samples do not freeze, the racks will be kept stacked
above and avoiding contact with the ice packs placed in the bottom of the icebox.
6- Stability of blood specimens at any constant temperature from -196 to 20 degrees
centigrade is better than at changing temperatures, especially freeze thaw changes.
Try to maintain the temperature of specimen storage at a constant temperature and
avoid exposing samples to heat.
7- During transportation care must be taken to avoid shaking of the blood samples on
bumpy roads, in order to minimise mixing of serum with cells and products of
haemolysis. Stability of immunoglobulins is also reduced if they are subject to
shaking or bouncing.
8- During transportation care must be taken to avoid exposing iceboxes to sunlight (by
covering and concealing them).
9- During transportation care must be taken to keep iceboxes upright.
10- During transportation checks should be made to make sure that the Ice in the
iceboxes has not melted.
19 Procedures for base handling and base storage of blood specimens:
1- Upon arrival to base, blood samples should be centrifuged for 15 minutes at 700 x g.
2- Serum should be separated from the residual blood clot using pipettes. Two serum
samples should be collected from each container with an equal volume of serum
placed in each of the two serum holders (labelled with the identification number).
3- The two serum specimens from each study subject should be stored in a freezer at -
20 degrees centigrade.
4- Unused hepatitis B vaccine should be placed in a refrigerator.
5- The freezer must be in a safe inaccessible place and locked with a key when possible.
6- The freezer must be checked that it is working properly every morning before the
survey and when adding the new batch of serum samples to it in the evening.
7- No items other than the serum samples should be stored in the freezer.
8- Throughout the process of handling blood study investigators should be wearing
disposable gloves.
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9- Residual products and containers must be disposed of safely at the local health centre
when possible.
10- Serological tests on the children's serum will be carried out according to the
following plan:
All children's sera will be tested for hepatitis B surface antigen (HBsAg). Children
positive for HBsAg will be further tested for Immunoglobulin M antibody to hepatitis
B core antigen (IgM anti-HBc). Children negative for HBsAg will be tested for total
antibody to hepatitis B core antigen (anti-HBc).
Vaccinated children will be tested for antibody to hepatitis B surface antigen (anti-
HBs), which will be measured in milli-international units per litre (mIU/L).
11- Serological tests on the mother's serum will be carried out according to the following
plan:
All mother's sera will be tested for HBsAg. Mothers positive for HBsAg will be
further tested for hepatitis B e antigen (HBeAg) and hepatitis B virus DNA (HBV
DNA Quantitative) concentration. Mothers negative for HBsAg will be tested for
anti-HBc.
20 Safety of study investigators:
1- Study investigators participating in the study will be screened for hepatitis B surface
antigen to exclude them being carriers, and thereby reducing the risk of infecting
study participants.
2- Study investigators, particularly those handling blood will be asked if they have been
vaccinated against HBV. Those who have not been vaccinated will be advised to get
vaccinated as early as possible before the fieldwork is initiated, thereby reducing the
risk of becoming infected.
3- Study investigators who have been vaccinated will be tested for anti-HBs. If their
anti-HBs level is lower than 10 mIU/L they will be given a booster dose of hepatitis B
vaccme.
4- Study investigators must wear disposable gloves whenever handling blood or blood
products in the households, during transportation, or at base.
5- White coats should be worn when handling blood or blood products in the
households, during transportation, or at base.
6- Extra care must be taken when handling sharp objects such as needles.
7- Antiseptic (eg. Dettol) must be available at all times of handling blood or blood
products and must be used for immediate decontamination of hands if exposed to
blood or pricked by needles.
8- Hands should be washed using soap or antiseptic after blood sampling or vaccine
administration.
9- All unpacked needles, whether new or used, should be re-sheathed and discarded into
safety boxes.
10-All syringes, holders, and packaging used in the blood sampling process must be
discarded into safety boxes.
11- Study investigators (mainly the medical doctor) must check that no blood sampling
equipment (new or used) is left in the household before leaving it.
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12- When travelling to malaria endemic areas you are advised to take the necessary anti-
malarial prophylaxis prior to travelling to high risk areas.
21 Daily Checklist before departine; from base:
On the night before the day in which household visits will be carried out, all the items
and equipment needed on next days survey should be prepared and confirmed using a
checklist.
Each day's fieldwork requires the following:
1- 20 questionnaires for children aged 1-3 years old.
2- 20 questionnaires for children aged 4-9 years old.
3- 50 vaccutainers, holders and needles.
4- 50 two millilitre syringes, 50 fifteen millilitre needles and 50 butterflies.
5- 50 five millilitre syringes and 50 needles.
6- 20 labels for children aged 1-3,20 labels for mothers, and 20 labels for children aged
4-9.
7- 60 antiseptic swabs.
8- 60 bandages.
9- 40 infant doses of hepatitis B vaccine.
10- Cotton wool.
11-2 racks.
12- 6 blue pens.
13-4 writing pads.
14- Antiseptic disinfectant (Dettol).
15- 12 bottles of water.
16- 1 normal room temperature storage box.
17- Icebox filled with ice on the morning of the journey.
18- Folder of new questionnaires for children aged 1-3.
19-Folder of new questionnaires for children aged 4-9.
20- Folder for filled in questionnaires of children aged 1-3.
21- Folder for filled in questionnaires of children aged 4-9.
22- Paper for drawing maps.
23- Log book and survey diary.
24- One 20 litre container of water.
22 Responsibilities:
The person in-charge of the fieldwork is the primary investigator. He has the right to
monitor and evaluate study investigators conduct. He also has the right to excuse study
investigators of their duties and participation in the survey ifhe has reason to do so.
It is the responsibility of the medical doctor to do the following:
1- Prepare the equipment and supplies on the night before everyday of the survey and go
over the supplies checklist.
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2- Check that the freezer is working properly every morning before the survey and when
adding the new batch of blood samples to it in the evening.
3- Fill the icebox with ice on the morning of the survey just prior to departure.
4- Fill in the household survey questionnaire (unless the medical doctor is a male and
has been refused entry to the household).
5- Answer any health related questions household members may raise whilst visiting the
household.
6- Hold the limbs of the child aged 1-3 and 4-9 whilst the second study investigator is
performing venepuncture (unless it is the doctor who is performing the venepuncture,
in which case the nurse or laboratory technician should hold the child's limbs).
7- Make sure that there is no new or used equipment used for blood sampling left in the
household prior to leaving the household.
8- Check that questionnaires and blood samples have been correctly labelled before
leaving the household.
9- Draw a map of surveyed parts and households of villages.
10- Observe and monitor the serum container labelling process at base.
It is the responsibility of the nurse or technician to do the following:
1- Prepare the blood sampling equipment in the household (vaccutainers, holders and
needles, syringes and needles, butterfly, swabs, bandages and labels).
2- Withdraw the blood sample from the children and mothers in the household.
3- Ensure that bleeding has stopped from the site of venepuncture.
4- Apply a bandage if necessary.
5- Dispose of used equipment in safety disposable box.
6- Place the blood samples in racks and then in the room temperature storage box and
leave them in it for 30 minutes to allow clotting.
7- Administer hepatitis B vaccine to children and mothers.
8- After 30 minutes check that blood clotting has occurred and transfer the samples from
the storage box to the icebox (if clotting has not occurred leave the samples in the
room temperature storage box for a further 30 minutes).
9- Check on the samples and make sure that they have not been tipped over, broken or
spilt, and that the ice has not thawed.
10-Upon arrival to base they must centrifuge the samples and place them is two labelled
serum holders.
11- Place the serum holders in the freezer.
12- Safely dispose of used vaccutainers.
23 Quality Control:
1- Everyday a minimum of 12 eligible and consenting households should be surveyed
and samples from these households obtained (6 households per study team).
2- The progress and quality of work of each study team and investigator will be
monitored and evaluated.
3- Each investigator should check the questionnaire after filling it for missing
information or skipped questions.
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4- Everyday upon returning to base the primary investigator should check and code
questionnaires.
5- Study investigators are obliged to consider all information obtained from study
participants strictly confidential and must not disclose of such information to other
parties.
6- Study investigators are obliged to consider all the procedures related to the survey
strictly confidential and must not disclose such information to any other party.
24 Working hours and holidays:
Work will be carried out 6 days a week (Saturday to Thursday).
Friday is a holiday although meetings may be held with study investigators on this day
during the fieldwork in rural areas.
Work starts at 8:30 am and ends at 6:30 pm (working hours may be longer if there is a
delay in transportation or a backlog of work).
25 Accommodation:
You will be provided with accommodation during the fieldwork. This will not include
cost of any phone calls, meals or room orders you make. If accommodation includes any
free meals you will be informed of this.
26 Salary:
Each study investigator will be paid a salary on a per diem basis (based on days spent in
the field). Study investigators will not be paid for transit days spent between surveys in
separate governorates.
27 Supervision:
Approval for conducting the survey has been obtained from the Ethics Committee at the
London School of Hygiene and Tropical Medicine (University of London) and The
Minister of Public Health.
28 Disclamier:
The primary study investigator, University of London, and University of Taiz will not be
held responsible for any illness, injuries, losses, or death that may occur to study
investigators participating in the survey throughout the period.
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